0001477932-24-00484210-Q VOLITIONRX LTD 20240814202408141620121620131620613 0 0001477932-24-004842 10-Q 72 20240630 20240814 20240814 VOLITIONRX LTD 0000093314 2835 911949078 DE 1231 10-Q 34 001-36833 241208271 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014 1 (646) 650-1351 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014 STANDARD CAPITAL CORP 19990812 10-Q 1 vnrx_10q.htm FORM 10-Q vnrx_10q.htm0000093314false--12-31Q220240.001100000000829283148189832100102647553053678084631016354651000028586061588261429234397593300.570.5500000933142024-01-012024-06-300000093314us-gaap:SubsequentEventMembervnrx:JulyOneTwoThousandFourMember2024-06-292024-07-010000093314us-gaap:SubsequentEventMembervnrx:JulyEightTwoThousandFourMember2024-07-022024-07-080000093314us-gaap:SubsequentEventMember2024-07-022024-07-130000093314us-gaap:SubsequentEventMember2024-07-022024-07-120000093314us-gaap:SubsequentEventMember2024-08-012024-08-040000093314us-gaap:SubsequentEventMember2024-07-020000093314us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberus-gaap:CommonClassBMember2024-08-080000093314us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2024-08-012024-08-080000093314us-gaap:SubsequentEventMemberus-gaap:CommonClassBMember2024-08-080000093314us-gaap:SubsequentEventMemberus-gaap:CommonClassAMember2024-08-080000093314us-gaap:SubsequentEventMember2024-08-080000093314us-gaap:SubsequentEventMemberus-gaap:CommonClassBMember2024-08-012024-08-080000093314us-gaap:SubsequentEventMemberus-gaap:CommonClassAMember2024-08-012024-08-080000093314us-gaap:SubsequentEventMembersrt:MinimumMember2024-07-020000093314us-gaap:SubsequentEventMember2024-08-012024-08-080000093314us-gaap:SubsequentEventMembersrt:MaximumMember2024-07-020000093314vnrx:UniversityMedicalCentreAmsterdamMembervnrx:JulyTwoThousandTwentyFourMember2024-01-012024-06-300000093314vnrx:XeneticBiosciencesIncAndCLSTherapeuticsMembervnrx:JulyTwoThousandTwentyThreeMember2024-01-012024-06-300000093314vnrx:GuysAndStThomasNHSFoundationTrustMembervnrx:AugustTwoThousandTwentyThreeMember2024-01-012024-06-300000093314vnrx:UnivercityOfTexasMDMembervnrx:TwoThousandTwentyTwoMember2024-01-012024-06-300000093314vnrx:UniversityOfTaiwanMembervnrx:InTwoThousandsEighteenMembervnrx:ClinicalStudyResearchAgreementMember2024-01-012024-06-300000093314vnrx:UniversityMedicalCentreAmsterdamMembervnrx:JulyTwoThousandTwentyFourMember2024-06-300000093314vnrx:XeneticBiosciencesIncAndCLSTherapeuticsMembervnrx:JulyTwoThousandTwentyThreeMember2024-06-300000093314vnrx:GuysAndStThomasNHSFoundationTrustMembervnrx:AugustTwoThousandTwentyThreeMember2024-06-300000093314vnrx:UnivercityOfTexasMDMembervnrx:TwoThousandTwentyTwoMember2024-06-300000093314vnrx:UniversityOfTaiwanMembervnrx:InTwoThousandsEighteenMembervnrx:ClinicalStudyResearchAgreementMember2024-06-300000093314vnrx:TwentyTwentySixMember2024-01-012024-06-300000093314vnrx:TwentyTwentyFiveMember2024-01-012024-06-300000093314vnrx:TwentyTwentyFourMember2024-01-012024-06-300000093314vnrx:TwentyTwentyThreeMember2024-01-012024-06-300000093314vnrx:ManagingDirectorsAgreementMember2024-01-012024-06-300000093314vnrx:ManagingDirectorsAgreementMember2024-06-300000093314202 4-02-012024-02-05000009331420 20-11-012020-11-030000093314vnrx:RestrictedStockOptionsVestedMembervnrx:TotalMember2024-01-012024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:OutstandingAwardThreeMember2024-01-012024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:OutstandingAwardTwoMember2024-01-012024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:AwardOneMember2024-01-012024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:TotalMember2024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:OutstandingAwardThreeMember2024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:OutstandingAwardTwoMember2024-06-300000093314vnrx:RestrictedStockOptionsVestedMembervnrx:AwardOneMember2024-06-300000093314us-gaap:RestrictedStockMembervnrx:TotalMember2024-01-012024-06-300000093314us-gaap:RestrictedStockMembervnrx:OutstandingAwardFiveMember2024-01-012024-06-300000093314us-gaap:RestrictedStockMembervnrx:OutstandingAwardFourMember2024-01-012024-06-300000093314us-gaap:RestrictedStockMembervnrx:AwardThreeMember2024-01-012024-06-300000093314us-gaap:RestrictedStockMembervnrx:TotalMember2024-06-300000093314us-gaap:RestrictedStockMembervnrx:OutstandingAwardFiveMember2024-06-300000093314us-gaap:RestrictedStockMembervnrx:OutstandingAwardFourMember2024-06-300000093314us-gaap:RestrictedStockMembervnrx:AwardThreeMember2024-06-300000093314vnrx:UMCMember2024-06-300000093314vnrx:XenticBioscienceMember2024-06-300000093314vnrx:GuysAndStThomasMember2024-06-300000093314vnrx:MDAndersonCancerCenterMember2024-06-300000093314vnrx:NationalUniversityOfTaiwanMember2024-06-300000093314vnrx:GrantsRepayableMember2024-06-300000093314vnrx:OperatingLeaseRightofUseObligationsMember2023-01-012023-12-310000093314vnrx:OperatingLeaseRightofUseObligationsMember2024-01-012024-06-300000093314vnrx:OperatingLeaseRightofUseObligationsMember2023-12-310000093314vnrx:OperatingLeaseRightofUseObligationsMember2024-06-300000093314vnrx:FinanceLeaseObligationsMember2024-06-300000093314us-gaap:RestrictedStockUnitsRSUMember2024-06-300000093314us-gaap:OptionMember2023-01-012023-06-300000093314vnrx:WarrantsMember2023-01-012023-06-300000093314us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300000093314us-gaap:OptionMembervnrx:TwoThousandFifteenEquityIncentivePlanMember2024-06-300000093314us-gaap:OptionMembervnrx:TwoThousandFifteenEquityIncentivePlanMember2024-01-012024-06-300000093314us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300000093314vnrx:OptionsSixteenMember2024-01-012024-06-300000093314vnrx:OptionsFifteenMember2024-01-012024-06-300000093314vnrx:OptionsFourteenMember2024-01-012024-06-300000093314vnrx:OptionsThirteenMember2024-01-012024-06-300000093314vnrx:OptionsTwelveMember2024-01-012024-06-300000093314vnrx:OptionsElevenMember2024-01-012024-06-300000093314vnrx:OptionTenMember2024-01-012024-06-300000093314vnrx:StockOptionNineMember2024-01-012024-06-300000093314vnrx:StockOptionEightMember2024-01-012024-06-300000093314vnrx:StockOptionSevenMember2024-01-012024-06-300000093314vnrx:StockOptionSixMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanTwentyMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanNineteenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanSeventeenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanSixteenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanFifteenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanFourteenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanThirteenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanTwelveMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanElevenMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanTenMember2024-01-012024-06-300000093314vnrx:RSUsCancelledPlanEighteenMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanNineMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanEightMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanSevenMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanSixMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanFiveMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanFourMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanThreeMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanTwoMember2024-01-012024-06-300000093314vnrx:RSUCancelledPlanOneMember2024-01-012024-06-300000093314vnrx:CompensationExpenseThreeMember2024-01-012024-06-300000093314vnrx:CompensationExpenseTwoMember2024-01-012024-06-300000093314vnrx:CompensationExpenseOneMember2024-01-012024-06-300000093314vnrx:StockOptionsMember2024-01-012024-06-300000093314vnrx:StockOptionsMember2024-06-300000093314vnrx:TotalStockOptionOneMember2024-01-012024-06-300000093314vnrx:OptionSevenMember2024-01-012024-06-300000093314vnrx:OptionSixMember2024-01-012024-06-300000093314vnrx:OptionFiveMember2024-01-012024-06-300000093314vnrx:OptionFourMember2024-01-012024-06-300000093314vnrx:StockOptionThreeMember2024-01-012024-06-300000093314vnrx:OptionTwoMember2024-01-012024-06-300000093314vnrx:OptionsOneMember2024-01-012024-06-300000093314vnrx:TotalStockOptionOneMember2024-06-300000093314vnrx:OptionSevenMember2024-06-300000093314vnrx:OptionSixMember2024-06-300000093314vnrx:OptionFiveMember2024-06-300000093314vnrx:OptionFourMember2024-06-300000093314vnrx:StockOptionThreeMember2024-06-300000093314vnrx:OptionTwoMember2024-06-300000093314vnrx:OptionsOneMember2024-06-300000093314us-gaap:OptionMember2024-01-012024-06-300000093314vnrx:WarrantsFiveMember2024-01-012024-06-300000093314vnrx:WarrantsFourMember2024-01-012024-06-300000093314vnrx:WarrantThreeMember2024-01-012024-06-300000093314vnrx:WarrantTwoMember2024-01-012024-06-300000093314vnrx:WarrantOneMember2024-01-012024-06-300000093314vnrx:WarrantsFiveMember2024-06-300000093314vnrx:WarrantsFourMember2024-06-300000093314vnrx:WarrantThreeMember2024-06-300000093314vnrx:WarrantTwoMember2024-06-300000093314vnrx:WarrantOneMember2024-06-300000093314vnrx:WarrantsMember2024-01-012024-06-300000093314vnrx:TwentyTwentyTwoEDAMember2024-01-012024-06-300000093314vnrx:EquityDistributionAgreementMember2022-05-012022-05-200000093314vnrx:EquityDistributionAgreementMember2024-01-012024-06-300000093314vnrx:EpiCypherLicenseAgreementMember2024-03-120000093314vnrx:EpiCypherLicenseAgreementMember2024-03-012024-03-120000093314vnrx:TwoThousandFifteenPlanMember2024-04-012024-04-160000093314vnrx:UnderwritingAgreementMember2023-06-300000093314vnrx:UnderwritingAgreementMember2023-06-012023-06-300000093314vnrx:UnderwritingAgreementMember2024-01-012024-06-300000093314vnrx:UnderwritingAgreementMember2023-01-012023-12-31000009331420 23-01-012023-12-310000093314vnrx:EquityIncentivePlanSevenMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanThreeMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanSixMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanFiveMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanFourMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanTwoMember2024-01-012024-06-300000093314vnrx:EquityIncentivePlanOneMember2024-01-012024-06-300000093314srt:MaximumMembervnrx:PatentsAndIntellectualPropertyMember2024-01-012024-06-300000093314srt:MinimumMembervnrx:PatentsAndIntellectualPropertyMember2024-01-012024-06-300000093314vnrx:LicensesMember2023-12-310000093314vnrx:LicensesMember2024-06-300000093314us-gaap:PatentsMember2023-12-310000093314us-gaap:PatentsMember2024-06-300000093314srt:MaximumMemberus-gaap:BuildingImprovementsMember2024-01-012024-06-300000093314srt:MinimumMemberus-gaap:BuildingImprovementsMember2024-01-012024-06-300000093314us-gaap:BuildingMember2024-01-012024-06-300000093314us-gaap:BuildingMember2024-01-012024-06-300000093314us-gaap:OfficeEquipmentMember2024-01-012024-06-300000093314vnrx:LaboratoryEquipmentMember2024-01-012024-06-300000093314us-gaap:ComputerEquipmentMember2024-01-012024-06-300000093314vnrx:LandsMember2023-12-310000093314vnrx:LandsMember2024-06-300000093314us-gaap:BuildingImprovementsMember2023-12-310000093314us-gaap:BuildingImprovementsMember2024-06-300000093314us-gaap:BuildingMember2023-12-310000093314us-gaap:BuildingMember2024-06-300000093314us-gaap:OfficeEquipmentMember2023-12-310000093314us-gaap:OfficeEquipmentMember2024-06-300000093314vnrx:LaboratoryEquipmentMember2023-12-310000093314vnrx:LaboratoryEquipmentMember2024-06-300000093314us-gaap:ComputerEquipmentMember2023-12-310000093314us-gaap:ComputerEquipmentMember2024-06-300000093314vnrx:LiquidityAndGoingConcernAssessmentMember2024-01-012024-06-300000093314vnrx:LiquidityAndGoingConcernAssessmentMember2024-06-300000093314us-gaap:FairValueInputsLevel3Member2024-06-300000093314us-gaap:FairValueInputsLevel2Member2024-06-300000093314us-gaap:FairValueInputsLevel1Member2024-06-300000093314us-gaap:NoncontrollingInterestMember2024-06-300000093314us-gaap:RetainedEarningsMember2024-06-300000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000093314us-gaap:AdditionalPaidInCapitalMember2024-06-300000093314us-gaap:CommonStockMember2024-06-300000093314us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000093314us-gaap:RetainedEarningsMember2024-04-012024-06-300000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000093314us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000093314us-gaap:CommonStockMember2024-04-012024-06-300000093142024-03-310000093314us-gaap:NoncontrollingInterestMember2024-03-310000093314us-gaap:RetainedEarningsMember2024-03-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000093314us-gaap:AdditionalPaidInCapitalMember2024-03-310000093314us-gaap:CommonStockMember2024-03-3100009331420 24-01-012024-03-310000093314us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000093314us-gaap:RetainedEarningsMember2024-01-012024-03-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000093314us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000093314us-gaap:CommonStockMember2024-01-012024-03-310000093314us-gaap:NoncontrollingInterestMember2023-12-310000093314us-gaap:RetainedEarningsMember2023-12-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000093314us-gaap:AdditionalPaidInCapitalMember2023-12-310000093314us-gaap:CommonStockMember2023-12-3100009331420 23-06-300000093314us-gaap:NoncontrollingInterestMember2023-06-300000093314us-gaap:RetainedEarningsMember2023-06-300000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000093314us-gaap:AdditionalPaidInCapitalMember2023-06-300000093314us-gaap:CommonStockMember2023-06-300000093314us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000093314us-gaap:RetainedEarningsMember2023-04-012023-06-300000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000093314us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000093314us-gaap:CommonStockMember2023-04-012023-06-3000000933142023-03-310000093314us-gaap:NoncontrollingInterestMember2023-03-310000093314us-gaap:RetainedEarningsMember2023-03-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000093314us-gaap:AdditionalPaidInCapitalMember2023-03-310000093314us-gaap:CommonStockMember2023-03-3100009331420 23-01-012023-03-310000093314us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000093314us-gaap:RetainedEarningsMember2023-01-012023-03-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000093314us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000093314us-gaap:CommonStockMember2023-01-012023-03-3100009331420 22-12-310000093314us-gaap:NoncontrollingInterestMember2022-12-310000093314us-gaap:RetainedEarningsMember2022-12-310000093314us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000093314us-gaap:AdditionalPaidInCapitalMember2022-12-310000093314us-gaap:CommonStockMember2022-12-3100009331420 23-04-012023-06-3000000933142024-04-012024-06-3000000933142023-12-3100009331420 24-06-3000000933142024-08-13iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureÂ UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FORM 10-QÂ â˜ÂÂ Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Â For the quarterly period ended June 30, 2024Â â˜ÂÂ Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Â For the transition period from to Â Commission File Number: 001-36833Â VolitionRx Limited(Exact name of registrant as specified in its charter)Â DelawareÂ 91-1949078(State or other jurisdiction of incorporation or organization)Â (I.R.S. Employer Identification No.)Â Â Â 1489 West Warm Springs Road, Suite 110Â Henderson, NevadaÂ 89014(Address of principal executive offices)Â (Zip Code)Â +1 (646) 650â€“1351(Registrantâ€™s telephone number, including area code)Â N/A(Former name, former address and former fiscal year, if changed since last report)Â Securities registered pursuant to Section 12(b) of the Act:Â Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock, par value $0.001 per shareVNRXNYSE American, LLCÂ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. â˜´ Yes â˜ NoÂ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜´ Yes â˜ NoÂ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting

company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Â Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Â Â Emerging growth companyâ˜Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). â˜ Yes â˜‘ NoÂ As of August 13, 2024, there were 92,101,479 shares of the registrantâ€™s $0.001 par value common stock issued and outstanding.Â Â Â Â VOLITIONRX LIMITEDÂ QUARTERLY REPORT ON FORM 10-QFOR THE SIX MONTHS ENDED JUNE 30, 2024Â TABLE OF CONTENTSÂ Â Â PAGEPART IFINANCIAL INFORMATIONÂ Â Â Â Item 1.FINANCIAL STATEMENTS (UNAUDITED)4Â Â Â Item 2.MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS29Â Â Â Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK36Â Â Â Item 4.CONTROLS AND PROCEDURES36Â Â Â PART IIOTHER INFORMATIONÂ Â Â Â Item 1.LEGAL PROCEEDINGS38Â Â Â Item 1A.RISK FACTORS38Â Â Â Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS38Â Â Â Item 3.DEFAULTS UPON SENIOR SECURITIES38Â Â Â Item 4.MINE SAFETY DISCLOSURES38Â Â Â Item 5.OTHER INFORMATION38Â Â Â Item 6.EXHIBITS39Â Â Â SIGNATURESÂ 40Â Â 2Table of ContentsÂ Use of Terms Â Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the â€œCompany,â€ â€œVolitionRx,â€ â€œVolition,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global Services SRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and its majority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to â€œ$â€ refer to the legal currency of the United States of America. Â NucleosomicsTM,, Capture-PCRTM. Nu.QÂ® and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of their respective owners.Â CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTSÂ This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, or this Report, contains forward-looking statements within the meaning of SectionÂ 27A of the Securities Act of 1933, as amended, or the Securities Act, and SectionÂ 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, statements regarding predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; clinical studies and results; industry trends; anticipated demand for our products, or the products of our competitors; manufacturing forecasts, and the potential impact of our relationship with contract manufacturers and original equipment manufacturers on our business; the commercialization of our products and the relationships and anticipated outcome of our engagements with our licensors; the future cost and potential benefits of our research and development efforts; forecasts of our liquidity position or available cash resources; our anticipated use of our cash reserves; the impact of pending litigation; and statements relating to the assumptions underlying any of the foregoing. Throughout this Report, we have attempted to identify forward-looking statements by using words such as â€œmay,â€ â€œbelieve,â€ â€œwill,â€ â€œcould,â€ â€œproject,â€ â€œanticipate,â€ â€œexpect,â€ â€œestimate,â€ â€œshould,â€ â€œcontinue,â€ â€œpotential,â€ â€œplan,â€ â€œforecasts,â€ â€œgoal,â€ â€œseek,â€ â€œintend,â€ other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).Â We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report.Â Some significant factors that may impact our estimates and forward-looking statements include, but are not limited to:Â Â·Our inability to generate any significant revenues or achieve profitability;Â·Our need to raise additional capital in the future;Â·Our expansion of our product development and sales and marketing capabilities could give rise to difficulties in managing our growth;Â·Our dependence on third-party distributors;Â·Our limited experience with sales and marketing;Â·The possibility that we may not be able to continue to operate, as indicated by the â€œgoing concernâ€ opinion from our auditors;Â·Our ability to successfully develop, manufacture, market, and sell our future products;Â·Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future products;Â·The acceptance by the marketplace of our future products;Â·The highly competitive and rapidly changing nature of the diagnostics market;Â·Protection of our patents, intellectual property and trade secrets;Â·Our reliance on third parties to manufacture and supply our intended products, and such manufacturersâ€™ dependence on third-party suppliers;Â·Pressures related to macroeconomic and geopolitical conditions;Â·The material weaknesses in our internal control over financial reporting that we have identified; andÂ·Other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission or (the â€œSECâ€).Â In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in the sections entitled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and â€œRisk Factorsâ€ within this Report, as well as in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on March 25, 2024, Â or our Annual Report, in the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. Except as required by law or the listing rules of the NYSE American Market, we expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections. We qualify all of our forward-looking statements with these cautionary statements.Â Â 3Table of ContentsÂ PART IÂ FINANCIAL INFORMATIONÂ ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)Â Â PageÂ Â Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Operations and Comprehensive Loss6Condensed Consolidated Statements of Stockholdersâ€™ Deficit7Condensed Consolidated Statements of Cash Flows9Notes to the Condensed Consolidated Financial Statements10Â Â 4Table of ContentsÂ VOLITIONRX LIMITED Condensed Consolidated Balance Sheets(Expressed in United States Dollars, except share numbers)Â Â Â June 30, Â Â December 31,Â Â Â 2024Â Â 2023Â Â Â $Â Â $ Â ASSETSÂ (UNAUDITED)Â Â Â Current AssetsÂ Â Â Â Â Â Cash and cash equivalentsÂ Â 5,998,928Â Â Â 20,729,983Â Accounts receivableÂ Â 166,262Â Â Â 242,617Â Prepaid expensesÂ Â 828,965Â Â Â 521,370Â Other current assetsÂ Â 350,927Â Â Â 360,125Â Total Current AssetsÂ Â 7,345,082Â Â Â 21,854,095Â Â Â Â Â Â Â Â Â Â Property and equipment, netÂ Â 4,878,417Â Â Â 5,523,013Â Operating lease right-of-use assetsÂ Â 512,317Â Â Â 549,504Â Intangible assets, netÂ Â 332,221Â Â Â 23,886Â Total AssetsÂ Â 13,068,037Â Â Â 27,950,498Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' DEFICITÂ Â Â Â Â Â Â Â Â Â Current LiabilitiesÂ Â Â Â Â Â Â Â Accounts payableÂ Â 3,348,322Â Â Â 3,211,287Â Accrued liabilitiesÂ Â 3,227,595Â Â Â 3,928,761Â Deferred revenueÂ Â 22,938,400Â Â Â 23,000,000Â Management and directorsâ€™ fees payableÂ Â 25,073Â Â Â 59,625Â Current portion of long-term debtÂ Â 1,043,142Â Â Â 1,207,007Â Current portion of finance lease liabilitiesÂ Â 47,718Â Â Â 48,570Â Current portion of operating lease liabilitiesÂ Â 190,099Â Â Â 199,323Â Current portion of grant repayableÂ Â 54,168Â Â Â 55,855Â Warrant liabilityÂ Â 101,097Â Â Â 126,649Â Total Current LiabilitiesÂ Â 30,975,614Â Â Â 31,837,077Â Â Â Â Â Â Â Â Â Â Long-term debt, net of current portionÂ Â 3,865,357Â Â Â 3,624,860Â Finance lease liabilities, net of current portionÂ Â 363,927Â Â Â 400,022Â Operating lease liabilities, net of current portionÂ Â 350,810Â Â Â 378,054Â Grant repayable, net of current portionÂ Â 409,940Â Â Â 422,707Â Total Long-Term Liabilities Â Â 4,990,034Â Â Â 4,825,643Â Total LiabilitiesÂ Â 35,965,648Â Â Â 36,662,720Â Â Â Â Â Â Â Â Â Â Stockholders' DeficitÂ Â Â Â Â Â Â Common StockÂ Â Â Â Â Â Â Authorized: 100,000,000 shares of common stock, at $0.001 par value per shareÂ Â Â Â Â Â Â Issued and outstanding: 82,928,314 shares and 81,898,321 shares, respectivelyÂ Â 82,928Â Â Â 81,898Â Additional paid-in capitalÂ Â 195,755,863Â Â Â 194,448,414Â Accumulated other comprehensive incomeÂ Â 282,252Â Â Â 243,940Â Accumulated deficitÂ Â (217,929,441)Â Â (202,576,507)Total VolitionRx Limited Stockholders' DeficitÂ Â (21,808,398)Â Â (7,802,255)Non-controlling interest Â Â (1,089,213)Â Â (909,967)Total Stockholdersâ€™ DeficitÂ Â (22,897,611)Â Â (8,712,222)Â Â Â Â Â Â Â Â Â Â Total Liabilities and Stockholdersâ€™ DeficitÂ Â 13,068,037Â Â Â 27,950,498Â Â Â Â Â Â Â Â Â Â (The accompanying notes are an integral part of these condensed consolidated financial statements)Â Â 5Table of ContentsÂ VOLITIONRX LIMITED Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Expressed in United States Dollars, except share numbers)Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Â $Â Â Â $Â Â Â $Â Â Â $Â Â RevenuesÂ Â Â Â Â Â Â Â Â Â ServicesÂ Â 116,090Â Â Â 50,163Â Â Â 155,866Â Â Â 55,519Â ProductÂ Â 279,707Â Â RevenuesÂ Â 395,797Â Â Â 216,310Â Â Â 567,332Â Â Â 366,118Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating ExpensesÂ Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â 3,715,797Â Â Â 5,451,287Â Â Â 8,345,324Â Â Â 10,356,965Â General and administrativeÂ Â 2,284,041Â Â Â 2,644,957Â Â Â 4,537,784Â Â Â 5,226,660Â Sales and marketingÂ Â 1,386,378Â Â Â 1,669,102Â Â Â 3,059,147Â Â Â 3,376,559Â Total Operating ExpensesÂ Â 7,386,216Â Â Â 9,765,346Â Â Â 15,942,255Â Â Â 18,960,184Â Operating LossÂ Â (6,990,419)Â Â (9,549,036)Â Â (15,374,923)Â Â (18,594,066)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Income (Expenses)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Grant incomeÂ Â -Â Â Â -Â Â Â -Â Â Â 165,795Â Loss on disposal of fixed assetsÂ Â (33,498)Â Â -Â Â Â (33,498)Â Â -Â Interest incomeÂ Â 450Â Â Â 27,109Â Â Â 9,104Â Â Â 84,757Â Interest expenseÂ Â (81,182)Â Â (58,321)Â Â (158,415)Â Â (109,643)Gain on change in fair value of warrant liabilityÂ Â 44,474Â Â Â 28,971Â Â Â 25,552Â Â Â 28,971Â Total Other Income (Expenses)Â Â (69,756)Â Â (2,241)Â Â (157,257)Â Â 169,880Â Net LossÂ Â (7,060,175)Â Â (9,551,277)Â Â (15,532,180)Â Â (18,424,186)Net Loss Attributable to Non-Controlling InterestÂ Â 74,629Â Â Â 80,298Â Â Â 179,246Â Â Â 173,659Â Net Loss Attributable to VolitionRx Limited StockholdersÂ Â (6,985,546)Â Â (9,470,979)Â Â (15,352,934)Â Â (18,250,527)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Comprehensive Income (Loss)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustmentsÂ Â 23,286Â Â Â 37,712Â Â Â 38,312Â Â Â (18,766)Net Comprehensive LossÂ Â (7,036,889)Â Â (9,513,565)Â Â (15,493,868)Â Â (18,442,952)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Loss Per Share â€“ Basic and Diluted Attributable to VolitionRx Limited Â Â (0.08)Â Â (0.14)Â Â (0.19)Â Â (0.29)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted Average Shares OutstandingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€“ Basic and DilutedÂ Â 82,669,335Â Â Â 66,884,368Â Â Â 82,312,161Â Â Â 63,613,224Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (The accompanying notes are an integral part of these condensed consolidated financial statements)Â Â 6Table of ContentsÂ VOLITIONRX LIMITED Condensed Consolidated Statements of Stockholdersâ€™ Deficit (Unaudited)(Expressed in United States Dollars, except share numbers)Â Â For the Six Months Ended June 30, 2024 and June 30, 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â (31,772)Proceeds from long-term debt Â Â 754,457Â Â Â 216,908Â Payments on long-term debtÂ Â (530,732)Â Â (475,965)Payments on finance lease obligationsÂ Â (23,643)Â Â (23,188)Net CashÂ Provided By Financing ActivitiesÂ Â 764,037Â Â Â 25,486,973Â Effect of foreign exchange on cashÂ Â (181,448)Â Â (16,439)Net change in cash and cash equivalentsÂ Â (14,731,055)Â Â 8,876,224Â Cash and cash equivalents â€“ beginning of the periodÂ Â 20,729,983Â Â Â 10,867,050Â Cash and cash equivalents â€“ End of PeriodÂ Â 5,998,928Â Â Â 19,743,274Â Â Â Â Â Â Â Â Â Â Â Supplemental Disclosures of Cash Flow InformationÂ Â Â Â Â Â Â Â Interest paidÂ Â 158,415Â Â Â 109,643Â Non-Cash Financing ActivitiesÂ Â Â Â Â Â Â Â Common stock issued upon cashless exercises of stock options and settlement of vested RSUsÂ Â 282Â Â Â 102Â Offering costs from issuance of common stockÂ Â -Â Â Â 239,772Â Fair value of warrants issued in connection with public offeringÂ Â -Â Â Â 366,960Â Common stock issued for License rightsÂ Â 125,258Â Â Â -Â Non-cash note payableÂ Â 294,603Â Â Â 356,258Â Â Â Â Â Â Â Â Â Â (The accompanying notes are an integral part of these condensed consolidated financial statements)Â Â 9Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 1 â€“ Basis of Presentation and Summary of Significant Accounting Policies Â Basis of PresentationÂ The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the â€œCompanyâ€ or â€œVolitionRxâ€) have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the â€œAnnual Reportâ€). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.Â ReclassificationsÂ Certain reclassifications within operating expenses have been made to the prior periodâ€™s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented.Â Recently Issued Accounting PronouncementsÂ In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements.Â Â 10Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)Â Fair Value MeasurementsÂ Pursuant to ASC 820, â€œFair Value Measurements and Disclosures,â€ an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrumentâ€™s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:Â Level 1Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.Â Level 2Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.Â Level 3Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.Â The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period.Â Included in the following table are the Companyâ€™s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024.Â Fair Value Measurements at June 30, 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â DescriptionÂ Level 1Â Â Level 2Â Â Level 3Â Â TotalÂ Â Â Â $Â Â Â $Â Â Â $Â Â Â $Â LiabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilityÂ Â -Â Â Â 101,097Â Â Â -Â Â Â 101,097Â Â Â 11Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued) Â As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows:Â Warrant LiabilityÂ Â Â Â TotalÂ Â Â $Â Balance at December 31, 2023Â Â 126,649Â Gain on change in fair value of warrant liabilityÂ Â (25,552)Balance at June 30, 2024Â Â 101,097Â Â Basic and Diluted Net Loss Per ShareÂ The Company computes net loss per share in accordance with ASC 260, â€œEarnings Per Share,â€ which requires presentation of both basic and diluted earnings per share (â€œEPSâ€) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, 2024, 9,297,073 potential common shares equivalents from warrants, options, and restricted stock units (â€œRSUsâ€) were excluded from the diluted EPS calculations as their effect is anti-dilutive.Â Â 12Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 2 â€“ Liquidity and Going Concern Assessment Â The Company's condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Companyâ€™s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the â€œlook-forward period,â€ as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors.Â For the six months ended June 30, 2024, the Company incurred a net loss of $15.5 million and used cash flows in operating activities of $15.1 million. As of June 30, 2024, the Company had cash and cash equivalents of $6.0 million and an accumulated deficit of $217.9 million.Â The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Companyâ€™s cash conservation efforts, directors and certain employees have elected to exchange a portion of their salary for RSUs in the Company for a period of up to six months.Â The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations.Â Management assessed the mitigating effect of its plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Companyâ€™s ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Companyâ€™s plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. The Company concluded that these plans do not alleviate the substantial doubt about the Companyâ€™s ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.Â The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.Â Â 13Table of ContentsÂ Â VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Â Note 3 - Property and Equipment Â The Companyâ€™s property and equipment consisted of the following amounts as of June 30, 2024 and December 31, 2023:Â Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Â Useful LifeÂ Cost $Â Â Cost $Â Computer hardware and softwareÂ 3 yearsÂ Â 723,206Â Â Â 724,534Â Laboratory equipmentÂ 5 yearsÂ Â 4,630,385Â Â Â 4,753,253Â Office furniture and equipmentÂ 5 yearsÂ Â 370,493Â Â Â 378,800Â BuildingsÂ 30 yearsÂ Â 2,049,211Â Â Â 2,113,031Â Building improvementsÂ 5-15 yearsÂ Â 1,574,428Â Â Â 1,610,016Â LandÂ Not amortizedÂ Â 128,467Â Â Â 132,468Â Total property and equipmentÂ Â Â Â 9,476,190Â Â Â 9,712,102Â Less accumulated depreciationÂ Â Â Â 4,597,773Â Â Â 4,189,089Â Total property and equipment netÂ Â Â Â 4,878,417Â Â Â 5,523,013Â Â During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $545,128 and $517,921, respectively, in depreciation expense.Â Â 14Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 4 - Intangible Assets Â The Companyâ€™s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assetsâ€™ estimated useful lives, which range from 8 to 20 years.Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Cost $Â Â Cost $Â PatentsÂ Â 1,098,717Â Â Â 1,130,936Â LicensesÂ Â 296,353Â Â Â -Â Total Patents and LicensesÂ Â 1,395,070Â Â Â 1,130,936Â Less accumulated amortizationÂ Â 1,062,849Â Â Â 1,107,050Â Total patents and Licenses, netÂ Â 332,221Â Â Â 23,886Â Â During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $(12,624) and $42,392, respectively, in amortization expense.Â The Company amortizes the patents and licenses on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:Â 2024Â $16,057Â 2025Â $20,448Â 2026Â $20,448Â 2027Â $20,448Â 2028Â $20,448Â Greater than 5 yearsÂ $234,372Â Total Intangible AssetsÂ $332,221Â Â The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 â€œProperty, Plant and Equipment,â€ as of December 31, 2023. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2023.Â Note 5 - Related-Party TransactionsÂ See Note 6, Common Stock, for common stock issued to related parties and Note 7, Stock-Based Compensation, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of consultancy services which are accrued under management and directorsâ€™ fees payable (see condensed consolidated balance sheets). Â Â 15Table of ContentsÂ Â VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 6 - Common Stock Â As of June 30, 2024, the Company was authorized to issue 100 million shares of common stock, par value $0.001 per share, of which 82,928,314 and 81,898,321 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. Â Stock Option Exercises Â During the six months ended June 30, 2024, no shares of common stock were issued pursuant to the exercise of stock options.Â Stock Options Expired / CancelledÂ On April 16, 2024, 36,821 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Plan on the expiration of the exercise period following the resignation of such employee.Â RSU SettlementsÂ Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â Â 153,356Â Â Â 48,905Â Â Warrants Issued in Equity Capital RaiseÂ In connection with the June 2023 underwritten public offering of the Companyâ€™s common stock pursuant to the underwriting agreement with Prime Executions, Inc. dba Freedom Capital Markets (â€œFreedomâ€) dated June 1, 2023, the Company issued Freedom warrants to purchase an aggregate of 448,500 shares of Company common stock at an exercise price of $2.00 per share. The Company evaluated the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815-40. The Company determined the warrants issued to Freedom failed the indexation guidance under ASC 815-40, specifically, the warrants provide for a Black-Scholes value calculation in the event of certain transactions (â€œFundamental Transactionsâ€), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Companyâ€™s own equity shares. Accordingly, pursuant to ASC 815-40, the Company has classified the fair value of the warrants as a liability upon issuance and marked to market each reporting period in the Companyâ€™s consolidated statement of operations until their exercise or expiration.Â Â 16Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Â Note 6 - Common Stock (continued) Â Warrants Issued in Equity Capital Raise (continued)Â The fair value of the warrants as of June 30, 2024, and December 31, 2023, were $101,097 and $126,649 respectively. The warrant liability was estimated using the Black-Scholes pricing model with the following assumptions.Â Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Â Â Â Â Â Risk-free interest rateÂ Â 4.43%Â Â 3.89%Expected volatilityÂ Â 82.80%Â Â 76.30%Expected life (years)Â Â 3.94Â Â Â 4.44Â Expected dividend yieldÂ Â -Â Â Â -Â Total fair valueÂ $101,097Â Â $126,649Â Â The fair value of the warrants deemed to be a liability, due to certain contingent put features, was determined using the Black-Scholes option pricing model, which was deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.Â Common Stock Issued for EpiCypher License AgreementÂ On March 12, 2024, the Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. at a price of $0.97 per share as partial consideration for license rights in connection with a License Agreement between EpiCypher and Belgian Volition.Â Equity Distribution AgreementÂ On May 20, 2022, the Company entered into an equity distribution agreement (the â€œ2022 EDAâ€) with Jefferies LLC (â€œJefferiesâ€) to sell shares of the Companyâ€™s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an â€œat the marketâ€ offering pursuant to the Companyâ€™s Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021) (the â€œ2021 Form S-3â€) through Jefferies acting as the Companyâ€™s agent and/or principal.Â The Company is not obligated to sell any shares under the 2022 EDA.Â Â During the six months ended June 30, 2024, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $605,221 under the 2022 EDA through the sale of 747,505 shares of its common stock. As of June 30, 2024, the Company has raised aggregate net proceeds (net of broker commissions and fees) of approximately $2.1 million under

the 2022 EDA through the sale of 1,378,037 shares of its common stock.Â Â 17Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 7 â€“ Stock-Based Compensation Â a) WarrantsÂ The following table summarizes the changes in warrants of the Company outstanding during the six-month period ended June 30, 2024.Â Â Â Number of WarrantsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 862,500Â Â Â 3.05Â GrantedÂ Â -Â Â Â -Â Expired/CancelledÂ Â -Â Â Â -Â Outstanding at June 30, 2024Â Â 862,500Â Â Â 3.05Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 862,500Â Â Â 3.05Â Â Below is a table summarizing the warrants issued and outstanding as of June 30, 2024, which have an aggregate weighted average remaining contractual life of 3.33 years.Â Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised
($)Â 448,500Â Â Â 448,500Â Â Â 2.00Â Â Â 3.96Â Â Â 897,000Â 54,000Â Â Â 54,000Â Â Â 3.05Â Â Â 4.26Â Â Â 164,700Â 50,000Â Â Â 50,000Â Â Â 3.45Â Â Â 1.67Â Â Â 172,500Â 125,000Â Â Â 12 based compensation expense related to warrants of $5,238 and $20,320 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of June 30, 2024, the total intrinsic value of warrants outstanding was $nil.Â b) OptionsÂ The following table summarizes the changes in options outstanding of the Company during the six-month period ended June 30, 2024.Â Â Â Number ofÂ OptionsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 4,699,569Â Â Â 3.87Â Expired/CancelledÂ Â (36,821)Â Â 3.40Â Outstanding at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â Â Â 18Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 7 â€“ Stock-Based Compensation (continued)Â b) Options (continued)Â Below is a table summarizing the options issued and outstanding as of June 30, 2024, all of which were issued pursuant to the Companyâ€™s 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (the â€œ2015 Planâ€) (for option and RSU issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 3.71 years. As of June 30, 2024, an aggregate of 9,700,000 shares of common stock were authorized for issuance under the 2015 Plan, of which 354,782 shares of common stock remained available for future issuance thereunder.Â Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised
($)Â 585,000Â Â Â 585,000Â Â Â 3.25Â Â Â 0.62Â Â Â 1,901,250Â 944,748Â Â Â 944,748Â Â Â 3.40Â Â Â 7.10Â Â Â 3,212,143Â 740,000Â Â Â 740,000Â Â Â 3.60Â Â Â 5.86Â Â Â 2,664,000Â 1,607 based compensation expense related to stock options of $nil and $235,368 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of June 30, 2024, the total intrinsic value of stock options outstanding was $nil.Â c) Restricted Stock UnitsÂ Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Â Â RSUs (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Outstanding at December 31, 2023Â Â 3,634,952Â Â Â 1.01Â GrantedÂ Â 426,340Â Â Â 0.72Â Vested/SettledÂ Â (202,261)Â Â 2.46Â Cancelled / ForfeitedÂ Â (87,206)Â Â 1.13Â Outstanding at June 30, 2024Â Â 3,771,825Â Â Â 0.89Â Â Â 19Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 7 â€“ Stock-Based Compensation (continued)Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs granted during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipientâ€™s continued service to the Company, and will result in the RSU compensation expense stated. On June 1, 2024, the Company granted 297,340 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on May 1, 2025, subject to continued service by the recipient.Â EquityÂ IncentiveÂ PlanÂ RSUs Granted (#)Â Â Grant DateÂ Vesting PeriodÂ First Vesting DateÂ Second Vesting DateÂ Â Third Vesting DateÂ Â RSU Expense ($)Â 2015Â Â 14,000Â Â Â Feb 22, 2024Â 36 MonthsÂ Â Feb 22, 2025Â Â Feb 22, 2026Â Â Â Feb 22, 2027Â Â Â 13,589Â 2015Â Â 115,000Â Â Â May 23, 2024Â 36 MonthsÂ Â May 23, 2025Â Â May 23, 2026Â Â Â May 23, 2027Â Â Â 85,389Â 2015Â Â 297,340Â Â Â Jun 1, 2024Â 11 MonthsÂ Â May 1, 2025Â Â N/AÂ Â Â N/AÂ Â Â 209,832Â Â Â Â 426,340Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 308,810Â Â Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â Â Â 153,356Â Â Â 48,905Â Â Â 20Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 7 â€“ Stock-Based Compensation (continued)Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs cancelled during the six months ended June 30, 2024, all of which were originally issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs (#)Â Â Cancellation DateÂ Vesting DateÂ RSUs Cancelled (#)Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2024Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2024Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2025Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2025Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2026Â Â 8,000Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2024Â Â 667Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2025Â Â 667Â 2015Â Â 666Â Â Â Feb 9, 2024Â Â Jun 15, 2026Â Â 666Â 2015Â Â 1,775Â Â Â Mar 25, 2024Â Â Mar 27, 2024Â Â 1,775Â 2015Â Â 2,098Â Â Â Mar 25, 2024Â Â Jun 15, 2024Â Â 2,098Â 2015Â Â 2,667Â Â Â May 17, 2024Â Â Oct 4, 2024Â Â 2,667Â 2015Â Â 2,666Â Â Â May 17, 2024Â Â Oct 4, 2025Â Â 2,666Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2025Â Â 1,000Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2026Â Â 1,000Â 2015Â Â 3,334Â Â Â May 17, 2024Â Â Sep 28, 2024Â Â 3,334Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2025Â Â 3,333Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2026Â Â 3,333Â 2015Â Â 9,334Â Â Â May 31, 2024Â Â Sep 11, 2024Â Â 9,334Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2025Â Â 9,333Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2026Â Â 9,333Â Â Â Â 87,206Â Â Â Â Â Â Â 87,206Â Â Â 21Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 7 â€“ Stock-Based Compensation (continued)Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024 and which have an aggregate weighted average remaining contractual life of 1.37 years.Â RSUs Outstanding (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Â Weighted Average Remaining Contractual Life
(Years)Â 40,000Â Â Â 0.58Â Â Â 1.37Â 450,000Â Â Â 0.68Â Â Â 2.80Â 450,000Â Â Â 0.69Â Â Â 1.76Â 1,535,000Â Â Â 0.70Â Â Â 1.25Â 297,340Â Â Â 0.71Â Â Â 0.84Â 115,000Â Â Â 0.74Â Â Â 1.90 based compensation expense related to RSUs of $614,028 and $1,030,143 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,256,598.Â Â 22Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 8 â€“ Commitments and ContingenciesÂ a) Finance Lease ObligationsÂ The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2024.Â 2024 - remainingÂ $28,840Â 2025Â $57,672Â 2026Â $57,661Â 2027Â $57,647Â 2028Â $57,633Â Greater than 5 yearsÂ $194,395Â TotalÂ $453,848Â Less: Amount representing interestÂ $(42,203)Present value of minimum lease paymentsÂ $411,645Â Â b) Operating Lease Right-of-Use ObligationsÂ Operating leases as of June 30, 2024, and December 31, 2023, consisted of the following:Â Â Â Â June 30, 2024Â Â Â December 31, 2023Â Â Â Â $Â Â Â $Â Operating leaseÂ right-of-use assetsÂ Â 512,317Â Â Â 549,504Â Â Â Â Â Â Â Â Â Â Operating lease liabilities, current portionÂ Â 190,099Â Â Â 199,323Â Operating lease liabilities, long termÂ Â 350,810Â Â Â 378,054Â Total operating lease liabilitiesÂ Â 540,909Â Â Â 577,377Â Â Â Â Â Â Â Â Â Â Â Weighted average remaining lease (months)Â Â 32Â Â Â 33Â Weighted average discount rateÂ Â 3.24%Â Â 3.02%Â During the six months ended June 30, 2024, cash paid for amounts included for the measurement of lease liabilities was $125,313 and the Company recorded operating lease expense of $126,217.Â Â 23Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Â Â Note 8 â€“ Commitments and ContingenciesÂ b) Operating Lease Right-of-Use Obligations (continued)Â The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, 2024.Â For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 117,231Â 2025Â Â 191,273Â 2026Â Â 164,435Â 2027Â Â 92,151Â 2028Â Â 10,212Â TotalÂ Â 575,302Â Less: imputed interestÂ Â (34,393)Total Operating Lease LiabilitiesÂ Â 540,909Â Â The Companyâ€™s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2024, the Company recognized $40,334 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:Â For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 42,723Â 2025Â Â 7,198Â Total Operating Lease LiabilitiesÂ Â 49,921Â Â c) Grants RepayableÂ As of June 30, 2024, the total grant balance repayable was $464,108 and the payments remaining were as follows:Â For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 54,169Â 2025Â Â 36,305Â 2026Â Â 43,756Â 2027Â Â 48,579Â 2028Â Â 51,951Â Greater than 5 years Â Â 229,348Â Total Grants Repayable Â Â 464,108Â Â Â 24Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 8 â€“ Commitments and Contingencies (continued)Â d) Long-Term DebtÂ As of June 30, 2024, the total balance for long-term debt payable was $4,908,499 and the payments remaining were as follows:Â For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 859,476Â 2025Â Â 1,005,297Â 2026Â Â 781,901Â 2027Â Â 583,641Â 2028Â Â 2,437,212Â Greater than 5 yearsÂ Â 314,022Â TotalÂ Â 5,981,549Â Less: amount representing interestÂ Â (1,073,050)Total Long-Term DebtÂ Â 4,908,499Â Â e) Collaborative Agreement ObligationsÂ In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, 2024, $510,000 is still to be paid by the Company under this agreement.Â In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $449,406. As of June 30, 2024, $449,406 is still to be paid by the Company under this agreement. As of June 30, 2024, $204,087 is due by the Company under this agreement.Â In July 2023, the Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd to evaluate the anti-tumoral effects of Nu.QÂ® CAR T cells for a cost to the Company of $107,589. As of June 30, 2024, $81,447 is still to be paid by the Company under this agreement and as of June 30, 2024, $26,142 is due by the Company under this agreement.Â In August 2023, the Company entered into a project research agreement with Guyâ€™s and St Thomasâ€™ NHS Foundation Trust to evaluate the practical clinical utility of the Nu.QÂ® H3.1 nucleosome levels in adult patients with sepsis to facilitate early diagnosis and prognostication for a cost to the Company of $164,235. As of June 30, 2024, $164,235 is still to be paid by the Company under this agreement. As of June 30, 2024, $nil is due by the Company under this agreement.Â In January 2024, the Company entered into an agreement with the University Medical Centre Amsterdam (â€œUMCâ€). UMC will perform a retrospective study to evaluate the diagnostic potential of the Nu.QÂ® H3.1 nucleosomes as diagnostic, prognostic and phenotyping biomarkers in sepsis for a cost to the Company of $138,653. As of June 30, 2024, $138,653 is still to be paid by the Company under this agreement. As of June 30, 2024, $46,218 is due by the Company under this agreement.Â Â Â 25Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 8 â€“ Commitments and Contingencies (continued)Â e) Collaborative Agreement Obligations (continued)Â As of June 30, 2024, the total amount to be paid for future research and collaboration commitments was $1,343,741 and the payments remaining were as follows:Â Â Â Total Amount RemainingÂ Â 2024 - EstimatedÂ Â 2025 - EstimatedÂ Â Â Â $Â Â Â $Â Â $Â National University of Taiwan Â Â 510,000Â Â Â 510,000Â Â Â -Â MD Anderson Cancer CenterÂ Â 449,406Â Â Â 285,860Â Â Â 163,546Â Guys and St ThomasÂ Â 164,235Â Â Â 61,588Â Â Â 102,647Â Xenetic BiosciencesÂ Â 81,447Â Â Â 26,142Â Â Â 55,305Â UMCÂ Â 138,653Â Â Â 92,343Â Â Â 46,310Â Total Collaborative ObligationsÂ Â Â 1,343,741Â Â Â 975,933Â Â Â 367,808Â Â Â f) Other CommitmentsÂ Volition GermanyÂ As of June 30, 2024, $209 is payable under the royalty agreement with the founder of Volitionâ€™s former German subsidiary based on sales to date towards the Companyâ€™s aggregate minimum royalty obligation of $117,761.Â Volition AmericaÂ Effective February 10, 2024 the Company and Diagnostic Oncology CRO, LLC (â€œDXOCROâ€) further amended and restated the August 2022 amended and restated Master Agreement by and between the Company and DXOCRO to expand the scope of DXOCROâ€™s consultant services provided thereunder (the â€œSecond A&R Master Agreementâ€). The Second A&R Master Agreement requires DXOCRO to conduct a prospective optimization/range finding study of Volitionâ€™s Nu.QÂ®Â H3.1 in vitro diagnostic test proposed for use in sepsis. The study is an extension of the sepsis monitoring clinical trial that was previously covered under a separate exhibit. The Company anticipates DXOCROâ€™s additional services under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million. The Companyâ€™s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 daysâ€™ prior written notice. Unless earlier terminated, the Second A&R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of June 30, 2024, $146,221 is payable under the Second A&R Master Agreement, and up to $363,778 may be payable by the Company in future periods for services rendered. Â VolitionRx Â On February 5, 2024, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024. As of June 30, 2024, the maximum has been drawn down under this agreement and the principal balance payable was $163,668. The agreement is in relation to the directors and officers insurance policy.Â Â 26Table of ContentsÂ VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 8 â€“ Commitments and Contingencies (continued)Â g) Legal ProceedingsÂ In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company knows of no legal proceedings which the Company believes will have a material adverse effect on its financial position.Â h) Commitments in Respect of Corporate Goals and Performance-Based AwardsÂ As of June 30, 2024, the Company has recognized total compensation expense of $1,291,594 of which $527,940 is in relation to RSUs from grants in 2022 that vested in 2023, $451,490 is in relation to RSUs from such grants that will vest in 2024, and $312,164 is in relation to RSUs from such grants that will vest in 2025. The Company has unrecognized compensation expense of $282,823 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.Â Total Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â AmortizedÂ Â Un-AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2022Â Â Â Â $Â Â Â Â Â $ Â Â Â $Â Â Â $ Â Â $Â 527,940Â Â 2023Â Â -Â Â Â 393,853Â Â Â 134,087Â Â Â -
Â 517,613Â Â 2024Â Â 126,283Â Â Â 260,119Â Â Â 65,088Â Â Â 66,123Â 528,864Â Â 2025Â Â 87,894Â Â Â 177,584Â Â Â 46,686Â Â Â 216,700Â 1,574,417Â Â Â Â Â 214,177Â Â Â 831,556Â Â Â 2 September 2023, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around revenue, operations and regulatory, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Pursuant to the terms of the grants, conditional upon the achievement by December 31, 2023 and June 30, 2024 of specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients to the Company, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of June 30, 2024, the Company has accrued compensation expense of $536,535 in relation to cash bonuses payable on the achievement of specified corporate goals based on the expected outcomes related to the prescribed performance targets. To the extent this is payable, this cash bonus compensation payment has currently been deferred indefinitely.Â As of June 30, 2024, the Company had recognized total compensation expense of $335,013. The Company has unrecognized compensation expense of $390,276 in relation to the RSUs from grants in 2023, of which $59,290 is in relation to RSUs that will vest in 2024, $150,277 in relation to RSUs that will vest in 2025, and $180,709 in relation to RSUs that will vest in 2026 based on the outcomes related to the prescribed performance targets on the outstanding awards.Â Total Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â Un-AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2024Â Â Â Â $Â Â Â Â $ Â Â Â $
Â 241,771Â Â 2024Â Â 118,511Â Â Â 63,970Â Â Â 59,290Â 241,764Â Â 2025Â Â 59,416Â Â Â 32,071Â Â Â 150,277Â 241,754Â Â 2026Â Â 39,645Â Â Â 21,400Â Â Â 180,709Â 725,289Â Â Â Â Â 21 of Contents Â VOLITIONRX LIMITEDNotes to the Condensed Consolidated Financial Statements (Unaudited)($ expressed in United States Dollars)Â Note 9 â€“ Subsequent EventsÂ Settlement

of RSUsÂ On July 13, 2024,Â 4,667Â RSUs previously granted to various employees vested and resulted in the issuance ofÂ 3,165Â shares of common stock. 1,502 shares of common stock were withheld for taxes and returned to the 2015 Plan.Â RSUs GrantedÂ Effective July 1, 2024, the Company granted RSUs of 38,198 shares of common stock to an employee of the Company in exchange their valid election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the employee.Â Effective July 8, 2024, the Company granted RSUs of 21,583 shares of common stock to an advisor of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. These RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025, subject to continued service, and will result in total compensation expense of $13,209.Â RSUs CancelledÂ On July 12, 2024, 19,666 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting.Â On August 4, 2024, 46,333 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting.Â Increase in Authorised CapitalÂ At the Annual Meeting on July 2, 2024, the Companyâ€™s stockholders approved a Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation providing for an increase in authorized shares from one hundred million (100,000,000) to one hundred seventy-five million (175,000,000) shares, consisting of one hundred seventy-five million (175,000,000) shares of common stock, par value $0.001 per share. Â Equity Capital RaiseÂ On August 8, 2024, the Company entered into a securities purchase agreement with a purchaser pursuant to which the Company issued and sold to such purchaser, in a registered direct offering under the 2021 Form S-3, an aggregate of 9,170,000 shares of the Companyâ€™s common stock, pre-funded warrants to purchase up to 3,557,273 shares of the Companyâ€™s common stock (the â€œPre-Funded Warrantsâ€), Series A common stock warrants to purchase up to 12,727,273 shares of the Companyâ€™s common stock (the â€œSeries A Warrantsâ€) and Series B common stock warrants to purchase up to 12,727,273 shares of the Companyâ€™s common stock (the â€œSeries B Warrantsâ€ and, together with the Series A Warrants, the â€œCommon Warrantsâ€).Â The exercise prices of the Pre-Funded Warrants and the Common Warrants are $0.001 per share and $0.57 per share, respectively.Â H.C. Wainwright & Co. acted as the exclusive placement agent for the Company in the offering.Â The combined offering price for a share of common stock and accompanying Common Warrants was $0.55 and the combined offering price for a Pre-Funded Warrant and accompanying Common Warrants was $0.549.Â The net proceeds received by the Company for the issuance and sale of the shares of Common Stock, the Pre-Funded Warrants and the Common Warrants (collectively, the â€œSecuritiesâ€) was $6.4 million, before deducting offering expenses of $0.1 million paid by the Company.Â In addition, the Company issued warrants to purchase an aggregate of 381,818 shares of Company common stock to the placement agent, on substantially the same terms as the Series B Warrants at an exercise price of $0.6875 per share.Â The net proceeds above assumes the exercise of the Pre-Funded Warrants but excludes any proceeds arising from the exercise of the Common Warrants or the Placement Agent Warrants.Â END NOTES TO FINANCIALSÂ Â 28Table of ContentsÂ ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSÂ The following discussion and analysis of our financial condition and results of operations should be read together with our Unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in this Report and in our Annual Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. These statements involve numerous risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in the section entitled â€œRisk Factorsâ€ in this Report and in our Annual Report, as well as our other public filings with the SEC. Please refer to the section of this Report entitled â€œCautionary Note Regarding Forward-Looking Statementsâ€ for additional information.Â OverviewÂ Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Companyâ€™s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patientâ€™s response to treatment.Â The tests offered by Volition and its subsidiaries are designed to diagnose and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. Â Our keyÂ pillars of focus are: Â Â Â·Nu.QÂ® Vet - cost-effective, easy-to-use blood tests for dogs and other companion animals. The Nu.QÂ® Vet Cancer Test is commercially available as a cancer screening test in dogs.Â Â·Nu.QÂ® NETs - monitoring the immune system to save lives.Â Â·Nu.QÂ® Discover - a complete solution to profiling nucleosomes.Â Â·Nu.QÂ® Cancer - monitoring disease progression, response to treatment and minimal residual disease.Â Â·Capture-PCRTM - isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection.Â Commercialization StrategyÂ Our commercialization strategy is guided by the following underlying principles ensuring our products:Â Â Â·Result in low capital expenditures for licensors and end users and low operating expenses for Volition,Â Â·Are affordable, andÂ Â·Are accessible worldwide.Â The principles above inform our overall commercialization strategy for our products, which is driven by the following:Â Â Â·Conducting research and development in-house and through our research partners;Â Â·Monetizing our intellectual property (â€œIPâ€) with upfront payments, milestone payments, royalties, and sales of kits and key components; andÂ Â·Commercializing our products via global players and in fragmented markets through regional companies.Â We aim to partner with established diagnostic companies to market, sell, and process our tests, leveraging their networks and expertise.We believe, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, they could potentially be used throughout the world.Â We aim to remain an IP powerhouse in the epigenetic space and expect to monetize our IP and technologies through licensing and distribution contracts with companies that have established distribution networks and expertise on a worldwide or regional basis, in both human and animal care across platforms (centralized labs and point-of-care / in-house diagnostics).Â To this end, on March 28, 2022, Volition entered into a master license and product supply agreement with Heska Corporation (â€œHeskaâ€). In exchange for granting Heska exclusive worldwide rights to sell our Nu.QÂ®Â Vet Cancer Test at the point of care for companion animals, Volition received a $10.0 million upfront payment upon signing, received $13.0 million based upon the achievement of two milestones and is eligible to receive up to an additionalÂ $5.0 million based upon the achievement of a final milestone upon the earlier of the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines, or the nine-month anniversary of the first peer reviewed paper evidencing clinical utility for the screening or monitoring of lymphoma in felines being published in any one of a number of periodicals identified by the parties. In addition, Volition has granted Heska non-exclusive rights to sell the Nu.QÂ®Â Vet Cancer Test as a kit for companion animals through Heskaâ€™s network of central reference laboratories. In June 2023 Heska was acquired by Mars Petcare and became part of its Antech Diagnostics division. In April 2024, Antech announced the launch of the in-clinic version of the Nu.QÂ®Â Canine Cancer test in the US and Europe. In the second quarter of 2024, Volition supplied key components forÂ 40,000 tests to Antech.Â Â 29Table of ContentsÂ In October 2022, we also entered into a licensing and supply agreement with IDEXX Laboratories, Inc. (â€œIDEXXâ€), a global leader in pet healthcare innovation. This contract provides for worldwide customer reach through IDEXXâ€™s global reference laboratory network as we continue to commercialize our transformational Nu.QÂ® technology within the companion animal healthcare sector and capitalize on the significant opportunities available. IDEXX launched the IDEXX Nu.QÂ® Canine Cancer Test in January 2023.Â In November 2023, we launched the Nu.QÂ® Vet Cancer Test in the UK and Ireland through our distributor, the Veterinary Pathology Group, and in the UK through Nationwide Laboratories. In March 2024, Fujifilm Vet Systems announced the launch of the Nu.QÂ® Vet Cancer Test in Japan. In July 2024, VetLab announced the launch of the Nu.QÂ® Vet Cancer Test in Poland.Â Liquidity and Capital ResourcesÂ We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of June 30, 2024, we had cash and cash equivalents of approximately $6.0 million.Â Net cash used in operating activities was $15.1 million for the six months ended June 30, 2024 and $16.1 million for the six months ended June 30, 2023. The decrease in cash used in operating activities for the period ended June 30, 2024 when compared to same period in 2023 can be attributed a reduction in clinical trial expenditure.Â Net cash used in investing activities was $0.2 million and $0.5 million for the six months ended June 30, 2024 and June 30, 2023, respectively. The decrease was mainly due to a reduction in purchases of laboratory equipment, partly offset by increased additions of licenses.Â Net cash provided by financing activities was $0.8 million for the six months ended June 30, 2024 and $25.5 million for the comparable period ended June 30, 2023. The decrease in cash provided by financing activities for the period ended June 30, 2024 when compared to same period in 2023 was primarily due to $17.6 million in net cash received from the issuance of shares of common stock in a registered public offering in June 2023, and $8.0 million in net cash received from the issuance of shares of common stock in a registered public offering in February 2023, as compared to $0.6 million in net cash received from the issuance of shares of common stock under our â€œat-the-marketâ€ facility during the period ended June 30, 2024.Â For additional information on our â€œat the market facility,â€ refer to Note 6, Common Stock â€“Equity Distribution Agreement, of the notes to the condensed consolidated financial statements included within this Report.Â The following table summarizes our approximate contractual payments due by year as of June 30, 2024.Â Approximate Payments (Including Interest) Due by YearÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â TotalÂ Â 2024 - RemainingÂ Â 2025 - 2028Â Â Greater than 5 yearsÂ DescriptionÂ Â $Â Â Â $ Â Â $ Â Â $Â Financing lease liabilitiesÂ Â 453,848Â Â Â 28,840Â Â Â 230,613Â Â Â 194,395Â Operating lease liabilities and short-term leaseÂ Â 625,223Â Â Â 159,954Â Â Â 465,269Â Â Â -Â Grants repayable Â Â 464,108Â Â Â 54,169Â Â Â 180,591Â Â Â 229,348Â Long-term debtÂ Â 5,981,549Â Â Â 859,476Â Â Â 4,808,051Â Â Â 314,022Â Collaborative agreements obligationsÂ Â Â 1,343,741Â Â Â 975,933Â Â Â 367,808Â Â Â - Â TotalÂ Â 8,868,469Â Â Â 2,078,372Â Â Â 6,052,332Â Â Â 737,765Â Â We intend to use our cash reserves to predominantly fund further research and development, and commercialization activities. We do not have any substantial source of revenues and expect to rely on additional future financing, through the sale of licensing or distribution rights, grant funding and the sale of equity or debt securities to provide sufficient funding to execute our strategic plan. There is no assurance that we will be successful in raising further funds.Â In the event additional financing is delayed, we will prioritize the completion of clinical validation studies for the purpose ofÂ the sale of licensing or distribution rights, and the maintenance of our patent rights. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.Â We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors included in their report on our audited financial statements for the year ended December 31, 2023, an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern. Â Â 30Table of ContentsÂ Results of Operations Â Comparison of the Three Months Ended June 30, 2024 and June 30, 2023Â The following table sets forth our results of operations for the three months ended June 30, 2024 and June 30, 2023.Â Â Â Three Months Ended June 30,Â Â Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â ChangeÂ Â Â Â $Â Â Â $ Â Â Â $Â Â Â % Â ServiceÂ Â 116,090Â Â Â 50,163Â Â Â 65,927Â Â Â 131%ProductÂ Â 279,707Â Â Â 166,147Â Â Â 113,560Â Â Â 68%Total RevenuesÂ Â 395,797Â Â Â 216,310Â Â Â 179,487Â Â Â 83%Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â 3,715,797Â Â Â 5,451,287Â Â Â (1,735,490)Â (32%)General and administrativeÂ Â 2,284,041Â Â Â 2,644,957Â Â Â (360,916)Â (14%)Sales and marketingÂ Â 1,386,378Â Â Â 1,669,102Â Â Â (282,724)Â (17%)Total Operating ExpensesÂ Â 7,386,216Â Â Â 9,765,346Â Â Â (2,379,130)Â (24%)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Discover services.Â Operating ExpensesÂ Total operating expenses decreased to $15.9 million from $19.0 million for the six months ended June 30, 2024 and June 30, 2023, respectively, as a result of the factors described below.Â Â 33Table of ContentsÂ Research and Development ExpensesÂ Research and development expenses decreased to $8.3 million for the six months ended June 30, 2024, from $10.4 million for the six months ended June 30, 2023. This decrease was primarily related to decreased direct research and development expenses as a result reduced clinical trial activity with DXOCRO, reduced personnel expenses and reduced stock-based compensation. The FTE personnel number decreased by 7 to 62 compared to the prior year period.Â Â Â Six Months Ended June 30,Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â Â Â $ Â Â $ Â Â $Â Personnel expensesÂ Â 4,291,580Â Â Â 4,409,655Â Â Â (118,075)Stock-based compensationÂ Â 162,574Â Â Â 292,474Â Â Â (129,900)Direct research and development expensesÂ Â 2,838,327Â Â Â 4,562,335Â Â Â (1,724,008)Other research and developmentÂ Â 515,700Â Â Â 552,621Â Â Â (36,921)Depreciation and amortizationÂ Â 537,143Â Â Â 539,880Â Â Â (2,737)Total research and development expensesÂ Â 8,345,324Â Â Â 10,356,965Â Â Â (2,011,641)Â General and Administrative ExpensesÂ General and administrative expenses decreased to $4.5 million from $5.2 million for the six months ended June 30, 2024 and June 30, 2023, respectively. This decrease was primarily due to lower personnel expenses and stock-based compensation during the period. The FTE personnel number decreased by 1 to 20 compared to the prior year period.Â Â Â Six Months Ended June 30,Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â Â Â $ Â Â $ Â Â $Â Personnel expensesÂ Â 2,258,402Â Â Â 2,668,045Â Â Â (409,643)Stock-based compensationÂ Â 294,762Â Â Â 562,649Â Â Â (267,887)Legal and professional feesÂ Â 1,172,666Â Â Â 1,156,658Â Â Â 16,008Â Other general and administrativeÂ Â 727,848Â Â Â 719,299Â Â Â 8,549Â Depreciation and amortizationÂ Â 84,106Â Â Â 120,009Â Â Â (35,903)Total general and administrative expensesÂ Â 4,537,784Â Â Â 5,226,660Â Â Â (688,876)Â Sales and Marketing ExpensesÂ Sales and marketing expenses decreased to $3.1 million compared to $3.4 million for the six months ended June 30, 2024 and June 30, 2023. This decrease was primarily due to reduced stock-based compensation and direct marketing during the period. The FTE personnel number decreased by 2 to 19 compared to the prior year period.Â Â Â Six Months Ended June 30,Â Â Â Â Â 2024Â Â 2023Â Â ChangeÂ Â Â Â $ Â Â $ Â Â $Â Personnel expensesÂ Â 2,456,716Â Â Â 2,436,742Â Â Â 19,974Â Stock-based compensationÂ Â 161,930Â Â Â 430,708Â Â Â (268,778)Direct marketing and professional feesÂ Â 416,206Â Â Â 482,753Â Â Â (66,547)Depreciation and amortizationÂ Â 24,295Â Â Â 26,356Â Â Â (2,061)Total sales and marketing expensesÂ Â 3,059,147Â Â Â 3,376,559Â Â Â (317,412)Â Other Income (Expenses)Â For the six months ended June 30, 2024, the Companyâ€™s other expenses were $157,257 compared to other income of $169,880 for the six months ended June 30, 2023. The increase in other expenses is due to increased interest paid partly offset by a reduction in grant income and interest received during the period.Â Â 34Table of ContentsÂ Net LossÂ For the six months ended June 30, 2024, the Companyâ€™s net loss was approximately $15.5 million in comparison to a net loss of $18.4 million for the six months ended June 30, 2023. The change was primarily a result of decreased clinical trial activity and personnel costs.Â Going ConcernÂ We have not attained profitable operations on an ongoing basis and are dependent upon obtaining external financing to continue to pursue our operational and strategic plans. For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.Â Off-Balance Sheet ArrangementsÂ There have been no material changes to our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.Â Future FinancingsÂ We may seek to obtain additional capital through the sale of debt or equity securities if we deem it desirable or necessary. These sales may include the sale of equity securities from time to time through an â€œat the market offering programâ€ under our Equity Distribution Agreement with Jefferies LLC. See Note 6, Common Stock â€“ Equity Distribution Agreement, of the notes to the condensed consolidated financial statements. However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.Â Critical Accounting Policies and EstimatesÂ Our interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles, or GAAP, applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.Â We also regularly evaluate estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, valuations of stock-based compensation and deferred revenue.Â We base our estimates and assumptions on current facts, historical experiences, information from third party professionals and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from our estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.Â We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements.Â A summary of these policies is included in the notes to our financial statements. There have been no material changes to the critical accounting policies and key estimates and assumptions disclosed in the section titled â€œCritical Accounting Policies and Estimatesâ€ in Part II, Item 7 within our Annual Report.Â Recently Issued Accounting PronouncementsÂ The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.Â Â 35Table of ContentsÂ ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKÂ We are a smaller reporting company and are not required to disclose this information.Â ITEM 4. CONTROLS AND PROCEDURESÂ Disclosure Controls and ProceduresÂ Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.Â Our management carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded, as they previously concluded as of December 31, 2023, that our disclosure controls and procedures were not effective as of June 30, 2024, because of material weaknesses in our internal control over financial reporting, as referenced below and described in detail in our Annual Report.Â A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.Â We identified material weaknesses in our internal controls over financial reporting. A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified include:Â Â Â·we do not have sufficient written documentation of our internal control policies and procedures, including written policies and procedures to ensure the correct application of accounting and financial reporting with respect to the current requirements of GAAP and SEC disclosure requirements.Â Notwithstanding the material weakness, we believe that our financial statements contained in this Report fairly present our financial position, results of operations and cash flows for the periods covered by this Report in all material respects.Â Our management, with the oversight of our audit committee, has initiated steps and plans to take additional measures to remediate the underlying causes of the material weakness, which we currently believe will be primarily through revising precision level management review controls and gaining additional assurance regarding our outside service providersâ€™ quality control procedures. It is possible that we may determine that additional remediation steps will be necessary in the future.Â Â 36Table of ContentsÂ Planned Remediation of Material WeaknessesÂ Our management has been actively engaged in developing and implementing remediation plans to address material weaknesses described above. These remediation efforts are ongoing and include or are expected to include:Â Â Â·engaging internal control consultants to assist us in performing a financial reporting risk assessment as well as identifying and designing our system of internal controls necessary to mitigate the risks identified;Â Â Â Â Â·preparation of written documentation of our internal control policies and procedures;Â Â Â Â Â·increasing personnel resources and technical accounting expertise within the accounting function to replace our outside service providers; andÂ Â Â Â Â·until we have sufficient technical accounting resources, we have engaged external consultants to provide support and to assist us in our evaluation of more complex applications of GAAP.Â We continue to enhance corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and accountability to enable remediation of our material weaknesses. We believe that our remediation plan will be sufficient to remediate the identified material weaknesses and strengthen our internal control over financial reporting. As we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary.Â Changes in Internal Control over Financial ReportingÂ Except for the ongoing remediation of the material weaknesses in internal controls over financial reporting noted above, no changes in our internal control over financial reporting were made during the six months ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.Â Limitations of the Effectiveness of Disclosure Controls and Internal ControlsÂ Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.Â The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.Â 37Table of ContentsÂ PART II OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGSÂ In the ordinary course of business, we may be subject to claims, counter claims, lawsuits and other litigation of the type that generally arise from the conduct of our business. We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our directors, officers or any affiliates, or any registered or beneficial stockholders, is an adverse party or has a material interest adverse to our interest.Â ITEM 1A. RISK FACTORSÂ There have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual Report.Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSÂ Recent Sales of Unregistered SecuritiesÂ None.Â Repurchase of Equity SecuritiesÂ No equity securities were repurchased during the second quarter of 2024.Â ITEM 3. DEFAULTS UPON SENIOR SECURITIESÂ None.Â ITEM 4. MINE SAFETY DISCLOSURESÂ Not applicable.Â ITEM 5. OTHER INFORMATIONÂ None.Â Â 38Table of ContentsÂ ITEM 6. EXHIBITSÂ Â Â Â Â Incorporated by ReferenceÂ Â Exhibit NumberÂ Exhibit DescriptionÂ FormÂ File No.Â ExhibitÂ Filing DateÂ Filed Herewith3.1Â Second Amended and Restated Certificate of Incorporation, as amended and currently in effect.Â S-8Â 333-280974Â 4.2Â 7/24/24Â Â 3.2Â Amended and Restated Bylaws, as amended and currently in effect.Â 10-QÂ 001-36833Â 3.2Â 5/13/24Â Â 10.1#Â 2024 Stock Incentive Plan.Â 8-KÂ 001-36833Â 10.1Â 7/3/24Â Â 10.1(a)#Â Form of Notice of Stock Option Grant and Stock Option Agreement under the 2024 Stock Incentive Plan.Â S-8Â 333-280974Â 99.1(a)Â 7/24/24Â Â 10.1(b)#Â Form of Notice of Performance Shares Award and Performance Shares Agreement under the 2024 Stock Incentive Plan.Â S-8Â 333-280974Â 99.1(b)Â 7/24/24Â Â 10.1(c)#Â Form of Notice of Restricted Stock Award and Restricted Stock Agreement under the 2024 Stock Incentive Plan.Â S-8Â 333-280974Â 99.1(c)Â 7/24/24Â Â 10.1(d)#Â Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the 2024 Stock Incentive Plan.Â S-8Â 333-280974Â 99.1(d)Â 7/24/24Â Â 10.1(e)#Â Â Â Â Form of Notice of Stock Appreciation Right Award and Stock Appreciation Right Award Agreement under the 2024 Stock Incentive Plan.Â Â S-8Â Â Â 333-280974Â Â Â 99.1(e)Â Â Â 7/24/24Â Â Â Â Â 10.1(f)#Â Form of Notice of Stock Bonus Award and Stock Bonus Award Agreement under the 2024 Stock Incentive Plan.Â S-8Â 333-280974Â 99.1(f)Â 7/24/24Â Â 31.1Â Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.Â Â Â Â Â Â Â Â Â X31.2Â Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.Â Â Â Â Â Â Â Â Â X32.1*Â Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Â Â Â Â Â Â Â Â Â X101.INSÂ Inline XBRL Instance Document.Â Â Â Â Â Â Â Â Â X101.SCHÂ Inline XBRL Taxonomy Extension Schema Document.Â Â Â Â Â Â Â Â Â X101.CALÂ Inline XBRL Taxonomy Extension Calculation Linkbase Document.Â Â Â Â Â Â Â Â Â X101.LABÂ Inline XBRL Taxonomy Extension Label Linkbase Document.Â Â Â Â Â Â Â Â Â X101.PREÂ Inline XBRL Taxonomy Extension Presentation Linkbase Document.Â Â Â Â Â Â Â Â Â X101.DEFÂ Inline XBRL Taxonomy Extension Definition Linkbase Document.Â Â Â Â Â Â Â Â Â X104Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)Â Â Â Â Â Â Â Â Â XÂ # Indicates a management contract or compensatory plan or arrangement.Â Â * The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed â€œfiledâ€ by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrantâ€™s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.Â Â 39Table of ContentsÂ SIGNATURESÂ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â VOLITIONRX LIMITEDÂ Â Â Â Dated: August 14, 2024By:/s/ Cameron ReynoldsÂ Â Cameron ReynoldsÂ Â Â President and Chief Executive Officer(Authorized Signatory and Principal Executive Officer)Â Â Dated: August 14, 2024By:/s/ Terig HughesÂ Â Terig HughesÂ Â Â Chief Financial Officer and Treasurer(Authorized Signatory and Principal Financial and Accounting Officer)Â Â Â 40Â EX-31.1 2 vnrx_ex311.htm CERTIFICATION vnrx_ex311.htmEXHIBIT 31.1 Â CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Cameron Reynolds, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of VolitionRx Limited; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â (c) Evaluated the effectiveness of the registrant's

disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent function): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 /s/ Cameron Reynolds Â Cameron Reynolds President and Chief Executive Officer (Principal Executive Officer) Â Â EX-31.2 3 vnrx_ex312.htm CERTIFICATION vnrx_ex312.htmEXHIBIT 31.2 Â CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Terig Hughes, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of VolitionRx Limited; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent function): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 /s/ Terig Hughes Â Terig Hughes Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) Â Â EX-32.1 4 vnrx_ex321.htm CERTIFICATION vnrx_ex321.htmEXHIBIT 32.1 Â CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER Â PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO Â SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â The following certifications are hereby made in connection with the Quarterly Report on Form 10-Q of VolitionRx Limited (the â€œCompanyâ€) for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€): Â I, Cameron Reynolds, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented. Â Date: August 14, 2024Â /s/ Cameron Reynolds Â Cameron Reynolds President and Chief Executive Officer (Principal Executive Officer) Â Â I, Terig Hughes, Chief Financial Officer and Treasurer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented. Â Date: August 14, 2024Â Â /s/ Terig Hughes Â Terig Hughes Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) Â Â EX-101.SCH 5 vnrx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Consolidated Balance Sheets(Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Liquidity and Going Concern Assessment link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Common Stock (Details 1) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - StockBased Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - StockBased Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - StockBased Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - StockBased Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - StockBased Compensation (Details 4) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - StockBased Compensation (Details 5) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - StockBased Compensation (Details 6) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - StockBased Compensation (Details 7) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - StockBased Compensation (Details 8) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - StockBased Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - Commitments and Contingencies (Details 1) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - Commitments and Contingencies (Details 2) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - Commitments and Contingencies (Details 3) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - Commitments and Contingencies (Details 4) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - Commitments and Contingencies (Details 5) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - Commitments and Contingencies (Details 6) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - Commitments and Contingencies (Details 7) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - Commitments and Contingencies (Details 8) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 vnrx-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Document Quarterly Report Document Transition Report Entity Interactive Data Current Condensed Consolidated Balance Sheets ASSETS Current Assets Cash and cash equivalents Accounts receivable Prepaid expenses Other current assets Total Current Assets [Assets, Current] Property and equipment, net Operating lease right-of-use assets Intangible assets, net Total Assets [Assets] LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable Accrued liabilities Deferred revenue Management and directors' fees payable Current portion of long-term debt Current portion of finance lease liabilities Current portion of operating lease liabilities Current portion of grant repayable Warrant liability Total Current Liabilities [Liabilities, Current] Long-term debt, net of current portion Finance lease liabilities, net of current portion Operating lease liabilities, net of current portion Grant repayable, net of current portion Total Long-Term Liabilities [Liabilities, Noncurrent] Total Liabilities [Liabilities] Stockholders' Deficit Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 82,928,314 shares and 81,898,321 shares, respectively Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Total VolitionRx Limited Stockholders' Deficit [Stockholders' Equity Attributable to Parent] Non-controlling interest Total Stockholders' Deficit [Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest] Total Liabilities and Stockholders' Deficit [Liabilities and Equity] Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Revenues Services Product Total Revenues [Revenues] Operating Expenses Research and development General and administrative Sales and marketing Total Operating Expenses [Operating Expenses] Operating Loss [Operating Income (Loss)] Other Income (Expenses) Grant income Loss on disposal of fixed assets Interest income Interest expense [Interest Expense, Other] Gain on change in fair value of warrant liability Total Other Income (Expenses) [Other Nonoperating Income (Expense)] Net Loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Net Loss Attributable to Non-Controlling Interest Net Loss Attributable to VolitionRx Limited Stockholders [Net Income (Loss) Available to Common Stockholders, Basic] Other Comprehensive Income (Loss) Foreign currency translation adjustments Net Comprehensive Loss [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited Weighted Average Shares Outstanding - Basic and Diluted Condensed Consolidated Statements of Stockholders Equity (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Noncontrolling Interest Balance, shares [Shares, Issued] Balance, amount Common stock issued for cash, net of issuance costs, shares Common stock issued for cash, net of issuance costs, amount Common stock issued for settlement of RSUs, shares Common stock issued for settlement of RSUs, amount Stock-based compensation Tax withholdings paid related to stock-based compensation Common stock repurchased, shares Common stock repurchased, amount Foreign currency translation Net loss for the period Common stock issued in lieu of license fee, shares Common stock issued in lieu of license fee, amount Balance, shares Balance, amount Condensed Consolidated Statements of Cash Flows (Unaudited) Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of operating lease right-of-use assets Loss on disposal of fixed assets Stock-based compensation Gain on change in fair value of warrant liability Changes in operating assets and liabilities: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts receivable [Increase (Decrease) in Accounts Receivable] Other current assets [Increase (Decrease) in Other Current Assets] Deferred revenue, current and non-current Accounts payable and accrued liabilities Management and directors' fees payable [Management and directors' fees payable] Right-of-use assets operating leases liabilities Net Cash Used In Operating Activities [Net Cash Provided by (Used in) Operating Activities] Investing Activities Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Purchase of License [Payments to Acquire Software] Net Cash Used In Investing Activities [Net Cash Provided by (Used in) Investing Activities] Financing Activities Net proceeds from issuances of common stock Tax withholdings paid related to stock-based compensation [Payment, Tax Withholding, Share-Based Payment Arrangement] Common stock repurchased [Payments for Repurchase of Common Stock] Proceeds from long-term debt Payments on long-term debt [Repayments of Long-Term Debt] Payments on finance lease obligations [Repayments of Debt and Lease Obligation] Net Cash Provided By Financing Activities [Net Cash Provided by (Used in) Financing Activities] Effect of foreign exchange on cash Net change in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash and cash equivalents - beginning of the period Cash and cash equivalents - End of Period Supplemental Disclosures of Cash Flow Information Interest paid Non-Cash Financing Activities Common stock issued upon cashless exercises of stock options and settlement of vested RSUs Offering costs from issuance of common stock Fair value of warrants issued in connection with public offering Common stock issued for License rights Non-cash note payable Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Liquidity and Going Concern Assessment Liquidity and Going Concern Assessment Substantial Doubt about Going Concern [Text Block] Property and Equipment Property And Equipment Intangible Assets Intangible Assets Intangible Assets Disclosure [Text Block] Related Party Transactions Related-Party Transactions Common Stock Common Stock Stockholders' Equity Note Disclosure [Text Block] Stock Based Compensation Stock-based Compensation Commitments and Contingencies Commitments And Contingencies Subsequent Events Subsequent Events Subsequent Events [Text Block] Basis Of Presentation Reclassification Recently Issued Accounting Pronouncements Fair Value Measurements Basic And Diluted Net Loss Per Share Schedule Of assets and liabilities measured at fair value on a recurring basis Schedule Of warrant liability measured at fair value Schedule Of Property And Equipment Schedule Of Intangible Assets Schedule Of Annual Estimated Amortization Summary of RSUs vested and settled during period Schedule of fair value of the warrants Summary Of Changes In Warrants Outstanding Summarizing The Warrants Issued And Outstanding Summarizes The Changes In Options Outstanding Summarizing The Options Issued And Outstanding Summarizing The Rsus Issued And Outstanding Schedule of RSUs granted during period Schedule of RSUs vested and settled

during period Schedule of RSUs cancelled Schedule of RSUs issued and outstanding and average contractual life Schedule of future minimum lease payments under financing leases Schedule of operating lease Schedule Of Future Minimum Lease Payments Under Operating Leases Schedule Of Recognized In Short-term Lease Costs Schedule Of Grants Repayable Schedule Of Long-term Debt Payable Schedule of annual payments Of Collaborative Agreement Obligations Schedule of commitments in respect of corporate goals and performance based awards Fair Value Hierarchy and NAV [Axis] Fair Value Inputs Level 1 [Member] Fair Value Inputs Level 2 [Member] Fair Value Inputs Level 3 [Member] Warrant liability [Warrant liability] Warrant Liability beginning balance Gain on change in fair value of warrant liability [Servicing Liability at Fair Value, Other Changes in Fair Value] Warrant Liability ending balance Warrant Liability Potentially Dilutive Securities Excluded From The Computation Of Eps Plan Name Axis Liquidity and Going Concern Assessment [Member] Accumulated deficit Cash and cash equivalents [Cash and Cash Equivalents, at Carrying Value] Cash flows from operating activities Net Loss Property Plant And Equipment By Type Axis Range [Axis] Computer Hardware And Software [Member] Laboratory Equipment [Member] Office Furniture and Equipment [Member] Buildings [Member] Building Improvements [Member] Land [Member] Minimum [Member] Maximum [Member] Total property and equipment Less accumulated depreciation Total property and equipment net Estimated useful life Depreciation Expense Finite Lived Intangible Assets By Major Class Axis Patents [Member] Licenses [Member] Total Patents and Licenses Less accumulated amortization Total patents and Licenses, net 2024 2025 2026 2027 2028 Greater than 5 years Total Intangible Assets Indefinite-Lived Intangible Assets [Axis] Minimum [Member] Patents And Intellectual Property [Member] Maximum [Member] Amortization Expense Amortization Of Patents On Straight Line Basis Derivative Instrument Risk Axis Equity Incentive Plan One [Member] Equity Incentive Plan Two [Member] Equity Incentive Plan Three [Member] Equity Incentive Plan Four [Member] Equity Incentive Plan Five [Member] Equity Incentive Plan Six [Member] Equity Incentive Plan Seven [Member] Incentive Plan Equity Incentive RSU Incentive Vest Date Incentive RSU Issued RSUs Held for Taxes Risk-free interest rate Expected volatility Expected term (years) Expected dividend yield Total fair value 2015 [Member] Underwriting Agreement [Member] EpiCypher License Agreement [Member] Equity Distribution Agreement [Member] 2022 EDA [Member] Common stock price per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Total fair value Warrants issued to purchase shares of common stock Exercise price Vested stock options Issuance of restricted common stock Common stock shares sold Aggeregate share of common stock offering price Aggregate net proceeds Commissions and fee Warrants [Member] Number of warrants Outstanding beginning balance Number of warrants outstanding ending balance Number of Warrants Exercisable Weighted Average Exercise Price Outstanding balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Expired/Cancelled Weighted Average Exercise Price, ending balance Weighted Average Exercise Price, exercisable Warrant One [Member] Warrant Two [Member] Warrant Three [Member] Warrants Four [Member] Warrants Five [Member] Number Exercisable Exercise Price Proceeds to Company if Exercised Weighted Average Remaining Contractual Life (Years) Number Outstanding Financial Instrument Axis Option [Member] Number of options outstanding beginning balance Number of options, Expired/Cancelled [Number of options, Expired/Cancelled] Number of option outstanding ending balance Number of options, exercisable Weighted Average Exercise Price Outstanding balance [Weighted Average Exercise Price Outstanding balance] Weighted Average Exercise Price expires/cancelled Weighted Average Exercise Price ending balance Weighted Average Exercise Price exercisable balance Options One [Member] Option Two [Member] Option Three [Member] Option Four [Member] Option Five [Member] Option Six [Member] Option Seven [Member] Total Option [Member] Number Exercisable, shares Exercise Price [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted Average Remaining Contractual Life (years) Proceeds to Company if Exercised [Proceeds from Stock Options Exercised] Number Outstanding, shares Stock Options [Member] Number Of Rsus Outstanding Begining Balance shares Granted Vested/Settled Cancelled / Forfeited Number Of Rsus Outstanding ending Balance Share Price Beginning Balance shares Share Price Granted Share Price Vested/Settled Share Price Cancelled / Forfeited Share Price ending Balance Award Type Axis Compensation Expense One [Member] Compensation Expense Two [Member] Compensation Expense Three [Member] Compensation Expense RSUs Equity Incentive Plan Compensation Expense grant date Compensation Expense Vesting Period First Vesting date RSU Expense Second vesting date Third vesting date Incentive Plan Equity Incentive RSU Incentive Vest Date Incentive RSU Issued RSUs Held for Taxes Equity Incentive RSUD RSUs Cancelled Plan One [Member] RSUs Cancelled Plan Two [Member] RSUs Cancelled Plan Three [Member] RSUs Cancelled Plan Four [Member] RSUs Cancelled Plan Five [Member] RSUs Cancelled Plan Six [Member] RSUs Cancelled Plan Seven [Member] RSUs Cancelled Plan Eight [Member] RSUs Cancelled Plan Nine [Member] RSUs Cancelled Plan Ten [Member] RSUs Cancelled Plan Eleven [Member] RSUs Cancelled Plan Twelve [Member] RSUs Cancelled Plan Thirteen [Member] RSUs Cancelled Plan Fourteen [Member] RSUs Cancelled Plan Fifteen [Member] RSUs Cancelled Plan Sixteen [Member] RSUs Cancelled Plan Seventeen [Member] RSUs Cancelled Plan Eighteen [Member] RSUs Cancelled Plan Nineteen [Member] RSUs Cancelled Plan Twenty [Member] Equity Incentive Plan Equity Incentive RSU Incentive Cancellation Date Incentive Vest Date Incentive RSUs Cancelled Equity Incentive RSU [Equity Incentive RSU] Option Six [Member] [Option Six [Member]] Option Seven [Member] [Option Seven [Member]] Option Eight [Member] Option Nine [Member] Option Ten [Member] Option Eleven [Member] Option Twelve [Member] Option Thirteen [Member] Option Fourteen [Member] Option Fifteen [Member] Option Sixteen [Member] Number Of Stock Outstanding Balance Share Price Weighted Average Remaining Contractual Life (years) [Weighted Average Remaining Contractual Life (years)] 2015 Equity Incentive Plan [Member] Restricted Stock Units (RSUs) [Member] Weighted Average Remaining Contractual Life Compensation Expense RSUs Common Stock, Shares Authorized [Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized] Common Stock Shares Reserved For Future Issuance Share-based Payment Arrangement, Noncash Expense Remaining unrecognized compensation cost related to non-vested RSUs Longterm Debt Type Axis Finance Lease Obligations [Member] 2024 - remaining 2025 [Finance Lease, Liability, to be Paid, Year Two] 2026 [Finance Lease, Liability, to be Paid, Year Three] 2027 [Finance Lease, Liability, to be Paid, Year Four] 2028 [Finance Lease, Liability, to be Paid, Year Five] Greater than 5 years [Finance Lease, Liability, to be Paid, after Year Five] Total [Finance Lease, Liability, to be Paid] Less: Amount representing interest [Finance Lease, Liability, Undiscounted Excess Amount] Present value of minimum lease payments Other Commitments Axis Operating Lease Right of Use Obligations [Member] Operating right-of-use assets Weighted average remaining lease (months) Weighted average discount rate Operating lease liabilities, current portion Operating lease liabilities, long term Total operating lease liabilities 2024 - Remaining 2025 [Lessee, Operating Lease, Liability, to be Paid, Year Two] 2026 [Lessee, Operating Lease, Liability, to be Paid, Year Three] 2027 [Lessee, Operating Lease, Liability, to be Paid, Year Four] 2028 [Lessee, Operating Lease, Liability, to be Paid, Year Five] Total [Lessee, Operating Lease, Liability, to be Paid] Less: imputed interest [Less: imputed interest] Total Operating Lease Liabilities 2024 - Remaining [2024 - Remaining] 2025 [2025] Total Operating Lease Liabilities [Total Operating Lease Liabilities] Grants Repayable [Member] 2024 - Remaining [2024 - Remaining 1] 2025 [2025 1] 2026 [2026] 2027 [2027] 2028 [2028] Greater than 5 years [Greater than 5 years] Total Grants Repayable 2024 - Remaining [Long-Term Debt, Maturity, Year One] 2025 [Long-Term Debt, Maturity, Year Two] 2026 [Long-Term Debt, Maturity, Year Three] 2027 [Long-Term Debt, Maturity, Year Four] 2028 [Long-Term Debt, Maturity, Year Five] Greater than 5 years [Long-Term Debt, Maturity, Year Four and Five] Total [Long-Term Debt, Maturity, after Year Five] Total Long-Term Debt National University of Taiwan MD Anderson Cancer Center Guys and St Thomas Xentic Bioscience UMC Total Amount Remaining 2025 - Estimated 2024 - Estimated Restricted stock option Outstanding Award 3 Outstanding Award 4 Outstanding Award 5 Total Member Outstanding award Amortized of outstanding award 2024 Amortized of outstanding award 2023 Amortized of outstanding award 2022 Unamortized of outstanding award Vesting period Unamortized of outstanding award [Unamortized of outstanding award] Unamortized of outstanding award [Unamortized of outstanding award 1] Restricted Stock Options Vested [Member] Total Member Outstanding Award 1 Outstanding Award 2 Outstanding Award 3 [Outstanding Award 3] Outstanding award Vesting period Amortized of outstanding award 2024 Amortized of outstanding award 2023 Unamortized of outstanding award Unamortized of outstanding award Award Date [Axis] Title Of Individual Axis Statement Geographical Axis Managing Director's Agreement [Member] RSU 2023 [Member] RSU 2024 [Member] RSU 2025 [Member] RSU 2026 [Member] University of Taiwan [Member] In 2018 [Member] Clinical Study Research Agreement [Member] Univercity Of Texas MD [Member] Two Thousand Twenty Two [Member] Guy's and St Thomas' NHS Foundation Trust [Member] August Two Thousand Twenty Three [Member] Xenetic Biosciences Inc and CLS Therapeutics [Member] July Thirty One Thousand Twenty Three [Member] University Medical Centre Amsterdam[Member] January TwoThousand Twenty Four [Member] Payments For Future Research And Collobration Total Grants Repayable Principal balance payable Aggerate Amount Payable, Description Loan agreement, Description Total Long-Term Debt Amount payable for services rendered Amount may be payable by Company in future periods for services rendered Accrued compensation expense Recognized total compensation expense Amount payable Royalty Payment Payment Of Lease Liabilities Operating Lease Expense Short Term Lease Costs RSU Vested in 2024 RSU Vested in 2023 RSU Vested in 2025 Unrecognized compensation expense Collaborative Obligations Amount Due Collaborative Obligations Amount Lease Agreement Expire Period Additional Cost Of Company Cost Subsequent Event Type Axis Class of Stock [Axis] Sale of Stock [Axis] Subsequent Event [Member] Series A common stock [Member] July 1, 2024 [Member] July 8, 2024 [Member] Series B common stock [Member] Placement agent[Member] Common Stock, Shares Authorized Stock issued during period, shares Pre-Funded Warrants Warrants to purchase Exercise price [Class of Warrant or Right, Exercise Price of Warrants or Rights] Offering price Proceeds from securities Offering expenses Warrants issued to purchase Common Stock, Shares Par Value Common Stock, Shares Issued RSUs granted cancelled Common stock, shares withheld for taxes RSUs, vested Agreement EX-101.CAL 7 vnrx-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 vnrx-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 vnrx-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 13, 2024 Cover [Abstract] Â Â Entity Registrant Name VolitionRx Limited Â Entity Central Index Key 0000093314 Â Document Type 10-Q Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Entity Small Business true Â Entity Shell Company false Â Entity Emerging Growth Company false Â Entity Current Reporting Status Yes Â Document Period End Date Jun. 30, 2024 Â Entity Filer Category Non-accelerated Filer Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2024 Â Entity Common Stock Shares Outstanding Â 92,101,479 Entity File Number 001-36833 Â Entity Incorporation State Country Code DE Â Entity Tax Identification Number 91-1949078 Â Entity Address Address Line 1 1489 West Warm Springs Road Â Entity Address Address Line 2 Suite 110 Â Entity Address City Or Town Henderson Â Entity Address State Or Province NV Â Entity Address Postal Zip Code 89014 Â City Area Code 646 Â Local Phone Number 650â€“1351 Â Security 12b Title Common Stock, par value $0.001 per share Â Trading Symbol VNRX Â Security Exchange Name NYSE Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current Yes Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -

Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current Assets Â Â Cash and cash equivalents $ 5,998,928 $ 20,729,983 Accounts receivable 166,262 242,617 Prepaid expenses 828,965 521,370 Other current assets 350,927 360,125 Total Current Assets 7,345,082 21,854,095 Property and equipment, net 4,878,417 5,523,013 Operating lease right-of-use assets 512,317 549,504 Intangible assets, net 332,221 23,886 Total Assets 13,068,037 27,950,498 Current Liabilities Â Â Accounts payable 3,348,322 3,211,287 Accrued liabilities 3,227,595 3,928,761 Deferred revenue 22,938,400 23,000,000 Management and directors' fees payable 25,073 59,625 Current portion of long-term debt 1,043,142 1,207,007 Current portion of finance lease liabilities 47,718 48,570 Current portion of operating lease liabilities 190,099 199,323 Current portion of grant repayable 54,168 55,855 Warrant liability 101,097 126,649 Total Current Liabilities 30,975,614 31,837,077 Long-term debt, net of current portion 3,865,357 3,624,860 Finance lease liabilities, net of current portion 363,927 400,022 Operating lease liabilities, net of current portion 350,810 378,054 Grant repayable, net of current portion 409,940 422,707 Total Long-Term Liabilities 4,990,034 4,825,643 Total Liabilities 35,965,648 36,662,720 Stockholders' Deficit Â Â Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 82,928,314 shares and 81,898,321 shares, respectively 82,928 81,898 Additional paid-in capital 195,755,863 194,448,414 Accumulated other comprehensive income 282,252 243,940 Accumulated deficit (217,929,441) (202,576,507) Total VolitionRx Limited Stockholders' Deficit (21,808,398) (7,802,255) Non-controlling interest (1,089,213) (909,967) Total Stockholders' Deficit (22,897,611) (8,712,222) Total Liabilities and Stockholders' Deficit $ 13,068,037 $ 27,950,498 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of fee payable for management of fund or trust. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_ManagementFeePayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification

-Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_GrantRepayableCurrent Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_GrantRepayableNonCurrent Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets(Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Condensed Consolidated Balance Sheets Â Â Common Stock, Shares Par Value $ 0.001 $ 0.001 Common Stock, Shares Authorized 100,000,000 100,000,000 Common Stock, Shares Issued 82,928,314 81,898,321 Common Stock, Shares Outstanding 82,928,314 81,898,321 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenues Â Â Â Â Services $ 116,090 $ 50,163 $ 155,866 $ 55,519 Product 279,707 166,147 411,466 310,599 Total Revenues 395,797 216,310 567,332 366,118 Operating Expenses Â Â Â Â Research and development 3,715,797 5,451,287 8,345,324 10,356,965 General and administrative 2,284,041 2,644,957 4,537,784 5,226,660 Sales and marketing 1,386,378 1,669,102 3,059,147 3,376,559 Total Operating Expenses 7,386,216 9,765,346 15,942,255

18,960,184 Operating Loss (6,990,419) (9,549,036) (15,374,923) (18,594,066) Other Income (Expenses) Â Â Â Â Grant income 0 0 0 165,795 Loss on disposal of fixed assets (33,498) 0 (33,498) 0 Interest income 450 27,109 9,104 84,757 Interest expense (81,182) (58,321) (158,415) (109,643) Gain on change in fair value of warrant liability 44,474 28,971 25,552 28,971 Total Other Income (Expenses) (69,756) (2,241) (157,257) 169,880 Net Loss (7,060,175) (9,551,277) (15,532,180) (18,424,186) Net Loss Attributable to Non-Controlling Interest 74,629 80,298 179,246 173,659 Net Loss Attributable to VolitionRx Limited Stockholders (6,985,546) (9,470,979) (15,352,934) (18,250,527) Other Comprehensive Income (Loss) Â Â Â Â Foreign currency translation adjustments 23,286 37,712 38,312 (18,766) Net Comprehensive Loss $ (7,036,889) $ (9,513,565) $ (15,493,868) $ (18,442,952) Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited $ (0.08) $ (0.14) $ (0.19) $ (0.29) Weighted Average Shares Outstanding - Basic and Diluted 82,669,335 66,884,368 82,312,161 63,613,224 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income earned from interest bearing assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_EarningsPerShareBasicsAndDiluted Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncomeFromGrants Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ProductRevenue Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ServiceRevenue Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageNumberOfShareOutstandingsBasicAndDiluted Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders Equity (Unaudited) - USD ($) Total Common stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Noncontrolling Interest Balance, shares at Dec. 31, 2022 Â 57,873,379 Â Â Â Â Balance, amount at Dec. 31, 2022 $ (3,126,962) $ 57,873 $ 164,397,468 $ 227,097 $ (167,257,429) $ (551,971) Common stock issued for cash, net of issuance costs, shares Â 5,225,703 Â Â Â Â Common stock issued for cash, net of issuance costs, amount 8,427,655 $ 5,225 8,422,430 0 0 0 Common stock issued for settlement of RSUs, shares Â 26,978 Â Â Â Â Common stock issued for settlement of RSUs, amount 0 $ 27 (27) 0 0 0 Stock-based compensation 693,657 0 693,657 0 0 0 Tax withholdings paid related to stock-based compensation (14,336) $ 0 (14,336) 0 0 0 Common stock repurchased, shares Â (13,294) Â Â Â Â Common stock repurchased, amount (31,772) $ (13) (31,759) 0 0 0 Foreign currency translation (56,478) 0 0 (56,478) 0 0 Net loss for the period (8,872,909) $ 0 0 0 (8,779,348) (93,561) Balance, shares at Mar. 31, 2023 Â 63,112,766 Â Â Â Â Balance, amount at Mar. 31, 2023 (2,981,145) $ 63,112 173,467,433 170,619 (176,036,777) (645,532) Balance, shares at Dec. 31, 2022 Â 57,873,379 Â Â Â Â Balance, amount at Dec. 31, 2022 (3,126,962) $ 57,873 164,397,468 227,097 (167,257,429) (551,971) Stock-based compensation 1,285,831 Â Â Â Â Â Net loss for the period (18,424,186) Â Â Â Â Â Balance, shares at Jun. 30, 2023 Â 78,137,364 Â Â Â Â Balance, amount at Jun. 30, 2023 5,118,175 $ 78,137 191,065,293 208,331 (185,507,756) (725,830) Balance, shares at Mar. 31, 2023 Â 63,112,766 Â Â Â Â Balance, amount at Mar. 31, 2023 (2,981,145) $ 63,112 173,467,433 170,619 (176,036,777) (645,532) Common stock issued for cash, net of issuance costs, shares Â 14,950,000 Â Â Â Â Common stock issued for cash, net of issuance costs, amount 17,086,606 $ 14,950 17,071,656 0 0 0 Common stock issued for settlement of RSUs, shares Â 74,598 Â Â Â Â Common stock issued for settlement of RSUs, amount 0 $ 75 (75) 0 0 0 Stock-based compensation 592,174 0 592,174 0 0 0 Tax withholdings paid related to stock-based compensation (65,895) 0 (65,895) 0 0 0 Foreign currency translation 37,712 0 0 37,712 0 0 Net loss for the period (9,551,277) $ 0 0 0 (9,470,979) (80,298) Balance, shares at Jun. 30, 2023 Â 78,137,364 Â Â Â Â Balance, amount at Jun. 30, 2023 5,118,175 $ 78,137 191,065,293 208,331 (185,507,756) (725,830) Balance, shares at Dec. 31, 2023 Â 81,898,321 Â Â Â Â Balance, amount at Dec. 31, 2023 (8,712,222) $ 81,898 194,448,414 243,940 (202,576,507) (909,967) Common stock issued for cash, net of issuance costs, shares Â 13,350 Â Â Â Â Common stock issued for cash, net of issuance costs, amount 15,734 $ 13 15,721 0 0 0 Common stock issued for settlement of RSUs, shares Â 68,169 Â Â Â Â Common stock issued for settlement of RSUs, amount 0 $ 69 (69) 0 0 0 Stock-based compensation 411,220 0 411,220 0 0 0 Tax withholdings paid related to stock-based compensation (3,062) 0 (3,062) 0 0 0 Foreign currency translation 15,026 0 0 15,026 0 0 Net loss for the period (8,472,005) $ 0 0 0 (8,367,388) (104,617) Common stock issued in lieu of license fee, shares Â 129,132 Â Â Â Â Common stock issued in lieu of license fee, amount 125,258 $ 129 125,129 0 0 0 Balance, shares at Mar. 31, 2024 Â 82,108,972 Â Â Â Â Balance, amount at Mar. 31, 2024 (16,620,051) $ 82,109 194,997,353 258,966 (210,943,895) (1,014,584) Balance, shares at Dec. 31, 2023 Â 81,898,321 Â Â Â Â Balance, amount at Dec. 31, 2023 (8,712,222) $ 81,898 194,448,414 243,940 (202,576,507) (909,967) Stock-based compensation 619,266 Â Â Â Â Â Net loss for the period (15,532,180) Â Â Â Â Â Balance, shares at Jun. 30, 2024 Â 82,928,314 Â Â Â Â Balance, amount at Jun. 30, 2024 (22,897,611) $ 82,928 195,755,863 282,252 (217,929,441) (1,089,213) Balance, shares at Mar. 31, 2024 Â 82,108,972 Â Â Â Â Balance, amount at Mar. 31, 2024 (16,620,051) $ 82,109 194,997,353 258,966 (210,943,895) (1,014,584) Common stock issued for cash, net of issuance costs, shares Â 734,155 Â Â Â Â Common stock issued for cash, net of issuance costs, amount 589,488 $ 734 588,754 0 0 0 Common stock issued for settlement of RSUs, shares Â 85,187 Â Â Â Â Common stock issued for settlement of RSUs, amount 0 $ 85 (85) 0 0 0 Stock-based compensation 208,046 0 208,046 0 0 0 Tax withholdings paid related to stock-based compensation (38,205) 0 (38,205) 0 0 0 Foreign currency translation 23,286 0 0 23,286 0 0 Net loss for the period (7,060,175) $ 0 0 0 (6,985,546) (74,629) Balance, shares at Jun. 30, 2024 Â 82,928,314 Â Â Â Â Balance, amount at Jun. 30, 2024 $ (22,897,611) $ 82,928 $ 195,755,863 $ 282,252 $ (217,929,441) $ (1,089,213) X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic

40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAdjustments to temporary equity resulting from foreign currency translation adjustments. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedForCashNetOfIssuanceCostsAmount Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedForCashNetOfIssuanceCostsShares Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedForSettlementOfRsuSAmount Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedForSettlementOfRsuSShares Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedInLieuOfLicenseFeeAmount Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedInLieuOfLicenseFeeShares Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockRepurchasedAmount Namespace Prefix: vnrx_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockRepurchasedShares Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating Activities Â Â Net loss $ (15,532,180) $ (18,424,186) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 532,504 560,313 Amortization of operating lease right-of-use assets 113,034 127,210 Loss on disposal of fixed assets 33,498 0 Stock-based compensation 619,266 1,285,831 Gain on change in fair value of warrant liability (25,552) (28,971) Changes in operating assets and liabilities: Â Â Prepaid expenses (307,595) (166,351) Accounts receivable 76,357 (196,487) Other current assets 9,198 (95,073) Deferred revenue, current and non-current (61,600) 0 Accounts payable and accrued liabilities (384,567) 961,764 Management and directors' fees payable (34,552) 9,019 Right-of-use assets operating leases liabilities (112,199) (125,393) Net Cash Used In Operating Activities (15,074,388) (16,092,324) Investing Activities Â Â Purchases of property and equipment (68,161) (501,986) Purchase of License (171,095) 0 Net Cash Used In Investing Activities (239,256) (501,986) Financing Activities Â Â Net proceeds from issuances of common stock 605,222 25,881,221 Tax withholdings paid related to stock-based compensation (41,267) (80,231) Common stock repurchased 0 (31,772) Proceeds from long-term debt 754,457 216,908 Payments on long-term debt (530,732) (475,965) Payments on finance lease obligations (23,643) (23,188) Net Cash Provided By Financing Activities 764,037 25,486,973 Effect of foreign exchange on cash (181,448) (16,439) Net change in cash and cash equivalents (14,731,055) 8,876,224 Cash and cash equivalents - beginning of the period 20,729,983 10,867,050 Cash and cash equivalents - End of Period 5,998,928 19,743,274 Supplemental Disclosures of Cash Flow Information Â Â Interest paid 158,415 109,643 Non-Cash Financing Activities Â Â Common stock issued upon cashless exercises of stock options and settlement of vested RSUs 282 102 Offering costs from issuance of common stock 0 239,772 Fair value of warrants issued in connection with public offering 0 366,960 Common stock issued for License rights 125,258 0 Non-cash note payable $ 294,603 $ 356,258 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireSoftware Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt and lease obligation. + ReferencesNo definition available. + Details Name: us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedForLicenseRightsForNonCash Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrantsForNoncash Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_FairValueOfWarrantsIssuedInConnectionwithPublicOfferingNonCash Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncreaseDecreaseInManagementAndDirectorsFeesPayable Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NotePayableNonCash Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OfferingCostsFromIssuanceOfCommonStockForNonCash Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Basis of Presentation and Summary of Significant Accounting Policies Â Basis of Presentation and Summary of Significant Accounting Policies Note 1 â€“ Basis of Presentation and Summary of Significant Accounting Policies Â Basis of PresentationÂ The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the â€œCompanyâ€ or â€œVolitionRxâ€) have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the â€œAnnual Reportâ€). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.Â ReclassificationsÂ Certain reclassifications within operating expenses have been made to the prior periodâ€™s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented.Â Recently Issued Accounting PronouncementsÂ In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements.Fair Value MeasurementsÂ Pursuant to ASC 820, â€œFair Value Measurements and Disclosures,â€ an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrumentâ€™s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:Â Level 1Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.Â Level 2Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.Â Level 3Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.Â The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period.Â Included in the following table are the Companyâ€™s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024.Â Fair Value Measurements at June 30, 2024Â DescriptionÂ Level 1Â Â Level 2Â Â Level 3Â Â TotalÂ Â Â Â $Â Â Â $Â Â Â $Â Â Â $Â Â Â LiabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilityÂ Â -Â Â Â 101,097Â Â Â -Â Â Â 101,097Â As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows:Â Warrant LiabilityÂ Â Â Â TotalÂ Â Â Â $Â Balance at December 31, 2023Â Â Â 126,649Â Gain on change in fair value of warrant liabilityÂ Â (25,552)Balance at June 30, 2024Â Â Â 101,097Â Â Basic and Diluted Net Loss Per ShareÂ The Company computes net loss per share in accordance with ASC 260, â€œEarnings Per Share,â€ which requires presentation of both basic and diluted earnings per share (â€œEPSâ€) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, 2024, 9,297,073 potential common shares equivalents from warrants, options, and restricted stock units (â€œRSUsâ€) were excluded from the diluted EPS calculations as their effect is anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-

gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liquidity and Going Concern Assessment 6 Months Ended Jun. 30, 2024 Liquidity and Going Concern Assessment Â Liquidity and Going Concern Assessment Note 2 â€“ Liquidity and Going Concern Assessment Â The Company's condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Companyâ€™s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the â€œlook-forward period,â€ as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors.Â For the six months ended June 30, 2024, the Company incurred a net loss of $15.5 million and used cash flows in operating activities of $15.1 million. As of June 30, 2024, the Company had cash and cash equivalents of $6.0 million and an accumulated deficit of $217.9 million.Â The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Companyâ€™s cash conservation efforts, directors and certain employees have elected to exchange a portion of their salary for RSUs in the Company for a period of up to six months.Â The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations.Â Management assessed the mitigating effect of its plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Companyâ€™s ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Companyâ€™s plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. The Company concluded that these plans do not alleviate the substantial doubt about the Companyâ€™s ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.Â The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment 6 Months Ended Jun. 30, 2024 Property and Equipment Â Property And Equipment Note 3 - Property and Equipment Â The Companyâ€™s property and equipment consisted of the following amounts as of June 30, 2024 and December 31, 2023:Â Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Useful LifeÂ Cost $Â Â Cost $Â Computer hardware and softwareÂ 3 yearsÂ Â 723,206Â Â Â 724,534Â Laboratory equipmentÂ 5 yearsÂ Â 4,630,385Â Â Â 4,753,253Â Office furniture and equipmentÂ 5 yearsÂ Â 370,493Â Â Â 378,800Â BuildingsÂ 30 yearsÂ Â 2,049,211Â Â Â 2,113,031Â Building improvementsÂ 5-15 yearsÂ Â 1,574,428Â Â Â 1,610,016Â LandÂ Not amortizedÂ Â 128,467Â Â Â Â 132,468Â Total property and equipmentÂ Â Â Â Â 9,476,190Â Â Â 9,712,102Â Less accumulated depreciationÂ Â Â Â 4,597,773Â Â Â 4,189,089Â Total property and equipment netÂ Â Â Â 4,878,417Â Â Â 5,523,013Â Â During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $545,128 and $517,921, respectively, in depreciation expense. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets 6 Months Ended Jun. 30, 2024 Intangible Assets Â Intangible Assets Note 4 - Intangible Assets Â The Companyâ€™s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assetsâ€™ estimated useful lives, which range from 8 to 20 years.Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Cost $Â Â Cost $Â PatentsÂ Â 1,098,717Â Â Â 1,130,936Â LicensesÂ Â 296,353Â Â Â -Â Total Patents and LicensesÂ Â 1,395,070Â Â Â 1,130,936Â Less accumulated amortizationÂ Â 1,062,849Â Â Â 1,107,050Â Total patents and Licenses, netÂ Â 332,221Â Â Â 23,886Â Â During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $(12,624) and $42,392, respectively, in amortization expense.Â The Company amortizes the patents and licenses on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:Â 2024Â $16,057Â 2025Â $20,448Â 2026Â $20,448Â 2027Â $20,448Â 2028Â $20,448Â Greater than 5 yearsÂ $234,372Â Total Intangible AssetsÂ $332,221Â Â The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 â€œProperty, Plant and Equipment,â€ as of December 31, 2023. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions Â Related-Party Transactions Note 5 - Related-Party TransactionsÂ See Note 6, Common Stock, for common stock issued to related parties and Note 7, Stock-Based Compensation, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of consultancy services which are accrued under management and directorsâ€™ fees payable (see condensed consolidated balance sheets). X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock 6 Months Ended Jun. 30, 2024 Common Stock Â Common Stock Note 6 - Common Stock Â As of June 30, 2024, the Company was authorized to issue 100 million shares of common stock, par value $0.001 per share, of which 82,928,314 and 81,898,321 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. Â Stock Option Exercises Â During the six months ended June 30, 2024, no shares of common stock were issued pursuant to the exercise of stock options.Â Stock Options Expired / CancelledÂ On April 16, 2024, 36,821 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Plan on the expiration of the exercise period following the resignation of such employee.Â RSU SettlementsÂ Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â 153,356Â Â Â 48,905Â Â Warrants Issued in Equity Capital RaiseÂ In connection with the June 2023 underwritten public offering of the Companyâ€™s common stock pursuant to the underwriting agreement with Prime Executions, Inc. dba Freedom Capital Markets (â€œFreedomâ€) dated June 1, 2023, the Company issued Freedom warrants to purchase an aggregate of 448,500 shares of Company common stock at an exercise price of $2.00 per share. The Company evaluated the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815-40. The Company determined the warrants issued to Freedom failed the indexation guidance under ASC 815-40, specifically, the warrants provide for a Black-Scholes value calculation in the event of certain transactions (â€œFundamental Transactionsâ€), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Companyâ€™s own equity shares. Accordingly, pursuant to ASC 815-40, the Company has classified the fair value of the warrants as a liability upon issuance and marked to market each reporting period in the Companyâ€™s consolidated statement of operations until their exercise or expiration.Warrants Issued in Equity Capital Raise (continued)Â The fair value of the warrants as of June 30, 2024, and December 31, 2023, were $101,097 and $126,649 respectively. The warrant liability was estimated using the Black-Scholes pricing model with the following assumptions.Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Â Â Â Â Risk-free interest rateÂ Â 4.43%Â Â 3.89%Expected volatilityÂ Â 82.80%Â Â 76.30%Expected life (years)Â Â 3.94Â Â Â 4.44Â Expected dividend yieldÂ Â -Â Â Â -Â Total fair valueÂ $101,097Â Â $126,649Â Â The fair value of the warrants deemed to be a liability, due to certain contingent put features, was determined using the Black-Scholes option pricing model, which was deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.Â Common Stock Issued for EpiCypher License AgreementÂ On March 12, 2024, the Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. at a price of $0.97 per share as partial consideration for license rights in connection with a License Agreement between EpiCypher and Belgian Volition.Â Equity Distribution AgreementÂ On May 20, 2022, the Company entered into an equity distribution agreement (the â€œ2022 EDAâ€) with Jefferies LLC (â€œJefferiesâ€) to sell shares of the Companyâ€™s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an â€œat the marketâ€ offering pursuant to the Companyâ€™s Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021) (the â€œ2021 Form S-3â€) through Jefferies acting as the Companyâ€™s agent and/or principal.Â The Company is not obligated to sell any shares under the 2022 EDA.Â Â During the six months ended June 30, 2024, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $605,221 under the 2022 EDA through the sale of 747,505 shares of its common stock. As of June 30, 2024, the Company has raised aggregate net proceeds (net of broker commissions and fees) of approximately $2.1 million under the 2022 EDA through the sale of 1,378,037 shares of its common stock. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock Based Compensation 6 Months Ended Jun. 30, 2024 Stock Based Compensation Â Stock-based Compensation Note 7 â€“ Stock-Based Compensation Â a) WarrantsÂ The following table summarizes the changes in warrants of the Company outstanding during the six-month period ended June 30, 2024.Â Â Â Number of WarrantsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 862,500Â Â Â 3.05Â GrantedÂ Â -Â Â Â -Â Expired/CancelledÂ Â -Â Â Â -Â Outstanding at June 30, 2024Â Â 862,500Â Â Â 3.05Â Â Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 862,500Â Â Â 3.05Â Â Below is a table summarizing the warrants issued and outstanding as of June 30, 2024, which have an aggregate weighted average remaining contractual life of 3.33 years.Â Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised
($)Â 448,500Â Â Â 448,500Â Â Â 2.00Â Â Â 3.96Â Â Â 897,000Â 54,000Â Â Â 54,000Â Â Â 3.05Â Â Â 4.26Â Â Â 164,700Â 50,000Â Â Â 50,000Â Â Â 3.45Â Â Â 1.67Â Â Â 172,500Â 125,000Â Â Â 12 based compensation expense related to warrants of $5,238 and $20,320 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of June 30, 2024, the total intrinsic value of warrants outstanding was $nil.Â b) OptionsÂ The following table summarizes the changes in options outstanding of the Company during the six-month period ended June 30, 2024.Â Â Â Number ofÂ OptionsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 4,699,569Â Â Â 3.87Â Expired/CancelledÂ Â (36,821)Â Â 3.40Â Outstanding at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â Â Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â b) Options (continued)Â Below is a table summarizing the options issued and outstanding as of June 30, 2024, all of which were issued pursuant to the Companyâ€™s 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (the â€œ2015 Planâ€) (for option and RSU issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 3.71 years. As of June 30, 2024, an aggregate of 9,700,000 shares of common stock were authorized for issuance under the 2015 Plan, of which 354,782 shares of common stock remained available for future issuance thereunder.Â Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised
($)Â 585,000Â Â Â 585,000Â Â Â 3.25Â Â Â 0.62Â Â Â 1,901,250Â 944,748Â Â Â 944,748Â Â Â 3.40Â Â Â 7.10Â Â Â 3,212,143Â 740,000Â Â Â 740,000Â Â Â 3.60Â Â Â 5.86Â Â Â 2,664,000Â 1,607 based compensation expense related to stock options of $nil and $235,368 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of June 30, 2024, the total intrinsic value of stock options outstanding was $nil.Â c) Restricted Stock UnitsÂ Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Â Â RSUs (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Outstanding at December 31, 2023Â Â 3,634,952Â Â Â 1.01Â GrantedÂ Â 426,340Â Â Â 0.72Â Vested/SettledÂ Â (202,261)Â Â 2.46Â Cancelled / ForfeitedÂ Â (87,206)Â Â 1.13Â Outstanding at June 30, 2024Â Â 3,771,825Â Â Â 0.89Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs granted during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipientâ€™s continued service to the Company, and will result in the RSU compensation expense stated. On June 1, 2024, the Company granted 297,340 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on May 1, 2025, subject to continued service by the recipient.Â EquityÂ IncentiveÂ PlanÂ RSUs Granted (#)Â Â Grant DateÂ Vesting PeriodÂ First Vesting DateÂ Second Vesting DateÂ Â Third Vesting DateÂ Â RSU Expense
($)Â 2015Â Â 14,000Â Â Â Feb 22, 2024Â 36 MonthsÂ Â Feb 22, 2025Â Â Feb 22, 2026Â Â Â Feb 22, 2027Â Â Â 13,589Â 2015Â Â 115,000Â Â Â May 23, 2024Â 36 MonthsÂ Â May 23, 2025Â Â May 23, 2026Â Â Â May 23, 2027Â Â Â 85,389Â 2015Â Â 297,340Â Â Â Jun 1, 2024Â 11 MonthsÂ Â May 1, 2025Â Â N/AÂ Â Â N/AÂ Â Â 209,832Â Â Â Â 426,340Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 308,810Â Â Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â Â 153,356Â Â Â 48,905Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs cancelled during the six months ended June 30, 2024, all of which were originally issued pursuant to the 2015 Plan.Â Equity Incentive PlanÂ RSUs (#)Â Â Cancellation DateÂ Vesting DateÂ RSUs Cancelled (#)Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2024Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2024Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2025Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2025Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2026Â Â 8,000Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2024Â Â 667Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2025Â Â 667Â 2015Â Â 666Â Â Â Feb 9, 2024Â Â Jun 15, 2026Â Â 666Â 2015Â Â 1,775Â Â Â Mar 25, 2024Â Â Mar 27, 2024Â Â 1,775Â 2015Â Â 2,098Â Â Â Mar 25, 2024Â Â Jun 15, 2024Â Â 2,098Â 2015Â Â 2,667Â Â Â May 17, 2024Â Â Oct 4, 2024Â Â 2,667Â 2015Â Â 2,666Â Â Â May 17, 2024Â Â Oct 4, 2025Â Â 2,666Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2025Â Â 1,000Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2026Â Â 1,000Â 2015Â Â 3,334Â Â Â May 17, 2024Â Â Sep 28, 2024Â Â 3,334Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2025Â Â 3,333Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2026Â Â 3,333Â 2015Â Â 9,334Â Â Â May 31, 2024Â Â Sep 11, 2024Â Â 9,334Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2025Â Â 9,333Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2026Â Â 9,333Â Â Â Â 87,206Â Â Â Â Â Â 87,206Â c) Restricted Stock Units (continued)Â Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024 and which have an aggregate weighted average remaining contractual life of 1.37 years.Â RSUs Outstanding (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â 40,000Â Â Â 0.58Â Â Â 1.37Â 450,000Â Â Â 0.68Â Â Â 2.80Â 450,000Â Â Â 0.69Â Â Â 1.76Â 1,535,000Â Â Â 0.70Â Â Â 1.25Â 297,340Â Â Â 0.71Â Â Â 0.84Â 115,000Â Â Â 0.74Â Â Â 1.90 based compensation expense related to RSUs of $614,028 and $1,030,143 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,256,598. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Â Commitments And Contingencies Note 8 â€“ Commitments and ContingenciesÂ a) Finance Lease ObligationsÂ The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2024.Â 2024 - remainingÂ $28,840Â 2025Â $57,672Â 2026Â $57,661Â 2027Â $57,647Â 2028Â $57,633Â Greater than 5 yearsÂ $194,395Â TotalÂ $453,848Â Less: Amount representing interestÂ $(42,203)Present value of minimum lease paymentsÂ $411,645Â Â b) Operating Lease Right-of-Use ObligationsÂ Operating leases as of June 30, 2024, and December 31, 2023, consisted of the following:Â Â Â Â June 30, 2024Â Â Â December 31, 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

least 30 daysâ€™ prior written notice. Unless earlier terminated, the Second A&R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of June 30, 2024, $146,221 is payable under the Second A&R Master Agreement, and up to $363,778 may be payable by the Company in future periods for services rendered. Â VolitionRx Â On February 5, 2024, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024. As of June 30, 2024, the maximum has been drawn down under this agreement and the principal balance payable was $163,668. The agreement is in relation to the directors and officers insurance policy.g) Legal ProceedingsÂ In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company knows of no legal proceedings which the Company believes will have a material adverse effect on its financial position.Â h) Commitments in Respect of Corporate Goals and Performance-Based AwardsÂ As of June 30, 2024, the Company has recognized total compensation expense of $1,291,594 of which $527,940 is in relation to RSUs from grants in 2022 that vested in 2023, $451,490 is in relation to RSUs from such grants that will vest in 2024, and $312,164 is in relation to RSUs from such grants that will vest in 2025. The Company has unrecognized compensation expense of $282,823 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.Â Total Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â AmortizedÂ Â Un-AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2022Â Â Â $Â Â Â Â $ Â Â Â $Â Â Â $ Â Â $Â 527,940Â Â 2023Â Â -Â Â Â 393,853Â Â Â 134,087Â Â Â -
Â 517,613Â Â 2024Â Â 126,283Â Â Â 260,119Â Â Â 65,088Â Â Â 66,123Â 528,864Â Â 2025Â Â 87,894Â Â Â 177,584Â Â Â 46,686Â Â Â 216,700Â 1,574,417Â Â Â Â Â 214,177Â Â Â 831,556Â Â Â 2
September 2023, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around revenue, operations and regulatory, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Pursuant to the terms of the grants, conditional upon the achievement by December 31, 2023 and June 30, 2024 of specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients to the Company, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of June 30, 2024, the Company has accrued compensation expense of $536,535 in relation to cash bonuses payable on the achievement of specified corporate goals based on the expected outcomes related to the prescribed performance targets. To the extent this is payable, this cash bonus compensation payment has currently been deferred indefinitely.Â As of June 30, 2024, the Company had recognized total compensation expense of $335,013. The Company has unrecognized compensation expense of $390,276 in relation to the RSUs from grants in 2023, of which $59,290 is in relation to RSUs that will vest in 2024, $150,277 in relation to RSUs that will vest in 2025, and $180,709 in relation to RSUs that will vest in 2026 based on the outcomes related to the prescribed performance targets on the outstanding awards.Â Total Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â Un-
AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2024Â $Â Â Â Â $ Â Â Â $ Â Â $
Â 241,771Â Â 2024Â Â 118,511Â Â Â 63,970Â Â Â 59,290Â 241,764Â Â 2025Â Â 59,416Â Â Â 32,071Â Â Â 150,277Â 241,754Â Â 2026Â Â 39,645Â Â Â 21,400Â Â Â 180,709Â 725,289Â Â Â Â Â 21
X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events Â Subsequent Events Note 9 â€“ Subsequent EventsÂ Settlement of RSUsÂ On July 13, 2024,Â 4,667Â RSUs previously granted to various employees vested and resulted in the issuance ofÂ 3,165Â shares of common stock. 1,502 shares of common stock were withheld for taxes and returned to the 2015 Plan.Â RSUs GrantedÂ Effective July 1, 2024, the Company granted RSUs of 38,198 shares of common stock to an employee of the Company in exchange their valid election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the employee.Â Effective July 8, 2024, the Company granted RSUs of 21,583 shares of common stock to an advisor of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. These RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025, subject to continued service, and will result in total compensation expense of $13,209.Â RSUs CancelledÂ On July 12, 2024, 19,666 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting.Â On August 4, 2024, 46,333 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting.Â Increase in Authorised CapitalÂ At the Annual Meeting on July 2, 2024, the Companyâ€™s stockholders approved a Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation providing for an increase in authorized shares from one hundred million (100,000,000) to one hundred seventy-five million (175,000,000) shares, consisting of one hundred seventy-five million (175,000,000) shares of common stock, par value $0.001 per share. Â Equity Capital RaiseÂ On August 8, 2024, the Company entered into a securities purchase agreement with a purchaser pursuant to which the Company issued and sold to such purchaser, in a registered direct offering under the 2021 Form S-3, an aggregate of 9,170,000 shares of the Companyâ€™s common stock, pre-funded warrants to purchase up to 3,557,273 shares of the Companyâ€™s common stock (the â€œPre-Funded Warrantsâ€), Series A common stock warrants to purchase up to 12,727,273 shares of the Companyâ€™s common stock (the â€œSeries A Warrantsâ€) and Series B common stock warrants to purchase up to 12,727,273 shares of the Companyâ€™s common stock (the â€œSeries B Warrantsâ€ and, together with the Series A Warrants, the â€œCommon Warrantsâ€).Â The exercise prices of the Pre-Funded Warrants and the Common Warrants are $0.001 per share and $0.57 per share, respectively.Â H.C. Wainwright & Co. acted as the exclusive placement agent for the Company in the offering.Â The combined offering price for a share of common stock and accompanying Common Warrants was $0.55 and the combined offering price for a Pre-Funded Warrant and accompanying Common Warrants was $0.549.Â The net proceeds received by the Company for the issuance and sale of the shares of Common Stock, the Pre-Funded Warrants and the Common Warrants (collectively, the â€œSecuritiesâ€) was $6.4 million, before deducting offering expenses of $0.1 million paid by the Company.Â In addition, the Company issued warrants to purchase an aggregate of 381,818 shares of Company common stock to the placement agent, on substantially the same terms as the Series B Warrants at an exercise price of $0.6875 per share.Â The net proceeds above assumes the exercise of the Pre-Funded Warrants but excludes any proceeds arising from the exercise of the Common Warrants or the Placement Agent Warrants. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Basis of Presentation and Summary of Significant Accounting Policies Â Basis Of Presentation The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the â€œCompanyâ€ or â€œVolitionRxâ€) have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the â€œAnnual Reportâ€). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Reclassification Certain reclassifications within operating expenses have been made to the prior periodâ€™s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.Â The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements. Fair Value Measurements Pursuant to ASC 820, â€œFair Value Measurements and Disclosures,â€ an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrumentâ€™s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:Â Level 1Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.Â Level 2Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.Â Level 3Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.Â The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period.Â Included in the following table are the Companyâ€™s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024.Â Fair Value Measurements at June 30,
2024Â DescriptionÂ Level 1Â Â Level 2Â Â Level 3Â Â TotalÂ Â Â Â $Â Â Â $Â Â Â $Â Â Â $Â LiabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilityÂ Â -Â Â Â 101,097Â Â Â -Â Â Â 101,097Â As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows:Â Warrant LiabilityÂ Â Â Â TotalÂ Â Â $Â Balance at December 31, 2023Â Â 126,649Â Gain on change in fair value of warrant liabilityÂ Â (25,552)Balance at June 30, 2024Â Â 101,097Â Basic And Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, â€œEarnings Per Share,â€ which requires presentation of both basic and diluted earnings per share (â€œEPSâ€) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, 2024, 9,297,073 potential common shares equivalents from warrants, options, and restricted stock units (â€œRSUsâ€) were excluded from the diluted EPS calculations as their effect is anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ReclassificationsPolicyTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Basis of Presentation and Summary of Significant Accounting Policies Â Schedule Of assets and liabilities measured at fair value on a recurring basis Fair Value Measurements at June 30,

2024Â DescriptionÂ Level 1Â Â Level 2Â Â Level 3Â Â TotalÂ Â Â Â $Â Â Â $Â Â Â $Â Â Â $Â LiabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilityÂ Â - Â Â Â 101,097Â Â Â -Â Â Â 101,097Â Schedule Of warrant liability measured at fair value Warrant LiabilityÂ Â Â Â TotalÂ Â Â $Â Balance at December 31, 2023Â Â 126,649Â Gain on change in fair value of warrant liabilityÂ Â (25,552)Balance at June 30, 2024Â Â 101,097Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfWarrantLiabilityFairValueTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Tables) 6 Months Ended Jun. 30, 2024 Property and Equipment Â Schedule Of Property And Equipment Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â Useful LifeÂ Cost $Â Â Cost $Â Computer hardware and softwareÂ 3 yearsÂ Â 723,206Â Â Â 724,534Â Laboratory equipmentÂ 5 yearsÂ Â 4,630,385Â Â Â 4,753,253Â Office furniture and equipmentÂ 5 yearsÂ Â 370,493Â Â Â 378,800Â BuildingsÂ 30 yearsÂ Â 2,049,211Â Â Â 2,113,031Â Building improvementsÂ 5-15 yearsÂ Â 1,574,428Â Â Â 1,610,016Â LandÂ Not amortizedÂ Â 128,467Â Â Â 132,468Â Total property and equipmentÂ Â Â Â 9,476,190Â Â Â 9,712,102Â Less accumulated depreciationÂ Â Â Â 4,597,773Â Â Â 4,189,089Â Total property and equipment netÂ Â Â Â 4,878,417Â Â Â 5,523,013Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 980 -SubTopic 20 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481834/980-20-45-1 + Details Name: us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Intangible Assets Â Schedule Of Intangible Assets Â Â June 30, 2024Â Â December 31, 2023Â Â Â Cost $Â Â Cost $Â PatentsÂ Â Â 1,098,717Â Â Â 1,130,936Â LicensesÂ Â 296,353Â Â Â -Â Total Patents and LicensesÂ Â 1,395,070Â Â Â 1,130,936Â Less accumulated amortizationÂ Â 1,062,849Â Â Â 1,107,050Â Total patents and Licenses, netÂ Â 332,221Â Â Â 23,886Â Schedule Of Annual Estimated Amortization 2024Â $16,057Â 2025Â $20,448Â 2026Â $20,448Â 2027Â $20,448Â 2028Â $20,448Â Greater than 5 yearsÂ $234,372Â Total Intangible AssetsÂ $332,221Â X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock (Tables) 6 Months Ended Jun. 30, 2024 Common Stock Â Summary of RSUs vested and settled during period Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â 153,356Â Â Â 48,905Â Schedule of fair value of the warrants Â Â June 30, 2024Â Â December 31, 2023Â Â Â Â Â Â Â Risk-free interest rateÂ Â 4.43%Â Â 3.89%Expected volatilityÂ Â 82.80%Â Â 76.30%Expected life (years)Â Â 3.94Â Â Â 4.44Â Expected dividend yieldÂ Â -Â Â Â -Â Total fair valueÂ $101,097Â Â $126,649Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfFairValueOfWarrantsTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Stock Based Compensation Â Summary Of Changes In Warrants Outstanding Â Â Number of WarrantsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 862,500Â Â Â 3.05Â GrantedÂ Â -Â Â Â -Â Expired/CancelledÂ Â -Â Â Â -Â Outstanding at June 30, 2024Â Â 862,500Â Â Â 3.05Â Â Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 862,500Â Â Â 3.05Â Summarizing The Warrants Issued And Outstanding Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised ($)Â 448,500Â Â Â 448,500Â Â Â 2.00Â Â Â 3.96Â Â Â 897,000Â 54,000Â Â Â 54,000Â Â Â 3.05Â Â Â 4.26Â Â Â 164,700Â 50,000Â Â Â 50,000Â Â Â 3.45Â Â Â 1.67Â Â Â 172,500Â 125,000Â Â Â 12 Summarizes The Changes In Options Outstanding Â Â Number ofÂ OptionsÂ Â Weighted Average Exercise Price ($)Â Outstanding at December 31, 2023Â Â 4,699,569Â Â Â 3.87Â Expired/CancelledÂ Â (36,821)Â Â 3.40Â Outstanding at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â Â Â Â Â Â Â Â Â Â Exercisable at June 30, 2024Â Â 4,662,748Â Â Â 3.88Â Summarizing The Options Issued And Outstanding Number OutstandingÂ Â Number ExercisableÂ Â Exercise Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â Â Proceeds to Company if Exercised ($)Â 585,000Â Â Â 585,000Â Â Â 3.25Â Â Â 0.62Â Â Â 1,901,250Â 944,748Â Â Â 944,748Â Â Â 3.40Â Â Â 7.10Â Â Â 3,212,143Â 740,000Â Â Â 740,000Â Â Â 3.60Â Â Â 5.86Â Â Â 2,664,000Â 1,607 Summarizing The Rsus Issued And Outstanding Â Â RSUs (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Outstanding at December 31, 2023Â Â 3,634,952Â Â Â 1.01Â GrantedÂ Â 426,340Â Â Â 0.72Â Vested/SettledÂ Â (202,261)Â Â 2.46Â Cancelled / ForfeitedÂ Â (87,206)Â Â 1.13Â Outstanding at June 30, 2024Â Â 3,771,825Â Â Â 0.89Â Schedule of RSUs granted during period EquityÂ IncentiveÂ PlanÂ RSUs Granted (#)Â Â Grant DateÂ Vesting PeriodÂ First Vesting DateÂ Second Vesting DateÂ Â Third Vesting DateÂ Â RSU Expense ($)Â 2015Â Â 14,000Â Â Â Feb 22, 2024Â Â 36 MonthsÂ Â Feb 22, 2025Â Â Feb 22, 2026Â Â Â Feb 22, 2027Â Â Â 13,589Â 2015Â Â 115,000Â Â Â May 23, 2024Â Â 36 MonthsÂ Â May 23, 2025Â Â May 23, 2026Â Â Â May 23, 2027Â Â Â 85,389Â 2015Â Â 297,340Â Â Â Jun 1, 2024Â Â 11 MonthsÂ Â May 1, 2025Â Â N/AÂ Â Â N/AÂ Â Â 209,832Â Â Â Â 426,340Â 308,810Â Schedule of RSUs vested and settled during period Equity Incentive PlanÂ RSUs Vested (#)Â Â Vest DateÂ Shares Issued (#)Â Â Shares Withheld for Taxes (#)Â 2015Â Â 21,582Â Â Â Feb 8, 2024Â Â 21,582Â Â Â -Â 2015Â Â 9,000Â Â Â Mar 1, 2024Â Â 6,057Â Â Â 2,943Â 2015Â Â 44,217Â Â Â Mar 27, 2024Â Â 40,530Â Â Â 3,687Â 2015Â Â 51,000Â Â Â Apr 4, 2024Â Â 32,337Â Â Â 18,663Â 2015Â Â 50,000Â Â Â May 1, 2024Â Â 34,496Â Â Â 15,504Â 2015Â Â 11,500Â Â Â Jun 1, 2024Â Â 6,670Â Â Â 4,830Â 2015Â Â 14,962Â Â Â Jun 15, 2024Â Â 11,684Â Â Â 3,278Â Â Â Â 202,261Â Â Â Â 153,356Â Â Â 48,905Â Schedule of RSUs cancelled Equity Incentive PlanÂ RSUs (#)Â Â Cancellation DateÂ Vesting DateÂ RSUs Cancelled (#)Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2024Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2024Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2025Â Â 8,000Â 2015Â Â 6,000Â Â Â Jan 16, 2024Â Â Oct 4, 2025Â Â 6,000Â 2015Â Â 8,000Â Â Â Jan 16, 2024Â Â Sep 28, 2026Â Â 8,000Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2024Â Â 667Â 2015Â Â 667Â Â Â Feb 9, 2024Â Â Jun 15, 2025Â Â 667Â 2015Â Â 666Â Â Â Feb 9, 2024Â Â Jun 15, 2026Â Â 666Â 2015Â Â 1,775Â Â Â Mar 25, 2024Â Â Mar 27, 2024Â Â 1,775Â 2015Â Â 2,098Â Â Â Mar 25, 2024Â Â Jun 15, 2024Â Â 2,098Â 2015Â Â 2,667Â Â Â May 17, 2024Â Â Oct 4, 2024Â Â 2,667Â 2015Â Â 2,666Â Â Â May 17, 2024Â Â Oct 4, 2025Â Â 2,666Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2025Â Â 1,000Â 2015Â Â 1,000Â Â Â May 17, 2024Â Â Mar 27, 2026Â Â 1,000Â 2015Â Â 3,334Â Â Â May 17, 2024Â Â Sep 28, 2024Â Â 3,334Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2025Â Â 3,333Â 2015Â Â 3,333Â Â Â May 17, 2024Â Â Sep 28, 2026Â Â 3,333Â 2015Â Â 9,334Â Â Â May 31, 2024Â Â Sep 11, 2024Â Â 9,334Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2025Â Â 9,333Â 2015Â Â 9,333Â Â Â May 31, 2024Â Â Sep 11, 2026Â Â 9,333Â Â Â Â 87,206Â Â Â Â Â Â Â Â 87,206Â Schedule of RSUs issued and outstanding and average contractual life RSUs Outstanding (#)Â Â Weighted Average Grant Date Fair Value Share Price ($)Â Â Weighted Average Remaining Contractual Life (Years)Â 40,000Â Â Â 0.58Â Â Â 1.37Â 450,000Â Â Â 0.68Â Â Â 2.80Â 450,000Â Â Â 0.69Â Â Â 1.76Â 1,535,000Â Â Â 0.70Â Â Â 1.25Â 297,340Â Â Â 0.71Â Â Â 0.84Â 115,000Â Â Â 0.74Â Â Â 1.90 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfRsusCancelledDuringPeriodTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfRsusGrantedDuringPeriodTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfRsusIssuedAndOutstandingAndAverageContractualLife Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfRsusVestedAndSettledDuringPeriodTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SummarizingTheRsusIssuedAndOutstandingTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SummarizingTheWarrantsIssuedAndOutstandingTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Â Schedule of future minimum lease payments under financing leases 2024 - remainingÂ $28,840Â 2025Â $57,672Â 2026Â $57,661Â 2027Â $57,647Â 2028Â $57,633Â Greater than 5 yearsÂ $194,395Â TotalÂ $453,848Â Less: Amount representing interestÂ $(42,203)Present value of minimum lease paymentsÂ $411,645Â Schedule of operating lease Â Â Â June 30, 2024Â Â Â December 31, 2023Â Â Â Â Â Â Â Operating leaseÂ right-of-use assetsÂ Â 512,317Â Â Â 549,504Â Â Â Â Â Â Â Â Â Â Operating lease liabilities, current portionÂ Â 190,099Â Â Â 199,323Â Operating lease liabilities, long termÂ Â 350,810Â Â Â 378,054Â Total operating lease liabilitiesÂ Â 540,909Â Â Â 577,377Â Â Â Â Â Â Â Â Â Â Weighted average remaining lease (months)Â Â 32Â Â Â 33Â Weighted average discount rateÂ Â 3.24%Â Â 3.02% Schedule Of Future Minimum Lease Payments Under Operating Leases For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 117,231Â 2025Â Â 191,273Â 2026Â Â 164,435Â 2027Â Â 92,151Â 2028Â Â 10,212Â TotalÂ Â 575,302Â Less: imputed interestÂ Â (34,393)Total Operating Lease LiabilitiesÂ Â 540,909Â Schedule Of Recognized In Short-term Lease Costs For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 42,723Â 2025Â Â 7,198Â Total Operating Lease LiabilitiesÂ Â 49,921Â Schedule Of Grants Repayable For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 54,169Â 2025Â Â 36,305Â 2026Â Â 43,756Â 2027Â Â 48,579Â 2028Â Â 51,951Â Greater than 5 years Â Â 229,348Â Total Grants Repayable Â Â 464,108Â Schedule Of Long-term Debt Payable For the Six Months Ending June 30, 2024Â AmountÂ Â Â $Â 2024 - RemainingÂ Â 859,476Â 2025Â Â 1,005,297Â 2026Â Â 781,901Â 2027Â Â 583,641Â 2028Â Â 2,437,212Â Greater than 5 yearsÂ Â 314,022Â TotalÂ Â 5,981,549Â Less: amount representing interestÂ Â (1,073,050)Total Long-Term DebtÂ Â 4,908,499Â Schedule of annual payments Of Collaborative Agreement Obligations Â Â Total Amount RemainingÂ Â 2024 - EstimatedÂ Â Â Â $Â Â Â $Â Â Â $Â National University of Taiwan Â Â 510,000Â Â Â 510,000Â Â Â -Â MD Anderson Cancer CenterÂ Â 449,406Â Â Â 285,860Â Â Â 163,546Â Guys and St ThomasÂ Â 164,235Â Â Â 61,588Â Â Â 102,647Â Xenetic BiosciencesÂ Â 81,447Â Â Â 26,142Â Â Â 55,305Â UMCÂ Â 138,653Â Â Â 92,343Â Â Â 46,310Â Total Collaborative ObligationsÂ Â Â 1,343,741Â Â Â 975,933Â Â Â 367,808Â Schedule of commitments in respect of corporate goals and performance based awards Total Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â AmortizedÂ Â Un-AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2022Â Â Â Â $Â Â Â Â $Â Â Â Â $Â Â Â $Â 527,940Â Â 2023Â Â - Â Â Â 393,853Â Â Â 134,087Â Â Â - Â 517,613Â Â 2024Â Â 126,283Â Â Â 260,119Â Â Â 65,088Â Â Â 66,123Â 528,864Â Â 2025Â Â 87,894Â Â Â 177,584Â Â Â 46,686Â Â Â 216,700Â 1,574,417Â Â Â Â Â Â 214,177Â Â Â 831,556Â Â Â 2 Â Â VestingÂ AmortizedÂ Â AmortizedÂ Â Un-AmortizedÂ AwardÂ Â Â YearÂ 2024Â Â 2023Â Â 2024Â $Â Â Â Â $Â Â Â Â $Â Â Â $

Â 241,771Â Â 2024Â Â 118,511Â Â Â 63,970Â Â Â 59,290Â 241,764Â Â 2025Â Â 59,416Â Â Â 32,071Â Â Â 150,277Â 241,754Â Â 2026Â Â 39,645Â Â Â 21,400Â Â Â 180,709Â 725,289Â Â Â Â Â 21 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-2 + Details Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfOperatingLeaseTableTextblock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleOfRecognizedInShortTermLeaseCostsTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ScheduleofCommitmentsInRespectOfCorporateGoalsAndPerformanceBasedAwardsTableTextBlock Namespace Prefix: vnrx_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Warrant liability $ 101,097 $ 126,649 Fair Value Inputs Level 1 [Member] Â Â Warrant liability 0 Â Fair Value Inputs Level 2 [Member] Â Â Warrant liability 101,097 Â Fair Value Inputs Level 3 [Member] Â Â Warrant liability $ 0 Â X - ReferencesNo definition available. + Details Name: vnrx_WarrantLiabilityFairValueOnRecurringBasis Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies (Details 1) 6 Months Ended Jun. 30, 2024 USD ($) Basis of Presentation and Summary of Significant Accounting Policies Â Warrant Liability beginning balance $ 126,649 Gain on change in fair value of warrant liability (25,552) Warrant Liability ending balance $ 101,097 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(4)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481229/860-50-50-3 + Details Name: us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WarrantLiabilityFairValueOnRecurringBasis Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($) 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Basis of Presentation and Summary of Significant Accounting Policies Â Â Warrant Liability $ 101,097 $ 126,649 Potentially Dilutive Securities Excluded From The Computation Of Eps 9,297,073 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WarrantLiabilityFairValueOnRecurringBasis Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liquidity and Going Concern Assessment (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Accumulated deficit $ (217,929,441) Â Â Â $ (217,929,441) Â $ (202,576,507) Cash flows from operating activities Â Â Â Â (15,074,388) $ (16,092,324) Â Net Loss (7,060,175) $ (8,472,005) $ (9,551,277) $ (8,872,909) (15,532,180) $ (18,424,186) Â Liquidity and Going Concern Assessment [Member] Â Â Â Â Â Â Â Accumulated deficit (217,900,000) Â Â Â (217,900,000) Â Â Cash and cash equivalents $ 6,000,000.0 Â Â Â 6,000,000.0 Â Â Cash flows from operating activities Â Â Â Â 15,100,000 Â Â Net Loss Â Â Â Â $ (15,500,000) Â Â X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PlanNameAxis=vnrx_LiquidityAndGoingConcernAssessmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Details) - USD ($) 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Total property and equipment $ 9,476,190 $ 9,712,102 Less accumulated depreciation 4,597,773 4,189,089 Total property and equipment net 4,878,417 5,523,013 Computer Hardware And Software [Member] Â Â Total property and equipment $ 723,206 724,534 Estimated useful life 3 years Â Laboratory Equipment [Member] Â Â Total property and equipment $ 4,630,385 4,753,253 Estimated useful life 5 years Â Office Furniture and Equipment [Member] Â Â Total property and equipment $ 370,493 378,800 Estimated useful life 5 years Â Buildings [Member] Â Â Total property and equipment $ 2,049,211 2,113,031 Estimated useful life 30 years Â Building Improvements [Member] Â Â Total property and equipment $ 1,574,428 1,610,016 Building Improvements [Member] | Minimum [Member] Â Â Estimated useful life 5 years Â Building Improvements [Member] | Maximum [Member] Â Â Estimated useful life 15 years Â Land [Member] Â Â Total property and equipment $ 128,467 $ 132,468 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_PropertyPlantsAndEquipmentUsefulLife Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnrx_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnrx_LandsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Details Narrative) - USD ($) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Property and Equipment Â Â Depreciation Expense $ 545,128 $ 517,921 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Total Patents and Licenses $ 1,395,070 $ 1,130,936 Less accumulated amortization 1,062,849 1,107,050 Total patents and Licenses, net 332,221 23,886 Patents [Member] Â Â Total Patents and Licenses 1,098,717 1,130,936 Licenses [Member] Â Â Total Patents and Licenses $ 296,353 $ 0 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_LicensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details 1) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Intangible Assets Â Â 2024 $ 16,057 Â 2025 20,448 Â 2026 20,448 Â 2027 20,448 Â 2028 20,448 Â Greater than 5 years 234,372 Â Total Intangible Assets $ 332,221 $ 23,886 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details Narrative) - USD ($) 6 Months Ended Jun. 30, 2024

Jun. 30, 2023 Amortization Expense $ (12,624) $ 42,392 Minimum [Member] | Patents And Intellectual Property [Member] Â Â Amortization Of Patents On Straight Line Basis 8 years Â Maximum [Member] | Patents And Intellectual Property [Member] Â Â Amortization Of Patents On Straight Line Basis 20 years Â X - ReferencesNo definition available. + Details Name: vnrx_AmortizationAndAccretionExpense Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_PatentsAndIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock (Details) 6 Months Ended Jun. 30, 2024 USD ($) shares Equity Incentive RSU 202,261 Incentive RSU Issued 153,356 RSUs Held for Taxes | $ $ 48,905 Equity Incentive Plan One [Member] Â Incentive Plan 2015 Equity Incentive RSU 21,582 Incentive Vest Date Feb. 08, 2024 Incentive RSU Issued 21,582 RSUs Held for Taxes | $ $ 0 Equity Incentive Plan Two [Member] Â Incentive Plan 2015 Equity Incentive RSU 9,000 Incentive Vest Date Mar. 01, 2024 Incentive RSU Issued 6,057 RSUs Held for Taxes | $ $ 2,943 Equity Incentive Plan Three [Member] Â Incentive Plan 2015 Equity Incentive RSU 44,217 Incentive Vest Date Mar. 27, 2024 Incentive RSU Issued 40,530 RSUs Held for Taxes | $ $ 3,687 Equity Incentive Plan Four [Member] Â Incentive Plan 2015 Equity Incentive RSU 51,000 Incentive Vest Date Apr. 04, 2024 Incentive RSU Issued 32,337 RSUs Held for Taxes | $ $ 18,663 Equity Incentive Plan Five [Member] Â Incentive Plan 2015 Equity Incentive RSU 50,000 Incentive Vest Date May 01, 2024 Incentive RSU Issued 34,496 RSUs Held for Taxes | $ $ 15,504 Equity Incentive Plan Six [Member] Â Incentive Plan 2015 Equity Incentive RSU 11,500 Incentive Vest Date Jun. 01, 2024 Incentive RSU Issued 6,670 RSUs Held for Taxes | $ $ 4,830 Equity Incentive Plan Seven [Member] Â Incentive Plan 2015 Equity Incentive RSU 14,962 Incentive Vest Date Jun. 15, 2024 Incentive RSU Issued 11,684 RSUs Held for Taxes | $ $ 3,278 X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentiveRsu Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentivePlan Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveRsuIssued Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveVestDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RsusHeldForTaxes Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock (Details 1) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Common Stock Â Â Risk-free interest rate 4.43% 3.89% Expected volatility 82.80% 76.30% Expected term (years) 3 years 11 months 8 days 4 years 5 months 8 days Expected dividend yield 0.00% 0.00% Total fair value $ 101,097 $ 126,649 X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ShareBasedGoodsAndNonemployeeServiceTransactionsValuationMethodExpectedVolatilityRate Namespace Prefix: vnrx_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendsRate Namespace Prefix: vnrx_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTermYear1 Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRates Namespace Prefix: vnrx_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_TotalFairValueOfWarrants Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock (Details Narrative) - USD ($) 1 Months Ended 6 Months Ended 12 Months Ended Mar. 12, 2024 Apr. 16, 2024 Jun. 30, 2023 May 20, 2022 Jun. 30, 2024 Dec. 31, 2023 Common stock price per share Â Â Â Â $ 0.001 Â Common stock, shares authorized Â Â Â Â 100,000,000 Â Common stock, shares issued Â Â Â Â 82,928,314 81,898,321 Common stock, shares outstanding Â Â Â Â 82,928,314 81,898,321 Total fair value Â Â Â Â $ 101,097 $ 126,649 2015 [Member] Â Â Â Â Â Â Vested stock options Â 36,821 Â Â Â Â Underwriting Agreement [Member] Â Â Â Â Â Â Total fair value Â Â Â Â $ 101,097 $ 126,649 Warrants issued to purchase shares of common stock Â Â 448,500 Â Â Â Exercise price Â Â $ 2.00 Â Â Â EpiCypher License Agreement [Member] Â Â Â Â Â Â Common stock price per share $ 0.97 Â Â Â Â Â Issuance of restricted common stock 129,132 Â Â Â Â Â Equity Distribution Agreement [Member] Â Â Â Â Â Â Common stock shares sold Â Â Â Â 747,505 Â Aggeregate share of common stock offering price Â Â Â $ 25,000,000.0 Â Â Aggregate net proceeds Â Â Â Â $ 605,221 Â 2022 EDA [Member] Â Â Â Â Â Â Common stock shares sold Â Â Â Â 1,378,037 Â Commissions and fee Â Â Â Â $ 2,100,000 Â X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrimarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SalesCommissionsAndFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AggeregateShareOfCommonStockOfferingPrice Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AggregateNetProceeds Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockPricePerShares Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_CommonStockShareAuthorized Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_ExercisePricePerShareOfWarrants Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_TotalFairValueOfWarrants Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WarrantsIssuedDuringPeriodSharesPurchaseOfCommonStock Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_EpiCypherLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_EquityDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_TwentyTwentyTwoEDAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details) - Warrants [Member] 6 Months Ended Jun. 30, 2024 $ / shares shares Number of warrants Outstanding beginning balance | shares 862,500 Number of warrants outstanding ending balance | shares 862,500 Number of Warrants Exercisable | shares 862,500 Weighted Average Exercise Price Outstanding balance $ 3.05 Weighted Average Exercise Price, Granted 0 Weighted Average Exercise Price, Expired/Cancelled 0 Weighted Average Exercise Price, ending balance 3.05 Weighted Average Exercise Price, exercisable $ 3.05 X - ReferencesNo definition available. + Details Name: vnrx_NumberOfWarrantsExercisable Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfWarrantsOutstandingBeginningBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfWarrantsOutstandingEndingBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceEndingBalanceOne Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceExercisable Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceOutstandingBalanceOne Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedExercisePriceExpired Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedExercisePriceGrantedDuringPeriod Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 1) 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Warrants [Member] Â Number Exercisable 862,500 Proceeds to Company if Exercised | $ $ 2,634,450 Number Outstanding 862,500 Warrant One [Member] Â Number Exercisable 448,500 Exercise Price | $ / shares $ 2.00 Proceeds to Company if Exercised | $ $ 897,000 Weighted Average Remaining Contractual Life (Years) 3 years 11 months 15 days Number Outstanding 448,500 Warrant Two [Member] Â Number Exercisable 54,000 Exercise Price | $ / shares $ 3.05 Proceeds to Company if Exercised | $ $ 164,700 Weighted Average Remaining Contractual Life (Years) 4 years 3 months 3 days Number Outstanding 54,000 Warrant Three [Member] Â Number Exercisable 50,000 Exercise Price | $ / shares $ 3.45 Proceeds to Company if Exercised | $ $ 172,500 Weighted Average Remaining Contractual Life (Years) 1 year 8 months 1 day Number Outstanding 50,000 Warrants Four [Member] Â Number Exercisable 125,000 Exercise Price | $ / shares $ 3.95 Proceeds to Company if Exercised | $ $ 493,750 Weighted Average Remaining Contractual Life (Years) 2 years 6 months 3 days Number Outstanding 125,000 Warrants Five [Member] Â Number Exercisable 185,000 Exercise Price | $ / shares $ 4.90 Proceeds to Company if Exercised | $ $ 906,500 Weighted Average Remaining Contractual Life (Years) 2 years 7 months 2 days Number Outstanding 185,000 X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ExercisePrice Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 2) - Option [Member] 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Number of options outstanding beginning balance | shares 4,699,569 Number of options, Expired/Cancelled | $ $ (36,821) Number of option outstanding ending balance | shares 4,662,748 Number of options, exercisable | shares 4,662,748 Weighted Average Exercise Price Outstanding balance $ 3.87 Weighted Average Exercise Price expires/cancelled 3.40 Weighted Average Exercise Price ending balance 3.88 Weighted Average Exercise Price exercisable balance $ 3.88 X - ReferencesNo definition available. + Details Name: vnrx_NumberOfExpiredCancelled Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfOptionOutstandingEndingBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfOptionsExercisable Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfOptionsOutstandingBeginningBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceEndingBalance Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceExercisableBalance Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageExercisePriceOutstandingBalance Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 3) 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Option Six [Member] Â Number Exercisable, shares 50,000 Exercise Price | $ / shares $ 4.80 Weighted Average Remaining Contractual Life (years) 2 years 6 months 3 days Proceeds to Company if Exercised | $ $ 240,000 Number Outstanding, shares 50,000 Option Seven [Member] Â Number Exercisable, shares 646,000 Exercise Price | $ / shares $ 5.00 Weighted Average Remaining Contractual Life (years) 2 years 8 months 26 days Proceeds to Company if Exercised | $ $ 3,230,000 Number Outstanding, shares 646,000 Options One [Member] Â Number Exercisable, shares 585,000 Exercise Price | $ / shares $ 3.25 Weighted Average Remaining Contractual Life (years) 7 months 13 days Proceeds to Company if Exercised | $ $ 1,901,250 Number Outstanding, shares 585,000 Option Two [Member] Â Number Exercisable, shares 944,748 Exercise Price | $ / shares $ 3.40 Weighted Average Remaining Contractual Life (years) 7 years 1 month 6 days Proceeds to Company if Exercised | $ $ 3,212,143 Number Outstanding, shares 944,748 Option Three [Member] Â Number Exercisable, shares 740,000 Exercise Price | $ / shares $ 3.60 Weighted Average Remaining Contractual Life (years) 5 years 10 months 9 days Proceeds to Company if Exercised | $ $ 2,664,000 Number Outstanding, shares 740,000 Option Four [Member] Â Number Exercisable, shares 1,607,837 Exercise Price | $ / shares $ 4.00 Weighted Average Remaining Contractual Life (years) 2 years 2 months 26 days Proceeds to Company if Exercised | $ $ 6,431,348 Number Outstanding, shares 1,607,837 Option Five [Member] Â Number Exercisable, shares 89,163 Exercise Price | $ / shares $ 4.38 Weighted Average Remaining Contractual Life (years) 3 years 6 months 25 days Proceeds to Company if Exercised | $ $ 390,534 Number Outstanding, shares 89,163 Total Option [Member] Â Number Exercisable, shares 4,662,748 Proceeds to Company if Exercised | $ $ 18,069,275 Number Outstanding, shares 4,662,748 X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=vnrx_OptionSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=vnrx_OptionSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 4) - Stock Options [Member] 6 Months Ended Jun. 30, 2024 $ / shares shares Number Of Rsus Outstanding Begining Balance shares | shares 3,634,952 Granted | shares 426,340 Vested/Settled | shares (202,261) Cancelled / Forfeited | shares (87,206) Number Of Rsus Outstanding ending Balance | shares 3,771,825 Share Price Beginning Balance shares | $ / shares $ 1.01 Share Price Granted | $ / shares 0.72 Share Price Vested/Settled | $ / shares 2.46 Share Price Cancelled / Forfeited | $ / shares 1.13 Share Price ending Balance | $ / shares $ 0.89 X - ReferencesNo definition available. + Details Name: vnrx_GrantedShares Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfRsusOutstandingBeginingBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_NumberOfRsusOutstandingEndingBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_NumberOfStockCancelled Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_NumberOfStockVested Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SharePriceBeginningBalance Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_SharePriceCancelled Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SharePriceEndingBalance Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_SharePriceGranted Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SharePriceVested Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=vnrx_StockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 5) 6 Months Ended Jun. 30, 2024 USD ($) shares Compensation Expense RSUs | shares 426,340 RSU Expense | $ $ 308,810 Compensation Expense One [Member] Â Compensation Expense RSUs | shares 14,000 Equity Incentive Plan 2015 Compensation Expense grant date Feb. 22, 2024 Compensation Expense Vesting Period 36 Months First Vesting date Feb. 22, 2025 RSU Expense | $ $ 13,589 Second vesting date Feb. 22, 2026 Third vesting date Feb. 22, 2027 Compensation Expense Two [Member] Â Compensation Expense RSUs | shares 115,000 Equity Incentive Plan 2015 Compensation Expense grant date May 23, 2024 Compensation Expense Vesting Period 36 Months First Vesting date May 23, 2025 RSU Expense | $ $ 85,389 Second vesting date May 23, 2026 Third vesting date May 23, 2027 Compensation Expense Three [Member] Â Compensation Expense RSUs | shares 297,340 Equity Incentive Plan 2015 Compensation Expense grant date Jun. 01, 2024 Compensation Expense Vesting Period 11 Months First Vesting date May 01, 2025 RSU Expense | $ $ 209,832 X - ReferencesNo definition available. + Details Name: vnrx_CompensationExpenseGrantDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CompensationExpenseRsus Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CompensationExpenseVestingPeriod Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentivePlan Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_FirstVestingDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RsuExpense Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SecondVestingDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ThirdVestingDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=vnrx_CompensationExpenseOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=vnrx_CompensationExpenseThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 6) 6 Months Ended Jun. 30, 2024 USD ($) shares Equity Incentive RSU 202,261 Incentive RSU Issued 153,356 RSUs Held for Taxes | $ $ 48,905 Equity Incentive RSUD 202,261 Equity Incentive Plan One [Member] Â Incentive Plan 2015 Equity Incentive RSU 21,582 Incentive Vest Date Feb. 08, 2024 Incentive RSU Issued 21,582 RSUs Held for Taxes | $ $ 0 Equity Incentive Plan Two [Member] Â Incentive Plan 2015 Equity Incentive RSU 9,000 Incentive Vest Date Mar. 01, 2024 Incentive RSU Issued 6,057 RSUs Held for Taxes | $ $ 2,943 Equity Incentive Plan Three [Member] Â Incentive Plan 2015 Equity Incentive RSU 44,217 Incentive Vest Date Mar. 27, 2024 Incentive RSU Issued 40,530 RSUs Held for Taxes | $ $ 3,687 Equity Incentive Plan Four [Member] Â Incentive Plan 2015 Equity Incentive RSU 51,000 Incentive Vest Date Apr. 04, 2024 Incentive RSU Issued 32,337 RSUs Held for Taxes | $ $ 18,663 Equity Incentive Plan Five [Member] Â Incentive Plan 2015 Equity Incentive RSU 50,000 Incentive Vest Date May 01, 2024 Incentive RSU Issued 34,496 RSUs Held for Taxes | $ $ 15,504 Equity Incentive Plan Six [Member] Â Incentive Plan 2015 Equity Incentive RSU 11,500 Incentive Vest Date Jun. 01, 2024 Incentive RSU Issued 6,670 RSUs Held for Taxes | $ $ 4,830 Equity Incentive Plan Seven [Member] Â Incentive Plan 2015 Equity Incentive RSU 14,962 Incentive Vest Date Jun. 15, 2024 Incentive RSU Issued 11,684 RSUs Held for Taxes | $ $ 3,278 X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentiveRsu Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentiveRsuD Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentivePlan Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveRsuIssued Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveVestDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RsusHeldForTaxes Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 7) 6 Months Ended Jun. 30, 2024 shares Equity Incentive RSU 202,261 Incentive RSUs Cancelled 87,206 Equity Incentive RSU 87,206 RSUs Cancelled Plan One [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 8,000 Incentive Cancellation Date Jan. 16, 2024 Incentive Vest Date Sep. 28, 2024 Incentive RSUs Cancelled 8,000 RSUs Cancelled Plan Two [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 6,000 Incentive Cancellation Date Jan. 16, 2024 Incentive Vest Date Oct. 04, 2024 Incentive RSUs Cancelled 6,000 RSUs Cancelled Plan Three [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 8,000 Incentive Cancellation Date Jan. 16, 2024 Incentive Vest Date Sep. 28, 2025 Incentive RSUs Cancelled 8,000 RSUs Cancelled Plan Four [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 6,000 Incentive Cancellation Date Jan. 16, 2024 Incentive Vest Date Oct. 04, 2025 Incentive RSUs Cancelled 6,000 RSUs Cancelled Plan Five [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 8,000 Incentive Cancellation Date Jan. 16, 2024 Incentive Vest Date Sep. 28, 2026 Incentive RSUs Cancelled 8,000 RSUs Cancelled Plan Six [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 667 Incentive Cancellation Date Feb. 09, 2024 Incentive Vest Date Jun. 15, 2024 Incentive RSUs Cancelled 667 RSUs Cancelled Plan Seven [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 667 Incentive Cancellation Date Feb. 09, 2024 Incentive Vest Date Jun. 15, 2025 Incentive RSUs Cancelled 667 RSUs Cancelled Plan Eight [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 666 Incentive Cancellation Date Feb. 09, 2024 Incentive Vest Date Jun. 15, 2026 Incentive RSUs Cancelled 666 RSUs Cancelled Plan Nine [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 1,775 Incentive Cancellation Date Mar. 25, 2024 Incentive Vest Date Mar. 27, 2024 Incentive RSUs Cancelled 1,775 RSUs Cancelled Plan Ten [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 2,098 Incentive Cancellation Date Mar. 25, 2024 Incentive Vest Date Jun. 15, 2024 Incentive RSUs Cancelled 2,098 RSUs Cancelled Plan Eleven [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 2,667 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Oct. 04, 2024 Incentive RSUs Cancelled 2,667 RSUs Cancelled Plan Twelve [Member] Â Equity Incentive

Plan 2015 Equity Incentive RSU 2,666 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Oct. 04, 2025 Incentive RSUs Cancelled 2,666 RSUs Cancelled Plan Thirteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 1,000 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Mar. 27, 2025 Incentive RSUs Cancelled 1,000 RSUs Cancelled Plan Fourteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 1,000 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Mar. 27, 2026 Incentive RSUs Cancelled 1,000 RSUs Cancelled Plan Fifteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 3,334 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Sep. 28, 2024 Incentive RSUs Cancelled 3,334 RSUs Cancelled Plan Sixteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 3,333 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Sep. 28, 2025 Incentive RSUs Cancelled 3,333 RSUs Cancelled Plan Seventeen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 3,333 Incentive Cancellation Date May 17, 2024 Incentive Vest Date Sep. 28, 2026 Incentive RSUs Cancelled 3,333 RSUs Cancelled Plan Eighteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 9,334 Incentive Cancellation Date May 31, 2024 Incentive Vest Date Sep. 11, 2024 Incentive RSUs Cancelled 9,334 RSUs Cancelled Plan Nineteen [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 9,333 Incentive Cancellation Date May 31, 2024 Incentive Vest Date Sep. 11, 2025 Incentive RSUs Cancelled 9,333 RSUs Cancelled Plan Twenty [Member] Â Equity Incentive Plan 2015 Equity Incentive RSU 9,333 Incentive Cancellation Date May 31, 2024 Incentive Vest Date Sep. 11, 2026 Incentive RSUs Cancelled 9,333 X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentivePlan Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentiveRsu Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_EquityIncentiveRsus Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveCancellationDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveRsusCancelled Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_IncentiveVestDate Namespace Prefix: vnrx_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUCancelledPlanTenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanElevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanThirteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanFourteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanFifteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanSixteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanSeventeenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanEighteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanNineteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_RSUsCancelledPlanTwentyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details 8) 6 Months Ended Jun. 30, 2024 $ / shares shares Option Ten [Member] Â Number Of Stock Outstanding Balance 702,654 Share Price | $ / shares $ 1.46 Weighted Average Remaining Contractual Life (years) 9 months 3 days Options One [Member] Â Number Of Stock Outstanding Balance 40,000 Share Price | $ / shares $ 0.58 Weighted Average Remaining Contractual Life (years) 1 year 4 months 13 days Option Two [Member] Â Number Of Stock Outstanding Balance 450,000 Share Price | $ / shares $ 0.68 Weighted Average Remaining Contractual Life (years) 2 years 9 months 18 days Option Three [Member] Â Number Of Stock Outstanding Balance 450,000 Share Price | $ / shares $ 0.69 Weighted Average Remaining Contractual Life (years) 1 year 9 months 3 days Option Four [Member] Â Number Of Stock Outstanding Balance 1,535,000 Share Price | $ / shares $ 0.70 Weighted Average Remaining Contractual Life (years) 1 year 3 months Option Five [Member] Â Number Of Stock Outstanding Balance 297,340 Share Price | $ / shares $ 0.71 Weighted Average Remaining Contractual Life (years) 10 months 2 days Total Option [Member] Â Number Of Stock Outstanding Balance 3,771,825 Option Six [Member] Â Number Of Stock Outstanding Balance 115,000 Share Price | $ / shares $ 0.74 Weighted Average Remaining Contractual Life (years) 1 year 10 months 24 days Option Seven [Member] Â Number Of Stock Outstanding Balance 14,000 Share Price | $ / shares $ 0.97 Weighted Average Remaining Contractual Life (years) 1 year 7 months 24 days Option Eight [Member] Â Number Of Stock Outstanding Balance 6,000 Share Price | $ / shares $ 1.31 Weighted Average Remaining Contractual Life (years) 1 year 2 months 12 days Option Nine [Member] Â Number Of Stock Outstanding Balance 14,000 Share Price | $ / shares $ 1.32 Weighted Average Remaining Contractual Life (years) 1 year 14 days Option Eleven [Member] Â Number Of Stock Outstanding Balance 17,332 Share Price | $ / shares $ 1.58 Weighted Average Remaining Contractual Life (years) 8 months 23 days Option Twelve [Member] Â Number Of Stock Outstanding Balance 12,500 Share Price | $ / shares $ 1.69 Weighted Average Remaining Contractual Life (years) 2 months 23 days Option Thirteen [Member] Â Number Of Stock Outstanding Balance 54,333 Share Price | $ / shares $ 1.72 Weighted Average Remaining Contractual Life (years) 1 year 2 months 1 day Option Fourteen [Member] Â Number Of Stock Outstanding Balance 29,000 Share Price | $ / shares $ 2.01 Weighted Average Remaining Contractual Life (years) 1 month 17 days Option Fifteen [Member] Â Number Of Stock Outstanding Balance 666 Share Price | $ / shares $ 2.15 Weighted Average Remaining Contractual Life (years) 11 months 1 day Option Sixteen [Member] Â Number Of Stock Outstanding Balance 34,000 Share Price | $ / shares $ 2.95 Weighted Average Remaining Contractual Life (years) 2 months 8 days X - ReferencesNo definition available. + Details Name: vnrx_NumberOfStockOutstandingBalance Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_SharesPriceRsu Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageRemainingContractualLifeYears Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=vnrx_OptionTenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsElevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsThirteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsFourteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsFifteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsSixteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 StockBased Compensation (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Compensation Expense RSUs Â Â Â Â 426,340 Â Share-based Payment Arrangement, Noncash Expense $ 208,046 $ 411,220 $ 592,174 $ 693,657 $ 619,266 $ 1,285,831 Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Weighted Average Remaining Contractual Life Â Â Â Â 1 year 4 months 13 days Â Compensation Expense RSUs Â Â Â Â 297,340 Â Share-based Payment Arrangement, Noncash Expense Â Â Â Â $ 614,028 1,030,143 Remaining unrecognized compensation cost related to non-vested RSUs $ 1,256,598 Â Â Â 1,256,598 Â Option [Member] Â Â Â Â Â Â Share-based Payment Arrangement, Noncash Expense Â Â Â Â $ 0 235,368 Option [Member] | 2015 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Weighted Average Remaining Contractual Life Â Â Â Â 3 years 8 months 15 days Â Common Stock, Shares Authorized 9,700,000 Â Â Â 9,700,000 Â Common Stock Shares Reserved For Future Issuance 354,782 Â Â Â 354,782 Â Warrants [Member] Â Â Â Â Â Â Â Weighted Average Remaining Contractual Life Â Â Â Â 3 years 3 months 29 days Â Share-based Payment Arrangement, Noncash Expense Â Â Â Â $ 5,238 $ 20,320 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expected cost remaining for the specified restructuring cost. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_CompensationExpenseRsus Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WeightedAverageRemainingContractualLife Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) - Finance Lease Obligations [Member] Jun. 30, 2024 USD ($) 2024 - remaining $ 28,840 2025 57,672 2026 57,661 2027 57,647 2028 57,633 Greater than 5 years 194,395 Total 453,848 Less: Amount representing interest (42,203) Present value of minimum lease payments $ 411,645 X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 1) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Operating right-of-use assets $ 512,317 $ 549,504 Operating lease liabilities, current portion 190,099 199,323 Operating lease liabilities, long term 350,810 378,054 Operating Lease Right of Use Obligations [Member] Â Â Operating right-of-use assets $ 512,317 $ 549,504 Weighted average remaining lease (months) 32 months 33 months Weighted average discount rate 3.24% 3.02% Operating lease liabilities, current portion $ 190,099 $ 199,323 Operating lease liabilities, long term 350,810 378,054 Total operating lease liabilities $ 540,909 $ 577,377 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_OperatingLeaseWeightedAverageRemainingLeaseTermOne Namespace Prefix: vnrx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 2) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Less: imputed interest $ (1,073,050) Â Operating Lease Right of Use Obligations [Member] Â Â 2024 - Remaining 117,231 Â 2025 191,273 Â 2026 164,435 Â 2027 92,151 Â 2028 10,212 Â Total 575,302 Â Less: imputed interest (34,393) Â Total Operating Lease Liabilities $ 540,909 $ 577,377 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_LessImputedInterest Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 3) Jun. 30, 2024 USD ($) Commitments and Contingencies Â 2024 - Remaining $ 42,723 2025 7,198 Total Operating Lease Liabilities $ 49,921 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OperatingLeasesFutureMinimumLeasePaymentDue Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 4) Jun. 30, 2024 USD ($) Total Grants Repayable $ 464,108 Grants Repayable [Member] Â 2024 - Remaining 54,169 2025 36,305 2026 43,756 2027 48,579 2028 51,951 Greater than 5 years 229,348 Total Grants Repayable $ 464,108 X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_GrantsRepayable Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_GrantsRepayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 5) Jun. 30, 2024 USD ($) Commitments and Contingencies Â 2024 - Remaining $ 859,476 2025 1,005,297 2026 781,901 2027 583,641 2028 2,437,212 Greater than 5 years 314,022 Total 5,981,549 Less: imputed interest (1,073,050) Total Long-Term Debt $ 4,908,499 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E + Details Name: us-gaap_LongTermDebtMaturingInYearsFourAndFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10

-Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_LessImputedInterest Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 6) Jun. 30, 2024 USD ($) Total Amount Remaining $ 1,343,741 2025 - Estimated 367,808 2024 - Estimated 975,933 National Universty of Taiwan Â Total Amount Remaining 510,000 2025 - Estimated 0 2024 - Estimated 510,000 MD Anderson Cancer Center Â Total Amount Remaining 449,406 2025 - Estimated 163,546 2024 - Estimated 285,860 Guys and St Thomas Â Total Amount Remaining 164,235 2025 - Estimated 102,647 2024 - Estimated 61,588 Xentic Bioscience Â Total Amount Remaining 81,447 2025 - Estimated 55,305 2024 - Estimated 26,142 UMC Â Total Amount Remaining 138,653 2025 - Estimated 46,310 2024 - Estimated $ 92,343 X - ReferencesNo definition available. + Details Name: vnrx_Lease2024Estimated Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_Lease2025Estimated Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_TotalAmountRemainingLease Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PlanNameAxis=vnrx_NationalUniversityOfTaiwanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_MDAndersonCancerCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_GuysAndStThomasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_XenticBioscienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_UMCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 7) - Restricted stock option 6 Months Ended Jun. 30, 2024 USD ($) Outstanding Award 3 Â Outstanding award $ 527,940 Amortized of outstanding award 2024 0 Amortized of outstanding award 2023 393,853 Amortized of outstanding award 2022 $ 134,087 Vesting period 2023 Unamortized of outstanding award $ 0 Outstanding Award 4 Â Outstanding award 517,613 Amortized of outstanding award 2024 126,283 Amortized of outstanding award 2023 260,119 Amortized of outstanding award 2022 $ 65,088 Vesting period 2024 Unamortized of outstanding award $ 66,123 Outstanding Award 5 Â Outstanding award 528,864 Amortized of outstanding award 2024 87,894 Amortized of outstanding award 2023 177,584 Amortized of outstanding award 2022 $ 46,686 Vesting period 2025 Unamortized of outstanding award $ 216,700 Total Member Â Outstanding award 1,574,417 Amortized of outstanding award 2024 214,177 Amortized of outstanding award 2023 831,556 Amortized of outstanding award 2022 245,861 Unamortized of outstanding award $ 282,823 X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AmortizedOfOutstandingAwarCurrentYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AmortizedOfOutstandingAwarPreviousYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AmortizedOfOutstandingAwardPriorYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OutstandingAwardVestingPeriod Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnAmortizedOfOutstandingAward Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnamortizedOfOutstandingAward Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnzmortizedOfOutstandingAward Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_AwardThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_TotalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 8) - Restricted Stock Options Vested [Member] 6 Months Ended Jun. 30, 2024 USD ($) Total Member Â Outstanding award $ 725,289 Amortized of outstanding award 2024 217,572 Amortized of outstanding award 2023 117,441 Unamortized of outstanding award 390,276 Outstanding Award 1 Â Outstanding award $ 241,771 Vesting period 2024 Amortized of outstanding award 2024 $ 118,511 Amortized of outstanding award 2023 63,970 Unamortized of outstanding award 59,290 Outstanding Award 2 Â Outstanding award $ 241,764 Vesting period 2025 Amortized of outstanding award 2024 $ 59,416 Amortized of outstanding award 2023 32,071 Unamortized of outstanding award 150,277 Outstanding Award 3 Â Outstanding award $ 241,754 Vesting period 2026 Amortized of outstanding award 2024 $ 39,645 Amortized of outstanding award 2023 21,400 Unamortized of outstanding award $ 180,709 X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AmortizedOfOutstandingAwarCurrentYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AmortizedOfOutstandingAwarPreviousYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OutstandingAwardVestingPeriod Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnAmortizedOfOutstandingAward Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnamortizedOfOutstandingAward Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=vnrx_RestrictedStockOptionsVestedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_TotalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details Narrative) - USD ($) 6 Months Ended Feb. 05, 2024 Nov. 03, 2020 Jun. 30, 2024 Payments For Future Research And Collobration Â Â $ 1,343,741 Total Grants Repayable Â Â 464,108 Principal balance payable Â Â 163,668 Aggerate Amount Payable, Description Â under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million Â Loan agreement, Description 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024 Â Â Total Long-Term Debt Â Â 4,908,499 Amount payable for services rendered Â Â 146,221 Amount may be payable by Company in future periods for services rendered Â Â 363,778 Accrued compensation expense Â Â 536,535 Recognized total compensation expense Â Â 335,013 RSU 2023 [Member] Â Â Â Unrecognized compensation expense Â Â 390,276 RSU 2024 [Member] Â Â Â Unrecognized compensation expense Â Â 59,290 RSU 2025 [Member] Â Â Â Unrecognized compensation expense Â Â 150,277 RSU 2026 [Member] Â Â Â Unrecognized compensation expense Â Â 180,709 Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member] Â Â Â Collaborative Obligations Amount Due Â Â 204,087 Additional Cost Of Company Â Â 449,406 Cost Â Â 449,406 August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member] Â Â Â Collaborative Obligations Amount Due Â Â 0 Additional Cost Of Company Â Â 164,235 Cost Â Â 164,235 July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member] Â Â Â Collaborative Obligations Amount Due Â Â 26,142 Additional Cost Of Company Â Â 81,447 Cost Â Â 107,589 January TwoThousand Twenty Four [Member] | University Medical Centre Amsterdam[Member] Â Â Â Collaborative Obligations Amount Due Â Â 46,218 Additional Cost Of Company Â Â 138,653 Cost Â Â 138,653 Managing Director's Agreement [Member] Â Â Â Amount payable Â Â 209 Royalty Payment Â Â 117,761 Clinical Study Research Agreement [Member] | In 2018 [Member] | University of Taiwan [Member] Â Â Â Collaborative Obligations Amount Due Â Â 510,000 Collaborative Obligations Amount Â Â $ 25,500 Lease Agreement Expire Period Â Â three-year Restricted Stock Units (RSUs) [Member] Â Â Â Recognized total compensation expense Â Â $ 1,291,594 RSU Vested in 2024 Â Â 451,490 RSU Vested in 2023 Â Â 527,940 RSU Vested in 2025 Â Â 312,164 Unrecognized compensation expense Â Â 282,823 Operating Lease Right of Use Obligations [Member] Â Â Â Payment Of Lease Liabilities Â Â 125,313 Operating Lease Expense Â Â 126,217 Short Term Lease Costs Â Â $ 40,334 X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: duration X - DefinitionAmount of long-term notes payable classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term lease payment excluded from lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_ShortTermLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AccruedCompensationExpense Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AdditionalCostOfCompany Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AggerateAmountPayableDescription Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_AmountMayBePayableByCompanyInFuturePeriodsForServicesRendered Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AmountPayable Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_AmountPayableForServicesRendered Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_CollaborativeObligationsAmount Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_CollaborativeObligationsAmountDue Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_DescriptionOfLoanAgreement Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_GrantsRepayable Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_LeaseAgreementExpirePeriod Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_PaymentsForFutureResearchAndCollobration Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_RestrictedStockUnitsVestedInNextThreeYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RestrictedStockUnitsVestedInNextTwelveMonth Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RestrictedStockUnitsVestedInPreviousYear Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_UnrecognizedCompensationExpense Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardDateAxis=vnrx_TwentyTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_TwentyTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_TwentyTwentyFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_TwentyTwentySixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_TwoThousandTwentyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=vnrx_UnivercityOfTexasMDMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_AugustTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=vnrx_GuysAndStThomasNHSFoundationTrustMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_JulyTwoThousandTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=vnrx_XeneticBiosciencesIncAndCLSTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_JulyTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=vnrx_UniversityMedicalCentreAmsterdamMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_ManagingDirectorsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vnrx_ClinicalStudyResearchAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_InTwoThousandsEightteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=vnrx_UniversityOfTaiwanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Aug. 08, 2024 Aug. 04, 2024 Jul. 13, 2024 Jul. 12, 2024 Jul. 08, 2024 Jul. 01, 2024 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Jul. 02, 2024 Dec. 31, 2023 Common Stock, Shares Authorized Â Â Â Â Â Â 100,000,000 Â Â Â 100,000,000 Â Â 100,000,000 Common Stock, Shares Par Value Â Â Â Â Â Â $ 0.001 Â Â Â $ 0.001 Â Â $ 0.001 Common Stock, Shares Issued Â Â Â Â Â Â 82,928,314 Â Â Â 82,928,314 Â Â 81,898,321 Share-based Payment Arrangement, Noncash Expense Â Â Â Â Â Â $ 208,046 $ 411,220 $ 592,174 $ 693,657 $ 619,266 $ 1,285,831 Â Â Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares 9,170,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pre-Funded Warrants 3,557,273 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering price $ 0.549 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from securities $ 6,400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering expenses $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase Â Â 3,165 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Shares Par Value Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0.001 Â Common Stock, Shares Issued Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 175,000,000 Â RSUs granted cancelled Â 46,333 Â 19,666 Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares withheld for taxes Â Â 1,502 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs, vested Â Â 4,667 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | Placement agent[Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase 381,818 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Shares Authorized Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 100,000,000 Â Subsequent Event [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Shares Authorized Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 175,000,000 Â Subsequent Event [Member] | July 1, 2024 [Member] Â Â Â Â Â Â Â Â Â Â Â Â RSUs, vested Â Â Â Â Â 38,198 Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | July 8, 2024 [Member] Â Â Â Â Â Â Â Â Â Â Â Â RSUs, vested Â Â Â Â Â 21,583 Â Â Â Â Â Â Â Â Â Â Share-based Payment Arrangement, Noncash Expense Â Â Â Â $ 13,209 Â Â Â Â Â Â Â Â Â Â Agreement Â Â Â Â RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | Series A common stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants to purchase 12,727,273 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.57 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering price $ 0.55 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | Series B common stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants to purchase 12,727,273 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.57 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering price 0.55 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Subsequent Event [Member] | Series B common stock [Member] | Placement agent[Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.6875 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash inflow (outflow) from sales and purchases of trading securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9 + Details Name: us-gaap_ProceedsFromPaymentsForTradingSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_CommonStockSharesWithheldForTaxes Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_DescriptionOfagreement Namespace Prefix: vnrx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OfferingExpenses Namespace Prefix: vnrx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_OfferingPrice Namespace Prefix: vnrx_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vnrx_PreFundedWarrants Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_RsusGrantedCancelled Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vnrx_WarrantsToPurchase Namespace Prefix: vnrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_JulyOneTwoThousandFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=vnrx_JulyEightTwoThousandFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ((6"#ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$ \IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*1#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "%@@Y9E!!91_ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>.NTV!%'7"]-.("$Q"<0M2KPMHOFCQ*C=VY.6K1."!^

8^Y?/ MGR4W*@CE(SY''S"2P70SV,XEH<*:'8F" $CJB%:F,B=<;NY]M)+R,QX@2/4A M#P@UY[=@D:26)&$$%F$FLK;12JB(DGP\X[6:\>$S=A-,*\ .+3I*4)45L':< M&$Y#U\ 5,,
((HTW?!=0S<:K^B9TZP,[)(9DYU?=]V2^F7-ZA@K>GQY=IW<*X M1-(IS+^2$70*N&:7R:^+A\UNR]J:U\N"WQ75I]=/WA=Q6V7IN] M^&PO M=&AE64O=&AE64Q+GAM;.U:6W/:.!1^[Z_0>&?
V;0O&-H&VM!-S:7;;M)F$ M[4X?A1%8C6QY9)&$?['-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4 M\GA@V2_;UKNW+][@5S(D4P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?
(+3E'S/X%/F7/Z3H=,H%N,!M8(' .;Z?D3EJ(X53"Q,!J9S]6 M:\)?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T,1K@X_%X.+;+ MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-
4T_3]WW?ZYMHG J-6T_3 M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_;%!-9ITAF6-$9RG9 %#@ W MQ-
%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*]]9>[R:0S>IU].LYK ME']]JP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N()>IP+,BUY1&)$6? MR"VZY!$XM4D-
,A, ")V&F&10' *D"3&6H8;XM,:L$> 3?;>^,C?C8CWJV^: M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)0816:I^JAS0^J!XR"@7QN1X^Y7IXC>6QKQ0KH)[? 1VC?"J_B"
MP#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?YI[3-"S-#MW)+ZK:4OK4F
M.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1 MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/ MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH
>#KU$\"\E)58#%;Q@,K MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5; M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;Z MEW?!8/+]
<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX# M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1
M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S"[PVPPL2.X>*(U^IP+0QP02P,$% M @ A8(.60M,S@[K!0 K!\ !@
!X;"]W;W)K]SVC8MV>R%L!7RU+4^2(?GO M))E@TY[\Q?.5OBC8^'FBC_7KD33:J2A,V+U ,HMC M*EZF+.+;RP[N[& ,P]5:F1O.>)32%5LP]4=Z+_254[H$80;>7!=V10EIQ_,QR?Q_ MM"V>
[;D=Y&=2\7@GUB6(PZ3XI,^[%W$HP#4"LA.0'P2X5R/P=H+\S3E%R7*L M]U31\4CP+1+F:>UFON3O)E=KFC QU;A00O\::IT:S_B&"=1%-R&=L41S1NA&-]YG]#M[L;'"3J[Y M-
0\;&VLH+8E8[]D(,E>}3 ^X"CV\I-9*A.78[7ZV(8&]ED@7)=(%6*:) MY@ERINN(KFQ,L/Z)1M+V*F:@K"74H(0:@6:94+D2*T=5O\RJ@PHRG2X[FU
MVF"W;A>3KH=MD*"P)>2PA!PVZ7"+F$81FF92_RRMTPULHT1FK3]0U1(-N]4< MZC:"6^LT@F8\3FEB'4F.V-2V3EC7%N\@(N F>%S <50ZZ)KK+XJ6U/TV/F+@N[GK@>=9
M"W^*R(.KS(,;A9Z;Q.="3R4TW[@PIW\ ^[,+.[Z^LN*>(0:2* M0:11#'J@S^@FT-TS? K]@KF^=H]8#G$7#WM#]V)@W0HX12XB52XBC7+1) BT MNRP_;_5CR!; IT?\
<&\P1%^85.@+%3%:I$+W<(GFG%K7S[!;6_HJ+)%&8<_U MC!JAO*T=D0^8C@8NO8M(%C7%K3*2@2.-WE;G0A&Z\%;2Z=G$,G++ ^LD..K/I M5X]:I2F;!U(II!II+;[F>C7?
XDTX$C)7#0/NB/:815E,([]F1@?XT$G5[QHC MFX<2%_M>8W!Z]QV=!",' #92ZK$#+D024'J$2?:"J U'Z[[Y26;B<!&4C^?2 M8PFIG"*!\3-^-QY#8 Q$@!QLP!L[R[=VBX55=>;5N.1"E6F9EN=-MO
M9?2*5+IYF!O5UK@%N?PRQ1J,T%,,#$-DT$3VZ5V73[Q-V MT#D7W!Y&IBDEY@^,Q&':B,V$))-(]C7X^H>S5 MZ.$G930;T]-G!TD290&51_O"24Z-RM(S!-WW=9)]46N_!G$AB'CNS[3%,
(!))8#"'P$.8YN';4.+X M(C\\$$RXNY'QV"&IZ!'^3[T86 G3K!Q7W?^O'RXD<4,FV!BF/KM4T#A0A\. M4IA&Z4^G2>2+M+N0Q+U7%CG:/798V82H! --X27[R7XQ_&$7P[FEZ^(QRC")
M@P%Q$D4RN(#1V&:HWO%9W2Z%.18?>#X3M[V6"9) BF$5NF 3,@F-Q1W M1NK_XU.PKL]79Z;#90EI^AK*YKA&OO/+G9FK5N MRW]5<4D8I1=T]T.ZM<2Q^T6R,^^L^061AGQ+7U'*L
!MR:.LMHI@EMC9DW== M9WJ/OBLO M1[D+<0&>8SR/&1.A'2@?6,^G67]3%*7-%!C?]JAL7C8DEYL2X]TKU@/S+$ZQ MZDC&MC7-(HB$;%
]N,#^ODT^G%OMJVW57_PK7='':+K&R%K;KQ6/BI0-WGLK M*^[2'01 /*]):?781/TZ2I]*/CGC/[GX/THQP\N0NQ^? T@QP"L(Q%2D#"%57?" [?Q'9!T[V2?'E3J3.MXK D9S' M,G
DMSCZTF8_<_XJVX>RZ;#\6V%3^BK%>6AW7PYW-T9O^H]O]]H87?>7:R51 MNS7 OZ^T-L\W]GO>X?OM\G]02P,$% @ A8(.6;>1&_MZ @ . < !@ M !X;"]W;W)K]OTS 0_5>L@!!(H_G59MU(
M(VV=$$-"5*L8G[WDVEAS[& [[>"OY^QD43NRT0KZH?'9]Y[?.\OG="O5O2X! M#'FHN- SKS2F/O=]G9=043V2-0A<64E548.A6ONZ5D +!ZJX'P5!XE>4"2]+ MW=Q"9:EL#&
<"%HKHIJJH^GD)7&YG7N@]3MRP=6GLA)^E-5W#$LRW>J$P\GN6 M@E4@-)."%^C-O(OP?)[8?)=PRV"K=\;$.KF3\MX&U\7,"ZP@X) ;RT#QLX$Y M<&Z)4,:/CM/KM[3 W?$C^T?
G';W<40USR;^SPI0S;^J1 E:TX>9&;C]!YV=B M^7+)M?LGVS8W23R2-]K(J@.C@HJ)]DL?NCKL ,+Q,X"H T2' N(.$#NCK3)G MZXH:FJ5*;HFRVD]?$)[K69WZ!F58,C_OMKQLMXR>V?)S(T8D
M#DY(%$3C ?C\9?@5Y @/'3S>A_MNDJ U%<@&-6AJ9WY^@87NL!(^< MW%+>P)#UEN_4\=D^L'*_W.V.TH:)@8CTD.CE4]$#BL&A_IZ_9-^4+56LF-.&P0F@P.D4.U?;I M-
C"R=JWN3AILG&Y8XM,&RB@^DI*\QC8[MD_EMEO4$L#!!0 ((6"#EDK MK2K\1P< +$@ 8 >&PO=V]R:W-H965T&ULK5IM<]LV
M$OXK&+5SD\Z<(^*5H, 63&RIN73:Q&,WZ6=8@BTV%*$C(=GY][>D9%$"5HS; MZDLDTL\N\"P6NP^$7#RYZFL]M]:3YT51UI>#N??+\^&PGL[MPM1OW=*6\)<' M5RV,A\?
J<5@0*VMFK=&B&+(D4<.%R!KNO,SRA2WKW)6DL@^7@W?T M?,+2QJ!%?,GM4[WWG314[IW[VCQ\F%T.DF9&MK!3W[@P\+&VU[8H&D\PC_]M MG0YV8S:&^]]?O/_5
#\C,/IA5X6_=TW_MEI!L_$U= M4;? DJCB\H]D:I!@[?F2QO]UAKBE9=-HMSY"OZ:@YT? M7;MR!LMN9P2^U:[(9\;#PYV'#\@'7Q/W0#XM;66:=:V)*1OD I)RWF3+VI)? M75V3-Y]+LYKE8/H3.2.?
[\;DS8_70P]S+ 99SC=SN9J,QMV9#:<_.9*/Z_) M!&8U0^S' .?;JQWX(D=F%A[V$YXKU.OQE5;XE//DW80D3R'RN7V_.,3K_;/3) MWQ[](!A\ERN\]<>/^+NU:UNN;(VMZ\92X)9-
M3NOEV9J+P>0.;6MUG8P^M30#<@ M&\,8K"<-UGTX9=/CL>70<2JD%$G &">% MI$R'VRW&:2XD;]K:00K&.)IPJ3(E\23,=MRS7N[O;0E96+34S0R$5%[[]BO7 M%F.?
Q=N*:9${&K!'<$H(V*@!^Q@'W--4A^QCG&1,*97@Y&G2JRDXW>8PF[$ M&QP'OMIF-Z+J+(G#$[7BJ0Z(8T*E,IH$)66, #G4SZ@>3S @3Y641THMW5.X M]!7%]G55:.MJ?Q8I! "*:AB
&)C!;+E080!B)698$S*, ((4F3MRQV)9GE]=+5 M4(#@'/V0/\/9VM2U]?@FC-7F&>R=63MIK"@;--X M,33H:A821G!22[TU>-ND]G9ORT<)*
MDP>35V1MBI5M4OW)5.T6+W)SGQ>Y_X;&)59[0HA4A&&)84QG:105! 8GTO"0 M\UUOAQ'I!";M5YA;F?$7FDVL]#EIC*2&@B.L5"+CC$8*'86BM$) J0JT_K(MOF>=R&3](O.C]4?
U!8OEW5F:@+A)@YR]QI"9A#-%&JIJ#$DE"'JH#LL\"M4" MHJB/Z O6Z4O6KR]?:)-WWE?Y_MK).F[#72]/#W])?:T80/K1OLI"+UI-[&] 4V.96WP]7I1"KK%ZD_N\KFC]#C
M5E5ER^DWXJ&EU879W'#-_ES5OKTB010%$Z<<# / MY2P*U4*P;$\" :AD[6L7];N:MH-[-F[N:DL.2-7ILZG[0\KX[Q8->7L^Q4/ MC=MF;+T_\>1M$BI_'$9%&#$S32S6MC(@#]MH
MU>33RM<>8M4T0R1T:%QB!:N94AGGD6Z(D0K23O P2<:H3]A-5-$P0(A/KBAG M+/Q)9KAW!;NPU6-[]UV3N5?G/#MGN[NU]_U]XJ!^^OZ/DU1=Z/Z?ED
MN=]K\$EA'V"HY&T*TZTV]^.;!^^6[07PO?/>+=JO&PO M=\R:H965T&ULO5U=;^,V%OTK0G:Q:(&F$3\E=3,!6EMB MN]AV!YW.[K-
J*V.AMI5*\DS[[Y=R/)9)7I%6>I$^=.+D\)"^O)1XCB[M^T]- M^UNWJ:H^^F.WW7=O;C9]__3-W5VWVE2[LONZ>:KV^B^/3;LK>_VR_7#7/;55 MN3XVVFWO:!S+NUU9[V\>[H^_>]L^W#>'?
EOOJ[=MU!UVN[+]\[MJVWQZ[:M_5SZJ]\!A1M:U6_4!1ZG\^5HMJNQV8]#A^ M/Y'>G/L<&E[^)F].+YY_69^+

[Q%W?WT)6Q.!Z.HVO8*GI_J M%J- M7]EN/K72=GMM.!UN!=?=,GQF[ZX4GYFF^J%@X9I$X]%D'(#NUG1'6-7XU;A2 MEA:M_]S2S0:U8Z#_:T5CM2><@N&NM/@'4$L#!!0 ((6"#EF:G3*L&P(M /,$ 9 >&PO=V]R:W-H965TQ^\! M'\>-TD=3 %CR(K@T"2VLK19!8+(",!#,C58'$E;W2@ED,]2$PE0:6>Y'@012& M\T"P4M(T]G-KG<:]MKR4L-;U(P_;HKIJCNEI8E,>"NLF@C2NV &V8)^J MM<8HZ"EY*4":4DFB89_0N_%B.77Y/N%G"8TY&Q-7R4ZIHPN^YPD-G2'@D%E' M8/AZAA5P[D!HXW?'I/V63G@^/M&_^MJQEATSL%+\5YG;(J&WE.2P9S6W&]5\ M@ZZ>F>-
EBAO_)$V;&]U0DM7&*M&)T8$H9?MF+]UW.!/(O.JV(^_R M,[,LC;5JB';92',#7ZI7HJE2NI^RM1I72]39= .<6:BD[EE=!7XHY8C,@D') JC MZ17>I"]VXGF3_U)LRYJ^SW+-LC 5RR"AV T&]#/0]..\3S\=,7IM'QG^XZ^:P_RG_3V.KAG^E"B,0Y[E(:CFQDE MNFVQ-K"J\L=ZIRPVB1\6>"N!=@FXOE=83A>X#?I[+GT#4$L#!!0 ((6" M#EF1[B&O7PD 'T7 9 >&PO=V]R:W-H965T(2E9 M3M*T]P(7 6*)FAG.\\R09UNE;\U:",,ON-V5ES@=K:^O7HY')UV+#S5#5HL*7 MI=(;;O&J5R-3:\$+Q[0I1VD<3T<;+JO!Q9E;^ZPOSE1C2UF)SYJ99K/A>O=6 ME&I[/D@&
[<*U7*TM+8PNSFJ^$C?"_E-_UG@;=5(*N1&5D:IB5/!Y?)Z[=C MHG<$7Z78FMXS(TL62MW2#]WXDJ4)0F+R&O+&R+8-N2V+L M/[?
2/SC;8R9D+Q9E3E[V/YKGN<=/5W43"KF#2F$2R)8Z1765*EF#6'M20H M](-R8Y8S36[XR6HC^)A'"">L%MH31T2\79I=)K.HRP9,UX5;)Y$\U.\ MIDDK=BNT\)L6C@)
(82P>9+5B_+'ZCN:=R,5F@=VRQ*UF$0#!U,*5=+D;!NO_ MKEVEO[\7.I<&>[UK-(DE!QAYSS8^604EZT,G5>H'=A\H7#?:-+RRY#B2*L)6 MQ.2IE=/!'*J$ KFOI8: $;)OB50X0PO?/
%;NLM2Q9,FVUR*;1'*ZZ$\:"X$ B M0PK>2=68T\(VNJ*7@[@'4QMX0CM#TCB9 ML,\EI,%N;QD4YLZ?L.W 5H1=JH(M50E(;_T+<7)5=0RF02ZTB@W9]PPCKE@Q:]'E)?/E/BV?"V)G^Y"]
M_[>1=L<^PH45Y99WB5/FJU?FU8MC]\@ MX+=>#]^](+I6UCY)NUZ+4KRDF9? M^#V6Z*O;*DVBR3QE\'2"S4.2AZ433W :Q2C'/U%N2?@^C>+)C*&TQIDG&8^C M-)DYFG06B,9Q-
,EBED73^5M-9#,ES[.IQM'I/4TDT $OND<$J-T-J>5 M*)TF^/]%V63*QO/H-)ZP;UQ31G>.E%4;B2M>2\M+=LTI\SY6*,VJ"AU]"Q^[M +K $RSXA-YJ::VH$.=%*7/DP%*XI EY'*#PMQ>HM-D;-
\830)F]T:YI_"9\=V_)FV-6 M<-LF<(=P?=@.F=N*W;;^@I;0.%]C+B$DX"MHN*+$A*UC.)U5MJ!Q=PZ M#.F*6\O\D+[DQF'9UOSE@@M KO]/,3NMXDZ,X!/N^A0>JW5G2R$
PW.WI8\OSVYR=>J1/Q\YP57 MWI1^#QF0^B[X*!?:*=]3 L89^O_L2I.,- MLUH530XM2EBG<3IHZQ&^@#\?!]^)R5534LLS&,E)01[4*>0A]N^^-#%%';*B1]*+@AN\QSI6FNH3CW@:6?
M#?:!:WJ509^07>W0]2C?*49=2;&rF)L9VB07+K]/#\)?!_15VA%$@ M.78)\[SIC\?<'PR*KO,?)3%:X>G,$1TE*3K7^/3!#/EEOT//K30PH]W+C?-# M8]KIX[X"37IRT85HMPWIOV(A*
VFW8T/!QP'^G,KJ6Y/5D"7Z@2H#ZF#4V@ M/AZB_;]DV7!^BA^,E% >2O7*!T3,+& M^^^%).*!%(Y8ZT4\!1?^)% %]4N7@BB\7K9&&.1<3;>8 MY6._H@RK&\N6*-$&AD?._SVX^%$ 0G$>Q*&%-
"^BKTA%C4(K4)-;?="""0B3Z MZ?[BH3*".F"ZC'"T;O,.NRBP\.S64A_PO;WM;S:U=0G/X&N L-E-UK@5(!I M 6HGZ5,'N-" DO0T2K*TU]PI3; K!?.@O\.F;KLPH5#+[S7Z>(B0=HV>B@LG M/2L1?,(
I$4X!RQ=" ?Z:KKM,$P^'LCX$S8MA-T*3&6[2[N\E+,. 2L)&+0%3#C MH2+@PCMJIBS<5/70,SOXQ/DE/?2+<)5"Z!(.15Y4T1>UG]]>$6H]2+O7]W
MV0UCSHP_A!L;X=M/GZZZ+MJM=L38S>"XU0O$SV;,*/CI<%P+,VH7E:8FT4?I M9-@=S".VU!@X+$V=E*GN=ZU5LW+2@HJNG8H ^4'-GOP\^U#1:_%BCSF WZS
M1_V*T248NSG)V*L/&'C87VK(LBP[22>GLWEVS,@Q#DKQY<[CF3_<),#&;LO4[CB;\1>$I-[I "231'3L)G52YK7AX.&A@I*@75<0A8\7!:=J&B MCT\<@'T6#/^;2X-^ FIJ8D4OIA4Z+D FQYB(,8S>$-
:%5K?8D?(!E>QZ*)7" M4@C@,HT=A$OWKM0@G'\TC2<1//2$GIW+G)Z\=$0S&\\P\D]ZR2CM8?(-2WY% M%)(_\68=)AT=TR_:% 29;-Y%./ ^HQ)3]W%C7I7HANA5^[BE_@PL?C;T6ZU
MNUN^]%>]>W) ,0TT7N&0@E%T"=9X.)L,,//RU+U;5[H)UH:Q5& _>X%ASV$0&^ M+Y6R[0MMT-VX7_P'4$L#!I0 ((6"#EGDAVF'VPD .\? 9 >&PO M=V]R:W-H965T[K8;8.F%YR?
BDS;.I4E5Y)S.4^_,T-2D1+'3;99H"A2B>3PF^'<*1]3I9=MWX^G;;Y4J^RUJ_7NH*5>=VLL@Z&S6+:KAN=S6C3JIR*
M(%#35594DZ,#FCMIC@[J35<6E3YI6+M9K;+FZJ4NZXO#"9^XB8_%8MGAQ/3H M8)TM]*GN/J]/&AA->Y19L=)56]05:_3\<'+,G[^,D)X(OA3ZHAV\,SS)65U_ MP\&
[V>$D0(%TJ?,.$3)XG.M7NBP1",3X;C$G/4O<.'QWZ&_I[''6LZS5K^KR M:S'KEH>39,)F>IYMRNYC??$?;<\C$2^ORY;^9Q>&5L@)RS=M5Z_L9I!@553F MF5U:/0PV),$=&X3=
($ANPXBD?)UUV=%!4U^P!JD!#5_HJ+0;A"LJ-,IIU\!J M ?NZH].NSK^QEW"N&7M5K\#6;8;J.IAV@(XTT]PBO31(X@XDQ?ZJJV[9LC?5 M3,_&^Z<@52^:<**]%#L! _A4/@L#CXE
1#OPPOZH(>&%CW!4@Q1M1\) >=ZN MLUP?3B 26MVE9O.ZA&@MJ@7KLK-2VY M_J];UL%ROLRJ!;P7 M%;MPV^HY+2%N5ETQB/^VRZH98LPV#4'! 'I\;EN(%NP-Y>ZR8M6LY.FR#7;>
[K//@QX9AU[K7-- M."$GX) E2G@R"%CH!Y+]CL ^ S^O;E<%XV>35]E50X)PL[>P!L).<:RPI"N M=E-2&F1%"SH?J]9IJ%=HT;8;$ 3XCY29D:I'#QVL2SR)5MFY\ >S+E8-'J1 M@>TOG-
8RJ[5&8Z)&G!RLT$!.W&0E*XNY1M30#T-VI;.F[6TPU(&=&AYVBQ5N M6>ICS_/5@.>?R'/OO\AL'W;7N=8S*ZZ]2!BWJ//"#B*$M*C>PJ?E)HJEJ2Q M%\! 1L,'Z3ORA6)<15Z,"X%9#^QZ)!GW5K&$
ME<12V&?DIRB(3%*;)PUG9X:DP\B+8.XSK?!A^^A+?T3AEAHH#)0S#ZJGT M1)B0(SP5@1>*)9;H,[K!H,'HM'&%EN9#+PEJ&C[<";T *%=:ZJ*Y97//M4= ME.7:0385QI590^.][FKRAO1_P*\(@"
M2GS.SK-R0UYX??:![^&)#> 9!/H:Y7AHJJKMXB'LC:SU$YG*R?0HB2KR5)IZ M4J7@@DF\)3WMA$%4 M.$MC_F)_Q ,/^O'T\X 71 [TL#F>&GR0&"+1HV7LF+N,O3721N"PG&(BI-35 M+C-(
#B'(H+L+1V=%)]MNF7=4.3CX=QI("?,]$!9J ;OVF8A)-XX$7X(+CT4.[JT\, MUV\\\0*5>B*6#ZIMQAOZ;#RGO&[+6RB]4"6 ;GT;R_X31>Z&$K96NARR[T?@ M"UZ-O$UJ^EP54!I_F(A"?U+V;>/?-
\PV7NR)=RHN6:O,>F\S8J&?:%SGV)B M>$@=#*EY2B5$EQ_POF6/A +'#R#N8L&^D&6FI[KK]#+"1D\H+(W"CQ2[KIE3 M!O?XN2X082^)/1$H(.(^W?73^C\8@[5%N,\27=9Y4$EDI12EWL"<:-
QX[/R? M&>J3XX=NS/1WR'TEW-' 6+:[:<$AR=UK$VPS&+3@^##E@>1G_X,X5 ,W7QI0F6,BS=CF6&C=EKD^DEK+1VAD1%ZU:L/.HSXN922N#HY"%6FLC MTA,9"J#_RJ[LX>7($+=5?
G8UMHY_1TM$/%PD8? .8A5C"?WPQ!SE;=& %&Z2 M*$XA9X+R1G.?ED5S8PH-^\:;$B.=?)&;LO96GS$A7'#UGXT&TW(X4,,!E,+0 MDQ"%L!"=*X'3.9\#+D-
:PSV?GI,?R)(MH3"+/B>%0>(E4.KO%_^VK* _MC:!_3T04 >:I;BA+GRPV7HA5*Q*(&^ M4#YNU:K73#BO,>M$JFZ3?H!<&%W[CZ/<#2KO#2KO#ZI&H"HFUT\MWZB4K1HO!):%&E"Q?$9Q8U9-
Z'I!6DR)AW)9]8M*8I!01-OT;A9[BG5791N MV4K:!V)\6U*W?@]2-22%4 NC,>G(C2>K6[T&JAJ1I+T#(!Z3<#=)K M =(>=1NI6[\'J;+KMI6UCT=--/>_0+!'_*C!?4C?!],&B3%LSW_BNO%//@K8
M*W+@R\3(%4DW _=4@7?IP4P*-#%ZI@REG8/RP?$;@>LL OQB Q>)J:> KQI M<_R0;!NDP$]C _##M\@_PY0C2$\ $W8@B%D.U41*WPU4G(-[AE9!8)@(&;?? MME&ZP(=+E8S(;3A>GN#V
R%LJK' *U: UR&*5I_CA2<56"G-_\-A)05B&5)]/$W_8KWW3P (Q*-POZJ1GO M1INJ,[_']K/]K]GYD?<:W+S4SBD.2C,+2OU'+:"%>6$->;G93/HZC7]I'M6 M=UV]HM>ESF:Z00)8G]=P<[,#9-#_QG_T-
U!+ P04 " "%@@Y9>JRA^AH. M 5)P &0 'AL+W=O)!^'X]!$%L @.$0QOSY/]P @2%&R=K-YWU*5 M" QF>GKZ>/H 7FYT_6NS5JH5=T5>-J].UFU;/;^X:-*U*F0STY4J\62IZT*V MN*U7%TU5*
[G@145^X=IV>%'(K#@Q_9+'OM2O7^JNS;-2?:E%TQ6%K=+O5*XW MKTZ/VRDBMUH]IOU9<:=Q1:T$GF6O]*-S\M7IW8Q)#*5=H2!8F?6W6E\IP(@8U_J31/QBUI MX?
1ZH/Z>SXZSS&6CKG3^MVS1KE^=Q"=BH9:RRJMKO?F+ZL\3$+U4YPW_%QLS MU[-/1-HUK2[ZQ>"@R$KS*^]Z.4P6Q \M#N:PDI=RT-9YF6->^OM)%D;60>%Z/Z7E_U'D-.?\X.7*9YTTE4_7J!#
[1J/I6G;S^X4]..:+]XA%E_9-9_ MC/H>LY=/8?919 :1;)6+QPY]BUW%>B$?E(^29>)^5LDR5^*#@"^+S/,]6 MDORK$5_72BQU#C?' I%AMB ,672Y$LW:C+8TIVN[6I$Q9T57B)P)57)K-NU@
M.+58]KOPPT;,MV*K9&U8(AK,?]F*6YEW2N@E#PX41UJRH4!+@+(BN,7+H+^[O0H;NHO_,CNHO[.\3/P(-6S#=KF4I M@I[34^$DON4E@?BJ6YGCW@\\:!-#@X/>Y9(02%K6K48-#"J__D^A?
N+P>[IX>:B'KCL<",;1N%8@>-: MGA.)P$^LP/;OK=CTT<6Y)@-5 M=2&\P+9BQQ9>%%MVX/<:U \O!G>VE=@)+"*RO"@2?^-H ,'(6RQ:J8FYF<7/ M"L;),^&Y B9T;_XB:U)C(#
MX?]\&YC%J>,&4(4W.B&PHI+E M%F=+=4WD#B6D[I [-&RT6!Q:KA/-?I-U/DL9?CJU./M#X44?6OT?"3#O>Z'> M0#>[:$B;[?M$CP"G R)=CR;B.)'E>HX!)"=Q+#?R#!XYH6_Y7F#@*'$M)W ,
M&#DVI.OVEAI$4!1,Q2!-5E0=F=:(+L\\ B;"%C/]4!T?CACVUYV^.51$+^CH MRPP8S2%EA(^:M5&WY^Q)AZ:RAL0X(P,_1A5LQ;L%9$NK,F/O57>JJ/BJU*UH M]?#PWXI6%0(/:/5PJ]%#=0%!F7L7?
H\+^W*<23R/6, M2466D\1/4#X@-W$=D9XAQ$EB_UKA)'C.[L\%B:(PY:IKFC^])EZ7,8XXL.(M'3O>^=!Z?P/!!!@TS Q O!"^$=@7,KWK"@(C4?YL15$B?&HP+$2>-?1X.ZZ MB"?^(,)
[PAD."-3Z@*!R_I4T_%;-V^^);1 8&0>%(V,;"UJY+T'X9&SYB&S_ MMS*,@\3RH[')LNV \M-(B/*(; [#Y3"F((/J4B/32X@*V)X.BI,S_$MVQVQ MRTI "-&^1R_Y6)[T##Q$'F*T/8+9@8_8YB6!'#
[Z8Z3Y6),]00ZDT9&%NHL%3=Q8$"$AY3CL/QJ&Q&>KKD=+L MN,&=!@@7MFU3%&U:T""*EU%20IZ:!\?P' M$OIZ7T+J#A;[\3V5.QC%T:[((6IQQ<2)3T4AF9(BVKK6.4?G4G5MK:MUEB-J
MM#5@.,^[*%+=84\XN33NZ_-R1E!>FH(5M 9.PQST]@*F>SC@C_U@8>^'3XD MU/[Q?]<;*N#?>((R*[0"KR5/7\W.7;/DU_BB4?:.;OJE1MEHHWF6Y0^4%B
MY!FI*0D_W)#F(%@(/4L;\:%=W%,,$##[;[L"O@&5+)<(^7RZ3]WLKR@VG=JL.POXNGU6M_PD2#_+[8[=+2XC'FQ8LZD(V_:CX])<;X!^D95SU:]T9 M'>\Q7=74)$K!
<8K:F2]PPKRW39IQP/[/$N&]WAY)) ;Y_QXV?%0+WHVL'*!] M6:"HJA>R$,^(?]=\>WC%5\Y+\YF C>@ @.#DU-;C04(\V\JQ3TNF%^WV-X[MW2*3JQ*F#;56*/JA("IJ[I_KB4 YSP>)%)S*
<52;#ISRWR=F!A2.@OD IB'B(4QI?YF!H6=5D4.K/=H2 .!!#Q7O&.$(U&^5_.:,<$9TJDI+' C9>>'GTL8O%YM MQ=7U9TM\^'
U.OS;OW_&V.#S\)6:)2\+4\@0'YY(98!"YJP9O:U)4SB2*'7LL06H$=7E+.3^U%3,R2T#V;;8P M[-7*:/(9$>E/>(.""V0O?Y!%]>+Z'G\[N*,LX3N3<5!$$O.N1A% M9G_(+S/:JCO)XBQY@K@?6>8,AE)
(> _8+LD(W<2W0MLSRY;9W;2RYV81)L4S MW_VSA66M*8:1]GQ";L@=.-.D>!"QAZVH4I^382QJN<%_C7_'DHU)QR0KTZR: M5#%[)0MA71C&?5D\KLZH&P7UY<;+^JQK 5VFK>
[[,:8VKFGF()X*6DBW,[%" MA077S<676J=*D<@XA24&ZPE MK)TL! Q3H)<+BEVJS\4((&EGTV>GYY5NV*YG8GVV!_!0S[5B_R%>KG1=:3:S M'[7,C2"^F#2$%'/^AN'WTH#M@T8V;0=-
&B\F6T#4I[:A['M DQ8BBDV$P\2G M.W/^T\"-K,2WC)C1]KSS-0L1C60D^F)];GGJ8]ZWV\)2554^- MJ;"DB51/J&^5GWJ.:R&" W?$@GUS(%EUY41:#\K)C5TK=KW#K7E#VM_:!4GV
MDZX%*=68R:R&L06:UMD<(]5.PZ*5]8H:\[O5B# &K"2K?=:G&+_@*#2*Q*MN MF>-C5]_*\\DP$1#_H)J80R>_*6"EG8Y_@\;ŸV;GP$L^*D>0XGBF3SI&)15) H M>(8"MYUCW(2VY3B)" /,BD6(9 G+
WKS$_HF\XN1Y<"VG"A"RN53NA3&R-6< MT(J0U\'P(M_R'21:CF]ADH@]C%'GR*=LSA&#V $ -ZIJ1[2=5#:CNHR#M6IL
M+; 1='**K#OHJRB$]O&=#86DB2G!5OL\CZY)W%PY7I1$3(@>Z_F2*&]AMB($L MF"TS=KM]6<(M&]52H$8\SLKA14'7[I_FONHM6KI1<'K)&90IIH8$:BCTV:<(M)+/*]"OV&Q/[> H4X32-
NB+T!@EEX20P7>'@2_%N4(_X;.+JKDG/S]^CJY/(6%X MOM%=OB [H][(:'LCI!QR^3AR,<4RF:9U]QB,!5YH!2B!#F!L:OV[QM=]W3ZJ MM#'T I$WYC<3O0T+"NYX.5=4F/]K5.I89F AN[\1] !TATO-
\;;+S$MMPH/);%/1"!@8>3^)T@J#\8=1* MLJ=.0+M&3U\4])'9B6W >?+TA>' .?[!\4HCTQP#I^HX514X?_YS8*AQ'(/M. M(EOTXN8I0]RCGKX3*L^U;*P:),M3
M^(P$OXPP(7*1*%PEZ&$:3JQ@F&3C MEU];^KXC!I,X]@7,Q>13)=3.*_X@JS&)MOEJ:1P=O_FZ-)\Z[::,#\8^0K:H M") ;+['G4D7!B?F"8+AI=<4?/LUUV^]"+]=*HH2A"7B^U+H=;FB#\4NXU_\!
M4$L#!!0 ((6"#ED_J'.8YP8 &X3 9 >&PO=V]R:W-H965T]\YWZD\XTV7VT!X-A#*96]&!3.5>]' M(YL54'([U!4H7%EJ4W*'MV8ULI4!GOM#I1RE<3P=E5RHP>6Y7W9K+L)U:10
M<&N8KTWV_X3<#&[EPSTF2A]5>Z^9Q?#&(B!!(R1P@<_ZWA!J0D(*3Q MK<$<=*+IX.YUB_[1ZXZZ+*B%&RU_%[DK+@;S Q/? /'[F0-H<2#WO(,BS_)X[?GEN](89
MVHUH=.%5]:>1G%#DE'MG<%7@.7=Y7R\L?*M!.?9AC;_Y/.00EA9'60-Q'2#2 M9R"F[(M6KK#L@\HAWS_OCH=I[3E=)T>!?RQ5D,VCB.6QNG)$;QQI^/8XXW_
MC8X!XN0P!*7&>UOQ#"X&&/L6S!H&EZ]?)=/X[C!DX[@R3'TEQ$\#O&3=L!. MV>M7\S1)SM@31(;IY224]$OOV=W]KY;]K-B/M7QDR3B8.F(GT70Z"XNHYEKH MVN+ZRG#E(&=.LS4W])!!64G]"
&BRM<95CCEK,!;P1BKD"F+"VYBH#$CB. MDNF$V8+C)KK/=%EB4F)\9U^'+(DFZK+C;JND/$N5YE)S.GV.% M KGJ[$#+NUAH 7C("JY60,^%0LM5SV+?D_"663-&__%Q2_)\+2QJU3.D.GF$
M3P5&,/*T(A<8@0BR:^"7&.,YH#TC>?O4E0[AR(=P+I+F8;@XU:4Q9Z)?:X- M=[Y"[_G=%*RMTH0IU,J;G:L:&]_++! Y^/9N"WGEQ6C'Y7Z8P -:^P#\#A,Y MC4^;T+^AU),2$;L\3UMG):>8Z--
CB;X;VSX!LPYN+^\XYF'M"FW$G\U2K2CO M29'@[AJ[@MES!U#Sc;&8+"A!2V0?1#G[5=AS!M?;H+QAJ3"5;W"=H@EJJU5TV@\ M'O^/=/BL,AR;T%6"E/'R+(JXX94@KUXY+^!*89!()@4;>ALVY+OT0)
[Y8C\[MLR&/"BV1)*I240J0(NP&C!-+D7'GX^,*B>5M.!/./6#8Y>%YH_D=LN5DO]Y9 M)*]-I4U0-209\?-52J%*6]UV;-F8;VETB9H *]"06/9PD)&2<-XD<1S%X>\M
M&6MWDP7J7(_OEE1LMB=FD^V)@!]1]EC1Y-GRGX'TRU+$*NZK=@WLNW@8QPG5 MXK 9J^"W6KC'SG=W"%VY$ZO'JR+R ..[(\4F,LMJ(QP5LZHV6,KLDQ+"NQ5# M5]1-?;'8%"(K]OM-"%?
RH,4XH$VVQCW=^&#+<; MXVG":.9E]^_&D2_.*R2V:D+A-$IFWG0[ECL4E3UK&GBWK'V<;;BA)+7$LE.] MKNAV'$TFLRB=C?\&-GM#.V@IC<]NZ41ACOOG=<]>:+Y^E@ MQ9RE_XI/)
[+/QONJ6;W^[PE=]PD1'XQ7O0+<;$+\A1K14R $=8-V$\3TE?-= M%5L3F(P2 VMAMJ5ZP$7>&(T:NW@,57R2??XS/IS,ML\B:I)5&$PD3CZ?AC=# M1!%J8^BUC+WF976&Z$-
Z#0PEWX\U#YFL+96&2N)P[S,/7T7QUX^9^P,=W;;9 M$A1(R\$=9 NB;RFS>@6R/:G'2+/LRS TI&^RAOD1MI-J,<% /4G"^7<7(: M%%% #4MG +E%2V8@J(ŞTLU]K@M8DW5COJPV7W?"
[C*BKR[U M:YSYS!-^\5R/$^B>3+?MXU'Z<_)*$7A1&U?YI6'-# KI;):=_ 5!+ P04 " "%@@Y9%L4OVCU?%5M)U,J2*\E _OUY7DEVG&!"3V?.M-/8EO3> M+\^KGCT:^\W-A?#LJ5#:G??
FWI>G@X'+YJ+@;M>40F-E:FS!/5[M;.!**W@> M#A5J,!H.CP8%E[IW<1:^W=J+,U-Y);6XMV^O5'^[D;.[I MP^#BK.0$,1;^Y=[IU0GM#QN^2/'H6L^,-)D8
M\XU>/N;GO2$)))3(/%'D0UT(I(@0QOB>:O88E'6P_U]0_1-VARX0[<6W4 M/S+W\ />28_E8LHKY> ,XQ\BZ7-{]#*C7/B?!:]PQ[+*N=-D0Y#@<D+J^,N? MDAU^Y, H'1@%N2.C(.4[[OG%F36/S-
)N4*.'H&HX#>&D)]>,O<6JQ#E_<<6= M=,Q,V:T53FC/HZUTSL;13;0VEC,MIS+CVK/++#.5]E+/V*U1,I/"L:WZ:?ML MX"$4D1YD28"K*,#H!0&.V">C_=RQ]SH7^>KY 91I:!K5&EV--A+\L]*[;'_8
M9Z/AZ& #O?W&0ON!WO[_T4)=9HE<#[JY4BZ>NI)GXKQ7$E_[('H7O_VR=S1\ MNT&G@T:G@TW4D7Y_K^K4)>1F,O=S@;3*3%%RO2!]*VK7'J1L\$ G=K%)PF-MGM@4VV_8
?))+PMAX6^VE23Y_?+RMI$!Q1(/'/784+96ECD6T MCI@"!&7VGE;A3+EF#>,Z@W;&<^[\FQC=B5FEXJ'QSG]V&8R^8+EAVG@.R#Q%9\KR398K)@&H0D3RGA!>=;@FB=JU;,,MR:3%
M:#WXA%Y>#V6R*NU<"&Z9H(K68<&D:,,C%=U[QV\=N]2Z MD[41KK&:2JX^%?M?5)U*15H!<]89)5%$D!,;)OY^XS>9L=!C+XDIRK;"K0SAZ MOX[AG\MK-S>5@ML$([A VN+,UTK'?
IP4@+!%_@2SV0WF4?XU=32AWTG<+7 M&IB"#O=#0\^*YII$);$(4Y#2ZWRE/!<['+_BY1<0(%< 646,-0DT^LB+TQ1A(Z MFV@Z&T-E"VE3JR#!7>H<-8EP3BUW3=3/N0?'!7E#/)?
1&3JM6@E*=,#]6!W M0[\Y,/K-X<9&</<21'"&'!-'8D]1"A;LW4 M=1*CW$-M{)8F;U*N,^AP ZFXM 4 '@42^ETUZF5X E)!#>AUZ+\2&1YYD,$ M&X\SB6;M(3@LZ4!:42IGW,W9%++#9A0Z&*(Y\7C
MN9VQT.9? MX\@;,$*QO>:7EZ62L=VCQ@A*2LN4Y!.I8H.E@ODXE]FŸ,WOE2%SHJR@#D>H M&?R%T>":2.4RV#K3KJ[28)1_M3DDA=5K0SQ!(B0Z_)U@2+F9 U0\+4 M+:.";BZO)!CE0Z=
<4#!"EVC^]PS*[SM(/&*48A(;<-.%8"2J^F4YBFX_\&H M"CD7:!DCH'SPC>D!%D(:"3,B@:.MCR1?-%TN5M"54'XZ: M$!@$?71Z*5=ZPV+(#.@*$!N$9W=0HEU?".:0'%D0L%!
MQC;M,^(&PLFK,'IJ%. %[8CMD_3NFD@*_C4$O!/ M!M(6))Z$"P@>"*W VMV7B[A^\@A,NL+$-0KU,R49-&]P%I_9K^W+3D_&?= M^&P'(]9>?_CFN/5T&21\L+UN_T79M?]?TŞ'_:.#-RD+UBQ,R
%^=60 +.T@-M%D FK_/B.'H[8=IO!JF=KZV] (R<-&CEY};8KP[A($!55(7_0F+>&+2& M6^@SGB/DNZ#9]JHKT Z_%5T2:.!!61C9ANH0. *SBR<"+:.C%FAYSZV&"UOR
MU/BD2_U!ZZJW$'86+K2!7* QEO?YFMS9WX9KXJ7V^.%^R=N9RC-3(DIC@YW MCS&!V7B)'5^*&ULM55M3]LP$/XKIVR:0&+DI2^\K(U8$>Q%H%64P6.,6EC*>B5HSRG$I0=5E2>3+
IG8SKW0 MVRW+Z8V//NP /%K=J; M@V6R%N+)&M_2N1?8A)!AHFT$8H8-7B)C-I!)XU<;T^L@K>/^?!?]VG$W7-9$ MX:5@CS35Q=P[}2#%C-1,WXGM5VSYN
03P93[AVUS]N3,@Z166I2ML\F@I+P9 MR7.KPY{#:?"&0]0Z1"[O!LAE>44TB6=2,$':TR::G3BJSMLD1[DMRDI+LTN- MGXX71%$%(H.E1(5%@L\\Q?2UOV^H='RB'9]%-!CP>\W/
M810<011$XX%XHTZ?D8LW^H_Z],G2H([[4>U-/%<527#N5197;M"+/[P+I%&G M 4[GCM-X*]\,C<[K1G"CPR(4JB5(0QH65-&M:UHB435E,&C)"}6P(Q$L M=4N*90 M>,5DUI*2W!MQ>EC-XC?
S^[:HCPXE-L&W%Q]FYD&4U/L:@I7J))*U>'&]P@ M@[_=HW8S1^R12&G+H"^/[A\A#,*CX.QD;S8@\J03>?+/(F__M NW7MT_*091^*7<<;SJXG1X+P@A/T*)>88+E&B6,0B?L",)H>C0=G\$7T\IM
MI9."\!S!&/M?0!^;@VAR-)E$<+@/\+IJ0\KZ>^VK1)F[)JW W:.FDW6KW3MP MT;2_/\>,1^26R)QR!0PSXQH&PO=V]R M:W-H965TFPI97*V$9Y&MI=Z#J+JAR3FCJ,.$_#1NDV6"_'N7N[
M7!K>U[K%>PNN,QIEGS98F\J$,%IXKW>[?TP$:Z7G=KA_J/W;VE43BCE+K! MUFG3@L5J%=R(ZTT\Q(\?VH\N#,/=,,.$Y\Q!E^CA+#W9SY+QQ#YDR1VD"3QHW#<8.)Q
M#TJ8C\8,8C_+QPZ5AAW3W59!TH/BR(_C,82YGV4]5\KZ]0[#>G'B)Y,,PM1/ M6>)0{4DD%!7AB:ILS(@YIU4=)O$G6>0P:0^PN"PG1C\,Y],B1UE(WMB/TPR2
MW)^P%"X43#H43'JY8*@U%VV%MF+67"C8\;KM9J9$V'.E>&/TN3*YR'N^3&RR& M.%Q%^(0KK)>H('8[$\.+T&\W:X4(HC&H;+TH6R_)B [P+XA'^80^C^],;.L14 M.#M9<2,J6WIY-
,H9^<;9*&.GF$]L$;X.R)6^])H))8LF27_Y*[$?!=#\.PM;= M-]W>1>'5Z6Y\A)!24S&=A31\263LWL?G#3/&M6F>R(TK&3;&-=!^OP"MVY MYOL+[IXP]M^:#I4N*90-
AK3=BOW++B)D=NN%2^EH<;>#4MZ25%9 /G74IKC MQ"XPO,WSGU!+ P04 " "%@@Y9[.#/57@'!Q&-&0 'AL+W=ON-K8"RJ)MUUD&WN9^WF\9FA9NT7LTYI7J^ MSLIJ=C[JQJZ;\]-
ZVZW*REXWI-VNUUGS]=*NZH>S&9OU S?E_;+#@?GYZ2:[MM[>V^V-SW4!O/J 4Y=I6;5E7I+&+LJD%>WW).$YP'!]+^]". O@ENY:ZN/V/G M77$VHRB17=F\0X@,FB_VRJY6B 1R_!E
9\.:."W:.. =9N'S=QEK;VJ5Y_* MHEN>S=(9*>PBVZZZF_KAGS9L2"%>7JJ;]Y<\>M9M9B3?MEV]#I-!@G59^39[M#(H834CI$Q-XF. 4,?<+.2E_RKL++2I'TB#W(^&'VZK;C8(5U9HE=NN 6H) M\
[KSVZ[./Y_+V%=!KNHU&+O-G+I./F1W*]N^.IUWL PRS_ ,>>DA^1.0FOQ6 M5]VR)6^JPA;[\^<@WB C[V6\Y). OVRKF @:$4ZYG, 3PYZ%PQ-'[OG05CV2
M/(R$(?.ZW62Y/9M!3+2V^6)GYW__@6GZCPDYY2"GG$(_O_610MXOR 4RJ^YM M2]Y5Y%/6 %G5M>3]MFN[K"K*ZOZ0Y)/8AR4GOV_7=[8A]6*WRB?GUZ"IBR^V M@3@E,QYMDY>M)==-
F5MR\K=78TE(UI&?,&X=CF#.9H*DFD>*4B)BJLC/" R MA+/F\=-V=AB?I55.41F&/T&#^QO!_OO8P5AT%?X9RPAQKLH5Y@C_+?*-:`MI=WIZ%W;,E%#5?&
<4287.&R48).Q3L+0>/,'K/*=Y6XLIFD$N((_;2 A;K,5 M^;5<./^_-:TKV!VG5M;M*2K76ADU5=2+@;TP@%+F3J]]BV/G9*-)JE)(@H= M)<>-T[^,N29,RRA! O5T&NA2$1;KA+#$6XQQY2A]"^
*EE&,2"-B1 $E#1RA-ME;%!090AAFJ'T5N_;WFDA8PDS)UP!3VX@GZ1*T!(HB>,PO/!E/)L}$Y"?]L M=/:+_$^"4T;:F$AI VI.DP,A>2)TE')&7J&EZ'1T ACH.Y$[@J73\?D-[X19 MDL$LR5$1VNOIY0$ZB?
__$J J!$7?BI@K0F/-'8L,91&'(#!2.M7WK3-M$C/@_MCCCC$9.*7JJ;]Y<\>*6 .HG&H,)NV#FT6:)E$JDM&7C%U6 !/K2(*?"UM92[[7*KY%(E%>$68 #[(M/'IX&#4IQ0VTVZ/\:Y\\">B_N,VCY:
<_'# 7=Q!2J#LL^1M5C;D8[,:6G*[MS}JCXE^XQ&@4>$=,V7 \2Z{!N0.R>L(@RZ"?IF,*5&8PE9DV%5Q@BBU$'N1+ MI\/L+%BVZ (&]N4=7'(2I.XAZWTYL]MV7V%_)_"]\9Y']557[97!]HPI'%

M4*,HQK43@[PMF[8;!AW'K=Q("^4CTB!QJ M!?0O\/" B!C8T 6\'Z?7[A?3@VD%SYXIJ!IE+++)\YS1W3V('NA'SV#"=9M!EM FH7TS",#!X%C@8."L\3Q*0_PC%YXY&AH7)P M7(HYI(M- TDXN F/!)X/*23E@!72_[*P 7%&920X&>*RM[!7.4V]A_=Z003 M?0JK]IYNX&!S/&IP(Y#''0Q)2OI4Q92(A-($BE8S?1]@H\LS.\Y\CX1'O2. M2;"CO0. &Q*OO[+OŸ94^-
[2CY#RX0^JT_PL@,1UT=FLWA/>^X>F.57 _/^C[O M!MQJ'>>#43W'VY"#I$&[)]Y+V]!>PZC$K M!)20^ZQ[;N3I ZMXDK6GOX!5CUG ((!@(U;6=\Q. #.@'F+MZ2]@U8$>BIO0 M3*43ODLG_+AT4OHDCV=0/:Z>H)^%/(C ?W116<%,XF'@ES7<>-SZXY+MORA! M_Y.+3BC[::R@AH_Q4J'Z$0V!@0>@+T8@!G2>L,&&%87,JA MEJ%X>V#X ,Z,B M^9"
[S4>OP&O;W+NW;CB2ZFW5^0?A871X3[_PK\@[=O\8#P%_7*]>647,!5V MHV:D\>_;OM/5&_>F?%=W7;UVGTN;%;9!!J OZKKK.[C \%^&\[\ 4$L#!!0 M ((6"#EE@@TFNN@8 ',2 9 >&PO=V]R:W-H965T>OER:LGD^FXC)ZXN[8K6V[L7T_'23K\R]L8^;VQ:CZ2!E452F M[HJFIM8LSR87XL.E\ O\C%*\]SM/),S9=8TO[G!SXNS"7<:F=+,K1.1X^?)
M7)FR=*@^Q^-]T,FPIUNX^_PJ_2=O/(R9Y9VY:LI?BX5=GTW2"2W,,M^6]JYY M_KOI#=.)WKPI._^ZGONY?$+S;6>;jE\,#:JB#K_YE1XARR0_0+I]0X;>2T
MYC8_/VV;9VK=;$AS#]Y4OQK*%,5#Y$=ZV^%I@G3V_:]JJL"'S[2BO%W35U+:.H M5Z:>%Z:CXX=\5IKNW>G48B^W8CKOY5X&N?(-N3'=0-*ZHQ_KA5E\NWX*'0=%
MY:NBEW)4X#^V]7M2G)'D,AJ1IP,#E9>G_A_#]]D;Q$7[Q;G@^=!M\KDYFR Z M.M,^FFAL7F(<:85M-M4KHV7?>!+JIF6UNHX37SL%%10XSI+"8?1Y))KN@=W8;O})276^^[-YRR M=II&L-
(#5OI@K) \V]P...R#8538?A@(L6"&6*"/9FZJ&9RHA'^C8,\1??YV M-VI=>CIIEB=;,#7+]\"F42$4'&=,\^M.:LLAG15E81 1,#F,!\Q\T_I\ M*C+.>);A-
V,*FXXN+ANˆ\'T(5*_I@,J(^N.\&9PJ1,*E$B&V1"283%4);Q!&+E Z1G4DFM AQ+3B30O:8 MZD0S!>&H"VJS=:!, 3JL7(QL(T3/^#'^AZ#P5&X$D&>)*#X;DS\V95%_^! M6C_7=+\<\\28,&5TUG]\
(QNL/W@@-9+9$JH)$PD<1^ UQC4DQYK9T<%MZ MC-0_I[FC[YU! G7]P3X7C4KE]PB[2$1-QO\MKKI>]GC\&4R#G2-4J;3+-!5 M"Y:!NG>FX1Q*<:)&KD_]H,D4(
<'3,==F@VNS@UU[C3P9*/C1S*Q+%6\Y>%3F M]W)PJC,6)7&?$ACGFLDL"4Y.4GB3]^5>IPKUM,*$LDB\8EAKZ>5B!B70]9@ M&02A(O5Y(Q\K]L?0(5&H(WQ({]Z##X,'(^B4LB@;S1V"?
^V6^<'%/:_K+38< MN@C A[-!F<\:%X]/ABY6K3'N&WV>E<4J=V5S;SX9W_2-)B"8VV/U%:(>LQ[M6^#,@LSFL=I]<>3__NG5@83'&KJV76%?G%$/>?'LL$$FYYP/OR=T\Y$N7+WJ
M4/JOT%P"Q2OC<* (62;B($6J61IS5 <%_&+ZM'T)K?6]I8=U@\L D+QP2A2,& MGZ]BC9*]+WA\RM,%"G^Z+ID(/[#>$=@021:Q=C)B))6OMH?KRY(j%2%FOEZHZ* M% (1+0SOO?&M_W>\#K(JEP5
R0QE*4.,H.*$I>,1+'9.4>)@7LQW3A:%.[IV M&QQ!PY=VT_BF8]7D97 .LK<_6\ H?[Q$F_*H# +MRM]V=.2,W7 E,+P= M;E0NPCW"U^GA.N8F,U<%XJ8?RSE[Q.
<4]IPPQ$&MMGX6X598VU3^<>UR9$@ MW 1\7S:.?1VX#89[IO/_ E!+ P04_" "%@@Y9I/]4=Z4" !R"0 &0 M 'AL+W=O0./&:BT>Y M!%#H*:=,#IVE4L6YZ\tT"3F6'5X
TRL9%SE6>BH6KBP$X+ M*0-/"]R %34'?%1.B9 MV[#,20Y,$LZ0@&SH7/CGHX&IMP7W!`9R8XR,DQGGCV9R/1\ZGA$*%%)E&+"^ MK& $E!HB+>-
OS>DT6QK@YOB%_)Y#=8*8J^H,OI&)U\/HU= MI=69/=RT5C)0*0G>4?*S9!T4>E]1X 7=?!1.WP,J8;[%AYNPVUM=DZ8Q0=.8 MP/)UW^%
[P$(8OY3@&:%$/>]R5%%$EL(\+ZO$]WSOK!^[JTWE.J"*.J>-65; M"L-&8=B]\ H3@>XQ+0%=LZ)4$OV"%5#DH]\WD,] __DEN973O#/.98%3&#J% M^4.(%3C)ET]^Y'W?%)+CS$6O=Z4 ?_<9'_Z
8P]886SGWC?&#R+;L M#QK[@^-C'+QY!;Y^$%LWV=>"NW$BFJ^1&RP6AE(=/T7J>O-"U^_6@2B\K8>*% M/21G7.DCUPZ7<J,(A"G0ZQGGZF5BSMWF,ROYIU!+ P04 "'%@@Y9I6K& MA8("
G!@ &0 'AL+W=O2:2):S2C'E035UC613TMDHEMX4V^W<4O+2ML /TT: M4N(:]5VSDL;R1Y6YKA;>6P]R M+$C+]*WH/N%03V3U,L&4^X5N\ T\R%JE13T$&X*:\OY)'H<^[6$X3,!X1 0
M.NX^D:.\)IJDB10=2.MMU.S"E>JB#1SE]J6LM32GU,3I=$D452 *6$E4R#7I M>\5S6/>OR9ZM:5@O<\Q_S7>-]4,Y84[DI:AD<%O[!\ K/@-81!.(>[)36< MO#P]HCL,6S5SNK/_V*I#[>FSS@]GM9?
R0C4DPX77V+QRBU[ZZL4T=MX=J6D^ MUC0-II_U=$>$RDMZE=*.I11_00,=1GGEE#&.$9'D+N16,G;]]-IV&<3P_3_SM M 9AHA(F.PGPT,P1,2[.*\!+!+ 6A$K:$M6A[VPVP; =[":U/$>VAO0FC* H/
MH\4C6OR/?4*>_Z5)\9] "J;!^=EO)/[>Y:U1EFY$*7!_G?X>C[OC%+SL+_]/ M]WZ$WA\!7IX"AH4)#29CI@VR'TN]H47C1L%&:#-8W+(RDQRE=3#GA1!Z9]@$
MX[&ULM57O;],P$/U73@&A(<&2)OU!1QII;3R#M5(&JX+QE7,Z_0NCKS M?9466!)U*BKDYB07LB3:+.765Y5$DCE0R?PP",9^22CWDMCMK602BUHSRG$E M0=5E2>3#')G8S[R!]
[AQ3;>%MAM^$E=DBV04-]5*FI?7L62T1*ZHX" QGWGG M@[/%R-]:[@)\4]^K@':R3C1!W=O$YFWF!%80,4VT9B'GL<(&,62(CXU?+Z74I M+?#P_9'T9TCD7C9$X4*P6YKI8N9]\"##G-1,7XO})VS].
(&I8,K]PKZ-#3Q(M:Z5%V8*-@1+RYDGNVSH< Q//R!L_>%SP/ %0-0"(F>T4>9L+8DF22S%'J2- M-FSVQ=7&H8T;RFT7UUJ;4VIP.ID3116(%82%7)-FN+R# 9-7^W9FFXYS6E* MN(;S-
!4UUY1O824832DJ.%FB)I0I^$:D)+8O,^$]W*R7QKH]-F\]-6 MT[S1%+Z@:0Q7@NM"P07/,'N*]XV_SF3X:'(>'B7\4O-3B()W$;AL$?/XCA\ MB:F!#QP\.B(GZFH>.,[H/]:\KZI-
UF%_5CL.SE1%4IQYE8T]N[34ROK]2LJ&,ZH<^MPW%V%'86,5+!L$@F$YB?W?H MHR#/UKXC<4JZ-86Z@>G$"")7-)&6TEE1N&&V$ J/_ MO1;FXX/2!IC5?C)*M@N,H/N<);\!4$L#!!0 (
(6"#EDD5IL2*@0 88 M 9 >&PO=V]R:W-H965T,/E$_P@Q*4LC*K3-HQM;W6=IAM40GJ#MZCB;U:8E)#Q1[+6Z98@ MF-6BLM MPW#U$N:5-1 6=8]D/L4[5N05>B2 [LH2D]_WJ,"'F69J+Q4?\O6&
MB0I]/MW"-7I"[./VD? GO:.D>8DJFN,*$+2:.7?F,6(:0E"W^\"M'!WI4!F(H MSQA_$@]_9#/-$#U'!4J90$#^LT<+5!2"Q/OQN85J74PA/"Z_T.-Z\'PPS\"B M!2[^SC.VF6F^!C*T@KN"?<"'!+4#
<@0OQ006M_X-E*^8]#/,J M^85?VHDX$G"-"U NM48%\03%K!9*S ;@\"3"!RQ8W!;@3LV@M<*O+$"
MOQ7X=7:,=_2Y#"&#\RG!!T!$.TX3A=H0M9JG,*^$=Y\8X6]SKF/S=_GG79[E M["N 50:6.*_68(&K%)$*W%&**.5&9>!UB!C,"PK>0T*@L-L;\!9\? K!ZU=O MICKC/1$\/6VCWC=1K0M1)^
!5VQ#051E*)/HXV&}.Z#7^0QTTV"]3,.]0C\ MUC0-II[

*Q&$P',(SB?MUXO(,B__')>"O>U(L M"2^[S8I54A/E6FQP3";>0H8@?$>\Z,^_P"CXS;)J46TX^A]6+?IIU6 Q",[4 M,E!;&5BMW'W?9O(5?*4QH9HR8)YCVI;=+H,"V+<49EB[&;Z],&N,)00)E]3-MEUWP,UE>_80^@O+W9W$XJAV.WN[P&Q$RHVLP)SQC29M+NVAXQ([%(P,%P,[MG#,N9.WI7-U<(LW"V986 G@__RL?#@I-0,"P/QRU^,0F=3(FGI!8D83L'/5 MQ*YR4I/(5A.#;VCG]V.:\0Z^[" (GO@8V7P,ET,[RUL?\<<^L2+5K7LA4.'8! M>,$VX*3J0?0$][!_EJO0,![.(=^9K X=!UJA(3VT,_H"N#H4[_$K0*$;KM#P M'UZP ;CQZE#MQ%>S T [K3ORU2[2+)UM>9'!/K(3NP->#PI-O [I X3F\(D-V M9"=[1{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rM.E2/50=O;VR(._^)8UQE<9X$, ^,FZ\ M^B$Z_.;@I['E=1R%,Y0+(-E'#W+$KG)%'5U%.>4X. E3PQR'.

(H/JD9)QWHB=S()^A8/F^3=.Y"\]QUE MLC"7Q7[M];Z·0A5CO$E1=AQISUI1W:/;EGTR%+KN+779_R9-"L'TJMV18& M#CP['+PVT,#++#K84%!.\CB5)K]/^}'1__8PH=,H4(8 5:.UVO[[=CW M>WTR".'9$>*2LYSO#>?/3QLUU:+K]·M-ROLB;*AE)$H5YD/I=9^$,'.YFCMS?SN_R=/.;Z,Z]C^!I:\.RTH)=#_*{Z8,F6OF^%_">[R&:O M-0·G!:[.#Y[M>WYHDS["#=WA 4L,:TFD·*"> JE&O_=# QY.9UV>·(0#/3@ M M;_Q.:T I %2 >FT*("YV@[X!94# LX/ J],'V#4'.P6*!EX,#?!4 _>ŪA<]^@ M@6]'@^\,_8.8AO,JARA?B·99_ĒW>3+AL,Z']'(.?K`-]Z'4FOZ.=_^W1_LU MBNI[9?!EQ%,1'$D(YYW6@R:F.YH.J4,^=YKO8)WUKZ7V3YOOV-/_G3OBY?Y#. ME0.[YK=^QU/"'" W9[^),Y)[WU[RCM29T*B\FVRRB!]>[&[^X#F].!QU&^__M'.TYA/P<[,=[+_DG7*S*'TO(5117O%>] [[_;N_M!AK/R9PC&YO#JUQRNF%A% M*G;%_%X5=8XF]FE$]0,)Ū0>9;&ULK=UM;]I8&L;QKV*QJ]6,U G8/*;1F]#GY^JB6;F MQ6I?N.0DH +,V"9I1_OAŪR8.CL$<<.?? 2BDAOG\'X_CJP;XQ5\]Q\C6="Y$1 MWU;+=?JA,|^RQ_?=,CJ,BU647L2/8IW_Y#Y.5E&6?YL\=-/'1$1WVZ+5LJOU·M>]/N*EJL.]=7V_L^)]=7\29;+M;B|>OB89X5 M=W2OKQZC!W$KLM\>/R? Y=]V=U7·MW=BN?+XR7Z)4W,3+/Q9WV?Q#9))1{L1]M%EFO\/EBA7:%AXLWB9,K\[S^6R·MO8XRVZ19O"J+\T>P6JQ?_HV^E4_$FP)U<*1 *PNTY>O8V5UW^LLO?/?E·WZ[NTRC+·+J^2N)G M)2F6S[WBQC:?V],G>\EB7<3#;9;D/Q\WD==GU[>9+*O[7]6?E%^NYTJ/_WSYZMNE@]:E'9GY0#6RP#:D0'ZBA^OLWFJ·MZ.L[<==0{\GK1Y+Z;KZRNS767M?XDR8%/VX>+I3>Y)VB],1!P^.Y.:=| <+1\ M*B]W·LL+1>T?+=?/*=>.EAMGE$O6W3RG7#U.;ITJ7U\H_=[1{D=)7GY\ M=.?\T?L·Y>[YHS>5>W]OW?V_J^"#K?*IP6T6S[Z^4V[G42)2Y>,FF\?)XJ_&D/@D!8LYU/OT,9J)#Y\U\DI2* MY$ETKO_U#W74^W?3'DYB4Q+32S3M=HK_UQUG]Y& CFL M0V(NB7EG/R$^.6Q 8N$YZU"+B\$N+@;MX^)SE"B_1\N·:$H+]=/#_SD2[U"9]=;"7$.2H#HFY).:= M^WSXY*@!B84 JZ!.+B=] [4A.C'8Y,9+FQ#89?BD.)][E$XCOJ^*PQ\+#2\Ū=;RWX[F'BXTN^Z/AN+Z8U["8>]F]AZ;?[B8 MJDV&·^?Y>7RX@G[<0PFI[\?BW%X_E>_`>,4OE/[Y8?1`)?YMV5RG5=GD\6L\.! ("9PX+'TC'Z=MQ]"·CFH&JIFH9J&:C6H.JKFH MYJ&.CVH!JH645L^;·SUIJC1OPOM[\?(·ZFC>] UY,QQ<[N>-=)S6>4-J.JH9 MJ&.BFH5]·JHYJ·.BFH=]/JH%!926CUOM'IOM!,OI·9$'>IJA56E??" [N8ZXN64JOFH%!:.2&GU[*DZ==4?:.65·O/+ MP=,Q@_,KHIJ.:@:JF.AFH9]·.@ZJN.CFH9J/.D&IG3@'%%*#UO.GZ@!6Y2W M+=\|(-=.AP_·[XMJ.JH9J&:.BFH5]·JHYJ..BFH=]/JH%I59[^%XV/0.RI·: MN!Y 5?.R*N]>_O7VMU1Y*%Y_Y.^\9M%Z)],+(]F#]BZ7VMMG.##]_>Z@*,H MH'K#H.KE.+·^%W4·'5'·0C4,U1Q45YD\[E8WBGW<.)DT,1)H=F#]LT$9D5# 1S4(U&]4<5'·1S4,U'}4"5 LIK7X·MZHE69.W)!] M#ZCR/^7S,A]W^][NZ"' *GMWJ'R4MIF$.E·4TU"·0#43U2Q4LU'·0347U3Q4·M\U$M0+60TNK95;4W:_+VYI:GWTNM=HI[HN9_]Y1_Y*.V3A^TV1G5#%0S4/EJ5/O)F9G,R5^L%ZO·2GI!#3G?>LJ$=DFC·MFHYJ[J9J&:AFHŪJ#]JYJ..AFH]J_J%E%8/K.I+6L.O&"P76^<4VEF·:CJ M&:AFHIJ%:C.J..CFHI']·CZJ!=K9USX.J8'K(52U3>723[6\T@-7 ^AJNE:.W'=9[6EC4URE3\Z3).?,DM*D,U:.HIJ..@6HFJEFH9J:.@VHN MJCFHYJ·.@&HAI=63]VK^UOY>\[>\O'4HHJOFH%!'.2&GU1*IZNOORGNZ/#XG89D]C MU)#]HS>H-D4U'=6,$_Y]DH*Q913V3&S:R6;"R6.S1:BZ>7·/_&]$MT]+=(X M^.X40RUF(LUOY# 89,]B7/YULVW?,*UHZKM\,K4UBTMRY[@3K3=1\GJ"%MC2@]=9PO5;%1S4,U% 0_5? %0+4"VDM'K2:572_7C_·^*U(%D5[@3]{CFH&JIFH9J&·C6H.JKFHYJ&·CVH!JH64 M5@^>JH,\ORD+GM,?I%8"DS>1T[O8_V3P&_DPK>.&U'14,U#·1#4+U6Q4['#=K"C6HZ]AFH9J*·A6HV MJCFHYJ*·AVH^]@6H%E),/6ZJ+N_^CW=YET>&/K4X,H2V>Z/.%·5T5# 0S40U M"]5L5'·0S44U#]5\5 M0+.2T>H15[=Y]>,OWV4>&&JYK?>3($_K2C6HZJAFH M9J*·A6HVJCFHYJ*·AVH^]@6H%E),/7BJSN^^O//C"·#D[..#*'MVJBFHYJ! M:B.J6:AFHYJ#·BZ]>·CFHUJ·.B&EU>.F:M?NRJNUSS@R} (4G\PM/32$=F*C MFHYJ!JJ9J&:.AFHUJ#JJYJ.:AFH]J ·J%E%;+FT'5L#WX\M_QA MM#UHA&I35_1S4 U$]4L5+·1S4$U%]4\5/·1+4"UD·+JX5;U?@_D?=*9_,HBZZO5B))Y$##=BN4SS^=!FG?·%6^/N7B41]\5';,W_J'6Z!_=;ZGM7·M,;C? 4]·[V_N[%7]]]9A/I_PH>5BL4V4I[O.A>A?C84=)%@_SW3=9_)@'5T?Y M$F=9O·K>G(OH3B3% OG/[^,X>_VF&. Y3KYN5^?Z_U!+ P04_" "%@@Y9 M_A6W"3D# #R$P #0 'AL+W·T>6QEF^!"&Y73,J8))BV1*X]38KIZ%9;$934L@·MY2+L=3IQF%,NR6@@%_E=;LI@JA,2#$GS=V5GGZ?\·WY1 9'R!ZU>G@P@!BXO%AXONT,>F;>EF M^+G5:KGG&+GO(:^9*"TY<*WV+Y:,4ECO^6B0*;G>^HBX@,U/·E·.9DK3RT##JAI6=,B$>X%G]CFU!M+[·.G>W OLJV:0W532?C,J"_J>.T·V6C5^D&!7]6YM/"3D=6?2@7=JJ9QI=5·M? YFU!C#U+JY.BT*L/@#^DSESDS\XX6A &UXP5YK_LMF@5*8VP#0)GIDV?+H9 M^.E!\Y5<[CF[^E>7]M\JN8;_' M^@5\{":O3\%D? HF3Z(F^\=O,DJ.WV·]N#LZDV%]R·@XR6R=8]IH·.?%(?D& MYU.Q3AI,%EP8+NO>G*T(G]@V9+WXY/6487PCRVX]"LVU]9RA=Y MTHZZAX6H1ZW;7V!ZW;@]K·I<7*9LR=)QW=6S2=4,,,.FK2\@[")VO>5';(|# M_A@6![_<9Q+"S/_S2?/CH? AV'>^EZDCW+Z*,>Q?,BX^F!Y_)S$?OZ9)DD4 MQ3&VHN.QU%86[R/1G:XWO·EXA^^L V-]_%8+·%*$;*;X·M6@/B7S=@)(E_M[$\P,!V·;L=R_/_S7EYT01["KF#?N"<21), 1JT5^C<8RL M3@P? __Y@3TD4)8D? *NQS·$P(L !?3T\$MP>·4#M M.*2VBZD8_1!2.5K5N·%(MB6/.(7·>=I3W,+T]!,X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5,&GC3·MY?YVX$G1H2)8%II%R=.B'.5_' A2=H"ZZ#6B)CHE(!$O2 M2=NC'U*N,[\F]H=N**]L4,1\!{'?X46O'HV]?QISG_WH6NWF^=K[S>5DXNJU M{(3[RVRD#F=6QC,"AT·[W$,*T?CUE+ZKV4T^ELT@FE\}>O]M>ZL1·Z8+RL MO3(Z%,·,"TH^NO_.Q\VL03FU5*WR/^=Y_[V5>=8IK3KU2S,S?)IG;FT>/QJK·M?AGM1;NHK6G;>5[L3GR3UJOZ6?$B0GX52]>7>+'\(@+(/)]·PP57RCK?U^BO M+P+C@PR5=T=;,]ZKUDM[),S\8,UVH_1=O$RXBPFYC;X=]I^{1KRT?]*,9K52·MM;PR],.3VN_·T!HLC>B%,J6&8$L 61Y0LC;DD R ,E. KF(..&G M!)(#2'Y"R$%+5@"R.B4D(Y S #E+"_E&..4RL\INK'2A:E\C$SIP,KM.$,@S·M 'F6%O*3^KY535K(H)·"/L=XfL O(D__M(&P7@.TB+=MU>+#Z+OYC,*^@!9K.4Q3,T[1@7V)AZ!0W(K,<5RNT$[V2!X10 M+,G·TG6A1RR\J>\I$^_) (D5@D/4SPQBY;NG EUU>B?$@A17*'=)WRL9+K>T/H MJS[T6.EK)0XBH% QIHTCL#1C) [D52!S%*A/%T*JU+BHGD422VQ[.$/DB(%%(D=@@-PD-P)?)(F=@C MQQ+Q·RC%1#(I1Y#)T6#,7E!,.$}) [!?J%.*O&:.·<\D79ZSG&%K(NV4XVOG=T,. MH\AUYIQQ[O*$FI44DB' L_3^_9"2A;6+9 SYAXTXF3GX!G2#DN^/G;.[G\/ M&;Z,C3"M>,;(0 M3{Y}@S!IO'·D(9[80AB3QCM'%N*)+80Q:,QS9"&>V$(8Z)0A&.14&#YE36V/+UW_B397O^DG9MV7.'O·GV M>7+<[PYYT6Q*Z1]"R,M·VK?YINO3X7QDU0W[MIR7PSKT[?*]7.>@T^DL##]G M·(_SGS,GKZ<^_65BMUIME^FI6W[LTZ'\,CA\=L [WJ14FLEK.ZQ3633AN+ON MSN&RD9OSY&;R_+9HAN"X(M!&(:+DBT$9@NB+01] M" [(M!&X+PBT$<@O2+01V"^(M!'HKZ]T$>BOJK01ZZ^AAFT!O1,V50&]%O95 M;T6]E4!O1,V50&]#O8U ;T:JC4!O0[V·0&\,O2PA MT·M0;R/0VU!O()#;4&\CT·M0;R/0VU!O(]#;4&\CT·M1;R?0VU%O)]#;46\G MT·M1;R?0VT MD4#OB'1' KTCZAT)}(ZH=R30.XX^5OZGWKF<=BE?>[[7>/W_1+JYNZ.OPX681@'QCS^8)] M[5·CJ8DC,^_J'>)?·V=6YTL])R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>·N7 MIADGCBJ?]!YW$]NL<:*MKE/MPHNNXRRVJ9@/VXI\>K[$B1[·,%;F5)A\5<.=.$7·M1*&NTEW1F /)(>XP[7[YU?E=F7.! <>;4&>SOCH3FZ/YP).WJOHV%R(7R_",> M$V/IJY^/VM,NJ/AE=MS>#^.6W7EXUEVNW^.O9WRL?V$? J0"=*' NDC ^EC M" +'+4@?=R!JW/(TP0&UL4$L! A0#% @ A8(.690064?P *P(!$ (! MKP &1O8U!R,W!S+V·O&UL4$L! A0#% @ A8(.69E&PO M=V]R:W·H965T&UL4$L! A0#% @ A8(.62·R^A,=!P MRQT !@ ("!, X ·AL+W=O@(#@'·8 " @8,5 M !X,"JW;W)K&PO=V]R:W·H965T&UL4$L! A0#% @ A8(.6?_XTKT.#0 T&T !@ M ("!L!\ 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% M @ A8(.66X$)& !X,"JW;W)K&PO M=V]R:W·H965T&UL4$L! A0#% @ A8(.69'N(.)?"0 ?1< !D ("! M5U$ 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% M @ A8(.63^H@ >&PO=V]R:W·H965T&UL4$L! A0#% @ A8(.6<;RTM46 M P JP8 !D ("!588 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% @ A8(.6>S@SU5X!P <1@ !D M ("!6) 'AL+W=O&PO=V]R M:W·H965T !X,"JW;W)K&UL M4$L! A0#% @ A8(.6:5JQH6" @)P8 !D ("!U*$ M 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% @ MA8(.62$=DWB1! &PO=V]R:W·H965T&UL4$L! A0#% @ A8(.62K>&N;8 @ >P@ !D M ("!]L 'AL+W=O&PO=V]R:W·H M965T&UL4$L! M A0#% @ A8(.6&PO=V]R:W·H965T 9 " M@2?5 !X,"JW;W)K&UL4$L! A0#% @ A8(. M68*E$&?Z @ 0 D !D ("!P]H 'AL+W=O&PO=V]R:W·H965T]]!;%@4 .H< 9 " @3?P !X,"JW;W)K M&UL4$L! A0#% @ A8(.6;=?'DF<" 7DL M !D ("!A.< 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% @ A8(.6172E%NM @ 3 < !D M ("!M/P 'AL+W=O&PO=V]R:W·H965T M&UL4$L! A0# M% @ A8(.6&PO=V]R:W·H965TU6&K@(,4' 9 " @9\+ M 0!X,"JW;W)K&UL4$L! A0#% @ A8(.68E[M)&^8 P]0X !D ("!A X! 'AL+W=O&PO=V]R:W·H965T&UL4$L! A0#% @ A8(.61X4WTZU"0 LD(!D M ("!F1H! 'AL+W=O&PO M=V]R:W·H965TX[K 0!;0VJN=&5N=%J4>7!E&UL4$L%!@__ #\ ,!$.\] 0 $! end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref= ((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0), e.removeAttribute('id');a.parentNode.appendChild(e)} if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='·'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} } XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .re table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .num { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 243 339 1 false 123 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://vnrx.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://vnrx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Consolidated Balance Sheets(Parenthetical) Sheet http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets(Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Unaudited) Sheet http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders Equity (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 000008 - Disclosure - Liquidity and Going Concern Assessment Sheet http://vnrx.com/role/LiquidityAndGoingConcernAssessment Liquidity and Going Concern Assessment Notes 8 false false R9.htm 000009 - Disclosure - Property and Equipment Sheet http://vnrx.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 000010 - Disclosure - Intangible Assets Sheet http://vnrx.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 000011 - Disclosure - Related Party Transactions Sheet http://vnrx.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 000012 - Disclosure - Common Stock Sheet http://vnrx.com/role/CommonStock Common Stock Notes 12 false false R13.htm 000013 - Disclosure - Stock Based Compensation Sheet http://vnrx.com/role/StockBasedCompensation Stock Based Compensation Notes 13 false false R14.htm 000014 - Disclosure - Commitments and Contingencies Sheet http://vnrx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 000015 - Disclosure - Subsequent Events Sheet http://vnrx.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 000018 - Disclosure - Property and Equipment (Tables) Sheet http://vnrx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://vnrx.com/role/PropertyAndEquipment 18 false false R19.htm 000019 - Disclosure - Intangible Assets (Tables) Sheet http://vnrx.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://vnrx.com/role/IntangibleAssets 19 false false R20.htm 000020 - Disclosure - Common Stock (Tables) Sheet http://vnrx.com/role/CommonStockTables Common Stock (Tables) Tables http://vnrx.com/role/CommonStock 20 false false R21.htm 000021 - Disclosure - Stock Based Compensation (Tables) Sheet http://vnrx.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) Tables http://vnrx.com/role/StockBasedCompensation 21 false false R22.htm 000022 - Disclosure - Commitments and Contingencies (Tables) Sheet http://vnrx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://vnrx.com/role/CommitmentsAndContingencies 22 false false R23.htm 000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) Details http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 1) Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails1 Basis of Presentation and Summary of Significant Accounting Policies (Details 1) Details http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Sheet http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Details http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 000026 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative) Sheet http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative Liquidity and Going Concern Assessment (Details Narrative) Details http://vnrx.com/role/LiquidityAndGoingConcernAssessment 26 false false R27.htm 000027 - Disclosure - Property and Equipment (Details) Sheet http://vnrx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://vnrx.com/role/PropertyAndEquipmentTables 27 false false R28.htm 000028 - Disclosure - Property and Equipment (Details Narrative) Sheet http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://vnrx.com/role/PropertyAndEquipmentTables 28 false false R29.htm 000029 - Disclosure - Intangible Assets (Details) Sheet http://vnrx.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://vnrx.com/role/IntangibleAssetsTables 29 false false R30.htm 000030 - Disclosure - Intangible Assets (Details 1) Sheet http://vnrx.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://vnrx.com/role/IntangibleAssetsTables 30 false false R31.htm 000031 - Disclosure - Intangible Assets (Details Narrative) Sheet http://vnrx.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://vnrx.com/role/IntangibleAssetsTables 31 false false R32.htm 000032 - Disclosure - Common Stock (Details) Sheet http://vnrx.com/role/CommonStockDetails Common Stock (Details) Details http://vnrx.com/role/CommonStockTables 32 false false R33.htm 000033 - Disclosure - Common Stock (Details 1) Sheet http://vnrx.com/role/CommonStockDetails1 Common Stock (Details 1) Details http://vnrx.com/role/CommonStockTables 33 false false R34.htm 000034 - Disclosure - Common Stock (Details Narrative) Sheet http://vnrx.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://vnrx.com/role/CommonStockTables 34 false false R35.htm 000035 - Disclosure - StockBased Compensation (Details) Sheet http://vnrx.com/role/StockbasedCompensationDetails StockBased Compensation (Details) Details 35 false false R36.htm 000036 - Disclosure - StockBased Compensation (Details 1) Sheet http://vnrx.com/role/StockbasedCompensationDetails1 StockBased Compensation (Details 1) Details 36 false false R37.htm 000037 - Disclosure - StockBased Compensation (Details 2) Sheet http://vnrx.com/role/StockbasedCompensationDetails2 StockBased Compensation (Details 2) Details 37 false false R38.htm 000038 - Disclosure - StockBased Compensation (Details 3) Sheet http://vnrx.com/role/StockbasedCompensationDetails3 StockBased Compensation (Details 3) Details 38 false false R39.htm 000039 - Disclosure - StockBased Compensation (Details 4) Sheet http://vnrx.com/role/StockbasedCompensationDetails4 StockBased Compensation (Details 4) Details 39 false false R40.htm 000040 - Disclosure - StockBased Compensation (Details 5) Sheet http://vnrx.com/role/StockbasedCompensationDetails5 StockBased Compensation (Details 5) Details 40 false false R41.htm 000041 - Disclosure - StockBased Compensation (Details 6) Sheet http://vnrx.com/role/StockbasedCompensationDetails6 StockBased Compensation (Details 6) Details 41 false

false R42.htm 000042 - Disclosure - StockBased Compensation (Details 7) Sheet http://vnrx.com/role/StockbasedCompensationDetails7 StockBased Compensation (Details 7) Details 42 false false R43.htm 000043 - Disclosure - StockBased Compensation (Details 8) Sheet http://vnrx.com/role/StockbasedCompensationDetails8 StockBased Compensation (Details 8) Details 43 false false R44.htm 000044 - Disclosure - StockBased Compensation (Details Narrative) Sheet http://vnrx.com/role/StockbasedCompensationDetailsNarrative StockBased Compensation (Details Narrative) Details 44 false false R45.htm 000045 - Disclosure - Commitments and Contingencies (Details) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 45 false false R46.htm 000046 - Disclosure - Commitments and Contingencies (Details 1) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails1 Commitments and Contingencies (Details 1) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 46 false false R47.htm 000047 - Disclosure - Commitments and Contingencies (Details 2) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails2 Commitments and Contingencies (Details 2) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 47 false false R48.htm 000048 - Disclosure - Commitments and Contingencies (Details 3) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails3 Commitments and Contingencies (Details 3) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 48 false false R49.htm 000049 - Disclosure - Commitments and Contingencies (Details 4) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails4 Commitments and Contingencies (Details 4) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 49 false false R50.htm 000050 - Disclosure - Commitments and Contingencies (Details 5) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails5 Commitments and Contingencies (Details 5) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 50 false false R51.htm 000051 - Disclosure - Commitments and Contingencies (Details 6) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails6 Commitments and Contingencies (Details 6) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 51 false false R52.htm 000052 - Disclosure - Commitments and Contingencies (Details 7) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails7 Commitments and Contingencies (Details 7) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 52 false false R53.htm 000053 - Disclosure - Commitments and Contingencies (Details 8) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetails8 Commitments and Contingencies (Details 8) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 53 false false R54.htm 000054 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://vnrx.com/role/CommitmentsAndContingenciesTables 54 false false R55.htm 000055 - Disclosure - Subsequent Events (Details Narrative) Sheet http://vnrx.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://vnrx.com/role/SubsequentEvents 55 false false All Reports Book All Reports vnrx-20240630.xsd vnrx-20240630_cal.xml vnrx-20240630_def.xml vnrx-20240630_lab.xml vnrx-20240630_pre.xml vnrx_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vnrx_10q.htm": { "nsprefix": "vnrx", "nsuri": "http://vnrx.com/20240630", "dts": { "schema": { "local": ["vnrx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["vnrx-20240630_cal.xml"] }, "definitionLink": { "local": ["vnrx-20240630_def.xml"] }, "labelLink": { "local": ["vnrx-20240630_lab.xml"] }, "presentationLink": { "local": ["vnrx-20240630_pre.xml"] }, "inline": { "local": ["vnrx_10q.htm"] } }, "keyStandard": 195, "keyCustom": 144, "axisStandard": 18, "axisCustom": 0, "memberStandard": 22, "memberCustom": 101, "hidden": { "total": 25, "http://fasb.org/us-gaap/2024": 6, "http://vnrx.com/20240630": 14, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 243, "entityCount": 1, "segmentCount": 123, "elementCount": 530, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 515, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://vnrx.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "longName": "000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R3": { "role": "http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "000003 - Statement - Condensed Consolidated Balance Sheets(Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets(Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "vnrx:ServiceRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "vnrx:ServiceRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "000005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["strong", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-03-31_us-gaap_CommonStockMember", "name": "vnrx:CommonStockIssuedForCashNetOfIssuanceCostsShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R6": { "role": "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R7": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://vnrx.com/role/LiquidityAndGoingConcernAssessment", "longName": "000008 - Disclosure - Liquidity and Going Concern Assessment", "shortName": "Liquidity and Going Concern Assessment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://vnrx.com/role/PropertyAndEquipment", "longName": "000009 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://vnrx.com/role/IntangibleAssets", "longName": "000010 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://vnrx.com/role/RelatedPartyTransactions", "longName": "000011 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://vnrx.com/role/CommonStock", "longName": "000012 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://vnrx.com/role/StockBasedCompensation", "longName": "000013 - Disclosure - Stock Based Compensation", "shortName": "Stock Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://vnrx.com/role/CommitmentsAndContingencies", "longName": "000014 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://vnrx.com/role/SubsequentEvents", "longName": "000015 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {

```
"contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://vnrx.com/role/PropertyAndEquipmentTables", "longName": "000018 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } } }, "R19": { "role": "http://vnrx.com/role/IntangibleAssetsTables", "longName": "000019 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } } }, "R20": { "role": "http://vnrx.com/role/CommonStockTables", "longName": "000020 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } } }, "R21": { "role": "http://vnrx.com/role/StockBasedCompensationTables", "longName": "000021 - Disclosure - Stock Based Compensation (Tables)", "shortName": "Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesTables", "longName": "000022 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:WarrantLiabilityFairValueOnRecurringBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfWarrantLiabilityFairValueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member", "name": "vnrx:WarrantLiabilityFairValueOnRecurringBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R24": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails1", "longName": "000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 1)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "vnrx:WarrantLiabilityFairValueOnRecurringBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfWarrantLiabilityFairValueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R25": { "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:WarrantLiabilityFairValueOnRecurringBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfWarrantLiabilityFairValueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R26": { "role": "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative", "longName": "000026 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)", "shortName": "Liquidity and Going Concern Assessment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30_vnrx_LiquidityAndGoingConcernAssessmentMember", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R27": { "role": "http://vnrx.com/role/PropertyAndEquipmentDetails", "longName": "000027 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "000028 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://vnrx.com/role/IntangibleAssetsDetails", "longName": "000029 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://vnrx.com/role/IntangibleAssetsDetails1", "longName": "000030 - Disclosure - Intangible Assets (Details 1)", "shortName": "Intangible Assets (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "longName": "000031 - Disclosure - Intangible Assets (Details Narrative)", "shortName": "Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:AmortizationAndAccretionExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:AmortizationAndAccretionExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://vnrx.com/role/CommonStockDetails", "longName": "000032 - Disclosure - Common Stock (Details)", "shortName": "Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:EquityIncentiveRsu", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://vnrx.com/role/CommonStockDetails1", "longName": "000033 - Disclosure - Common Stock (Details 1)", "shortName": "Common Stock (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRates", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfFairValueOfWarrantsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRates", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfFairValueOfWarrantsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://vnrx.com/role/CommonStockDetailsNarrative", "longName": "000034 - Disclosure - Common Stock (Details Narrative)", "shortName": "Common Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:CommonStockPricePerShares", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:CommonStockPricePerShares", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://vnrx.com/role/StockbasedCompensationDetails", "longName": "000035 - Disclosure - StockBased Compensation (Details)", "shortName": "StockBased Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30_vnrx_WarrantsMember", "name": "vnrx:NumberOfWarrantsOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30_vnrx_WarrantsMember", "name": "vnrx:NumberOfWarrantsOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://vnrx.com/role/StockbasedCompensationDetails1", "longName": "000036 - Disclosure - StockBased Compensation (Details 1)", "shortName": "StockBased Compensation (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-06-30_vnrx_WarrantsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:SummarizingTheWarrantsIssuedAndOutstandingTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_WarrantsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:SummarizingTheWarrantsIssuedAndOutstandingTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R37": { "role":
```

```
"http://vnrx.com/role/StockbasedCompensationDetails2", "longName": "000037 - Disclosure - StockBased Compensation (Details 2)", "shortName": "StockBased Compensation (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30_us-gaap_OptionMember", "name": "vnrx:NumberOfOptionsOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30_us-gaap_OptionMember", "name": "vnrx:NumberOfOptionsOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://vnrx.com/role/StockbasedCompensationDetails3", "longName": "000038 - Disclosure - StockBased Compensation (Details 3)", "shortName": "StockBased Compensation (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2024-06-30_vnrx_OptionSixMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_OptionSixMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://vnrx.com/role/StockbasedCompensationDetails4", "longName": "000039 - Disclosure - StockBased Compensation (Details 4)", "shortName": "StockBased Compensation (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-06-30_vnrx_StockOptionsMember", "name": "vnrx:NumberOfRsusOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:SummarizingTheRsusIssuedAndOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_StockOptionsMember", "name": "vnrx:NumberOfRsusOutstandingBeginningBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:SummarizingTheRsusIssuedAndOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://vnrx.com/role/StockbasedCompensationDetails5", "longName": "000040 - Disclosure - StockBased Compensation (Details 5)", "shortName": "StockBased Compensation (Details 5)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:CompensationExpenseRsus", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusGrantedDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:RsuExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusGrantedDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R41": { "role": "http://vnrx.com/role/StockbasedCompensationDetails6", "longName": "000041 - Disclosure - StockBased Compensation (Details 6)", "shortName": "StockBased Compensation (Details 6)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:EquityIncentiveRsu", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:EquityIncentiveRsuD", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusVestedAndSettledDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R42": { "role": "http://vnrx.com/role/StockbasedCompensationDetails7", "longName": "000042 - Disclosure - StockBased Compensation (Details 7)", "shortName": "StockBased Compensation (Details 7)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:EquityIncentiveRsu", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:IncentiveRsusCancelled", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusCancelledDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R43": { "role": "http://vnrx.com/role/StockbasedCompensationDetails8", "longName": "000043 - Disclosure - StockBased Compensation (Details 8)", "shortName": "StockBased Compensation (Details 8)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30_vnrx_OptionTenMember", "name": "vnrx:NumberOfStockOutstandingBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusIssuedAndOutstandingAndAverageContractualLife", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30_vnrx_OptionTenMember", "name": "vnrx:NumberOfStockOutstandingBalance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusIssuedAndOutstandingAndAverageContractualLife", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://vnrx.com/role/StockbasedCompensationDetailsNarrative", "longName": "000044 - Disclosure - StockBased Compensation (Details Narrative)", "shortName": "StockBased Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "vnrx:CompensationExpenseRsus", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfRsusGrantedDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "vnrx:WeightedAverageRemainingContractualLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R45": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails", "longName": "000045 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-06-30_vnrx_FinanceLeaseObligationsMember", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_FinanceLeaseObligationsMember", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "longName": "000046 - Disclosure - Commitments and Contingencies (Details 1)", "shortName": "Commitments and Contingencies (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_OperatingLeaseRightofUseObligationsMember", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "vnrx:ScheduleOfOperatingLeaseTableTextblock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R47": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "longName": "000047 - Disclosure - Commitments and Contingencies (Details 2)", "shortName": "Commitments and Contingencies (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:LessImputedInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_OperatingLeaseRightofUseObligationsMember", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R48": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails3", "longName": "000048 - Disclosure - Commitments and Contingencies (Details 3)", "shortName": "Commitments and Contingencies (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfRecognizedInShortTermLeaseCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "vnrx:ScheduleOfRecognizedInShortTermLeaseCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "longName": "000049 - Disclosure - Commitments and Contingencies (Details 4)", "shortName": "Commitments and Contingencies (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:GrantsRepayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_GrantsRepayableMember", "name": "vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } }, "R50": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails5", "longName": "000050 - Disclosure - Commitments and Contingencies (Details 5)", "shortName": "Commitments and Contingencies (Details 5)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails6", "longName": "000051 - Disclosure - Commitments and Contingencies (Details 6)", "shortName": "Commitments and Contingencies (Details 6)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:TotalAmountRemainingLease", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:TotalAmountRemainingLease", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "longName": "000052 - Disclosure - Commitments and Contingencies (Details 7)", "shortName": "Commitments and Contingencies (Details 7)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_RestrictedStockMember_vnrx_AwardThreeMember", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "vnrx:ScheduleofCommitmentsInRespectOfCorporateGoalsAndPerformanceBasedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_RestrictedStockMember_vnrx_AwardThreeMember", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "vnrx:ScheduleofCommitmentsInRespectOfCorporateGoalsAndPerformanceBasedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "longName": "000053 - Disclosure - Commitments and Contingencies (Details 8)", "shortName": "Commitments and Contingencies (Details 8)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2024-06-30_vnrx_RestrictedStockOptionsVestedMember_vnrx_TotalMember", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_vnrx_RestrictedStockOptionsVestedMember_vnrx_TotalMember", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "000054 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:PaymentsForFutureResearchAndCollobration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "vnrx:PaymentsForFutureResearchAndCollobration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://vnrx.com/role/SubsequentEventsDetailsNarrative", "longName": "000055 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-08-01to2024-08-08_us-gaap_SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": {
```

```
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36", "r619" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r681" ] }, "vnrx_AccruedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AccruedCompensationExpense", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued compensation expense" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Less accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r23", "r96", "r445" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r15", "r16", "r51", "r104", "r441", "r460", "r461" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r9", "r16", "r323", "r326", "r361", "r456", "r457", "r658", "r659", "r660", "r669", "r670", "r671", "r672" ] }, "vnrx_AdditionalCostOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AdditionalCostOfCompany", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional Cost Of Company" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r46", "r619", "r797" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r474", "r669", "r670", "r671", "r672", "r738", "r798" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "vnrx_AggerateAmountPayableDescription": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AggerateAmountPayableDescription", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggerate Amount Payable, Description" } } }, "auth_ref": [] }, "vnrx_AggeregateShareOfCommonStockOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AggeregateShareOfCommonStockOfferingPrice", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggeregate share of common stock offering price" } } }, "auth_ref": [] }, "vnrx_AggregateNetProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AggregateNetProceeds", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate net proceeds" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "vnrx_AmortizationAndAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmortizationAndAccretionExpense", "crdr": "debit", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization Expense" } } }, "auth_ref": [] }, "vnrx_AmortizedOfOutstandingAwarCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmortizedOfOutstandingAwarCurrentYear", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Amortized of outstanding award 2024", "verboseLabel": "Amortized of outstanding award 2024" } } }, "auth_ref": [] }, "vnrx_AmortizedOfOutstandingAwarPreviousYear": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmortizedOfOutstandingAwarPreviousYear", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Amortized of outstanding award 2023", "verboseLabel": "Amortized of outstanding award 2023" } } }, "auth_ref": [] }, "vnrx_AmortizedOfOutstandingAwardPriorYear": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmortizedOfOutstandingAwardPriorYear", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ], "lang": { "en-us": { "role": { "label": "Amortized of outstanding award 2022" } } }, "auth_ref": [] }, "vnrx_AmountMayBePayableByCompanyInFuturePeriodsForServicesRendered": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmountMayBePayableByCompanyInFuturePeriodsForServicesRendered", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amount may be payable by Company in future periods for services rendered" } } }, "auth_ref": [] }, "vnrx_AmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmountPayable", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amount payable" } } }, "auth_ref": [] }, "vnrx_AmountPayableForServicesRendered": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AmountPayableForServicesRendered", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amount payable for services rendered" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "[Assets]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r75", "r83", "r98", "r126", "r150", "r154", "r158", "r159", "r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r316", "r320", "r341", "r439", "r512", "r591", "r592", "r619", "r641", "r705", "r706", "r758" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "[Assets, Current]", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r92", "r107", "r126", "r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r316", "r320", "r341", "r619", "r705", "r706", "r758" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "vnrx_AugustTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AugustTwoThousandTwentyThreeMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "August Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "vnrx_AwardOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AwardOneMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Outstanding Award 1" } } }, "auth_ref": [] }, "vnrx_AwardThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "AwardThreeMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ], "lang": { "en-us": { "role": { "label": "Outstanding Award 3" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type Axis", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis Of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r61" ] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingImprovementsMember", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Building Improvements [Member]", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Buildings [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r64" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "[Cash and Cash Equivalents, at Carrying Value]", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r19", "r94", "r586" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and cash
```

equivalents - beginning of the period", "periodEndLabel": "Cash and cash equivalents - End of Period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r19", "r58", "r124"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": ["r0", "r58"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://vnrx.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r88", "r101", "r102", "r103", "r126", "r143", "r144", "r147", "r148", "r152", "r153", "r195", "r230", "r232", "r233", "r234", "r237", "r238", "r245", "r246", "r248", "r251", "r258", "r341", "r464", "r465", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r500", "r521", "r541", "r562", "r563", "r564", "r565", "r566", "r648", "r667", "r673"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r259"] }, "vnrx_ClinicalStudyResearchAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ClinicalStudyResearchAgreementMember", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Clinical Study Research Agreement [Member]" } } }, "auth_ref": [] }, "vnrx_CollaborativeObligationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CollaborativeObligationsAmount", "crdr": "debit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Obligations Amount" } } }, "auth_ref": [] }, "vnrx_CollaborativeObligationsAmountDue": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CollaborativeObligationsAmountDue", "crdr": "debit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Obligations Amount Due" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r65", "r224", "r225", "r570", "r699", "r704"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A common stock [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r798"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series B common stock [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r798"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock Shares Reserved For Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r45"] }, "vnrx_CommonStockIssuedForCashNetOfIssuanceCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedForCashNetOfIssuanceCostsAmount", "crdr": "credit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for cash, net of issuance costs, amount" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedForCashNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedForCashNetOfIssuanceCostsShares", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for cash, net of issuance costs, shares" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedForLicenseRightsForNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedForLicenseRightsForNonCash", "crdr": "debit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for License rights" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedForSettlementOfRsuAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedForSettlementOfRsuAmount", "crdr": "credit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for settlement of RSUs, amount" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedForSettlementOfRsuShares": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedForSettlementOfRsuShares", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for settlement of RSUs, shares" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedInLieuOfLicenseFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedInLieuOfLicenseFeeAmount", "crdr": "credit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued in lieu of license fee, amount" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedInLieuOfLicenseFeeShares": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedInLieuOfLicenseFeeShares", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued in lieu of license fee, shares" } } }, "auth_ref": [] }, "vnrx_CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrantsForNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrantsForNoncash", "crdr": "credit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued upon cashless exercises of stock options and settlement of vested RSUs" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r631", "r632", "r633", "r635", "r636", "r637", "r638", "r669", "r670", "r672", "r738", "r796", "r798"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Par Value", "verboseLabel": "Common Stock, Shares Par Value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r45"] }, "vnrx_CommonStockPricePerShares": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockPricePerShares", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock price per share" } } }, "auth_ref": [] }, "vnrx_CommonStockRepurchasedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockRepurchasedAmount", "crdr": "credit", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock repurchased, amount" } } }, "auth_ref": [] }, "vnrx_CommonStockRepurchasedShares": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockRepurchasedShares", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock repurchased, shares" } } }, "auth_ref": [] }, "vnrx_CommonStockShareAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockShareAuthorized", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r15", "r500"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Issued", "verboseLabel": "Common stock, shares issued", "terseLabel": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r45"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Outstanding", "verboseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r45", "r500", "r518", "r798", "r799"] }, "vnrx_CommonStockSharesWithheldForTaxes": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CommonStockSharesWithheldForTaxes", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares withheld for taxes" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 25.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock Authorized. 100,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 82,928,314 shares and 81,898,321 shares, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r45", "r440", "r619"] }, "vnrx_CompensationExpenseGrantDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseGrantDate", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Compensation Expense grant date" } } }, "auth_ref": [] }, "vnrx_CompensationExpenseOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseOneMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Compensation Expense One [Member]" } } }, "auth_ref": [] }, "vnrx_CompensationExpenseRsus": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseRsus", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Compensation Expense RSUs", "verboseLabel": "Compensation Expense RSUs" } } }, "auth_ref": [] }, "vnrx_CompensationExpenseThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseThreeMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Compensation Expense Three [Member]" } } }, "auth_ref": [] }, "vnrx_CompensationExpenseTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseTwoMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Compensation Expense Two [Member]" } } }, "auth_ref": [] }, "vnrx_CompensationExpenseVestingPeriod": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "CompensationExpenseVestingPeriod", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Compensation Expense Vesting Period" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net Comprehensive Loss", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r109", "r111", "r116", "r436", "r452", "r453"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://vnrx.com/role/PropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Computer Hardware And Software [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Warrant liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r261", "r262", "r263"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [

```
"http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r657" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation Expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r22" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives, or to record the reduction in book value of an intangible asset over the benefit period of such asset, or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r6", "r22" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails", "http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r489", "r491", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r529", "r530", "r531", "r532", "r535", "r536", "r537", "r538", "r555", "r557", "r558", "r559", "r631", "r633", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r753" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 }, "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Gain on change in fair value of warrant liability", "negatedLabel": "Gain on change in fair value of warrant liability", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r737" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails", "http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument Risk Axis", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r31", "r32", "r33", "r74", "r489", "r491", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r529", "r530", "r531", "r532", "r535", "r536", "r537", "r538", "r555", "r557", "r558", "r559", "r588", "r631", "r633", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r753" ] }, "vnrx_DescriptionOfLoanAgreement": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "DescriptionOfLoanAgreement", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan agreement, Description" } } }, "auth_ref": [] }, "vnrx_DescriptionOfagreement": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "DescriptionOfagreement", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://vnrx.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r272", "r273", "r300", "r301", "r303", "r604" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock Based Compensation" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r645" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r646" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "vnrx_EarningsPerShareBasicsAndDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EarningsPerShareBasicsAndDiluted", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic And Diluted Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r20", "r21", "r149" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Effect of foreign exchange on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r342" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized total compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r302" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r643" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r643" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r643" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r647" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r643" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r643" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r643" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r643" ] }, "vnrx_EpiCypherLicenseAgreementMember": { "xbrltype":
```

```
"domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EpiCypherLicenseAgreementMember", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "EpiCypher License Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r89", "r112", "r113", "r114", "r128", "r129", "r130", "r132", "r137", "r138", "r140", "r151", "r196", "r197", "r223", "r260", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r322", "r323", "r324", "r325", "r326", "r327", "r330", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r352", "r361", "r450", "r456", "r457", "r458", "r474", "r541" ] }, "vnrx_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityDistributionAgreementMember", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Distribution Agreement [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlan": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlan", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan", "verboseLabel": "Equity Incentive Plan" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanFiveMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Five [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanFourMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Four [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanOneMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan One [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanSevenMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Seven [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanSixMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanSixMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Six [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanThreeMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Three [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentivePlanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentivePlanTwoMember", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan Two [Member]" } } }, "auth_ref": [] }, "vnrx_EquityIncentiveRsu": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentiveRsu", "presentation": [ "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "Equity Incentive RSU", "verboseLabel": "Equity Incentive RSU", "terseLabel": "Equity Incentive RSU" } } }, "auth_ref": [] }, "vnrx_EquityIncentiveRsuD": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentiveRsuD", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "Equity Incentive RSUD" } } }, "auth_ref": [] }, "vnrx_EquityIncentiveRsus": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "EquityIncentiveRsus", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity Incentive RSU", "label": "[Equity Incentive RSU]" } } }, "auth_ref": [] }, "vnrx_ExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ExercisePrice", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [] }, "vnrx_ExercisePricePerShareOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ExercisePricePerShareOfWarrants", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r240", "r265", "r266", "r267", "r268", "r269", "r270", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r373", "r374", "r375", "r596", "r597", "r600", "r601", "r602", "r608", "r610" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Inputs Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r240", "r265", "r270", "r333", "r338", "r373", "r600", "r601", "r602", "r608" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Inputs Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r240", "r265", "r270", "r333", "r334", "r338", "r374", "r596", "r597", "r600", "r601", "r602", "r608" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Inputs Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r240", "r265", "r266", "r267", "r268", "r269", "r270", "r333", "r334", "r335", "r336", "r338", "r375", "r596", "r597", "r600", "r601", "r602", "r608", "r610" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r240", "r265", "r266", "r267", "r268", "r269", "r270", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r373", "r374", "r375", "r596", "r597", "r600", "r601", "r602", "r608", "r610" ] }, "vnrx_FairValueOfWarrantsIssuedInConnectionwithPublicOfferingNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FairValueOfWarrantsIssuedInConnectionwithPublicOfferingNonCash", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in connection with public offering" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Present value of minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r354", "r359" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r354" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r354" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "[Finance Lease, Liability, to be Paid]", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Greater than 5 years", "label": "[Finance Lease, Liability, to be Paid, after Year Five]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "2024 - remaining", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[Finance Lease, Liability, to be Paid, Year Five]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "[Finance Lease, Liability, to be Paid, Year Four]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "[Finance Lease, Liability, to be Paid, Year Three]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[Finance Lease, Liability, to be Paid, Year Two]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Amount representing interest", "label": "[Finance Lease, Liability, Undiscounted Excess Amount]", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r359" ] }, "vnrx_FinanceLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FinanceLeaseObligationsMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails4", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument Axis", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r242", "r256", "r328", "r340", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r451", "r594", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r620", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r682", "r683", "r684", "r685", "r739", "r742", "r743", "r744", "r751", "r754" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Less accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r97", "r208", "r216", "r595" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "Greater than 5 years", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r694", "r800" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year
```

following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r217", "r583", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": ["http://vnrx.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Annual Estimated Amortization", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails1"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r217", "r583", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails1"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r217", "r583", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails1"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r217", "r583", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails1"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r217", "r583", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets By Major Class Axis", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r210", "r211", "r212", "r213", "r215", "r216", "r219", "r220", "r404", "r405", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Total Patents and Licenses", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r208", "r216", "r405", "r595"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r210", "r211", "r212", "r213", "r215", "r216", "r219", "r220", "r583"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "http://vnrx.com/role/IntangibleAssetsDetails", "http://vnrx.com/role/IntangibleAssetsDetails1"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "verboseLabel": "Total patents and Licenses, net", "terseLabel": "Total Intangible Assets", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r404", "r693"] }, "vnrx_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod", "presentation": ["http://vnrx.com/role/IntangibleAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amortization Of Patents On Straight Line Basis" } } }, "auth_ref": [] }, "vnrx_FirstVestingDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FirstVestingDate", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "First Vesting date" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "Greater than 5 years", "label": "[Greater than 5 years]" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "[2026]" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[2025 1]" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven", "crdr": "debit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[2028]" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "[2027]" } } }, "auth_ref": [] }, "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "2024 - Remaining", "label": "[2024 - Remaining 1]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Loss on disposal of fixed assets", "negatedLabel": "Loss on disposal of fixed assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": ["r665", "r697", "r698"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r53", "r523"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth_ref": [] }, "vnrx_GrantRepayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GrantRepayableCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current portion of grant repayable" } } }, "auth_ref": [] }, "vnrx_GrantRepayableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GrantRepayableNonCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 22.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Grant repayable, net of current portion" } } }, "auth_ref": [] }, "vnrx_GrantedShares": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GrantedShares", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Granted" } } }, "auth_ref": [] }, "vnrx_GrantsRepayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GrantsRepayable", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Total Grants Repayable", "verboseLabel": "Total Grants Repayable" } } }, "auth_ref": [] }, "vnrx_GrantsRepayableMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GrantsRepayableMember", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails4"], "lang": { "en-us": { "role": { "label": "Grants Repayable [Member]" } } }, "auth_ref": [] }, "vnrx_GuysAndStThomasMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GuysAndStThomasMember", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails6"], "lang": { "en-us": { "role": { "label": "Guys and St Thomas" } } }, "auth_ref": [] }, "vnrx_GuysAndStThomasNHSFoundationTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "GuysAndStThomasNHSFoundationTrustMember", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Guy's and St Thomas' NHS Foundation Trust [Member]" } } }, "auth_ref": [] }, "vnrx_InTwoThousandsEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "InTwoThousandsEighteenMember", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "In 2018 [Member]" } } }, "auth_ref": [] }, "vnrx_IncentiveCancellationDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncentiveCancellationDate", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails7"], "lang": { "en-us": { "role": { "label": "Incentive Cancellation Date" } } }, "auth_ref": [] }, "vnrx_IncentivePlan": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncentivePlan", "presentation": ["http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6"], "lang": { "en-us": { "role": { "label": "Incentive Plan", "verboseLabel": "Incentive Plan" } } }, "auth_ref": [] }, "vnrx_IncentiveRsuIssued": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncentiveRsuIssued", "presentation": ["http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6"], "lang": { "en-us": { "role": { "label": "Incentive RSU Issued", "verboseLabel": "Incentive RSU Issued" } } }, "auth_ref": [] }, "vnrx_IncentiveRsusCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncentiveRsusCancelled", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails7"], "lang": { "en-us": { "role": { "label": "Incentive RSUs Cancelled" } } }, "auth_ref": [] }, "vnrx_IncentiveVestDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncentiveVestDate", "presentation": ["http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7"], "lang": { "en-us": { "role": { "label": "Incentive Vest Date", "verboseLabel": "Incentive Vest Date", "terseLabel": "Incentive Vest Date" } } }, "auth_ref": [] }, "vnrx_IncomeFromGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncomeFromGrants", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Grant income" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "label": "[Increase (Decrease) in Accounts Receivable]", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred revenue, current and non-current", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r584"] }, "vnrx_IncreaseDecreaseInManagementAndDirectorsFeesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "IncreaseDecreaseInManagementAndDirectorsFeesPayable", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Management and directors' fees payable", "label": "[Management and directors' fees payable]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": {

```
"http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } },
"presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets operating leases liabilities",
"documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r649", "r664" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": {
"http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } },
"presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current assets", "label": "[Increase
(Decrease) in Other Current Assets]", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r664" ] }, "us-
gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit",
"calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 8.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "label": "
[Increase (Decrease) in Prepaid Expense]", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that
bring economic benefits for future periods." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected
indefinite period of benefit." } } }, "auth_ref": [ "r210", "r214", "r218", "r595" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-
us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of
intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r210", "r214", "r218",
"r595" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock",
"presentation": [ "http://vnrx.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation":
"The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r209", "r221", "r222", "r582", "r583" ] }, "us-gaap_InterestExpenseOther": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": {
"http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order":
12.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest
expense", "label": "[Interest Expense, Other]", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOther": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": {
"http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order":
11.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Interest income",
"documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited
to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing
attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r119", "r122", "r123" ] }, "vnrx_JulyEightTwoThousandFourMember": { "xbrltype": "domainItemType", "nsuri":
"http://vnrx.com/20240630", "localname": "JulyEightTwoThousandFourMember", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": {
"label": "July 8, 2024 [Member]" } } }, "auth_ref": [] }, "vnrx_JulyOneTwoThousandFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname":
"JulyOneTwoThousandFourMember", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "July 1, 2024 [Member]" } } }, "auth_ref":
[] }, "vnrx_JulyTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "JulyTwoThousandTwentyFourMember", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "January TwoThousand Twenty Four [Member]" } } }, "auth_ref": [] },
"vnrx_JulyTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "JulyTwoThousandTwentyThreeMember", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "July Thirty One Thousand Twenty Three [Member]" } } }, "auth_ref": [] },
"vnrx_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "LaboratoryEquipmentMember", "presentation": [
"http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]" } } }, "auth_ref": [] }, "vnrx_LandsMember": { "xbrltype":
"domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "LandsMember", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": {
"label": "Land [Member]" } } }, "auth_ref": [] }, "vnrx_Lease2024Estimated": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "Lease2024Estimated", "crdr":
"credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "2024 - Estimated" } } }, "auth_ref": [] },
"vnrx_Lease2025Estimated": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "Lease2025Estimated", "crdr": "credit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "2025 - Estimated" } } }, "auth_ref": [] }, "vnrx_LeaseAgreementExpirePeriod": {
"xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "LeaseAgreementExpirePeriod", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease Agreement Expire Period" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cost", "documentation": "Amount of lease cost recognized by lessee for lease
contract." } } }, "auth_ref": [ "r356", "r618" ] }, "vnrx_LessImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "LessImputedInterest", "crdr":
"debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": {
"negatedLabel": "Less: imputed interest", "label": "[Less: imputed interest]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "[Lessee, Operating Lease, Liability, to be Paid]", "documentation":
"Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r359" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": { "role": { "label": "2024 - Remaining", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": { "role": {
"verboseLabel": "2027", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease
to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling
approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": {
"role": { "verboseLabel": "2026", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position
date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": {
"en-us": { "role": { "verboseLabel": "2025", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "documentation": "Amount of lessee's undiscounted obligation for lease payment
for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial
position date (rolling approach)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr":
"credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 31.0 } },
"presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "[Liabilities]", "documentation": "Amount of
liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r126",
"r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r317", "r320", "r321", "r341", "r499", "r589", "r641", "r705", "r758", "r759" ] }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit",
"calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders' Deficit", "label": "[Liabilities and Equity]",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r50", "r78", "r444", "r619", "r668",
"r686", "r755" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND
STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent",
"crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 23.0 } }, "presentation": [
"http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "[Liabilities, Current]", "documentation": "Total
obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r39", "r93", "r126",
"r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r317", "r320", "r321", "r341", "r619", "r705", "r758", "r759" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": {
"en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 24.0 } },
"presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Long-Term Liabilities", "label": "[Liabilities, Noncurrent]",
"documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r14", "r40", "r41", "r42", "r43", "r126", "r195", "r230", "r231",
"r232", "r233", "r234", "r235", "r236", "r237", "r238", "r317", "r320", "r321", "r341", "r705", "r758", "r759" ] }, "vnrx_LicensesMember": { "xbrltype": "domainItemType", "nsuri":
"http://vnrx.com/20240630", "localname": "LicensesMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Licenses [Member]" } } },
"auth_ref": [] }, "vnrx_LiquidityAndGoingConcernAssessmentMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname":
"LiquidityAndGoingConcernAssessmentMember", "presentation": [ "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liquidity
and Going Concern Assessment [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LocalPhoneNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } },
"auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesDetails5", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total Long-Term
Debt", "verboseLabel": "Total Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease
obligation." } } }, "auth_ref": [ "r14", "r76", "r239", "r243", "r596", "r597", "r617", "r767" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0, "order": 14.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of long-term debt",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [
"r99" ] }, "us-gaap_LongTermDebtMaturingInYearsFourAndFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturingInYearsFourAndFive", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel":
"Greater than 5 years", "label": "[Long-Term Debt, Maturity, Year Four and Five]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued
that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r708" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname",
"LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": {
"verboseLabel": "Total", "label": "[Long-Term Debt, Maturity, after Year Five]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that
are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are
```

```
reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r708" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel": "2024 - Remaining", "label": "[Long-Term Debt, Maturity, Year One]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r241" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[Long-Term Debt, Maturity, Year Five]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r241" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "[Long-Term Debt, Maturity, Year Four]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r241" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "[Long-Term Debt, Maturity, Year Three]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r241" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails5" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[Long-Term Debt, Maturity, Year Two]", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r127", "r241" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term debt, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r100" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Longterm Debt Type Axis", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r14", "r700", "r701", "r702" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r14", "r24", "r700", "r701", "r702" ] }, "vnrx_MDAndersonCancerCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "MDAndersonCancerCenterMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "MD Anderson Cancer Center" } } }, "auth_ref": [] }, "us-gaap_ManagementFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManagementFeePayable", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Management and directors' fees payable", "documentation": "Amount of fee payable for management of fund or trust." } } }, "auth_ref": [ "r493" ] }, "vnrx_ManagingDirectorsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ManagingDirectorsAgreementMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Managing Director's Agreement [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "http://vnrx.com/role/PropertyAndEquipmentDetails", "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r226", "r227", "r228", "r229", "r271", "r304", "r336", "r402", "r454", "r455", "r462", "r490", "r491", "r548", "r550", "r552", "r553", "r560", "r580", "r581", "r593", "r598", "r603", "r610", "r611", "r615", "r616", "r629", "r707", "r760", "r761", "r762", "r763", "r764", "r765" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "http://vnrx.com/role/PropertyAndEquipmentDetails", "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r226", "r227", "r228", "r229", "r271", "r304", "r336", "r402", "r454", "r455", "r462", "r490", "r491", "r548", "r550", "r552", "r553", "r560", "r580", "r581", "r593", "r598", "r603", "r610", "r611", "r615", "r629", "r707", "r760", "r761", "r762", "r763", "r764", "r765" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-controlling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r49", "r77", "r126", "r195", "r230", "r232", "r233", "r234", "r237", "r238", "r341", "r443", "r502" ] }, "vnrx_NationalUniversityOfTaiwanMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NationalUniversityOfTaiwanMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "National University of Taiwan" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided By Financing Activities", "label": "[Net Cash Provided by (Used in) Financing Activities]", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r121" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used In Investing Activities", "label": "[Net Cash Provided by (Used in) Investing Activities]", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r121" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used In Operating Activities", "label": "[Net Cash Provided by (Used in) Operating Activities]", "verboseLabel": "Cash flows from operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r58", "r59", "r60" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net loss for the period", "verboseLabel": "Net loss", "terseLabel": "Net Loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r52", "r60", "r79", "r91", "r108", "r110", "r114", "r126", "r131", "r133", "r134", "r135", "r136", "r137", "r139", "r140", "r145", "r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r311", "r314", "r331", "r341", "r449", "r520", "r539", "r540", "r639", "r705" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Loss Attributable to Non-Controlling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r30", "r72", "r108", "r110", "r137", "r139", "r140", "r448", "r660" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss Attributable to VolitionRx Limited Stockholders", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r117", "r133", "r134", "r135", "r136", "r141", "r142", "r146", "r148", "r314" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Non-Cash Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r27", "r260", "r669", "r670", "r671", "r672", "r798" ] }, "vnrx_NotePayableNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NotePayableNonCash", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Non-cash note payable" } } }, "auth_ref": [] }, "vnrx_NumberOfExpiredCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfExpiredCancelled", "crdr": "debit", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, Expired/Cancelled", "label": "[Number of options, Expired/Cancelled]" } } }, "auth_ref": [] }, "vnrx_NumberOfOptionOutstandingEndingBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfOptionOutstandingEndingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Number of option outstanding ending balance" } } }, "auth_ref": [] }, "vnrx_NumberOfOptionsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfOptionsExercisable", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Number of options, exercisable" } } }, "auth_ref": [] }, "vnrx_NumberOfOptionsOutstandingBeginningBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfOptionsOutstandingBeginningBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding beginning balance" } } }, "auth_ref": [] }, "vnrx_NumberOfRsusOutstandingBeginingBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfRsusOutstandingBeginingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails4" ], "lang": { "en-us": { "role": { "label": "Number Of Rsus Outstanding Begining Balance shares" } } }, "auth_ref": [] }, "vnrx_NumberOfRsusOutstandingEndingBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfRsusOutstandingEndingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails4" ], "lang": { "en-us": { "role": { "label": "Number Of Rsus Outstanding ending Balance" } } }, "auth_ref": [] },
```

```
"vnrx_NumberOfStockCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfStockCancelled", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails4" ], "lang": { "en-us": { "role": { "label": "Cancelled / Forfeited" } } }, "auth_ref": [] }, "vnrx_NumberOfStockOutstandingBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfStockOutstandingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Number Of Stock Outstanding Balance" } } }, "auth_ref": [] }, "vnrx_NumberOfStockVested": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfStockVested", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails4" ], "lang": { "en-us": { "role": { "label": "Vested/Settled" } } } }, "auth_ref": [] }, "vnrx_NumberOfWarrantsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfWarrantsExercisable", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Exercisable" } } }, "auth_ref": [] }, "vnrx_NumberOfWarrantsOutstandingBeginningBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfWarrantsOutstandingBeginningBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of warrants Outstanding beginning balance" } } }, "auth_ref": [] }, "vnrx_NumberOfWarrantsOutstandingEndingBalance": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "NumberOfWarrantsOutstandingEndingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Number of warrants outstanding ending balance" } } }, "auth_ref": [] }, "vnrx_OfferingCostsFromIssuanceOfCommonStockForNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OfferingCostsFromIssuanceOfCommonStockForNonCash", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Offering costs from issuance of common stock" } } }, "auth_ref": [] }, "vnrx_OfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OfferingExpenses", "crdr": "debit", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering expenses" } } }, "auth_ref": [] }, "vnrx_OfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OfferingPrice", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering price" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Furniture and Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses", "label": "[Operating Expenses]", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Loss", "label": "[Operating Income (Loss)]", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r82", "r590", "r675", "r676", "r677", "r678", "r679" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Lease Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r756" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2" ], "lang": { "en-us": { "role": { "label": "Total operating lease liabilities", "verboseLabel": "Total Operating Lease Liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r354" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "verboseLabel": "Operating lease liabilities, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r354" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, net of current portion", "verboseLabel": "Operating lease liabilities, long term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r354" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "verboseLabel": "Operating right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r353" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Amortization of operating lease right-of use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r665" ] }, "vnrx_OperatingLeaseRightofUseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OperatingLeaseRightofUseObligationsMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Lease Right of Use Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r358", "r618" ] }, "vnrx_OperatingLeaseWeightedAverageRemainingLeaseTermOne": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermOne", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease (months)" } } }, "auth_ref": [] }, "vnrx_OperatingLeasesFutureMinimumLeasePaymentDue": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OperatingLeasesFutureMinimumLeasePaymentDue", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Operating Lease Liabilities", "label": "[Total Operating Lease Liabilities]" } } }, "auth_ref": [] }, "vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "2024 - Remaining", "label": "[2024 - Remaining]" } } }, "auth_ref": [] }, "vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OperatingLeasesFutureMinimumPaymentDueInTwoYears", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[2025]" } } }, "auth_ref": [] }, "vnrx_OptionFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionFiveMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Five [Member]" } } }, "auth_ref": [] }, "vnrx_OptionFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionFourMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Four [Member]" } } }, "auth_ref": [] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": [ "r73", "r508", "r513", "r529", "r535", "r555", "r556", "r557", "r631", "r632" ] }, "vnrx_OptionSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionSevenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3" ], "lang": { "en-us": { "role": { "label": "Option Seven [Member]" } } }, "auth_ref": [] }, "vnrx_OptionSixMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionSixMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3" ], "lang": { "en-us": { "role": { "label": "Option Six [Member]" } } }, "auth_ref": [] }, "vnrx_OptionTenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionTenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Ten [Member]" } } }, "auth_ref": [] }, "vnrx_OptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionTwoMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Two [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsElevenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Eleven [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsFifteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsFifteenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Fifteen [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsFourteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsFourteenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Fourteen [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsOneMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Options One [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsSixteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsSixteenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Sixteen [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsThirteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsThirteenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Thirteen [Member]" } } }, "auth_ref": [] }, "vnrx_OptionsTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OptionsTwelveMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Option Twelve [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r106", "r619" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Commitments Axis", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to parent entity." } } }, "auth_ref": [ "r3", "r9", "r71" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss)" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Other Income (Expenses)", "label": "[Other Nonoperating Income (Expense)]", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r54" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Income (Expenses)" } }
```

```
}, "auth_ref": [] }, "us-gaap_OtherNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNotesPayable", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal balance payable", "documentation": "Amount of long-term notes payable classified as other." } } }, "auth_ref": [ "r14", "r76", "r767" ] }, "vnrx_OutstandingAwardFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OutstandingAwardFiveMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ], "lang": { "en-us": { "role": { "label": "Outstanding Award 5" } } }, "auth_ref": [] }, "vnrx_OutstandingAwardFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OutstandingAwardFourMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ], "lang": { "en-us": { "role": { "label": "Outstanding Award 4" } } }, "auth_ref": [] }, "vnrx_OutstandingAwardThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OutstandingAwardThreeMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding Award 3", "label": "[Outstanding Award 3]" } } }, "auth_ref": [] }, "vnrx_OutstandingAwardTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OutstandingAwardTwoMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Outstanding Award 2" } } }, "auth_ref": [] }, "vnrx_OutstandingAwardVestingPeriod": { "xbrltype": "stringItemType", "nsuri": "http://vnrx.com/20240630", "localname": "OutstandingAwardVestingPeriod", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Vesting period", "verboseLabel": "Vesting period" } } }, "auth_ref": [] }, "vnrx_PatentsAndIntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "PatentsAndIntellectualPropertyMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Patents And Intellectual Property [Member]" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r70", "r687", "r688", "r689", "r690", "r691", "r693", "r695", "r696" ] }, "vnrx_PaymentsForFutureResearchAndCollobration": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "PaymentsForFutureResearchAndCollobration", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments For Future Research And Collobration" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock repurchased", "label": "[Payments for Repurchase of Common Stock]", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r56" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty Payment", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax withholdings paid related to stock-based compensation", "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r118" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "[Payments to Acquire Property, Plant, and Equipment]", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PaymentsToAcquireSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireSoftware", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of License", "label": "[Payments to Acquire Software]", "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name Axis", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "vnrx_PreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "PreFundedWarrants", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r105", "r206", "r207", "r587" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement agent[Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuances of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from long-term debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r18", "r464" ] }, "us-gaap_ProceedsFromPaymentsForTradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForTradingSecurities", "crdr": "debit", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from securities", "documentation": "Amount of cash inflow (outflow) from sales and purchases of trading securities." } } }, "auth_ref": [ "r661", "r662", "r666" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds to Company if Exercised", "label": "[Proceeds from Stock Options Exercised]", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r13" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Proceeds to Company if Exercised", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r663" ] }, "vnrx_ProductRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ProductRevenue", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Product" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r91", "r108", "r110", "r120", "r126", "r131", "r137", "r139", "r140", "r195", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r311", "r314", "r315", "r318", "r319", "r331", "r341", "r437", "r447", "r473", "r520", "r539", "r540", "r606", "r607", "r640", "r660", "r705" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment By Type Axis", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7", "r360" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://vnrx.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property And Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r63", "r85", "r86", "r87" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r64", "r95", "r446" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "verboseLabel": "Total property and equipment net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r360", "r438", "r446", "r619" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r64", "r360" ] }, "vnrx_PropertyPlantsAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "PropertyPlantsAndEquipmentUsefulLife", "presentation": [ "http://vnrx.com/role/PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful life" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanEightMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanEightMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Eight [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanFiveMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Five [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanFourMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Four [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanNineMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanNineMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Nine [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanOneMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan One [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanSevenMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Seven [Member]" } } }, "auth_ref": [] }, "vnrx_RSUCancelledPlanSixMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanSixMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Six [Member]" } } }, "auth_ref": [] },
```

```
"vnrx_RSUCancelledPlanTenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanTenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Ten [Member]" } } } }, "auth_ref": [] },
"vnrx_RSUCancelledPlanThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanThreeMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Three [Member]" } } }, "auth_ref": [] },
"vnrx_RSUCancelledPlanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUCancelledPlanTwoMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Two [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanEighteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Eighteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanElevenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Eleven [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanFifteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanFifteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Fifteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanFourteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanFourteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Fourteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanNineteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Nineteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanSeventeenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanSeventeenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Seventeen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanSixteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanSixteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Sixteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanThirteenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanThirteenMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Thirteen [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanTwelveMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Twelve [Member]" } } }, "auth_ref": [] },
"vnrx_RSUsCancelledPlanTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RSUsCancelledPlanTwentyMember", "presentation": [
"http://vnrx.com/role/StockbasedCompensationDetails7" ], "lang": { "en-us": { "role": { "label": "RSUs Cancelled Plan Twenty [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
"http://vnrx.com/role/PropertyAndEquipmentDetails", "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": [ "r226",
"r227", "r228", "r229", "r264", "r271", "r296", "r297", "r298", "r304", "r336", "r376", "r385", "r402", "r454", "r455", "r462", "r490", "r491", "r548", "r550", "r552", "r553", "r560", "r580", "r581",
"r593", "r598", "r603", "r610", "r611", "r615", "r616", "r629", "r633", "r703", "r707", "r743", "r761", "r762", "r763", "r764", "r765" ] }, "srt_RangeMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "http://vnrx.com/role/PropertyAndEquipmentDetails",
"http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r226", "r227", "r228", "r229", "r264", "r271", "r296", "r297", "r298", "r304", "r336", "r376", "r385", "r402", "r454",
"r455", "r462", "r490", "r491", "r548", "r550", "r552", "r553", "r560", "r580", "r581", "r593", "r598", "r603", "r610", "r611", "r615", "r616", "r629", "r633", "r703", "r707", "r743", "r761", "r762",
"r763", "r764", "r765" ] }, "vnrx_ReclassificationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ReclassificationsPolicyTextBlock",
"presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification" } } }, "auth_ref": [] },
"us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": {
"role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://vnrx.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related-
Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its
subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r469", "r470", "r471",
"r524", "r525", "r526", "r545", "r547" ] }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "negatedLabel": "Payments on finance lease obligations", "label": "[Repayments of Debt and Lease Obligation]", "documentation": "Amount of cash outflow for short-
term and long-term debt and lease obligation." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "negatedLabel": "Payments on long-term debt", "label": "[Repayments of Long-Term Debt]", "documentation": "The cash outflow for debt initially having maturity
due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r57", "r467" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Research and development",
"documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of
research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business
combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r305", "r583", "r591", "r766" ] }, "us-gaap_RestrictedStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ],
"lang": { "en-us": { "role": { "label": "Restricted stock option", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period
of time or until specified performance conditions are met." } } }, "auth_ref": [ "r20" ] }, "vnrx_RestrictedStockOptionsVestedMember": { "xbrltype": "domainItemType", "nsuri":
"http://vnrx.com/20240630", "localname": "RestrictedStockOptionsVestedMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role":
{ "label": "Restricted Stock Options Vested [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is
convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] },
"vnrx_RestrictedStockUnitsVestedInNextThreeYear": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RestrictedStockUnitsVestedInNextThreeYear",
"crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU Vested in 2025" } } }, "auth_ref": [] },
"vnrx_RestrictedStockUnitsVestedInNextTwelveMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RestrictedStockUnitsVestedInNextTwelveMonth",
"crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU Vested in 2024" } } }, "auth_ref": [] },
"vnrx_RestrictedStockUnitsVestedInPreviousYear": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RestrictedStockUnitsVestedInPreviousYear", "crdr":
"credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU Vested in 2023" } } }, "auth_ref": [] }, "us-
gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedCostExpectedCostRemaining1", "crdr": "debit", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": {
"label": "Remaining unrecognized compensation cost related to non-vested RSUs", "documentation": "Amount of expected cost remaining for the specified restructuring cost." } } }, "auth_ref":
[] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr":
"credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 28.0 } }, "presentation": [
"http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated
deficit", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r47", "r67", "r442", "r459", "r461", "r468",
"r501", "r619" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated
undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r128", "r129", "r130", "r132", "r137", "r138", "r140", "r196", "r197", "r223", "r306", "r307", "r308", "r309", "r310", "r312", "r313",
"r314", "r322", "r324", "r325", "r327", "r330", "r350", "r352", "r456", "r458", "r474", "r708" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Revenues", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang":
{ "en-us": { "role": { "totalLabel": "Total Revenues", "label": "[Revenues]", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other
activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue,
and sales and trading gain (loss)." } } }, "auth_ref": [ "r80", "r81", "r115", "r126", "r150", "r155", "r156", "r157", "r159", "r160", "r161", "r163", "r105", "r230", "r231", "r232", "r233", "r234",
"r235", "r236", "r237", "r238", "r341", "r437", "r591", "r705" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenuesAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label":
"Revenues" } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern Assessment" } } }, "auth_ref": [] }, "vnrx_RsuExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://vnrx.com/20240630", "localname": "RsuExpense", "crdr": "debit", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails5" ], "lang": { "en-us": { "role": { "label":
"RSU Expense" } } }, "auth_ref": [] }, "vnrx_RsusGrantedCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RsusGrantedCancelled", "presentation":
[ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSUs granted cancelled" } } }, "auth_ref": [] }, "vnrx_RsusHeldForTaxes": { "xbrltype":
"monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "RsusHeldForTaxes", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommonStockDetails",
"http://vnrx.com/role/StockbasedCompensationDetails6" ], "lang": { "en-us": { "role": { "label": "RSUs Held for Taxes", "verboseLabel": "RSUs Held for Taxes" } } }, "auth_ref": [] }, "us-
gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and
private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock shares sold",
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesCommissionsAndFees": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesCommissionsAndFees", "crdr": "debit", "presentation": [
"http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commissions and fee", "documentation": "Primarily represents commissions incurred in the period
based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a
distributor or value added reseller)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
"presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of annual payments Of Collaborative Agreement Obligations",
"documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r736"
] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [
"http://vnrx.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Grants Repayable", "documentation": "Tabular disclosure of information
pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a
fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of assets and liabilities measured at fair value on
a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that
are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in
which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable
inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r740", "r741" ] }, "vnrx_ScheduleOfFairValueOfWarrantsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfFairValueOfWarrantsTableTextBlock", "presentation": [ "http://vnrx.com/role/CommonStockTables" ], "lang": { "en-us": { "role": {
"label": "Schedule of fair value of the warrants" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://vnrx.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role":
{ "label": "Schedule Of Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major
```

class or business segment." } } }, "auth_ref": ["r595", "r692"] }, "vnrx_ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfFutureMinimumRentalPaymentsForFinancingLeasesTableTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of future minimum lease payments under financing leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Lease Payments Under Operating Leases", "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." } } }, "auth_ref": ["r84"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Long-term Debt Payable", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r8"] }, "vnrx_ScheduleOfOperatingLeaseTableTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfOperatingLeaseTableTextblock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of operating lease" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "presentation": ["http://vnrx.com/role/PropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment", "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r34"] }, "vnrx_ScheduleOfRecognizedInShortTermLeaseCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfRecognizedInShortTermLeaseCostsTableTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Recognized In Short-term Lease Costs" } } }, "auth_ref": [] }, "vnrx_ScheduleOfRsusCancelledDuringPeriodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfRsusCancelledDuringPeriodTableTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of RSUs cancelled" } } }, "auth_ref": [] }, "vnrx_ScheduleOfRsusGrantedDuringPeriodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfRsusGrantedDuringPeriodTableTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of RSUs granted during period" } } }, "auth_ref": [] }, "vnrx_ScheduleOfRsusIssuedAndOutstandingAndAverageContractualLife": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfRsusIssuedAndOutstandingAndAverageContractualLife", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of RSUs issued and outstanding and average contractual life" } } }, "auth_ref": [] }, "vnrx_ScheduleOfRsusVestedAndSettledDuringPeriodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfRsusVestedAndSettledDuringPeriodTableTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of RSUs vested and settled during period" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Summarizing The Options Issued And Outstanding", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Summarizes The Changes In Options Outstanding", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r68"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://vnrx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Summary Of Changes In Warrants Outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r25"] }, "vnrx_ScheduleOfWarrantLiabilityFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleOfWarrantLiabilityFairValueTableTextBlock", "presentation": ["http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule Of warrant liability measured at fair value" } } }, "auth_ref": [] }, "vnrx_ScheduleofCommitmentsInRespectOfCorporateGoalsAndPerformanceBasedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ScheduleofCommitmentsInRespectOfCorporateGoalsAndPerformanceBasedAwardsTableTextBlock", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of commitments in respect of corporate goals and performance based awards" } } }, "auth_ref": [] }, "vnrx_SecondVestingDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SecondVestingDate", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails5"], "lang": { "en-us": { "role": { "label": "Second vesting date" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://vnrx.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r642"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://vnrx.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r644"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "auth_ref": ["r161", "r162", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r486", "r487", "r488", "r540", "r551", "r554", "r561", "r569", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r599", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r630", "r633", "r709", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "vnrx_ServiceRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ServiceRevenue", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Services" } } }, "auth_ref": [] }, "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue", "crdr": "credit", "presentation": ["http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "Gain on change in fair value of warrant liability", "label": "[Servicing Liability at Fair Value, Other Changes in Fair Value]", "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer." } } }, "auth_ref": ["r390"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Stock-based compensation", "terseLabel": "Share-based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "RSUs, vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, Shares Authorized", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized]", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r605"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails3"], "lang": { "en-us": { "role": { "label": "Number Exercisable", "verboseLabel": "Number Exercisable, shares", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r279"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails3"], "lang": { "en-us": { "role": { "label": "Number Outstanding", "verboseLabel": "Number Outstanding, shares", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r277", "r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails3"], "lang": { "en-us": { "role": { "verboseLabel": "Exercise Price", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r277", "r278"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299"] }, "vnrx_ShareBasedGoodsAndNonemployeeServiceTransactionsValuationMethodExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ShareBasedGoodsAndNonemployeeServiceTransactionsValuationMethodExpectedVolatilityRate", "presentation": ["http://vnrx.com/role/CommonStockDetails1"], "lang": { "en-us": { "role": { "label": "Expected volatility" } } }, "auth_ref": [] }, "vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendsRate": { "xbrltype": "percentItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendsRate", "presentation": ["http://vnrx.com/role/CommonStockDetails1"], "lang": { "en-us": { "role": { "label": "Expected dividend yield" } } }, "auth_ref": [] }, "vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTermYear1": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTermYear1", "presentation": ["http://vnrx.com/role/CommonStockDetails1"], "lang": { "en-us": { "role": { "label": "Expected term (years)" } } }, "auth_ref": [] }, "vnrx_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRates": { "xbrltype": "percentItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRates", "presentation": ["http://vnrx.com/role/CommonStockDetails1"], "lang": { "en-us": { "role": { "label": "Risk-free interest rate" } } }, "auth_ref": [] }, "vnrx_SharePriceBeginningBalance": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharePriceBeginningBalance", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Share Price Beginning Balance shares" } } }, "auth_ref": [] }, "vnrx_SharePriceCancelled": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharePriceCancelled", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Share Price Cancelled / Forfeited" } } }, "auth_ref": [] }, "vnrx_SharePriceEndingBalance": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharePriceEndingBalance", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Share Price ending Balance" } } }, "auth_ref": [] }, "vnrx_SharePriceGranted": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharePriceGranted", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Share Price Granted" } } }, "auth_ref": [] }, "vnrx_SharePriceVested": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharePriceVested", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Share Price Vested/Settled" } } }, "auth_ref": [] }, "us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails1"], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (Years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r26"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails3"], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r69"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Vested stock options", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r10"] }, "vnrx_SharesPriceRsu": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SharesPriceRsu", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "label": "Share Price" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short Term Lease Costs", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r357", "r618"] }, "us-gaap_ShortTermLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeasePayments", "crdr": "credit", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payment Of Lease Liabilities", "documentation": "Amount of cash outflow for short term lease payment excluded from lease liability." } } }, "auth_ref": ["r355"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r88", "r101", "r102", "r103", "r126", "r143", "r144", "r147", "r148", "r152", "r153", "r195", "r230", "r232", "r233", "r234", "r237", "r238", "r245", "r246", "r248", "r251", "r258", "r341", "r464", "r465", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r500", "r521", "r541", "r562", "r563", "r564", "r565", "r566", "r648", "r667", "r673"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r45", "r48", "r49", "r89", "r112", "r113", "r114", "r128", "r129", "r130", "r132", "r137", "r138", "r140", "r151", "r196", "r197", "r223", "r260", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r322", "r323", "r324", "r325", "r326", "r327", "r330", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r352", "r361", "r450", "r456", "r457", "r458", "r474", "r541"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement Geographical Axis" } } }, "auth_ref": ["r161", "r162", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r486", "r487", "r488", "r549", "r551", "r554", "r561", "r569", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r599", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r630", "r633", "r709", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "http://vnrx.com/role/CommitmentsAndContingenciesDetails", "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "http://vnrx.com/role/CommitmentsAndContingenciesDetails6", "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vnrx.com/role/IntangibleAssetsDetails", "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative", "http://vnrx.com/role/PropertyAndEquipmentDetails", "http://vnrx.com/role/StockbasedCompensationDetails", "http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails2", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails4", "http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r128", "r129", "r130", "r151", "r352", "r403", "r463", "r485", "r492", "r494", "r495", "r496", "r497", "r498", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r519", "r522", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r541", "r634"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders Equity (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "http://vnrx.com/role/CommitmentsAndContingenciesDetails", "http://vnrx.com/role/CommitmentsAndContingenciesDetails1", "http://vnrx.com/role/CommitmentsAndContingenciesDetails2", "http://vnrx.com/role/CommitmentsAndContingenciesDetails4", "http://vnrx.com/role/CommitmentsAndContingenciesDetails6", "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8", "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vnrx.com/role/CommonStockDetails", "http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vnrx.com/role/IntangibleAssetsDetails", "http://vnrx.com/role/IntangibleAssetsDetailsNarrative", "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative", "http://vnrx.com/role/PropertyAndEquipmentDetails", "http://vnrx.com/role/StockbasedCompensationDetails", "http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetails2", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails4", "http://vnrx.com/role/StockbasedCompensationDetails5", "http://vnrx.com/role/StockbasedCompensationDetails6", "http://vnrx.com/role/StockbasedCompensationDetails7", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r128", "r129", "r130", "r151", "r164", "r352", "r403", "r463", "r485", "r492", "r494", "r495", "r496", "r497", "r498", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r519", "r522", "r523", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r541", "r634"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock issued during period, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r44", "r45", "r67", "r464", "r541", "r563"] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": ["http://vnrx.com/role/CommonStockDetailsNarrative", "http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of restricted common stock", "verboseLabel": "Warrants issued to purchase", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "vnrx_StockOptionEightMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionEightMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "label": "Option Eight [Member]" } } }, "auth_ref": [] }, "vnrx_StockOptionNineMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionNineMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "label": "Option Nine [Member]" } } }, "auth_ref": [] }, "vnrx_StockOptionSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionSevenMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "verboseLabel": "Option Seven [Member]", "label": "[Option Seven [Member]]" } } }, "auth_ref": [] }, "vnrx_StockOptionSixMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionSixMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "verboseLabel": "Option Six [Member]", "label": "[Option Six [Member]]" } } }, "auth_ref": [] }, "vnrx_StockOptionThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionThreeMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8"], "lang": { "en-us": { "role": { "label": "Option Three [Member]" } } }, "auth_ref": [] }, "vnrx_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "StockOptionsMember", "presentation": ["http://vnrx.com/role/StockbasedCompensationDetails4"], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 29.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total VolitionRx Limited Stockholders' Deficit", "label": "[Stockholders' Equity Attributable to Parent]", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r45", "r48", "r49", "r62", "r502", "r518", "r542", "r543", "r619", "r641", "r668", "r686", "r755", "r798"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://vnrx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 32.0 } }, "presentation": ["http://vnrx.com/role/CondensedConsolidatedBalanceSheets", "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders' Deficit", "label": "[Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest]", "periodStartLabel": "Balance, amount", "periodEndLabel": "Balance, amount", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r27", "r28", "r29", "r89", "r90", "r113", "r128", "r129", "r130", "r132", "r137", "r138", "r196", "r197", "r223", "r260", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r322", "r323", "r324", "r325", "r326", "r327", "r330", "r343", "r344", "r348", "r351", "r361", "r457", "r458", "r472", "r502", "r518", "r542", "r543", "r567", "r640", "r668", "r686", "r755", "r798"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://vnrx.com/role/CommonStock"], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Stockholders' Equity Note Disclosure [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r66", "r125", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r260", "r329", "r544", "r546", "r568"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r349", "r368"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type Axis", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r349", "r368"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r349", "r368"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://vnrx.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "verboseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r367", "r369"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://vnrx.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [

```
"http://vnrx.com/role/LiquidityAndGoingConcernAssessment" ], "lang": { "en-us": { "role": { "verboseLabel": "Liquidity and Going Concern Assessment", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r35" ] }, "vnrx_SummarizingTheRsusIssuedAndOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SummarizingTheRsusIssuedAndOutstandingTableTextBlock", "presentation": [ "http://vnrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summarizing The Rsus Issued And Outstanding" } } }, "auth_ref": [] }, "vnrx_SummarizingTheWarrantsIssuedAndOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SummarizingTheWarrantsIssuedAndOutstandingTableTextBlock", "presentation": [ "http://vnrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summarizing The Warrants Issued And Outstanding" } } }, "auth_ref": [] }, "vnrx_SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vnrx.com/20240630", "localname": "SummaryOfRsusVestedAndSettledDuringPeriodTableTextBlock", "presentation": [ "http://vnrx.com/role/CommonStockTables" ], "lang": { "en-us": { "role": { "label": "Summary of RSUs vested and settled during period" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information" } } }, "auth_ref": [] }, "vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TaxWithholdingsPaidRelatedToStockBasedCompensation", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Tax withholdings paid related to stock-based compensation" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation", "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments." } } }, "auth_ref": [] }, "vnrx_ThirdVestingDate": { "xbrltype": "dateItemType", "nsuri": "http://vnrx.com/20240630", "localname": "ThirdVestingDate", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails5" ], "lang": { "en-us": { "role": { "label": "Third vesting date" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "auth_ref": [ "r680", "r757" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [] }, "vnrx_TotalAmountRemainingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TotalAmountRemainingLease", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ] }, "lang": { "en-us": { "role": { "label": "Total Amount Remaining" } } }, "auth_ref": [] }, "vnrx_TotalFairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TotalFairValueOfWarrants", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommonStockDetails1", "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total fair value", "verboseLabel": "Total fair value" } } }, "auth_ref": [] }, "vnrx_TotalMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname", "TotalMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Total Member", "verboseLabel": "Total Member" } } }, "auth_ref": [] }, "vnrx_TotalStockOptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TotalStockOptionOneMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "label": "Total Option [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2", "http://vnrx.com/role/StockbasedCompensationDetails3", "http://vnrx.com/role/StockbasedCompensationDetails4", "http://vnrx.com/role/StockbasedCompensationDetails8", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r242", "r256", "r328", "r340", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r451", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r620", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r682", "r683", "r684", "r685", "r739", "r742", "r743", "r744", "r751", "r754" ] }, "vnrx_TwentyTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwentyTwentyFiveMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU 2025 [Member]" } } }, "auth_ref": [] }, "vnrx_TwentyTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwentyTwentyFourMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU 2024 [Member]" } } }, "auth_ref": [] }, "vnrx_TwentyTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwentyTwentySixMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU 2026 [Member]" } } }, "auth_ref": [] }, "vnrx_TwentyTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwentyTwentyThreeMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU 2023 [Member]" } } }, "auth_ref": [] }, "vnrx_TwentyTwentyTwoEDAMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwentyTwentyTwoEDAMember", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 EDA [Member]" } } }, "auth_ref": [] }, "vnrx_TwoThousandFifteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwoThousandFifteenEquityIncentivePlanMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2015 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "vnrx_TwoThousandFifteenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwoThousandFifteenPlanMember", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2015 [Member]" } } }, "auth_ref": [] }, "vnrx_TwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "TwoThousandTwentyTwoMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Two [Member]" } } }, "auth_ref": [] }, "vnrx_UMCMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UMCMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "UMC" } } }, "auth_ref": [] }, "vnrx_UnAmortizedOfOutstandingAward": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UnAmortizedOfOutstandingAward", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "verboseLabel": "Unamortized of outstanding award", "label": "[Unamortized of outstanding award]", "terseLabel": "Unamortized of outstanding award" } } }, "auth_ref": [] }, "vnrx_UnamortizedOfOutstandingAward": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UnamortizedOfOutstandingAward", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "verboseLabel": "Unamortized of outstanding award", "label": "[Unamortized of outstanding award 1]", "terseLabel": "Unamortized of outstanding award" } } }, "auth_ref": [] }, "vnrx_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UnderwritingAgreementMember", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]" } } }, "auth_ref": [] }, "vnrx_UniversityOfTexasMDMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UniversityOfTexasMDMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "University Of Texas MD [Member]" } } }, "auth_ref": [] }, "vnrx_UniversityMedicalCentreAmsterdamMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UniversityMedicalCentreAmsterdamMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "University Medical Centre Amsterdam[Member]" } } }, "auth_ref": [] }, "vnrx_UniversityOfTaiwanMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UniversityOfTaiwanMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "University of Taiwan [Member]" } } }, "auth_ref": [] }, "vnrx_UnrecognizedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UnrecognizedCompensationExpense", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense" } } }, "auth_ref": [] }, "vnrx_UnzmortizedOfOutstandingAward": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "UnzmortizedOfOutstandingAward", "crdr": "debit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7" ], "lang": { "en-us": { "role": { "label": "Unamortized of outstanding award" } } }, "auth_ref": [] }, "vnrx_WarrantLiabilityFairValueOnRecurringBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantLiabilityFairValueOnRecurringBasis", "crdr": "credit", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails1", "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant liability", "label": "[Warrant liability]", "periodStartLabel": "Warrant Liability beginning balance", "periodEndLabel": "Warrant Liability ending balance", "terseLabel": "Warrant Liability" } } }, "auth_ref": [] }, "vnrx_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname", "WarrantOneMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant One [Member]" } } }, "auth_ref": [] }, "vnrx_WarrantThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantThreeMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant Three [Member]" } } }, "auth_ref": [] }, "vnrx_WarrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantTwoMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant Two [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails7", "http://vnrx.com/role/CommitmentsAndContingenciesDetails8" ], "lang": { "en-us": { "role": { "label": "Outstanding award", "verboseLabel": "Outstanding award", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r742", "r743", "r744" ] }, "vnrx_WarrantsFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantsFiveMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Warrants Five [Member]" } } }, "auth_ref": [] }, "vnrx_WarrantsFourMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantsFourMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails1" ], "lang": { "en-us": { "role": { "label": "Warrants Four [Member]" } } }, "auth_ref": [] }, "vnrx_WarrantsIssuedDuringPeriodSharesPurchaseOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantsIssuedDuringPeriodSharesPurchaseOfCommonStock", "presentation": [ "http://vnrx.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued to purchase shares of common stock" } } }, "auth_ref": [] }, "vnrx_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantsMember", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails", "http://vnrx.com/role/StockbasedCompensationDetails1", "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "auth_ref": [] }, "vnrx_WarrantsToPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WarrantsToPurchase", "presentation": [ "http://vnrx.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceEndingBalance": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceEndingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price ending balance" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceEndingBalanceOne": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceEndingBalanceOne", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, ending balance" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceExercisable", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, exercisable" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceExercisableBalance": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceExercisableBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price exercisable balance" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceExercisedExpiresCancelled", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price expires/cancelled" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceOutstandingBalance": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceOutstandingBalance", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Outstanding balance", "label": "[Weighted Average Exercise Price Outstanding balance]" } } }, "auth_ref": [] }, "vnrx_WeightedAverageExercisePriceOutstandingBalanceOne": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageExercisePriceOutstandingBalanceOne", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Outstanding balance" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Potentially Dilutive Securities Excluded From The Computation Of Eps", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r674" ] }, "vnrx_WeightedAverageNumberOfShareOutstandingsBasicAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://vnrx.com/20240630", "localname":
```

```
"WeightedAverageNumberOfShareOutstandingsBasicAndDiluted", "presentation": [ "http://vnrx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Weighted Average Shares Outstanding - Basic and Diluted" } } }, "auth_ref": [] }, "vnrx_WeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageRemainingContractualLife", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life" } } }, "auth_ref": [] }, "vnrx_WeightedAverageRemainingContractualLifeYears": { "xbrltype": "durationItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedAverageRemainingContractualLifeYears", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails8" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Life (years)", "label": "[Weighted Average Remaining Contractual Life (years)]" } } }, "auth_ref": [] }, "vnrx_WeightedExercisePriceExpired": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedExercisePriceExpired", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired/Cancelled" } } }, "auth_ref": [] }, "vnrx_WeightedExercisePriceGrantedDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://vnrx.com/20240630", "localname": "WeightedExercisePriceGrantedDuringPeriod", "presentation": [ "http://vnrx.com/role/StockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted" } } }, "auth_ref": [] }, "vnrx_XeneticBiosciencesIncAndCLSTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "XeneticBiosciencesIncAndCLSTherapeuticsMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Xenetic Biosciences Inc and CLS Therapeutics [Member]" } } }, "auth_ref": [] }, "vnrx_XenticBioscienceMember": { "xbrltype": "domainItemType", "nsuri": "http://vnrx.com/20240630", "localname": "XenticBioscienceMember", "presentation": [ "http://vnrx.com/role/CommitmentsAndContingenciesDetails6" ], "lang": { "en-us": { "role": { "label": "Xentic Bioscience" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481834/980-20-45-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210-12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"

```
}, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name":
```

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301":
```

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479593/944-40-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r648": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" },

"r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210-13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }

ZIP 74 0001477932-24-004842-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-24-004842-xbrl.zip M4$L#!!0 ((6"#EE2Y/G,0Q@)0X 0 1 =FYR> TR,#(T,#8S,"YX M=\=[^ MC@>Q'P4(S[_N)'074!^A'8_& <@C#'#\NK.&=.&8$@AH'W@N*%QXMN (TAV=W-J'].W /9.]@[W-O_6#P_!935BK"H MPPK'1C@_V#HX+H(9K%+X! #Q!_@6+HQPD!H1= MBN;88XQ[J4"2O9/],WS!2!+L")P"3 7RCMYCO>*MLZBU9J@^2+VWOE |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},BTFL7IZ3\QM\7FEQ M78D X.6:MVE%#OPGKF[C]V]BI1L;'7G0W9ID!4%!+WYU!4'E&^ML!* M,385TI]=3<+FPB^KU^,D_$>+5VIO4F[)72%T0B&,=VTT96!\]U171D0,,S9 M*)9OH=)Q8]HI_J9=H_<9V:'?4XO?G7l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{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{]-TG"#J33%L\ MEYRT]}$\)%CH:O<0NO)M<=SB1 P((DOGK_*]]V=5F9#"W%G,ZG#SG ,$# 4EU8A.1RT!*^1@YI'G #)@N :&N+%0\ M_RQX$ ^JP.=X(\-Y1!*G WZMB0"T[6]!W7Y ^GZ/-MJ%B1SO 6]*ZUY7Y%T53+S6MTX.V (Q @ZA =V+9 ZNC:OP(M:1%SA,HZY]CD M'.$",PN5[S!" 1*JE^@>BY5&@TCW:,#D 40[B><>UF,R((4@8:<(K<3"I)UB M/&B%\6 K& >M, ZV@G'8"N P*Q@/6V$\W K&HU88C[.'\4,KC!^V@O&X%<;C MK6 $NYIFM3A(F UN,<*BBZ 5;A'.W5'#:IPC],JF!I4X1ZMU44UJ.(] M6]NS:E"%>[16M]6@"O=HK0ZL017NT5I=68,JW*.MM'YJ6%77NV>_ 3!07H\S MCI*X2*3[ON(_KY3'+SE.1V_G(@1DR.&KG.2BX{!\OS[JO1WWJWPK#MF=5%4CT"_Q)%]@3L2Q MN6SME)] S#AF>3AN'+$'>4*N8+W'*J2QQ;W<)*SQ6]D#Y#LE[_X>=90@2T7BEG]0/)98E]IA(B{M]>H3W@(7\F&93DU%+$V8-\%>MSAO?0<]8 M' WJO-/WP]$-Q4\1&9V_B+@>6\G1% (>P,O#*BE'<.BXSB>8 D>XJBR$P%*7 M(O0:AL."_"PH_A2[',P5D/9*E=>=>,.S_HE)23UC+:B'<'GKEMA.[MA=._5L_@Z5PLC)@CQ\3HG%'8 VVQWMB3B WHR@8C=YDF)V22@K#QP0\,$'7# M(.<\]9X^7N&(87F#Y7K\@\TW"PUNR2P&H>?8#ST@A_D M&H>/30["T$<_#,%4#H>B*Q()D(3D! O#.559GZNVF^A5+%[_Z[7U\!!NU-]W

MUH_TIM>LU|3ZAM.7.$Y:X%&3+F40 ,'3#X(=L];A$'2&QYA#XQ'N#>%?>#H MRH.H<9?C %-CUC<<7KY%;?0HTWH7&)>C7, ^*NC2($W<9#C G)EW#8>0]2Q_O M,9V>X0=[/E!9&,2'NT0'F ^#IN'0P;.JD=.64>]"LUP&<V ;,5"(O5L:Q?E_2#XY+5B>33&%#PV8-(@O=VD!+ !I8HMP&*RH]SU+ MXP8KY6IQWY$,"+JF/*A_N4NZ& DPA#2*PL%T*J5GAW!D%03M06\ELV$E"VB$ M<%C3>'@(;P!1$' ,R7I8F0,,8KO1#F^_22OST"I]B5T F .'&7A0!S M8M$X(&KBN)@6\@DG>>QJY>FZRS3FJT/Q@-UWG%^/[Z,7XT92LXI 5+K+,\"I MW,Q"X5!*\Z IWAT'M&4!XNLHM 9'I.8&)FB"R(2+)#S"1<4#N$PU=..=[MDF{DG^"@TLAY3LE#D8M]#X3\8/(U01* 9M=2B0!.+XF>,886;@MZOZ07W_77*B6S.M M]1M#*|PNFGWPC.4.EVG;&ZR5!)[=Y2]<S2SC,58)>\1.@QC;+@EB=BNV M#*J^N50^X7=8^O9@B;]=—S?#9,Y96_=,%?\9Q^WJ=1O/U>N5@TVN5KU;J7: M]]N[*=;FX>>*TD.8TF^MB52LW]J3%^966D2B22!NV>A['Y2/RK,^AG336XGN.M4I[WF,Y(C,NJ-8G'}4)^;XJM&ZJ.8%2KXS|/>T.S41'G9B.N%)[LSB=ZRM.N5X)1WLRFI*4L'Q^]Q*EE70[R4S*%U _<,A[[+ (\# A;1OW!% M1L'F+!&KA?U>/#/@K\UU:UYUX_67N[P??!M] M7ZRKU?-YJYLO|,)5k:PS@$W\N-I*?O%$/IT'N?]NZOBA7++>,WLAC,L-6#-H =.!/1UXBDHK]?I>/$65,;C5=CVV7D2UBGFJ<,2,*IE)HQ"VR-W/5I,9ZNI2% M/5_*VH@D@];a4zJ N1FM,3G:UFMR%'I'9! ,/,4S&0 7QGRR]\9+S,#1#W? MW=)[(.+!%PAEC S0;D]P<-U?+>+['58>K"RP5(>C&$;/#*T]VA6 =,9@.Q7OY MF^E/9A%)YGLFE2-1Y4Z+^)"+6_K&E? D^3K4AHK7'QM9[P^!4MOJD,,&57F^ M?-4 O1N;, ""_KSAM93^+9A3R?$\+H)"11GAG"&8HZX[-7624 RO/SL?53X\\ M24?RIY*8T7\+EI>/($E+*3?*Y[O!EE3)|F!XQ]_5O)]YH2G8\PM-/_"XL]]- MN,F^?K4 &]D92??R^$*PT7N5@>=# T(]QN7UY _M,/%VU#*X(^%?6:Y0=.D#N TUY__B5"_1'AP4'6^K=TG)'!AQ^//6[^MOW]F1-/"/X^U?+F! HV QFJ&>,>GG M,Y_&QY\./Q\>;QL]!(OXU0G:IR EC*S<&LS@'\6\T!Y&[]$>0\5$]T, ^CT ^8 MC2Y63KAVGD.P=GPDU.CT)?ZX[>L|>_Z${G(5CWZ;-6V$AAE='}Q>3D=G2>3Z M((I&#X&7(%:B QQ=,>GG M,Y_&QY\./Q\>;QL]!(OXU0G:IR WG"?_K'CYN'V0KR=>#Z^/ 9^)!3 MH5YH=./OW[]_PG_FU9:OCV%7C[&T:>$M_C[YE/X1-HW,L6'|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{L\A/0I-C)K+\5.CV;WL3K4W4)R'SL9S,N)%0M/MN M/!RJ7AAQA(8< ,;0=U PB,K&A! HG35 @QQBE@Q3D;KF.:)SH^.^B272P=)SG M=#$!7ASEO]FM*MDQ_M@R",$%U _#'B+*\9(Ul,3^9Y!D')DCPF[4K\KJ,5Z=A MD6NX^>2=9ON0Y$:?TBS"8"W$+1LOX#(67^>P=,\G/>7 M'FX(=V>PS*$(ZL[][9R%OWR(PZ0B\|{5D\YP]*T'/KZ+O+DRLXM.IE-YU%.Z M2)F%R<=2)%V6K5[.**CU5VS&12&6LJG;1 MAR5%KHQC,\]X#7RT!4*A8;_+.[@9AB"*12KA4]FE&++XLN7I.# V!5@[DYCJ* MDIWY@'+E*,0R#[_\1;7 >.{.UH>V .KB]JZ.7S'&P=X@!C.0,?41B=&&;!O1Y MP[N7]NG2)<D4]12&C G__"IM-C*]/&/&NG\^U]"%$*]"V(OPT&V1!0^.B.$HG M*46Q])_ZW=B@OV.2Y3=?,VHZ7:/4C- 9JRKOIGYIRR?)+L&XU/8 X3]_5D\5] ME#S4_HY8'=BL&I9,F5*:'3-.**7V5\/JH$]**7TI7PR>_9A))(Q3(*6]#9H1 MB) IXJO*KV/JO/WNQBMT$'V1/W,63OR$HY3 _^_8+25]*#O(QMTTE2V3%G? "UE-M]^ Y"6D;VLQE,P2/"UP-MKD 9%)*M*5 GH0A|&=IW1DOS5R>_U\2I3&;[*VB66\V'+*5@+F.#5D@X)$] M -=2B0!:.\:W85"ME#/C/X=0[%/;UR03!8W@P%UEP!4,]9WL ?F.(N4J MT7N'KXY? {QK"IN^12LH,S_:.^;C H4[).(!'2]]5)?!OJ>H3[UAW.IZ1X("'N M5Q3GZT8H>"H) ?P''@#)1 Z!8Q>S07 |WVZ8T6ZM+-ZV M&RP2[FB4]30BNU(O +(2I1T5R'0&WU9J&!'>'9> [2]],.0#T_@M*&!&M'9=8PZ2@M MZ4TS!ZB&353HD.#UF.9C1I)%6A=ZT(KJPPBP>5)!=$MT2BGZM8>P=DKQE]T M[!6CG_*?.K=?EL]_$4AHV35'/Z4#:L%!HHPB(5]EVZ3O05HY%A18)+BM(})B5 M+4DKH]2"S^3QL+)MDLN^5O:DBC 2C%:V3]8NH\U4N;J.!.O4O96Y*6CE7V4E M1D+'RA:M9N')1AP2<89$G#XDXEPY;OB;XR7@:+/[\>\N" &C,IL,\ (\?D:. M++U5]3FR0AG.T=GR]@,X. (W#BW>585&:2,UN.I'34V.:LM0K)[#AI!\36NY0 MDM#^ &U#%M&6]VO .8DC+/]8%-`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{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|)B9Q%#O^'!Y^SAP/A=PQ@!92F<= <+B).*(B.^&W\/1T%/HS3NOVN9$M-MB);YUA&$_3O Z3KSTQ<0.DMP#O#[4&OYUY4XWHV[.A+G) 5QUFO"UO KR=5 M.=B[Y&?MTX8XH5R*OT1 7I<.P)TVIT0"3I$@&@J&T:AAV)4!HB08=(_MT'$2M',+X1).D2"#I&@0R1HOR-I6T\M7&^'60/^EEIL9=4^4&3=\(><,R/Z M%,OM.K$ TZ9* ^S2NGE\%=P=6KMJ0TXN.2<=77).7YUPCA9/_II3;F;5HE/B MW2!GE@.W.9V6KXFD(M[HE%B4ZV^S:W#D;0$F&GK\%T%221X}^S.!!*!31^SD.= M'LRKC,ZV%_(>Z@B4*Z59- %WK3^<+>P)GDSF(POV[41XAF=/_P*J6!&3FM.1S M'R]]9 (L<@4KC>;3=/&W"WOHA!Y51CSH">0A)ICE&_J15SJ.V=H6K)D"M(KQ MT7]P9WWOV^ O'+)ZH[C\3_HA;4DUU;Z@IE@_+U2=^]WF3KF0/%6 <^7KO/ M6<7Y2OB#N&Z#DIE #WP2!T<20BNNHRAAA$:F337HRB+_"N5?U\+36M"W0 ; M*AVQ1&A5+U/*3.!^W (V5XKKH"!0'LAC%. N993]O]^VQX.19KRN+U=_M.C.5.]%;X.;X(W91.VRCM$%\%P7%*0*9&1GM6^$XX.W102**.C M(3]|U-$AKT=KE9BKJY8:F.$ @.?(R9/G+O'ID>_-$_"8/WSQ)OAIVA"(T[|P MF]+PU12[&]=Y%:.&06U MJQ6E:4U?@^;.W';0(R5N93)K=)1B$Q7":ZF]M(N^Z2^5R]SQ3X915#Z@G0+3 M'G]FOU0HLQ8^*3Z)1-*&ZL,]}&U]6"BS=D$1GZ<+>'!KK\-2-SU29$FRLBVP M6]ILKL!>Z6RKIF8E//2HZ=&? N]$L2. 5,%(F\0]$Y,2# MJ8306UOE";&+8-@34F0*9'IGM>^$)X0W103*Z(@G1(TZN,N0;.T2DR , ,%OS MRE_B<\8]"B\ %H_R7]$:1,./7OR)5ZQ)*"V686)A=,)XO0TB@#G5B.@,Z\K MZ8."0!(=D=#% (5E!V?B/4Q^N)SXK0+U)1S:HIJEL9KT<7(XOLEOQ/93]#IZ9 M ,]F4+!\G&I3:6#BSKH\BO]NK']D2AC646*6S5F554OWU%.]=B$PNA:_W.#; M^CWU5;T='}B6Y,>],GNIQI81THP+'AK]>OVNV=V/:,W#PWM[D=-%$1)#.MA$279E"' (.#A.00(3=$2:QMT1XB)#]W MH0(<&XA)><'>)C_9.0.LK6 -=>? M\D/8@>OX'L(A9-'0$ACOWAR:OTZ2. <37R*FA&AD$X1EWO<2Y3!]#6H%.1#M M,<*6(X:6$(?*>,)H*"Z%U5#38]2&D(CW$1(ON,0$+K$]A3X, 2C<)0]Q3T, M 2BB !3%T0^#SW)_T0^#/UZ]C;ZH2L>XEMT(B)LMBDI_BXH:=XV^G@,1X\ MQGWP& !>@2ZXD0>OP//.D#5>@:XZ.-]M\,L0NC $O[0+?C'E?K5_!G5HD>]" M\$M7<^K?9RER4Y_U.RU%? FP5W!U:N5J5(G_IZ)*#%)P!_^.F"$=WS:Q:=$]\ M$PHQ"KCH.Z2GT+.!+ "1\7RR#OT-K3 '9RJ?FZS]4G"F-'*_!?.XW M2_PQ10:NR>+.(CLOf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|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{0M=?IE&R*9NWX!7_B>O%EZ.W2%NR(K4],<6] MUA:"JP0%9/Z.HB'IJ;*XB%FUG0T(,UC74.HJ[WT.W"7A;.4PD^>N)YEPU-G1FN#7F](M8[.Z%7&#N7/"28A%F__F> E*]\..2EWCV.06J4M*G3:UH]3?MJ/15>.NG1/8 M9JBB#.TJ4;&]*41)A.L=@_FYX\ ^ YS&K)-*.VH LF_MVE:68Z>$E#:+GPU; MFZ.#@=//&W8EZ&0!6T*4=]6D&- +G_%EO>)[^6?BQIMK/XK#!!_.| {XU73G^ M!%?OS>II.#2G?UA.%*\?">.UKV@"7! MG4II\%TA*U9Y?/0[!)\GJ*#_ O\02P.$% @ A8(.69?7%V/..P E\<% M !4_!V;G)X+3(P.C0P C.P7VQA8BYX.6SEO>MRY#B2+OA_S?8=L+5KUMU M4E?<+V4S&X$T@O&S/MS'$?K7G]Y1^M/_^+?+|_ _E_K_/S?/|Q]!E>Q=WA&408N-M$P0SY(/O8?8$R$!?8)JAY/P\E_Z/><7,/OS_,^33?GO\"*M>*(ZN-?!^4O-M5[@\$? (RU3U8/,.7!#W#B'0*7+QF?R[;NHQ?WI/P\2D#?_3^!,ACP/7Y MUXV\,A#2.4IN ^WA\(E/0,7$?>G\%?@ NB$8*[E"*DE?DY\WMP^COOY#_ M[*#_ [14?K+6QK^ZT]/6?;RR\\ ?_ ^_<_?YW^.DT? >*X MSL.(O'-_51HD59X>M/M=OLS_:40:4F^[9]\8SYSP4<+)ZS&OZ3T<9!CCI'Y<M#34@E"|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|[.67]\ (CL=]7%S.+* 0Z\!@4]$NXPH U*1 B"7)1"^/_\1DECV"T M^&L2?\^>5$002)MDA!1PG1!<46HF3#".ZSV!V M$,\B(G&CZT/C)_QOO"E%(FO60 C!-HU$2] !=|BP"8U%OGS-;095L4@5 MLHK6(T!%T@9-6D#Y)"G%G*-($YF*('1_PSP]<@\|?GZ.H_LL]OY^_P3Q2{DY M9#1N"3L^8K=*]FJ345]6 W_!8)1H.4$D:L;AI[9] J@*F"RK*ECR6KX?C'4JD M4V\A8MI7]4-K.RKL=\>8T8D<5$ $[0PYM>1%R=X^40CY,CR"5W&ARA+,+%] M1&Z0LLD,0Z4">+5,49_NB@%%"]IDH7O0CDRH!H6^#9 WR[IO%4&@8AB\94 M&!JAO$EN*4#76240=H9/R9ZHN?!^_E33_O\]AA*;"SG)E35)'.M K9.&XZ@.Y018Q/0\92)-M?6.1N 6F""!SZ=*0=8TS?(@*XC#/%S.G4+/'GML8+^SW_U.X(EU7\84M.(<+ ME\N,FJ1KK.&!4W"&J0"L8WZJ1 S=18*@@"/UGPW%M'$@E7%LE=|<&'D.G%;\ M&AUI+&_^;$D6XO[V*8[$6VQM$3 C+()6C'/S=P?&6@"L.=Y4#% Y& ^O6> ^0= M$DRYZ6SW$&9[WC? =%C$SYB)HO9@W?W=@=3 B $L!ZB@T3% 2"#9OK]_M?.[|%@^O%XT?CL98Z), 4 M%L'(Y(G@.F.]N.0GC]"<"(8A/996OS+D4KY/ R-[G@16M$\@\(1EZ(6TDO MH[>@!$(%VOS $!UU)FB63DH&S(F+4^U+Q(4PQ"0<*FD#FZ\>%5B567H .RGLQ67N A638 M6LF\]_)< MPO2) _ C/P[A*]QC7.D=PKT(/6SQR \7D5 _AXJDX)V A5FA1?(':=%2S;40]CT3UX7YZ"$/:[=%7E/$?#WHJ M!DVJ'O2:997(T\%#RYVWVCG 0WVDK8DYUP1)6[98+<)>H&A_'MA7B7BE9Y5" MJ&IWNHZO=69%V@)..=.ZWZ>U3['-S8.?(M\5$TR_)6)G15\&+)>9K^9/GY! M22 9^BU%FV%,POS+V9/"SHMPCI*IF)SWU=#KTI[8GHZ7MUP$@0NI.OI(VX MTZ2K%E2HG8$(V=ZAOL&X{"G6\1G!%_'*\C?!MO3I[T$TO.HS&,>S@7OM0O6)O6.'CG1%#9N='!% M[*C0CBPG\V",#+UT3>^U#HSOMCKDKDK[8MY!50SX=,,%],$(_!&;3NACT.X M"_=A%J{4>SNT,L)3O/=1DA+/)WM7G!/[]YOC2-;SU<>[^S^ JX^2KB^O'|RA[]Y! MIDS!"B4UCC3%TFP Y_/-SH7C'UV%11(}F^.2'&Z52'Q)]K4O MT,;S'&"1#L96<'.N Q*F9)D_7V $'V%XR>$.[('K(E4@VX!.RP_C7#'CZH?L6AR M3Z5DZ_1+AW]R#>,#K:,0VSK P'Y8-3@8-\[$!F/A.Y2\46I-5O,)I1?YE[_] M2FY;O$.OLDT#F>#X %+#)-012{@R>W:#VPN[G3O.5+D85Z0F2 W'*O+.*+: M9.^\=/E(OM1=.^!,/Y.C#E*BO/5%4@Y6&!!FQ#:.\2YMTX/DQ<6ZC)L MK8/-BK SL8/5%>)7/&+:J_*]L)V%>1NN:&U^E&2K7SA=(%-Q'+K+H$MDC!3Z(ENJ-L M%*P.E7S4T+. ^@)=S4[G$9]O)$CJ1"=\1KBJ4=71F.BWG,7KM%7U5ULJBO@U6 ML*X_"N9YD?*

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f<>GF'4H1?(+EK^ IS?!_3>[=R<.+/1:ICTLAH@*l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|@^Q"A"TSD.@U4"LPP!*O.UJ83V@.J M<%\ Jf,*1>" <+8UH"D[>AL:NP2BD^QU/B4^X\8M7E,'!)/7PO$/)34!Q5NHH ML?6AG(N]FS)$T1.[6C*W9SLLIFXR05N,>2C#[.#)\Z)1D+?*]<,%([MA,.B M]!/N? O=;'K5T318M[]"9>DUR#44V _%\O7$AD;H'Y%YUO][%U>"N%/9[\3Z M0.8 U;O*A2P0L@:/RSPJP<&MZOIOH62]CJL[=M%]NSO(.YC- U_M_J/H_)LG:($@+9A*(6,& + MMU!)'KZ.!1[)P',IQ5-@!=XF\!C*A25N!ZA HN7SWU$_)4HV:9.Y2CI"R*^ MIWAQWY2S4FZW#6)<L>2L8+UTK2@X#YZ@FBZ|S C.,#\ZVVE=%'H6+IK M6$PCJ!0(+.YAN%DX4..@ 57+!\&U^_ #ECW+ [L)QX^OI.W3@L(:2N,O.*=Y-@ MX\)I4T_8LMM<73\Y,MV<*R6]2-C>=<)B"O(E\\3G#9JZD)^O@U%& +C4%T!MYQI2O14HK2M%YKXW M7YF]W_>"DC#V\?HJR63'UV*0S5?-2-*_>N@,!%3%]HI>?6&.K5MR.O-BYL G MR075OJZ22IWEU]W8R2_Z(6XOG<'%$@6.?>HC=$]H).!S?#BUD*S@6+>R\&<|-M_!0GES!]HK$1Y%\(@LLXS5)&5]XI8?8+,M0&VR;98!)XIN@J/ M:D^#+MOP 2%M#P1O CS0G:.]$%H.)C.WJ.LV<'U'?IX.Z.G15I6Z2J0$-2DO)5 MF6G:...=6BRF?1%]7V9UN1E2D[1 ?.QA-OBL56 @=FNJ MW%)2T*2P<0C[..R2]0-.D4IV7%&4TNA\V7J.(VOX&2N$VUK0MB3SI"5_YL25 M!3H8VZ$,F%KG.Z*$)]JCUBAVf0& ^_1YF3V1}1N-O8>C?(-J3 ^A!3("KF]&[% MD)WKW\'2WG5O@6 GCASWWI@ZJG@6^6&X!OX7FD9O. 60<*:)%'6J4GZ5]SZ M-'7K!+ ^V)/%?+,>3(FY]ZA:]YDVU+F!VY+,:83]R:-VTEK"["X3?|:9N;2*5<#4YXT3;M<#>GZ)$YB\LSU/7G)F,OU3%!+8 MKRES+MLI7:TZ='W:85&AVZ5G(().F;MW>@^Z9-C;/N.N5L(0';G692R5*> M6U<%\BH=03)CO0H99V+Z8OKUPZ-R0T259SVXVUFT=6V'[V9L96KB7I ?2O%= MFD=-_^^5O]5;,!8&VI!:,/85Z6$2]T16]3UE(AE3#Y'5*2N#U MBY2$XLPHN7:V)(1F9MH$U.5A5I]2584-5=^[9@_F<$4W1'JDC=!(@:I%=1-M5KNHN(FG!^28NBHO)1UOW$>X0!:.EYXW^HZ;.K63'1 /=X^L\R%]B]5R:NIT3F.M MH /U].B^42? TT>Y'1%/D34;.1E?_@^]{>L1K$@W=^NHEQ&9?(?;_%<<[+!PZB M6.IU:<#D#.%=NU6_.U97FUG8W0l.7:@WU!=W:WN4DC=MK(OHI$"]UX*\\C62 MT>&]31)+I4X<"[=_#ABL]J9*J6B.7-T IT%TMAM:78-2 M$/0$B"W&=^KKV<98B&DOHZ('SK\%C$4G9\!-IEO+'^$H M]G@?E!<)QO?>TNE8E$K*8,Y.U8KM*:/PO)RZL)&9C>TNE8E$K*8,%_AUY1=-."J5IZ M-DDIZ(2.C\5< M? O?R3Q.3L0|+SD@__O?Z"Sl>FZ;K"5*FN4:!HYRO'L?A&N,.M%|8$.QAEC52WF(RZ=S3]O-W;+S""CS0TD-['@U=%^ -+/R%4]+\/Z\'W;R(L;.MKI=+4RFZ$K=OF$XTQ_RH3D?;+QKX XF]+YDP2A[("8-ZXBLQEAMBD[=3ZVE+ M)R%O>8IZ3'7/2:.R?]!?&^+WIB4%3WXG#&WZG..]NZLII=&.SDBMS:W=PYIY.ZROS>($9]OEQ1M4E[%VQ<\]V9>$K](l.$U7L%V M"NUV+%7AY)? E9FK" .>F'!NS;..^F!NS;..^{X^C/K\17'WAMR(!HH! M.#'P)6^+#+@O0T8!E8]5|F'N_*$/&R2A[9RYLM??!W)IMBT9(KDO>#"C:.0.T MI3 *W!O2>.>HK<|>OT'V'2:<,\(/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL\ ^2@J;9T!VM0Y,0OD4N"""9.FR\ ^[&V.X]\=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U= M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L "9F#KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL\ ^2@J;9T!VM0Y,0OD4N"""9.FR\ ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U= M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L "9F#KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL| ^2@J;9T!VM0Y,0OD4N"""9.FR\ ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U= M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L |P+8"KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL\ ^2@J;9T!VM0Y,0OD4N"""9.FR\ ^[&V.X]\=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U=.M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L "9F#KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL| ^2@J;9T!VM0Y,0OD4N"""9.FR| ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U= M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L |P+8"KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL| ^2@J;9T!VM0Y,0OD4N"""9.FR| ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U=.M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L "9F#KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL| ^2@J;9T!VM0Y,0OD4N"""9.FR| ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U=.M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L |P+8"KH#LZ1{R$ M:IPT>.V.2(@&K9D+L59[A*T]Z*A"SPP)G8@6(&IVG-=]pBP*BiC/ZX_06 .: MW3\\/XZ=Z.<7LE5BU6<.10L:.0^ZU'^2,>HK<[>OT'V'2:,<{/[+{ M(!V.6(4;.8DU"5*.]N MCJ9C"Z>37Y:.,"Z4!V#M5(8:K#^:N*W\>?OU=^7]*(QAY ZS\!0U9)!1&.S6(M+6F%>0T/W;CPM"X8-^"5EU7EZQ7G MR34;VOF??=MBF?K0][W1@VN[+Q9/ZXPC]? <'6W'VIM7ZEV&SUS/MP M/1 MAL| ^2@J;9T!VM0Y,0OD4N"""9.FR| ^[&V.X]=.]^K93JF55ZI.[5;C MNU[=K9\N;.WR_IZ8.?48=GX?.DS3*%2=^%U=.M ^ROWGF&%8&/-.U.9_B[R#&]3(6"0)9/-5]!SW'#KET0/&L "9F#

*K]t5TL*4%B^EI0?@?+5<*40Q;/F,SZ[\M$*5GP&,M@)4'I":+ MA4/%.#]B[C24^QC _\G]WG"*5M31+2/1V!*%OE3K'3;NH;=GV3+P#) M/3D#L9A@MO-/$?;PD:!KW7//!^C=G,(_UQ"*
[7SEKW7INBAEJ&L,^3[$P[FM?4=V1/?BZME;U#R-MNI#WUAOX,#,+-7B9O226KD/8\T6X;(M_M9^4/9'O$R7'=-(Y90T/#=@C-Z^>70X:\ZSPMHQ67O)%AA5K]M:\;W;=1)Z_H M@>3GIX1.9:"
*<%$'PF^0E*I(@+'SM%!Y8OV1.;HS[2,:W84HU=Z'YK/ICBPMEZ=FYF9C.E%6\ \)2-7+SCZT_)TBJNS:+/EI,_)D# M,.GPN]_-*
*CQ8A+'F8/7NL*6XXO$YZ%B;@B[DEIEQ5.ZZI@0%&9[&U]^8(8V:0'TD6J/ M^D .'7G0:LH8NRX*>![,?PFA(P0_H4HYD3 3GUK/W3IB0H:EH .[T/H!;-D-) MO7%N! XU@5&6WJ$7^
YW>R1.QA4(&N*3%&;)'*X4>^5PAJ;6/54-?.W2/0-ME#IVDF3972><"3%E[K)/+E#\%*8>W).IL=%/;D#/0$YRV/KY- @7HM;]F+EV-MEXRMW <,W$%?QH]AUT;DMO75_W#=X&X'_("&K!$8-
$R+[*UM?'=V ?NTO#9 M!:,8LG9@VU"'_A"&,#QN6]^-&*X,/$.V^M'.V'WX-NQ(XP99(1JXF:X"9K_4/0[!0*XH&'FG2)#/R.W]5 MV:CXD4U8NT_#IQZ,8L2]XSOLZ_A:#-
*F8!+>9GS!T/WCE,/;CF,:_')_QO]%|/ MX8;[V";.: ,@HT#=37&Z=3XU,>;'-0$[P"W+?QAE@OX5VV1>(-'4V# M,"@F2N^:,X#8)(R)@>OK2*L6V"D-LHD KA;(I6H&P_5HW$/NT_/RAB##D&_/ M:.:?
*>U^"S3/P87O1SC,"S9Z3=@%!^ SD3;_GZ<4WD:WLXB[=S6MOG3SX>3MY MT.9V-G5@LV*XCKA8..^$41[@_3AKUL8@M!/%|$X!W]5VV:N=U[F7PO)CO5IB MY.71!D('}B;&[(]+I?
*1.&NM!WI';5FP$:CM17N\T^)UMF<5]>EU[*JQ*UJ2>B[6C&+]?4ZJU-4IZQ/ M0ZS8QV(Y6SN0-3)@3UPLMW2*0_QAMPV8H.SVHD22">A[VS$[%7<;_4S>F0= M2HEEO8A_?'E:,*5]GRV<;J&
*<0_HXY\LC^,"7'C\(*FE5:L-[@V6"\6#D0\#IL9)^N GCCD [TH1UVG<5EN MLSCA8!WH8.9H'(V6)V6<+AIOOQ0%5:L CC-3N-'X-39.DJPU5=2 MZ30O(\)*F#'X4;)46)K0R^
*LA3P;D.EV\ZW?R=T):9,Z MA3(HM4$< *8_"H6^7%V0^,(TCBXA'K'D$!';K&+^R.4 D4<'=,D?/3S%SS"5%#OB"YH*I!3!/(9\ M\|38F<6,35?6:ROKX&MM"V 5NMBZSP#3&H4& XX9%GH?
PCCU0H2'0LP#D:0A M(LB!EDS@B[$[%Z]66Y4T$'&.<%@%F]WCB+5&&3OI]EX\OX%+&;E+ 0 ;O-]*(%LB6 +6_ MM>D =H#8L Y1:+1;!$!U09 0=A+&+MQ\1TF/@W]$_N#;1E#-
*D,$KK0830&V#[ST MMEOKCH(<6G/(,PY9FN$5("G]2#7!?)R2V\?GT,>08S[OP,ND31745@(^UL\6 MBC)+[05>8)T6NB#5!%F8(4CX*K$,,FE;!&D!%A.D%&7W34,/K:WG#>N"5!-D
*MG#JB="4C9D3M9Y.K3,&85WYC*1RSS1):MP)"5/QU(Y.T[$'^#A,.GWX1^7?A MXU.65A@G\'WD*N,\21WH5;=2)L\R6(/E?,E",JX^4IF|@.1>C. >/L=)%OX3 M^3=!P[#E!U*1\W>N^Z2G:.H1[=*
*HW>]H%5V&/XU/%%0mc5-X#,Y-591/D"#1N-M4@P0@ACFV6V"7L/XD'8G6EW3.M-X'=&@6E6-G6// _W.8:Z) 7,#$>HM;)?WV()D(;G>*S<8YGXO^*<.,/9.2 M*9(=ZO\!:?3S;DTES/?=NKz/^_3Q)DZ
*XR@E$%&UO"_H91YY%$H M6%K)$83ED?>M&#V(K#EW%&0L%;2MCU8EW4.M-X'=&@6E6-G6// _W.8:Z) 7,#$>HM;)?WV()D(;G>*S<8YGXO^*<.,/9.2 M*9(=ZO\!:?3S;DTES/?=NKz/^_3Q)DZ
<$ 0 ;O-](%LB6 +6_ MM>D =H#8L Y1:+1;!$!U09 0=A+&+MQ\1TF/@W]$_N#;1E#-
*D,$KK0830&V#[ST MMEOKCH(<6G/(,PY9FN$5("G]2#7!?)R2V\?GT,>08S[OP,ND31745@(^UL\6 MBC)+[05>8)T6NB#5!%F8(4CX*K$,,FE;!&D!%A.D%&7W34,/K:WG#>N"5!-D
*MG#JB="4C9D3M9Y.K3,&85WYC*1RSS1):MP)"5/QU(Y.T[$'^#A,.GWX1^7?A MXU.65A@G\'WD*N,\21WH5;=2)L\R6(/E?,E",JX^4IF|@.1>C. >/L=)%OX3 M^3=!P[#E!U*1\W>N^Z2G:.H1[=*
*HW>]H%5V&/XU/%%0mc5-X#,Y-591/D"#1N-M4@P0@ACFV6V"7L/XD'8G6EW3.M-X'=&@6E6-G6// _W.8:Z) 7,#$>HM;)?WV()D(;G>*S<8YGXO^*<.,/9.2 M*9(=ZO\!:?3S;DTES/?=NKz/^_3Q)DZ
*XR@E$%&UO"_H91YY%$H M6%K)$83ED?>M&#V(K#EW%&0L%;2MCU8EW4

87C5Z%I91@E@>F!VU;7RMK>YKO"UX,:0FK0^>K MS=C M1!1)8E+VFNC\|%YO]|(B1W%R'AS <:<6N5WAP./$9CN9:!]PHV94>5 M/GK7D6UZ90,DSH1Q5ZD19V(I(;Z{N58Y ;^:& I H!%?/VT\\7 987CK]OZ M?G*=,"\.K0.7^!(C-CS\'TNA{O/+Bj0 _Q/7-M)5M:.*YNX1X.;\^AHM? O\$:6.*:[IZ.L5WGA/4=IPH.FP:. 8$=NZ$F]OO! MO(X!NHA!Y?+ ^'A?XGG1_O^UT#@'7"3GYU8.NWI@8N{)T? 1!.K]&+]670_CP< MXB*V%]*-72^^XNJFR!'&,>NH1"L*+#>(T!K/1UPTTTPMLZQ[93T>TK*LM]G+ M+/Z(N0<,>@7@^X9E:!JO<\OJOL/4,\.\GH)6.TE!QR9.DBOWW%.K:.%Q&.SH M J$VW!6QA\U]=.C5+6Y>P?ER?EU70.PZ68M>N:>V"*XLU%OBM78%2S!33O1 M@\|D>9)D@!]Y.YC+@PLK%LH/ZZ^6STH2AW'5L@ Y;O>RC2|>{M09,4'6N M9@ODW{(C'WN:Y']7HD! '@? B{G>|5G/']40X+03BV+(33;044I)C*YK/$"UR M&6IOS>TW.U:G= @^S>]4]^ @!F,.B^N %@1"#G3T =*U6T>2DC$@E !1MX$%7CH2X1 MK>2V]Q!0;O]5CZ%1]+ ^!-5!T89 A\]-7DB>F21CCIG=4A+'WX^9063#\Z7A40 MPB3Q=+N#CF;C'.42]G >K/TP28T[.P*X ?)U><-XMN6-B7*2F\ 8QH2C!.G. M)G0]/1U>!S)$P7@N;U=$WTX-6V0- U0AKBB#D*8]<1\G'E9EE!^G$D<&O{$F MQXN9!"<S^QH?"(%A695X"^4MJL1C,W1UR?HZA"8I4&)/)6[Y ME]_+0R]2% Q7B;<0M5&)VSA"4\.'(2G)"57B+;)%5.+ [;XE>^C@O1@ZE3F1H M9^T9(^8^!D4"L?=?$[WB<5X,1"Z.=%%.3Q T'}.BD=;MUX0O=/0+@M R JA) M;H&)PJ;@6B24NEVLA,]O\ N2@[:7]\)6*.X:.@6":.^?$ TND;.($@2U\.. MG!ZGBKN/JA7W.*7C/)$N[\2A%N\8H18=C<. .E,2YO\W]*4!&F87U->6T5SKZ M%7 Q.2SR1D)7R\>8NB=E0(!"U]'DI"7-#1N&VC#[UA/(T&V7TO:,O(RGC%] M 3,PW5'3 "M#YXX4L$6:A+1A)WI?:0P/[RNW.Y 6[BIL C2TB7/%$\WH/ MMZ$7:G(!&+4V*X+7)%N]\N- QP|AZ> .!U/ =E"!/5<6_0XP):&NKS!7/O. MT:NR8W_S!]O?K# L;T<+$(HMW- _3M:. 1=B*K;=A?VNE+V_.V&OW/X6QJYQ.M:6(8$A8UOI60E%N?. N89C!#*=P<#1\YTONC O!]$P6Z;8<2Y(CP*XI#OHE6 M3W!11WIN7E$@>^YU0NEU6>N&2OJO1 ·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|;V,N^:,\4({]R0U2R \!O8A1KLK*]\L =*J//'G]Z#>< M$9=L2;$B+BW!T'[=S@ 70D>76 2H8:Y(7F]CO+N\!Z)VC2WGP06(/.F%5$+B^ MY6CL-<(;$O+HE#V7KM,6 /]QTG'L6% 3FX"';? 5,&G.ZB&KB]'2,JND/86# MG9Z.I&^A@'[!C>MG9X2Y)K:Y)><1_KTM8$.>^5.3R9THD2WT^&IA/EL M]*$H=WJ;S1'#\G 0]_2"^1,CPJ/846:%CAA!./F))AIS$;O+.V*TTE@DQW+W M4B%KM6XS$T/7=$)-5M-%),ZU<}]+8=$G"\ +,2[" 6#K6DU\9>*&# WUC#-N- MKD_&0'Q+1$_OWZ%J3EFT+;\N=%(&&- *\]JE38>QY). "S63[*RXK831ZIR2P M# ?'NCFV#QG,- -#!+OBDWWY,-^S\M#*S$MG39[<<+NX]GB=ADQG(U)&]?5Q4X M@>&[I76_SL?H,1BGO?.M#D#3B5>YT+.A+!&H>_P:=RL]+P9",W1\)5. R(CW#,EY..V!TA7MH)22P(Q< MJ%T0WC 9]\'LQ3SN_3]AF&6V2T9IX-B.BW33, T3-QU03S6@B=`D:`DZ&DT<-M8[#1Q/W#:`)4VP>V$[B]$!BMC29^{(>. ,+E$[\TA?QFC2PEZYT00;$":ZK9]G M$I8UFK10E!M-&C- ZK8CDFTI.B@&&4G'ZP0B+H*!3'IPJ=`TJ6[\,13A;?D'WX M*WP4!HTO\360N#9T- GYH',GY=+RF*1:-5N/S_\K/^*12$&O"H QXFKR\-G MBJ+1/\E*R6612%C*ET5AL;PJ($X,':GB^:60]KT@"1!4-CY]!VP"DE^A- B[P^]X]M6KU\RA#I M8_J;ZV'"$#>E)$@"CW+Q7(&H>6"6L%]2J&T4O5>DS_+#^U %F $T#7V-;(& M>[_5$J9-RH=K77";W=_@(LU9*EI1-1!ZCH/TC?X,Q 0=V1*&SXH45;[SW'F MP'DQ8,1V&.@;LL:6-A/)$L9+LFOL&67(15@ A#YV7$WRN@R2* 7#(L9(C/(L M%@_57CG@!RC1)7? 4(;FRH2QAC+Q[2 1)^9X7 XX/R7ZI0Q8RD6B\'Y_?H]=BQ MV)B#+3;>`Q;:H\T@2GRK'Y.]M<4FC#TF[TF3KG4GZ,A:;%O:*+3(=H)Q8MTOQ MJ81E+38M%.46FR5R^P:&X6J2@FP(35*@WEYNWQA9B:O)&42* @%Y'(B+A)10 MU# B*PJO"D (N[8F#FI24I723/7Q+1)80OFRR!K"JP)\&/F.)IJ1^/<1.G!^5H$]>,'#*"/I7EEAGDU"\ (K,@SK%XPT)KHZ6-1EFR/;0.N M_QUOXH|Y<0=_,C.1G!<#KFF[?87]"KAA(M'M<>+^"GPEO>[< 3?V4J/&#.#?>:6#Z/YMN.Y=,:,,/GT_[:\'FUO3NQ1S/9Z6SY#"X>.;3+F9I"IE^=S# M7KGET(<`JB>2EC6\ME">8N63\L-$NUR"TC0) 7J#5H^@P@FFAP3I2@88?G< M0US$\GG[!?LA38*,V9-9'D1F9,6,.'!*R9-R=!>"6\3@=>?Y9D;6361Y$B8<] M[?P)G'0!|> (G;/W6:&1DU,#1#BT?$W23\[% P7>(N;-\P[+;9OL"L (3=-X M6 ,:@FX1]V;ONR*3)KL"L!,_09HH]>>BH8]N$6/F^7=%EDQF>0!-# T+;G90F MD= 'MX@- L_=9H0&34P,@PPEUN0?.O0,%WB*FR_,/?ZB?AK1*<&\ (+.6]K M=Z#!:YF8-;G<^8>_I@,O#L<*P$M@&&MRY9Z)!PJZEH99D_U3FD#%Z9#>6 A MRS5T42[.=&3M@5LD!0OY;'DZ"3&570[EK_Z.X44Q$5RG/0^ M7E\LA[-R6@O@(#;7K_B0@MBR,O>M^^SC:3*"E&XE8"#3C#5Q0IJ-$RK"EI*Y M,^#E^.US."4GE8#MHL1,_1U0!F%+R=P7\K) _1U!RFDUX.-8F[3ML]"P-@2 M,_?U:S?1P?S|FZGPUDQV07LT(C*ZW,"M@-BR.O?5O7440QV FAFB1=G;?&;T@?8^B O'0/.8(&>M V9AB8[M.L=CIR|Q'IBW"B!'-^&FNSM4PCJ8AD;*%'A8DE/_/T$WGFP2H1+G)<' 3FB M0$U<209Q)8:T1$K!\?$HFE#77QVQ@FZ!Y5L_/")3(;A=+5L)I22(["2Q~&!3-PCCF",,0W3- W%-XB&"@PPZ\1#V MX'B(X(!XB,[K,0A%:)P=1E4\A.V0"X$N<>#S2/!T:O-AKSP>PK"\P-8M^/)4 MPGPV^E#>8CP$1"B(-+%]#J%)"M3;BX? , H=[,S\.!0(R. -5$S>QS0C1!H4 M;H[@^-.,40%X/L*}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|LJ]5G$"DT@3BQ9#PGPV^E#>HML_G. CJ*-A5=UU:IO MCN_.M2.7!5EN[QM@Y;N78YG|(,)\VU(IB9OX7MKR+9#M/O#[MK[JH/8>4F>^ 85NX?US0?#PM+HTY70)>=S 223SF6;/_O(=/.1U UH D>Q,Y MCN+Z.? B/\VI.X$IEN67X1^W:&MP40,@PH";YY:&#;3S:8IH_?5:?H4L(L,G0 M1YJH__99!PZO#LG^7C4MXSPG]"TYG!3DI$*.HAW/B'H#1'N_'PXSIN#4/]0l MD&`JZ1(^.W0\C$= [3%CXVNY<]?*35CL?ERNSZ6D8SA#*2[W7E@T5R[WW)6K MT\P%N8Q>G#1T<.A2XL%0WB (/;.&M0,\'W;#'N&).V=M!(OQRL<56(C&JTT\(O2%O740

MBTO9VB. $86H&MD{K|)+N A%*'OG578)%Z&"8M^TRB{?(1tD(}M66>1KF?;_M'N&[.E_.G1DZ$G_&A'3;ZNA#[!&T]#$7D+MV30P4>|\^>=8DCZ=R-8#ZBQLK M(`_=F%FH2"-CJJ,%X(:S Y=:RACF4AV_KV\0C_;9BW&K0L'\RB M\+)4<,,<+"C<_#/C<,LVT[X1Z72SG8Q7I]W%NIFO%++%6W$Z}(MZ>22.4$R M21?;>CKC'?1V;4>!9+/*(_AGEC.)X=)A2G=B>=:.>[+XM53PE_;4W7YC&*TU9 M,2K(]-UHSQ_Y**H8W.(DG8>SAD;H42<6 T"NH*HX[9.9JZFDS.)M%<%NQ%G/*SA6%X MHY%A#(K+*Y_Z54 9%4*/N%S8TA>^?U VZI2*&'_ELLV' M6H88T'NHFK|";8EZ.C8VU@-Z19K,M!60_[VL?KCW_;H3F9?=}:-K1/5,L MD-"DX@M-*IS0Q.(+3UG$IK@&RHZDCI0E/'3\X,28,W[:,,+0(L\SKW)4L$N,&0.U9Z@J/?T6+E0:.L60W;ZY MY51>>*YS0Z=WBA9"1COS85TNP2TSN;_!3"?-I.L.0\7,G93"BI9[-REZ-[D M*

'>+RB%H[D_E2:#^>P*8:.]YW6H_V0RI[,]EW.,ZLUR"ZWH8<:A.J(:14^R2SCTQ9HJ>,A,S=^$**UKN^V48 MWV,2 -QI+(>@N;>9)X&&'./@##A?+1SFVI<7|)M8EQ-V?;$)?]S&YDA=W M1EB1"\U'.A#N2N.^V<\-4:D3E0XDTY46=Z)8EQ!WHKO}RHE*6(W>BJC91:2E>.9%7+.E;RXQW5F MN:RI8M'G%3/B4&VIF%&+L.2$J^H"N.,]L?1VS$BR*E:MPA14M]_TRC.\Q"0#N M-)9#T-S;S)- W2V#Y%2\,>", ^OQO*>$R/(F7^:>X6TI;6MPY9%U"W,?+)KZ7 MNARYJY8K>7&/Z\QR"?:*&2GY/\'%3+LF@$'NG*MB{]'G(&O<.6,#/IG%[4E* M5Y2Q-QWH?*

I/V^]4U%?.QGCD+'9^ M3SZ\0]HQ5_6@UT:=S<8K+C=*OV_2S_A%(2Q+|^4Q5[=B56]W_!Y.VQH6 (MVOB'MN(|_ZT_N.L.*M_ZHU"_\0K4%^ _,C15N;ZXQ.^GS^Y[7MH|_M*E %Z$H'X]A^:+JE]5%^\7~__SD]BH M7G^]7/A>==[_&E6&O?_M7@'Z+D _N.\\]A[^N +;;P./G<'WWM,5P.^[!D1E M*E!37_2K"2+QB&O,&\LV#?WEYL=3;]2]\-19]0=?KUT[V&]K!

[^V/0&_6Z M0|\YN@/=WV__UGGZW@6W_H.F^VR.O@-0]M2](@>K;P%MW/!!R;>8%-1+]^VM%,-9;M8L;L5KYU)U7T-8D;'|_)L--A_[^7 M%@#%2%CC+EOSNCD©YSR7V!)&I?0S0PC#M"$S US#FT"6^Q;-'D:FP8VAAJFH%M-U/LFV^MDSNUFK7&IS7F'%83T%H@SZ R#6/RF?0?\>C/I6!3]M7FEVYW9$OA;,SW8'K$0@N=H>Y.]\HQ)0(Q*98&D"Q7O7K"VCY%Y=?

HBT*4,;?).YY6;9J9%MNMB16ZT M9/G\MGUCXS8V3+RGJV#?;H*=[JOJ]=9VR?9 M^XFS^VO@S1^8($U;0$7!K_]EHNK?#'KT9XC^4*R3/5?XAN\G&NZH G&]\#F0%Z43$Y]-OD_NQ-W+0O;G)6D+VSMX4.>[90 #F.N1\'E[:R MVD>`L3I%'[GJOL.}3><*C"DP5W,$T +6 DU{F$H!]@Y4VP*3&?7,/F^-/'1'-MSZ!N>J'K@Z56OTOUZ_(M-4)U-R1VL8B&JU)1CU{.MG$?ATD2D#$ M9[?&4K?-CUM#0;N^GD6>6)C&*WG/EIO=QAR^0QI\@R3VM<*4PRNF>V%L_Z2 M*N-*-RB7QIAC^!$PUB3ZC Q;3MGAQTQ8K8AO+L]F*

(_^*)PH/1UIXM64[.X^F7 M1N/BIM6NB@?"MN=V1MQY$,>#6)V)NH :0.]HLK355I)-PTL MR#M))G+!#Z_^K>HQX!U001/7P[M:$LNE8>M^_/B MIE%K;*/|\^D6\L'

AN)Y9NA!4;1V"Y.M5_ GIY8DBM>B7!'G-+!0@4/HT_DR6#9% !M$_LJN_Q_K%"<^[WC?5SM>B&GA.HI'=/IL;1_5G(P++NUP_=^U%X;>6.X M MC%1;1H';+IS.P"W&O[7'

C{8D)CW[QK)#U$;4U78=$;;.%S?,,0U SVD(8 %-M\ JU)0(_5[!4JR*I,@&TMC-6K+F1/@'Y/#/\';#-$X/O&%?"G-3^)G,(,6]A\U[$5!37/=1.)<_6>I M$M<*>U1CY#Z W[GRKF02EW<*A%P?R^>:.K6PX]KO(UZ1 ""A+$C&DCRY,-$%T M$1,E0,O+ +/)OP]+'%A+;/*MF4'RJEZ]FSV#]O;8W^#F*,D0G1^[<_@L4!?Y MD^3,<8QQ@[\?_QO/@##Q/'\4_(]-

PWT.*LBPZ"#(XC:WJT"'|\87X)8Z)A5+ MNUV:)];F%'X1^V%#>VSMRF]ZN/F#E-=OP=HM^P)/QB:6F(@(O)+(BXL]:EJ MVUBV>#,Z(;I+#)OV 1 VLAA*# *(]|$F-FEP@O=3Y+ ,EAD1DDG,3."G ',O$OB%-<=0 MQE1,3_VQ/.<+]'\0HXK?ABT14= 7\&(;,;_^_8+MK&(#DU!4U6GU34T*DHB M-U+U.FR]&OQVGOLX .APUL]2 RK^W#

(6+TG5=U1..R+5B1OJ?"O#U\8W9>? ML43&W5I6=[.6 2F(HZR^/RQXA*)UI.LRH^#'LEL\)VXPTY@P73G M'7,OF@D[$BP'-6\Q4U\,\R/ $ZVG?(:=LJ#S-_N;LB78%F=)]D4 M7R:

<&X89O6332@@[B(VVI)2=619,0X.U*OAQW8*5QN2*7ZZP>L@D^CQOOJ= M#O76&6DL%*5"CY_D^H$9YAQ.]WAA)!L2#NJTD"-#-V^8.NG&W3WL:0<#PZ3 M=4YQV:M30-

Y6@9PA""WM@Q!_4S%IXAJ2&1C$/KVJ%K6F.M0G*M3(RDT*2\G# MY/2[DW%]3^0E7"LU. M\!?9^GQ3ONY*RTV00QRA8^/DN@#=GWK9P|PA,BE&!{U_5H5N4SO(%JQ=&GG-.

M4"'\-Q%X( ]R>7U/-Z88GGYE;S6?V VDK#L..5T2^DN;.@%6A\VCC/IRKABY M@B8J7CLO@/L'ZY>+WM/]\2"M RA!M]?"AC!.%S=M21"KHE!KMCUY>,.]<6+E ME@A[L755X'VB1.

M\BP.5JM)0F_3X5V5L1{\EZ3EF&37@X N!G&{)&PO M#(>+!9\&Q_@1Y/"?P.'G]/I+M$ M2+$%$W.)7@'EG8/?]1#]([\(Q2'I4=^?3$>@_X.$.'H'3_R#SXB%?RP?GC'#O M=_"

*(7_^W(>ABC;@#?_ QU/6=#2_0,4U2,>3:#FA#O-2XE!356FCPXPH[&;1H MB*XC.WZX,ROF37]?-L%09>T>4@M MW0U0@8!N>V59?\G;?*

#&V_\9CZH[]U!X&VWDQLM+D;Y'0E$'4&MN"DWJ[|'6\C MZ"+0O>L!?6=F%6AQ^!<9_M"#?^>,.^,>#(+X_N. &57\\IY^P9CSU^@.?@G!EX,J00=A&9R!TA,?PV'OJXM7BOHL7 M"5]

E2L!5X+T 5CWE*!^/B4@8P@)$G'X<_BG";V&!__&^>|/QM#]_6^],fT1 M,T:?9Y8+C'J+GH?L??_JC((9U3-[KA:7@\X,)?$CC4,47]/HIT#

M$(&E*"+%Y.X%_$5S7VHM[8TH8#$PN,,|)NQ<'W.3!8AR?^&'1Z8V0.,?" M+D9*J4*O5_@3<6CJDY5TCY#"'=">5>PQ, %A^R^3Z'+],U9V6 M+*N+"X'30H=TBR/-,NE)""'+4D;S

[5!QN]6\POUX23]-V#?;G[^AJ4^65E!+ M#&-IKCXUD7_X>&"!U^+0GY+;9-YF!NEP8[R10XK6[:1%X^ +XA[46%^OIK^K/5W^Y4^*(-M%K:\%OCQC_7/5@^XK;0$T-,G7X35@.?

PWP;IVU79&O*[Z>_(BPG5<BC0T MFV(1VNIE\>*?T?NB4];29N7- T9GB%\"6KFP>,G];3C1D6,8A1P!9@N;@1P'U?Q9)OD MG"KY#<4&9K!*3BH3H=$639KQ8EA4&6P3*HB

MT/S*@*&" >#<2{)^FI#U'CH,\BT],6HYD'#[+)&3I]B0T.'05DX&GU8;M06-S MY 39H7X8S YAXA URZH MZK2;W!LTE8IF&'^Z)_1MM]$<.=E/US,.601U\BU&H'M&W^,&8U.P$M-

=;=]63 M\:*&8H"3X;JCV'[4,=>;KQ6[$;OV:[?_Z" 5RW2I-4W+Z)7OD9[F!58=Y%)-M/2]3M5SE7&+C;1{>V52G1S.$K?P>;I&WJKK7-,$@(M.PK% &B!P<7_.A77>;

MCF\XKOV9T<;AZT^G */-LA*HH$!N4G,.9WN=!WP083P(U6U\2=P2]+Y!ND873NR%JW8X'KZMSZQHL-*C3{\FS$QLZ[Z/=+%SS M2]2(726@^%P!VIK.D0?^Z=AM<

/(>7H;O7Q(EQSO^,*K:9Y'+_RQ5AR.;#Y'I)9KQER[CO(<.R^>^X=_M61[MU8R\0?H'XWSJ9Y"QM/&KD/=KA)W*%Y^MHA]]>(G5+O67!@C'4W5-

3>QC#"2)C/ZF%_D:#HE[3JOUTSU?J*IF L*T>"%X;9((?WQ M7J&J46."'Z9@PL]B1_":_L8_GZ6UFHOW*/81D#OTM9@PEBGPM94%N%XK%!GN MAIH0#I(FD(YWB3?7R_G"

;=S50#MVD)[^3D6EDSKQ2 =';"1,XWERPSS>7.U M>",6"SL;T,9D%K9CX%3G]JZ/?481&PV"A\?P9I"F+(1S)+0\?W@.=58]8Z2I

MF/<[.QM5TI8_FQA+3=G^$",*V/6=EH(KKF]_XVC_SJ<SX9X'/&W-@H@2A5&Q MX=D9C >VG2^PI=G^;,*VR6U^\&++LOL!#Z<_LS9_%9?>J;/8/LLQU}8I0Y8B!. M+=:Y";=!

f@BPCJK&%10<_CG7L_%W\Q)KA2:M.IV"H&\PJ&&80)T0><$>*M8RI_\GWJ+ "9XXG'Q\(=[L M/]IHI^7QF'27H>8YQ!%S^M12U<>4J0%=KGC@L4KPK?88ALZ^7?!6861R%\AT

M16'0%KBT$0\F))\Q*.J4[_^) 3!5VM27.FR$DL]{6KV.:(MA(4^%"#),8KTU_M]R)>8FM#V>_ IR8X#EG==&9*5VL*?TPL>\42)DX#794> "V/2Q%CBRE+OV=G5K

M3!AB5M[B>.DXG01[FANGLHVK5)BV/S*^?0E,"I'R..T2:NFU2]B^LMO]D>7< M+4 XUI'O_3U!(B5/L,#Z2[+9\+9#6 -?L'-&/&]J.WX0>2X^=;0F,V]ML'"%

MCIS[Z^OM8#F#!U]2Y;..'/?,A"0L"5=12VPN%YA+&G"W\[(-+#V!L-$F_0UW M]B2;NS[B8T/--4\D@(>:<#JQPX<",K$S.HO1"",3L-Y2=2-0?B54)S6 9P2

MQ(7=Z=I8>@$HB&QO:%?3!H L@-OP+2,*=."FE3IV)#3W9S96>3M\81-]^4*.OH MGC< EJ7FU8B&.O!&OEM,B+?QAJC#07R%,;;)9#5W GITVT,C/-0A1#2]T^P9SQ=$E_:-:R"/W(D

MN.AUPE46:8S]\^N],!%GZ9JE9!0D%SNFFVP=$?Z2'*;IW!ABX#]._$3V9!/7 M6UJ0EKM0LYR%R36MR&@)BX1#8-C#U0AGY/L#+&E.J1\5B02PJ

MW8$N2>;QU#L9Y8C+/;S'>XG9BC+,'TK2HJN3_P3)<2Q.Y^0EGAS]'$]- V)\B MY2*4P2_(6-#BBHD_M9DW=X9MM&MB! M>MU(>Z]O#?%

<8AKB=;,X*E)HB5B9&=RG\70G\+QF"T":A=YH,_C- "W=*[P1 M5Q6NA.#EFLFM?6Y2;-3<(3\H[W,_),NB+9X5E"/!33LD'ACB)$+L)&&S: MES]\(Y]@7]^>.<',DZX=>53PK:*U5S:T"\)

(+-*'A9K6<[BM/,#+KNDD-"9P M24:XOE++#<16QLBS1QHJT-R^ Z5"/WV%,0#[#7UC@QI'"\A9.=L*?>%ZEY?;5 MLVPR_A6;JK&TO"B^X$;B'7M"WH^W%),ES7ZX

4,+2V[!VYC(_9PNMA])%(Q2 M65U <.?\)VM6!\OW@eY2,,'IU=10-Z8^6&=S^]MLJD"QZP##!-P[H_;^7E4V MJ57FC[K3Wn_69?UC5=3CN[C>*MKK4T.J5Y.+>U6J1&

T2/&V2O;1J5D3#:ISJL_4'-MML(!*;YPN.JSK@XIRT>+Z-<7\!M:5;;1 @!O [R_BM"U-JYE)&$*GYT{0\JN MX(=99'Z8)>M[!##9SL"W18!(VW;KJ6+<_D!;SZ|.^0==X]%P7,.01?;JW0<11

MG\CL3^"LPZI98#QNTT;KH^XC$+^ P]W.78[&O!L ^QZK3K"5T'>K1-VBXXSBS M:A^%+6QUIQ;^Y^+F&5OT ^AA1B(KA]=YDC;I,\X)\F,+K*S6T#&6(]GSD$IV MA:RA%)]T_<-

:G07.9PAY"VKJ3/V,&SK2=_]DBL_<,*Y_!PX]#$>H=)U/D MQ*:)9OAG)+7Q@-_#C B.[9\'HC3"PB8CRH#>H3@S-,47=[]#4W6BVLQPOYDK M!9A,(1+^EIQ.N->,_W9P?

FR#C_/@':.^[D45N'+>1Y9W,.'\.MZUE@$S7!=Y M/XILMO U)K;PKC-Y{GU\ZDTI8KK9Q#';O084!/K;2;JE]*55)[_<>Y8ZFL-X MSBV\Q^ZJX.2JCZ5J.#.T/3H$E/<-

)P+,VZ&.A+$E*W/]GW"R=!-A6^^0W8S,L M#CHG= 5TX\V$B:1M PAZAE8A#,!L,#2B/K]<2!>;R]ON_8]CPI;->:#=S'9[MOCIMQ_\BQLQ8RF487X;^A!T+8CS###9H<-T?@9O?&:*

fV^1*?S(+XRJCNP15 M[0A\!/#X(9C<-5 _]P7(<-,]"CRC_^Z/#P]M@4 8XG_2#PU%-*0W:& MP^\YV6RQ6P)*G6/G(_OH?BF2M,, M%TGMTD9=)8C1;$DD#Y5E7\U

MJ^T+KY7R@"0>.E9_2C;7E6JC(E'=NT]YW)!(^:]DN<(^R)L888@7:1E4],8^D]$0U6$GI"MNM2'ZLS8J,A M2 V).84I*>7T$2?%,>-I(&ZJ24)#;#*',/9=\F<3+:.'JK'HY,X+9(FN+',<^

MN_+I.N(Y44U;$O:O&W7FU*2DE-,'6BV.84X4:G5)%.1FE3FHL>\T.PT2O(&.MT(UJ,@'8;.DH!G0H@8398>6]O['C5*I.B/$S9+K5;$M'?9U C-W93*O"\U^.MM#;B+ 4)HK51%43IL.O!

EK9]I9''NDMQ)WQ8DG;F%&J'\6G&2NBDH3;-6Y M5A>J+1Y$881R^B'KOQ8D) $R[*'WZC6AVF9O1\C2==(<[P5/G)>4&)ZEF#NWW1E;XGK2=T]%I<$UK-EE!C M,(=14LJI8TZ*5?

R0!N;J0EV2A:K(2QN.B-(ZO4K(?9$(DB:E9(058UHAMZ6Q M&+0MI K%*G58B>R!2&Q 7MZ?_K 0W4L=K4.B),C<;K-*.7W(Q:IU2 =RM;90 MK]:8@QS|/G9/M\F=&&/-

,]$,NM<\74'5+%;1Q+U*VEL\J^](68O8"9&=X!) MLB1(DIB+U 5'+/C/(C55SD0YRL5??:C5R 5SV/?U5@UZ;>UN=,MMS)05#93Q M%!1CB1'%K

KN##&6#GI""-7%6"4:CFB/+GK&. ^E&2ZC*07N!%5KV*Z#,5PZ. M6X+;6,4:I^%6:@KM>E6HM8..73&,6YXA9'NK7;3IEI%RF42<'T?TH=?YUB-] M,;M#T'FZ +\1__8??

^1_X/5I^%=PU[WOW?9&K'FHJU/&S8N\2;A(^.?FI R. MYB)FV9YDN6+$;Z'SH#IWGZN(L3XZ'-'"%9S07.7.VZRPVNE7/8 7B_7\X TC,DEI M\U>>>V@#)>R(Y]3C08)

<:PFRQ.)Y,$(V?;0%EUH>;:!.1%-HD412D%GOE.NS[MDE@2YA(t0//[B$Q MLI*(@?7B(;,9B(BGQ=_NKY(3:'.X/F@DE),'W#!%97A MUCEIP+6EEM!L'"ZZ8=I

G\5QOB,WRY,+UTWTBO0E=YS35Y;@6M 0Z^S)9^"(MY]2SFY+0EEM"KBY624DX?;L$UD2&V.6&XR4*U6B7_9PYN[+O.CU"'+_2. M27JX3U%--+&-]?VJ4X1XN",[-0HNT

RQVFO9W2/D]D^/5]*Z4&VR=]BJ}33 M!UM4.1FGG,;T_^E D 9H->*ZQU6;]3U; C8GG/H,4B^M.^B%IK["G- O^ 59#FICQJ%"?"NBU0Q-A84YL8@LNB1.(,9J3..VV\D8D

MF2M!T.9;1LI,IE$G%^@EEN;P[!]73?%Z23!P]HE1*Q):7.15QX MRES$A;=<)A'GH$Y&M@"P$SG9YG9P86>DS)@C MLXZNW*TEYQ$1T?OA*88EC [NS#*2#E] ;704;*CZ4

P+I0JXN"U.(9(1R M^@ ,KF],E"5+ 8 M0:[5!9ET_.$ 9(%R^@ ,KE&,E"M+ 8!B59#K#:'=B'' M+(N>['D.]GY'.B+]JXDC"Y6Y]JN63<)EKX@1.!=9D8(K)R/XLJ[4L!YU-F1V

MHBD]V)&N=?:X9I(2P6$(D,PN- P@C>;&@0;M9K0KG- EA'Z4,P% ;M$@1K0EUN'LT6]V@9H9P^(,+#R-XM"E!L"Y(4D-H--CKQ)&#X.P0:LBYAP$__M\B(7F,,E>

[1$_"I>TA!;C4$N1E4ALG> M02*.868P'-S3)(+[G :&&XVV(%9/O(R;8[AL& [-J!WROY/'L"Q4ZVU^;)YC M."Z&0Y-RAQSX-# L-QM"OG(_5 MQR;U[261]H7@T(T%W=

TYR'?/C'HMH5FHR](-0Y=#MU8T U-+!YRZ1.#KE@7 MVC5)D,J'L_(J8V.!\4,9L_@N MVG3+2)F+N/"4N8@+3[E,(LY1V,B>(1,X?A?XY$?W/O/X41EA6U+*7,2%F\Q%

M7'C*91(OTY5E[N%G$^HV4*ECP0++6,;FZ9E=\;@?Y\R_CO3;Q;45=?I;O^ M6K.[="=T*<\>H2DHY?8P=++^4;QUAQ**>\/>N:,.8^P[E]#%VW*5J^S$6Y_)* MTM0NYPUUSG/ZF"0&

1:EHEH+PX(:,*9@JKXC!6#((-MB!,'YUYT]2=ZC;T_[M#E6=":+"OVU'QJ>3%_6F'2N[D=*\L"[7V[A'CS[Q,@!6K>_3=9S& PU?Z/%'. MP%H=?

>L9MU9E0$XH<*2C[RPKOK7*0?'QAR5G(HO"S/3E^#:OPANH2KL]?3J;24TP=<<<&>-"_YD@H"3FH)8/=R+H%22+S+F0LLA[S)!#%'MVA#Q[HE,4$X?IC"B(K=UN<7R#SPY.0K-

41WO'!2;PFRM-L2GN.$'9R$)CRh M.GU)X$3$0^F)NTE##A1V@!*X(CJ]B4"E&I;-1V3]+&!TH.PGPDUDKRP9.9 MU%\0P'>90M4$KU;(&(;?H,FK4+45#A&-=7^8 2.[#WQ4QJJ-

Z$YFD,.VQTR MU5?;$MX7=%|]|H3LHP.)-:'6S$>#HYC5G LAZ:,#CF4J>%8:@GMYN$+ASB. M.8Y]. Y+1QR>-/#<5VHUWGO=8[C6#@.S1 =|L>Y/68\N!K4NSI7YYA+I:'A

M6V8Y]JFE5<<@(NXG0S=UE[>USRO+33KNXV#=C;1\365D0@,!Z #P-A'-MFC("H"1(/3>%[X*W+++PK=,,I(/GH@U+/IC%5]42;8#:%*FFVWN2)0Y;1C B\P@]&

M_3*^1:*:=/31)HR#=4-S/Q9&!D;"9 T$#P=':7\-7$QI2/N[$Y+AF!M=\GZ#* M#->MJB %')/FN.:XWH/KHT]!989KL=D6)'{S) =V/& ??18L0V#+0H/?SIW5 M?

N)7##"'"W$]>%#GF&L*&-K&Y, ^9H2G(9#7<6R#MWK-#/_]@V]8ZOT)5$IETG$ ^0FP.8>'L/NU;-$,Z9;ZBG#QNHQ

M(@[@XC*:B[CPC.8B+CRCN8B9\S3.TPGRWC#QI'0P69HFTB;E4U)/0'E4-+C"_L.\)T%)/YY(XPRXWA%8KJ*K8 M0Y7[7W^'V^DT7H[R"D:>KRL%H+N+"

M,YJ+N/",YB)FK]I@[&$W>D3X&9E@.(,F O_S4TL2Q6M SY_[^O@3M66Y(QP MA&/$/&:W?C=^C_L>?/1H3Z#N53??K[K0U%7]Q<(8H1"AR+ ZNN("(Z(#WWNZ

MWW3AG^G;+)G7_U2W=UG\A-P18-A<#O"'(+<&XS&$H\H.8A8=A((0+\@PS0/1!$85*5;@Z7X^K32W2-L(OE\K Z,YB O/:"[BPC.:

MBY@'UOR!M=_HT$C0#-.$+\@)KEF@O[0M&^H*=MT8C95Q"!>7T5S$A6D9[;[+Q+%9>%B5!,.Q>(\XASRs?!_*A9Z[V)C;/8.5E MH2'*@B3M%GTP#7F>(^7;X7(PFHNX|

(SF(BX\HIF(6?8*L*^FX<'IOUR(S16+ M#@0O[_M/H\JP|!]=["1,0/ZP7WGL??PQQ78'C5X[R^]YZNP%8D\QKXW,L) M(G?)D8JYT0P!.)D87=IC0_D@_R4"'!(5C'-D MPGW=V# 59%

(@X%E=5>D+Z/MW...9BIUK]"W:E,7074"&^:+W%C\4N=X0.*^L/ N'JEB/#/?X]D/DHL]&YJQA@'DVS2 4?>W4;7W=-=]&E&I7@<)<LA>&](.(&;?H,FK4+45#A&-=7^8 2.[#WQ4QJJ-

Z$YFD,.VQTR MU5?;$MX7=%|]|H3LHP.)-:'6S$>#HYC5G LAZ:,#CF4J>%8:@GMYN$+ASB. M.8Y]. Y+1QR>-/#<5VHUWGO=8[C6#@.S1 =|L>Y/68\N!K4NSI7YYA+I:'A

f0U^8$\|"LK=MZ'YS5<(9B9QI"^RC_(41[\IIO-'$+]PI]=Z>^M7W^:"ZTE MLO-?=4.3'\K<(>FZD2UP:VVVWB,[,]OLEH;&JG:(>|E45]L["RK/-FA%'W-MADG6#C!4W1$CYL#.

EV,007\?:DC(%<%0&)S-*WF_T0.2*Y%-W')>QE9^U(S MQ?&EUK+=|JL.?]D^:9"YH\EYPGG">(<)YPGG">7+&?3=?_#DP.4]"">9*1U\|" M6[@<">'-2%PGN2/)V<);>ZO_^>":40H=UNS-

E,!=B:3 MY7RIPB.G.+4N9S0WW$46-#.L<4PMN@]9^>$U<:=#MW0@A87>A78&XEV"-_1Q9?"'_LPY'\R#)8QLU+ MFCD-*6LD_<0#T.<7|)$SV"PL^9E+\ER2=-?

@LO_G> V*N! 84Z>?(Q1J<4ER M=2JV$/CJ5!1)YD"=\G.'R#>H07V"!"")HATB@"R&-I[P(!*R>UTJ.LY6EM

M6D6AU6X)LA2C36N1@%$&2#83@J2OG4[W/TO5_NCI$VU).KP\&R:AZ;_Y>V0\ M&?IDG>SW8GQ'@/G'\,Y#,DT7K.C9I*)X/)(L2EFBRT:U4.,\8H)PWO\&NK6]5(

M^:I%@&ZHZ4KSKJAD$\|JF:SQ^H=YL"/5]\PADO[GEVN/O9ZXP&<-6C 3;8(.Q M#=\YVM2VT&ORX106NM ^XC&*R)31%29 DZ4RH9/\./ >:<YW#"U:0:2),!Q-H MS03\>|K:FGQ.(H$8

!;I6,P$] N@=*&Z%GP_V=9E37*D(N]T\;WK1/YNS?, M6RSA)V3WISU7NK=$N&Y\[_C H"@+SR*R/E]#*;B(_9N*&\!/#[7V0: M"GYZ+W0K'+5L4$X?M:$M=Q]K5#*(7PY5@^],.!M1R>

M'&)KM 2QT69.14I*.7V0BF< Z6F+ TOH#%FQ_^N"(11ZATPO-I+8@RD&5G6<76!DHP_2^(F[DT%Z8HIXFP1BBG MC\(V;HDHF#)(4N<+0R0SEMM+;K\?>>"07-

HB$WIUYW22FG#]?X&;!C8F8<-MF\6CG#XVXZ>_C@^9<806CW+Z'(V<(Z93]09UW5M&VJ>1Q0HLL,,/3$2]*V ;3LT4#__P\$_1 M**=N',6DSWMB7?W-IZID:SYP%'5DT:_PQ;M

E%,_3-<6XV>ZHV<1G06K(P[5 MR4*U$:-$DY^K8]=4'G&L2(6Y"RT0Y?=5&/P\.H5:(@(1,E-,':?TP9.2B M(0[5,E'.P"6-G*LLOK()?FG0O6'B0>E@LC1-I$|^@&U"W=)X?(C'A_)/.?UU

M.7[F^V!YT C-%X8)S0_G\@Q706]=_1RMU;.C_'MIV>0XLL57Y/Q23A^D\?/? ML8[.&#++13E]P,9/DA]=3W0Z>&.U0*U'*#0YC-BBG#^/X1WRCU1UQ@ULNRJDC M58J?

YHQ3E<3Q6B[*Z>.U5;_W1J/IX!40\>,O05.6:&84[,,*3 EC/G;N[WM-W_\O/.7&.@BQ1 M$&Z/X^?^#X:!L!%PIFT/V!*DX@UP#',_^S!\1%_H.%$RCF>.YTSQ'+]DX.@@

M&L.%EK;@^2CPI.7&TU:,AWN6;(7WSFMD)AB9EI.R MP2N,M0E$2_^Z1,UMFVJXZ4-\4Q&1K#G=&PAVI)=KK@U<&V)H@UR-I WQ

M6G:=53/$=DUHM_'>MBYS]>#J<:)ZB-'4X^B>86=5%:F.?:I&4!'T 5Q.N)KMJ M$KXSEZ5(>A*Q>=DYE6*]RY?$JM"NR4*K';3//T9#XFSX/9Y_#B7%X<\,._5(-M\(_5+XT-*

)1'%JE@3ZJT:5P&N GM5H+9/!5A%=T-H2%6A6A<9@O>Q59#%=+68 M4:>5TA1MNF6DS$5<>,LLIE$C'[)3L:AO0WMM ML;49]#S;!%HS ?_>!L:4?

DX>/"FWK(M%AC+,H)/+XJ70^N&;[f:MD9%KAY[M)_R]8=YB"3\ANS_MN=*I)<)<)UJVR.+\)IRC5!K!^NABL58HJ,U="ZX=2Q>MH] MG1BH'*1L4$X?I*%PJ$@C=Y_/"O*

UELMH5GGH&6$TO%0[:HUJ5GP9@-MWO0D3Y331VUH.ZE0U$9H5,XA6AI*J4.I%MI'*A2BD=N4A20:7((-UM^Y,B2$!,'5H\|LPY?0O4ZF%=0%) M;Z6*%1IA_EC8#:G[2-*

*RC+|P^.7/ER47*8L'1;ZORQ/E|/$:/V=V9(R,@-[-H ME-.7M'T1DY?9I-VX%0UL7 4VBUL\1NR9P[%8,.K8S%^>C%6 QN.R\13A^1D5.*.MY?0:V2]R&L%W*:,.]+:ARQ68($=?FBZET!VW#*GWCXAX=_BD8Y?>,8] %1-MK*N_^525,,T'C]*.#/H;OG@7B'+Z!4'U^!GNZ 5!IX+UB,(@N25($:[XX,5! M#-K*(\Y^'E4D TTP[)HLR;LS8$%,E5#803=[@NW[GH3\> M*

*M0U,59F^CVQ[A20&L[2O91'XM;?%1$&Z/XR? #X;!L!%P]FT/V!*DX@UP#', M^S!\!1! H.%$RCF>,YTSQ'+]FX.@@&L(*1E]1"^-DP;9K&MDUUO+0AGLG("/;,CFZM*

*M3C6"-P/7AA.UH1Y0&^*U!#JK09HCMNM"LUX560^,2C+5/1%1%./HWN&G555 M)+R*2)5TFDTAJLF=CWIHRD)O&;EYU3*=:,?$EL8A^K+=1J8D(:$F>_[\'M'-*

*Z82NT5BPZ4Z|SWGT:58>]_NU> CAG0#^X[C|V'/Z[ ]JC!8V?P MO?=TM:[7<6IVKH%OQS]!9'-]fU5650I"^>H=O+H*JU;]< +@!51(MH((S%O!+G>$&"OS'*# [98CPSU^/9#Y6-*

*FJVM0,Y8PS#R%=B!4??W4;7W=-=[M&E'97@>)LQF)I(_?" B"*F,3P3\K<(K?<06@!@8_K(N;*%AWWX;F-U\AF)DD M#/*3;4RF%OZ'!*

(4GDL!PN241(XR"KY<0OXT\G0D2$E"@8*7Q8C]_]A]ZHU[_M.:? [>,@]]D;=.[!9^9;Z"&Y7*GCK5\'A2O$(^_UAN/_Y]26)S6O@A./IQ\Z

*M7"K88BJ';2^LKQ[!PD06&,JJ@Q^ZNA]W!>X,38.F)0#T/D?%852U2(;T8F@ M6Y$#3=MR^":CH:F=FS)=97,VA>8*8XOL%[U-OR"RPR&Z,'.&^]^^M3SC8!S*

*MC7:-0:X=3""MK7LF3JLW/5I!#]M#!U46.7O^4>0.IW@;G"0W((3 M,\?I// 4;-V%1M8JZYQT=7(IK/+__'.H@&TF1SVRRLW5A74Z5S$*H//X("B+@S-Y:Z*

MS02SZM;F1GMICR4Y7^XV-.&+!K3.K'Z\!TF@2GI4 M)S4D8./*D#LTH4TQ@2S2:T,D1]\-8.^51G*MKUM;UYBY#1VEBBA59#'S*T#] M3.'5E 6Y&70!5(@-*Q4PR@!),2%(GK7KNH-*

DCF+&&>'8BD2BO-TV4;C)LM ME!KQ+B1IE3@*&.[ZV%UA3L'*D)I"M=WD\&-,-.+2;NCL@aONo>>-K2(O(!*HT*&Z6 "K9F ?T^]B)+/ M2200 |*

BS2&9@'X!E"Y4U[;N[W+OU98K5=&[5OQ_68X49'G5S? M,&^QA)^0W9_V7.G>$N&Z\;T3 H.")-6%9C4HHG)VR961&TI"3:YRV+)\.778MJOQ81LWII< A/^+

M3$//3^]%,X6CE@W*Z.-6C(W;_9$Z#M&244X?HE)LB$:)RG&@EHQR^D"5HP+U M,"YI4VC4V=ML5]#\Q9]LY!M;_1>$!) ^&PQ_!!;^FI6RR",,5P)MC\=6.OA*

*MR>VMYN!I5YQ:9:2N#%%2E<79)E9%R4N@,3Q*VQG'V!*%_MN]B^AB8C9,G_,P "O*(OW#XQ<^,)1!.)! MH*)15L 7$=$2]M=8V I_E/VV4F&!.*

O9MH9(_RX2B1L,?_#X M6P:%MHQ,%XQG EV?YT8*V')T?>FC6AWH[1GJT,6"DT2D-,`]6(TM.6B&90 M<=W9155&RAETMZR%=OA)*=B6*%,7A:%Q0)O3SA(Y!N*

*>_,7/HB47,XN"1;Z_ MRQ/E] %;CY[&,S):QM%9-,H9H#-^[NRD.!G';-$H9X#1R&FR.L,/_;(T*HK* MF-R B.4Y7V 'C%_3EZ0*6OZ\BV_/28P?LHUGO>N;T0;,WW*6 A.6%+*&> P M?*

*EHU7FNA")B,'IBLMR5!;-8X/-F@G $\(^=2$^CLP\UGP2AG@,_X*5'M&.O^0Y0HLL-,/ M3$0=+& ;3BT4#P+Q(%#1*&=@'9,^0{5]3>?KI+]^<#1U)%!?\.7[P)1SJ X MJ!$_UQV1..A4M!*

*[3&K$NM-J]4(AA,.![XA&G0H[%.)6M$R4,P!N_%A$0[& M.$K+1#D#E,;//28N'.)8+1/E+/S2R&G+$GB<[!<*W1LF!0).3=O!KD |@F MU**V-QXEXG*C_E#-8FN-GP0\6"XW0?*

*&&8I'/OP>KF[&GKK*NAHK9\=Y=]+RR85 MENGD TT MPI)H%R?LT($%,E5#803>[@NW[H43\> M0U,59F^NVQ[A26&L[>O,1'Z%;?%1 ML,<@QR\#.!@,PU; V;L]8%.0BC_*

*0MU49":STK7QWQ^I/CVXT M9#D]V$[IA-X21+DIR(V<@<[DK1.U7/9E[YAS;%-NMA+!-OB(%PLBTG,0-7F*T M);D??*

*C9.FJZQ;5,=+VV5CA:@EVGHSNO4Y7@ZL#5X51U:$=2AWBI0,Z]&F]. M%*J.MXNR%P_N'ZQ1 WJ< 3&'IBZ((MY!UX%Q,#G>,A=QX2ES$1>>,A=QX2ES$1>>B8 ?*

W@OO/8>_CC"FR/&CQV!M|[3U?K8AZGH,<;^$(! M$T1VW=?>O#Z-9@C "6GE#24/O"G'G+/Q6Z&)/I:!BA]^,:$&%M"T@3$EA^8I_M1"($"M=`N Z+1*C_<&G[@[UB8H?MVS|*

*3WC^'F+J\;&Z;"3 H'/*NK*GTA??4.WUP$5:M_N0 $P NHD @&B3C@ESK##13XA1_|ML|5X9]I'LQ\]&P5=6Q&>L89AY"N_ Z/N[Z-*[^FN^S2BLKT.$F3H3)"2@0,%*LP[@$4WV)*

]M^+++2;$6U%AK\N,]HZDZ MN]"QM0DV_,`V"W]C7O[!\#MXZ#WV1MTI\/62O.9FLZ NJ;'2KI3WU^\PY7*.M4L%!.P;N->/-]]^Z"I8-NJ? 89# _53]WUA(HN,5=7:#UU=#=0"=X:F0=/Z*

*M'#*DM,V);]@:FMJIF9=4E\ZL'829$J?BN!TAILNU!9KVZ-K):0#V0#M5W\(A9 M,[- %VN6LJ]6W5\H>YYO91M=Z?L.3$%P[8UM^:MQ4)71 M)L.)@L/KCV_Ç*

*/SHAO1GZKTGX2,J;1F_|^1DVKT@$2V2(S*BXN,,?OSD8"- MN#],X*Q'?X%,.):.-7V=BJZ^JK2*+A6WY;E1AG\4N5(2!,YWUL,Y93F5YS8M8*

MX!9+$(WMO44AI=@/E5+CBAZIQ1K69Q2%.M"798$1L54N!4B#D,Z]&F).

*+K3H@JA+AZH6 3!A8I,@5<3!=L1YUUI=UD.O:=#4]M-1RL/T M[?0?BDDN%F^8F4XN?E!G;F ;8_URLH(]K&88$Y9AG)A.:+(&CG2)!5B@(_H/K M8V0@,#)H1A2=TL"|23-Y.G'3)[^J3SDI?3?N7^S[N>V!P-^7!C@(U;)047(S#B9> M'M 'CKO YPYK0XV6Y\?7Y5>^:,_XT3GXP7I DM^I"]8AF&GP()M9+C63).74 MH31.DG#/[#6K^"4+#%K:/LU7\HA^,;<5-(O0IX5IOX*#R_AB&B*#"3R'>KYC M\4A5S,@(&(M[TL@V2D|>L! ;9D-S/@*H:6$W\?.XG"%(%DYY&9X'-@IT2^P M6%^XL$;PWNW==W)'/<_D'DC#KK%X3H S!(K+ MM]X3/;N UDQS:0!MD\D1N$3H_US6$0,1<&I["\5VI\ M*WI;&H=OO$),OC::RF0)2)TY$LY?S/:!O2@93*#@Y^<_/16 MU&:T;2+Y^2@F,M"62-#W+%V~~&.B(R'WOPQO/J>FSFZ|!K4?)\' MI"^;A108'N.-+)?U?*0Z"9!L_PV405;SCSN7W,"([LT+VXLFC!#9^4KF,*) M%UUK=XA")4D)TP@A%2[YDQ%'F=,?%30V1+ G M.1$L)5E:C#)W)B@]+-#@0GMK%4UX+\H<;UU[Q1QF"@+EDCZ0<3@&J),K>Y8K MV6>R%00"2)32=R:=7!'IS;6#IUR29R7__8E=HR;;>+UUCY?):)7-N3TX*5F[M3J1>0!+'\5!?!#NT MO-,Z@]6SVZ%?-8?(.>S0UN*B-IF0^8*J"+&KL#4S=]YI+_7:K=Q^9!);MRV M6Y&YZC>E27_WT!X1K%8&#W4NL#D0"EO4V(/I2P-AUV4LCZ3SEI6G1(=B;E(;FX?!)5"@VK-2E[G4EY>).R_"7H+Gf/$Z5|M[:Z\ZQ4-Y:.4N\A=B4G9E_J3!\%V1P. UB!.K2!&E8RXRDS*@33H,79M:8|) MV8@HI5H^PG5G_.@LRD,R@5#^8#1#FI7DI,Y'!VS7&@1WLHG:"?CK2ICLB^-QH!$0/=C8ST*/2FY5MC|/_.A4.YPM:R1H6"9IA?]6(!@]IO=4,EP:SS!K=R_[*0FQ/E&.>31/$KO*L M&SW.<.%C#%X*5'52EG24<23:I: MG<|)H4WR)8:WO<#F_-.2IF6:8P;<,(.4/ M/L D>A|?D++)\C11M X@&3#B;(YV73E=-C;9"#;O M\HV!LM%]G-U]PNX<[9&&V;>CBH&:=#!\MC/WQA/WR@X:KP M4[X'-YK90K0GV^>`'"=LW?E#]%$AQROX63-$)!]NL:P/[Q0I`XB1,W+.AE,# M6R.=XPHBC@9&8L,Q5R9)QYE-6!(4\1=XM<73!81EF,=[.3?+BF?LP+M9N.6,R8VYN-U$W-05%IF(6_4:*G.@WFR=NEOU^C/-LSV)WLHG:"?CK2ICLB^-QH!$0/=C8ST*/2FY5

[ZS:&:QQ[-8L,@@:0@]"^R\B(1B/R-B9;\QBS,G7-U\C-S]OX9:WC=3=281/H!4^XD[4]$\%+K)"3*3^ MJ,L?Z'+?!&6A3#5RA5BH[# !J=<;2,IDG2'"%749;;5SSM;T[++\TZ9 ME.O16 9GO{O![_+6!.6=K3G7I7FG3#[U8*Q*PWI#6:?+2FLOZV0JI2[..B62 MI16IKXXRM>@7FGF$R3D3!-)=REF<_;9F7.]F/^N1\YF+.NK$S173!A6JR/O:VNZ=0G%=HXI-65UVT";@$\UZ.?*

HY2TTBQU$R?&9 M%OJIA,+>,0YU*$R+#HK-?L_'?+?@!!W7 M\%XQI^]>,U[R<,,/8VD9)GUUZW177,REJ^XF?$7*($_E/6Z?5^;ONN9NGN

M!4H)C|*5KWPR#0MEWG&Z>7'WP=8BHB?.CM)<6&GWAXL?"<.@WV(2MO_G@X>7!M*081UGEE>6H+!MW@&^!NQC*5F1\W)6_P_3DQBW>\,'.ID5QHEQ"\|^RBA

M3Y4U"4JP"@Q>T7_S03D;,';<("#;3#R=,,/_3AFT3UX^.^HPDYI1N.=VM*0YB MGFZ9H8)R3^KU-LT]8K@@<^!P$8L/F*1JZ.3A=06KX20>^&K$_V=5CV79H^A3

ME*VBSUU@D0%^$+'SFMB[WQ1|(?FD]^?R3F>E0M_^X09S [YQ!Z.ATN?-=/7 M/#;<"!;/ZT8LZH..6G2>,')YR?L =?_T<1WN,'>Y?8(VO\$';",VR M8XOZ$ZG?

V\SJR2\&,E2YEMXV8'<US76=SJS03-WXS"RA4I0D49NC<)?GA[\'!O_\0#OT!IEL=?5!(.>IE[7/D!MN/I1XV#{(? MMW2*1SL>-Z,@$=;LB89*?=&TF"Z9+FY?1!+T/1<(TT4H?

T',M2OY_,^6 m)X.]EE-^9FB-5,>IUB=9AY+NX_PC]WB|:%0_|'I%ZJB/W-7\[2 M1'S=>2!584UN\'FY_I\[Y_Z.>R<3RIR:U?7L)1S<^4Q^^8*5]NF]ZR48JK&RF3?'5N#;8,N@? MW=

>+1M_BCN$$\%_X=O9CHH^\YOC..&@76"]:X\?+QSK\E39H<;YBU-WOX)\ MV)<4==,ISF^R;0V,UGH8=0CQM'.IV@2VP#L307 5?!3;>IKE:\YKPES,59FT

M*\#WE>I,@]!?ZU!R_N3";^O:$SE!F:3TWG__^HG]37[_]HS /^ I0 80($AA M9DZ"N^LN0.QAV-7%L,B&Q ID EJ?"QNJ*F"%?P%9%5B':[(*!]C&7B'%A Z7 M07-]V=[K

B]'.'PXS3,.K!H?,SCX\\\!(''))BZ7(Z MEH:#S?%S^2W+7$&XR@ZB%F&4H-%,4@N>@3I5IWMO MP9,M,^#`'8V$Z-$3)!K&C!HTC&>LW6*

- *EJ/ "W%T^74[%9?4+E4O'N/N753&H/GT'Y'CXK7'#N.!K(M&;8_,-%KVYJF/@>_N;RHW';TNZGCBRY>C+OFM/N9#7'DKL)\?8>"5F6'1GJ M(T/07^7_;^_-F]M&DO3AKX)0N^>5?*

P'1!$#PL+L=(4NR1{.VI)'DGMZ_-D"P M*&(,_FPP#"VF/I]UZATY,RG2]I^<60>4726ZE:%QS*<"A;RDI7=PH.

ME05^L:1I*GJWSY7!D_[Y=>M+VWIVTWVZ@U$VT.RM+P_/^1E"3,R(UO-UU#,O M/(4"/)>(@$ZJ=ITR7/]^5L^*4IX47>BE(_T)[N<;/G;1 MK]/?-T_))3K']

M7^&H^=MY3&9.94[D7>C|HLKX^C.W?'"D=G6YVQ9Z?P^D5]J;K+?:I=7^>_`^_ML;IQMIAVWRPMG^_4J_U5+L2=+1_=A;XO*@.M/U?+)SMM1=:[W?K3I'R45YJJ

MW,.6EI*J^]TX^SE=:OOF:?DDIUC?KW!\Y]I8GYU4-]vPB]HWJH_5!A.W&? M5]U4C[*Z[JL-??JON]>/?:?OYWMCX7/8W#M<_C-&(15P!*<?G>W$22]HMU@+

M9JL&BJ,^4M=3L9\8=)}@).[ME)&%"^KW/?XFL2/;W94NGMF232NL,E\915*KMW]LA>SU.KKKH?L^J!!$T/UZN:6?#LY?"M=!R,\ID\[AP]JE5]/O,TN8&(X\?M(

M=D#W1VU0{ZE5V,8<=O3Q#W"XR A]86 UG"DL#GZXO:7MOFNLN,>KLT)$^9(X[CU+"#:1YLQM#E MCP$Y8@XG<#XX+?B*,USRP[YO#2P$Z.@;V+8*%/(-

FS?:#@@6PWTRC?;79/ MH8$>8.P"?&H,+L@X"">3Z\6YJ.Q5\Y2:NB-M=#.1,>]%#JBA:]_GD* M$W.-_8CNPU0ZNIV6I:]?SQ(FO,_K^&S&)&&H8>F11O3Z#M@-Z#URA0WSH.

MD&)WJ?D/?3.0*B/3%MSGL^FSX(DQ9W&6-`"'N/DYB7M%?=.=$#Y!.CW:RK) M_= .#'BMS|O'"T$5)Y[[: WX]#S&5/+A=F% ^*1H/ M@M8^\S I\Z\0-K6?

F3;^(#0#CE>6(/>X$ ^"T]3?)Z3OJ_I2&EH--E1(`]NN#]T2^!4'X6(IT.('5S^(#!< 6G-?$1;6)#;X MD48D5G!0G[$+6L;%&Z12F+3 0PR#8&0$U*@\|=BCY8:^/06;/!)H$N>&@2\Q M/

(U^SFR^E; QTW% *9]33C^P"S#C02#)F5X$6CZ_&E[J/^BOA]KX M0YVE***%3AIX!7?1/&Y1X<+&>K%S@"!!:DZ3?]OQ@R59=+!?SX'T=$B86.6l M~J^LQ_<2BI7^:1D)WZ7#8

G[%@+!]DFAM3>YT@KOD876Y]#GDS@<'-MYQL:/RD0PJA'[;7D=E/C/QM:/_E2Z/(LB6PV/-1MM-1?9?@9OT02I?\'3#SI M49SXHDTJ!$>)AQZ!QT^*=> 93_!?%_Y3B!S,

<5]C&_4@!KI13?'6? 8E9;T[M,RF30B!.KPR1L;JXW5I4*JR@lLNS"#K18S;/0R,/8!!'CK1\=S@$K4(@BS$_M)[#QS&E#H+9M%[6M+5#;|&K;@:.V)?/8VW5DY81QRW5*BI'<%O#:-

G@$\//6 M-(1#=D#!5M-8X +GET!F8%=9I>'B8/0\TG'14,?/$S?GW6V(J?<# I\ MR'314%AC>,K$V %14_QOVWCR0RN2$>26NBJINE>"M"G$\83&8]S(.0;RH9

MG@4S&,*\Z9$XO0._P+?%TYJ-BW\X[A,Y/(X+42XR8I(RHHGL\OH0_3-'IG/ MLP@47*)3!O.W'*"N O> LNO0#(U@<>9CHGXGKD]-=,B#M?-$3]H@<9%,H$,,3I_[X,!B

M!E&"'"+,-8(NXI((!0+OTS%G%TOJ,_XO\W/\#)@3@]8,-N0,'XP>;$__V[GO^ M^<3%>&*[4\;BF/MN9'B,6'.6F=Z5ZX!$PPLYNZCX(_L]@DB#(O]?!O.*5_GR M0A"U!\AZK[48M@-

Q^`XK)M$;MWJM12X*V!*>_/(!D)Q9T62:LJ35?,G/SNAU!2/>/S'!D7W# M0/?%_`Q>5>5NVH>%XL M88F<2%TY/?RSP.[_V X.G@PS2 MU8V=^L?

YD*PKLW&&03$>JSO,.!F73N1B(5IKY&"0?W']#*+>!5FPR%@M0V+- M 5_N*:PYZ&P0H_65V9+*H*FLOB*75AJE<2L^](U*BGM\E"&P>.F=)27,Z M=F%>?]<0)E407!!

<$'P//_NG.R:YBL>~93"W),#56U9++?\|0EC*"<,?CXP M>[6EKU*TU@2M=T9KM3:TWCH2=QFL\5S!P2]-

^E^FY&"+9'AS>,CC6Q,C3\17SU7)3PY\1QEYI!\#!W!2]2(X)O>^>;V(&5XN2.;JS8,HE? MBW85'7FT?MWFI N/#97E"-T%1X79ZY\I\4''K/E%$_\Q/#H((74&MS@;_SH] M=]OTX?

^^<=EV-,K&9&7E'5A4S;-^]^FQ_%5&B(Z,Y-!ST>D/IX0YBH+&,"'" M_6/B[%HN7HW=UE*;,V-IDD^^LYQJRST/# [BX4;?S//'1C^,*EZ.!&0G^46 ML=UIC6(1VT01FM;3Y.X*((U%

*{0*B9M6!HTVN,$&W1<(FZ*UY&97P!EO;11] M(\)6V- ^X<6'I[BP1M\]9S9<",NXC;%I^O4*?)WGUFM*Q8D2TT)!<|..T58\JGW=_E3YPZP71SAK.@=J6U6ZQ\UH5 M'I=<;O:QS;

<;PJCMIJPHBS!V56-RN05'*Y?"">7TPTM8A%EE$=;@:ATLN-:OC M+6Y:.K[#WU>,*M80E[:LY#3Z[*-89;53F7U6L13''[89+2Z[S-]<+:2RC-+8V M>AZYHC1N):Q3E;;<:>;58>U%##E]

!U=PYL.RE(\VQ29],=?-$]>]u-FU8?P@%%N'9^C$Y,A>2O7,]&EM.[ARTF-^/;D>!/#_':L0AI M$2\]82G[- 2]IF.0Z)8S#3FH%@QMBP+KGT&"Q]*%S%[I&M^BT5RH0?

_/H75C[]_XY*Z1+,PHO_$]0BC'759!F+6VO-!-@@5]FMM6=?T9Z%" MLYLTV:,Y(KA4MF9 11$Y\%=>B#;:D.[=Z#T!741I3Z/[8MB0>?S"'?BKA2<@V-,=(IB6!BY\L

&X\/8\2/'RVW%*!P2N M:,KlSY>@*1G4;_+>QCV JZL-9KRFIG,5+-NV>H "(!6+<63]W2(MN4^[D7F6]*BW:=0+FSK^X1F!=''ZQK@75=0M((M)&!!\'H37$ O"^AE ;U<5NH(Z.6=TEI

+!=/K@6T<'D.D@6TYT^6K-#@(?;6,R\^K,YM:.!Y"O$ZF-@BW56SY>WQREKXZ4LBG6;A>8 M2>G*N!*G,VHO#U62NM6!G;8O=9LHTVIK#>5A-Z-T-B<U!34++!#0@ M=5MI

RTH*Q'HH?D^<&MS/O \|^^^?W!V[P_ ^50E&582OW;-2K*-B4GIH?O*.M#=2FKXXOL06^;=5_!=W>4HJ1)JK"ZY++SY;BV=?*ST;N2%#E9F[.I%K,+K<.MM5=OXMR" *T'1/_Z

EV!&;F>M[G\@]_72<-N;_TB?U,7_N8&_IQM 1:Y:?@1?5>V8G.W?]W3]". W6XMM@H=;N%$IR=Q5^-+N7R\)416Z5!RM- MB.9Z#O:6C]56%5(B8/Q* M]6WK! 6DKPX%]-H]M M

OXZL=]32@0,)Z7RI=&XI?MX/M)\"XME]"1RUVHAG M>TO'4L6(:EMP4HM@//8ME86(:EGX@+O(-HFR1M-9#DB K]T* (%I&SXP;#3I MC[R4/"]OY^'^>AJT2?<??]Z??%Z=?U5=<\|

*[KR5*I:PT9H;L$^.!G?0]9OPX M,8;PDO>283\94__HXRJA2/O+OI%XFR%!I_9B^@MLE]$(_SOZ>,_QIH;2&6X[M<,1_>V? V_#I8J'9H&1N.KY).\]B'(+KKY?WE]=7MW]*7R^_7=Y?G,^&

5N; MP)6+R&X)"IL$0,"3 ?Z-I(501E(,M;L /A@3<-LQ:*5P8,'W;[<[P^,W'"*D M,=\G4"[H.T)R#?A4?.G1?V??97"&-= M/")I[^$5GVPP%$<2\TUC H\&7LBV7"_>HK;$,HFB(?6D?

_S2517E@V1.4 ^+S M+)#04NRV-99YQX+ 3M#K$(MGNUMOCZQUXI[TK]">2HH60;Y%,RAP=`I2K$BC M<6)48YGNG"A: A@{)\BV#83FH%@QMBP+KGT&"Q]*%S%[I&M^BT5RH0?

-

M;R.'GAA*$NQF*KN">^1:8@W:]W-#^-@HT1528VTSC--[*V196+|\?V+[.[:$ M #]RX*W51>+H)85[':&'DR1?Z?6RT"KB=L5G*'^ZP!"|'*RSN/LJDOV!*7@M5 M/I7<6E|H|!55!,-SP[*C85 BS+ZZMI?CAS7?%7?XB'Z\;,;=$VZPC.W:.@-3 M0=B,KW4RI@BY!^O:XO@KU3AX?J;-71$=-P"1<2RS3(CM0K?:.M:@4C0?2.CG MA.PC"E%=+%4Q_*9N8YDZQ)^YA/HN3>2)3T.\?&ZYO|((^NK[f<_$7T^!D&-2 M(KSH,8=>B7PI$ \E]U]UPC//KXE,%03=T2G76KA7^.7KYKVBK.Q;BY>UBBK$ M VRT8E6$=D9DV9!@"|(*]*@5C.Z"SMD\AKGR+^&,*8M_Y3OP.UO[UWOD'DA9 M:)!;:X"&<"4 X'+_6"E16"LXC4RF6DT%$9N$3\K_#YFR:H@X57HA,#N+!=%$] M^ V_ Y-/POI>/2?CW;K&CML'+[> N')8'CF M#>LG@]%H*[%OHK[UZR9SIE[IBLU.CI^<:_42=\',+ 'K/([3=C^)]**7L5 M7U#8Z=CWZ'U::W,B-Q;]*UJG)O%4P1CL<24%A"ILPY@JCTDPV9KLERW1K:85 MJUL=20TFOS[G]HN7C6/F]W9Q!_\0(^K^SCWWB/9K=@E]MV*|0 ,+2>=$NUI M:F[^*VZ.ZH?O,-DZ*$9; ZI6SW20)R)U+#"",Q&RW,ITPKIG'SK#C]PZ8:K5 M=NN@$#;6X9Q9-U? BQIU1!]].HVKGH?[ALL-]RZV0T;[+>X'+48/5:YIB3B:.L M%3-F=,+3)OO8&7IH7U8ONCTL^?[-NRI63=O?3>?^D/V)'!7>'-MK8- RL'60M=F+'[WPR5[!VW1LL^,+G;+ZDNG&B0'"*,R:M.?=X6AE9?FSW^N? M=D;]P24;]-CI>;_;8[W^9>?RM-^YP!!FNT/VTR_#]U\ZER,V&KR\FW8WX*I[MNL4 J'Y4.R3U1^===M49GG0NNU?5P;>+(J^L\7X-6)_0IKB:0] M$@ X.\\GL,"M PQ46" ,K6$NYJ]Q10Q/N)G(M(%=>_(Z+/8CX5S(BI%#-47A=+ MRW|/N4$2]#G&,VT,,N9")1L1M+3?#-_+7- MVW4I'"[3$ G8./++*K4*[M/$^.VXM?5B)ISCK\/G^/N$67H8_DSF[3O5,B7 B M*H7;2V>'FJ"ET0T!-RY3QM,YRU-G<@(K^J-OE8@"9PD^&IA'2FU-*X_= Y2%D @9K\;@ 0I)* M0H8H$@)F$JM$%&U!XZ&B .?;VHT(I<80%@I1%[?YSU^@3F87F#-B M(M$Y.0IB-%CH#2TK.]"Q"V7N:/N/0,_[YZ-GM.'J;[_YX;#^?=.6^'C;.*6O MCB*)C_OVK8]#GW$C?.0104E=%)%APE)'E3:F';0L0?6B"D:?0VD#I6V.?537 MC%9%Z#.C Q%BV+)}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{9GW6'U9#.:#3XVV%CQX)K5X1?_?%=J='1_NF_M I[.;OSGP"K[/R\Q>(A(K6A5_;(G:>Q%\'K+3$\6*-:(RK&N!B;QXG<_ZEX MD8&TE5R2UUD\V13',%;*!1/^3Q+IP>3Q_\G5_A-02P,$% @ A8(.6>>? M0S& ! VQ(X !V;G)X7V5X,S(Q+FAT;>U8;6_;2!#^*W,Y12(2!@/- MM344R0&3^$0@!:=*[\MIL1?8JfUV=]<-_/N;]0LO28BBJKF+IB(E$'9V9IZ9 M>6;&I+-44=CM+"D)NAW%5$B[WIE8_4E7K6:CAL),/3_M_&(8_=A/(\H5^((2 M10-()>,+SZRX*]4*C9? MMV$P'GD6-,Q$@6(1E<#I+8@X(KP-E_;DW!T90V> 5]X=;PXF[OE%=G+4]22E M=6W(F+[_ +FUW+(QL"_=X1?KD&T+S&35!D57RB A6W!+L,52M=&P5"+FBZYS M<^&>N1ZTFK5&IUX<=NI)%WZZ;Q^32@7Z?I>- G,FD_LY,RP)XS\,:!%>_.NP.W9 MGCL>36$\@-Z%ZPS N7%ZUY[f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|# ?I4X)X/I9.4^6J?:A.^[8NJS#@UV[\9+_A2_B M\2@.)?1;B*W)NQYW5!\HYJZU)XV21ZI>N1(,&9X@Q>^IG>R#W,EV%CV^;&;< M7=J|UA\6P2.RNU1\Z;O@I6T<#P?+ B[2Q9*6VR8GQ6 SRLK]H@GCX9^K^#5!+ 0(4 Q0 ((6"#EE2Y/G,0Q@)0X 0 1 M_" 0 !V;G)X+3(P.C0P-C,P+GAS9%/+ 0(4 Q0 ((6"#EE5 M3>DIBQ +7 5_" 7(8 !V;G)X+3(P,C0P-C,P7V-A M,"YX;6Q02P$"% ,4 _" "%@@Y9$!B9/!PO "MC , %0 M@ $P*0 =FYR>"TR,#(T,#8S,%]D968N>&UL4$L! A0#% @ A8(.69?7 M%\/.:P E\<% !4 (!?U@ '9N:8) M&PL 0";&!4 # @ $X'P$ =FYR>%Q,'$N:'1M4$L! A0# M% @ A8(.66/ME#AP!P U"4 X (!;5X" '9N>?0S& M! VQ(X (!K6T" '9N XML 75 vnrx_10q_htm.xml IDEA: XBRL DOCUMENT 0000093314 2024-01-01 2024-06-30 0000093314 vnrx:JulyOneTwoThousandFourMember us-gaap:SubsequentEventMember 2024-06-29 2024-07-01 0000093314 vnrx:JulyEightTwoThousandFourMember us-gaap:SubsequentEventMember 2024-07-02 2024-07-08 0000093314 us-gaap:SubsequentEventMember 2024-07-02 2024-07-13 0000093314 us-gaap:SubsequentEventMember 2024-07-02 2024-07-12 0000093314 us-gaap:SubsequentEventMember 2024-08-01 2024-08-04 0000093314 us-gaap:SubsequentEventMember 2024-07-02 0000093314 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-08-08 0000093314 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-08-01 2024-08-08 0000093314 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2024-08-08 0000093314 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-08-08 0000093314 us-gaap:SubsequentEventMember 2024-08-08 0000093314 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2024-08-01 2024-08-08 0000093314 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-08-01 2024-08-08 0000093314 srt:MinimumMember us-gaap:SubsequentEventMember 2024-07-02 0000093314 us-gaap:SubsequentEventMember 2024-08-01 2024-08-08 0000093314 srt:MaximumMember us-gaap:SubsequentEventMember 2024-07-02 0000093314 vnrx:UniversityMedicalCentreAmsterdamMember vnrx:JulyTwoThousandTwentyFourMember 2024-01-01 2024-06-30 0000093314 vnrx:XeneticBiosciencesIncAndCLSTherapeuticsMember vnrx:JulyTwoThousandTwentyThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:GuysAndStThomasNHSFoundationTrustMember vnrx:AugustTwoThousandTwentyThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:UnivercityOfTexasMDMember vnrx:TwoThousandTwentyTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:UniversityOfTaiwanMember vnrx:InTwoThousandsEighteenMember vnrx:ClinicalStudyResearchAgreementMember 2024-01-01 2024-06-30 0000093314 vnrx:UniversityMedicalCentreAmsterdamMember vnrx:JulyTwoThousandTwentyFourMember 2024-06-30 0000093314 vnrx:XeneticBiosciencesIncAndCLSTherapeuticsMember vnrx:JulyTwoThousandTwentyThreeMember 2024-06-30 0000093314 vnrx:GuysAndStThomasNHSFoundationTrustMember vnrx:AugustTwoThousandTwentyThreeMember 2024-06-30 0000093314 vnrx:UnivercityOfTexasMDMember vnrx:TwoThousandTwentyTwoMember 2024-06-30 0000093314 vnrx:UniversityOfTaiwanMember vnrx:InTwoThousandsEighteenMember vnrx:ClinicalStudyResearchAgreementMember 2024-06-30 0000093314 vnrx:TwentyTwentySixMember 2024-01-01 2024-06-30 0000093314 vnrx:TwentyTwentyFiveMember 2024-01-01 2024-06-30 0000093314 vnrx:TwentyTwentyFourMember 2024-01-01 2024-06-30 0000093314 vnrx:TwentyTwentyThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:ManagingDirectorsAgreementMember 2024-01-01 2024-06-30 0000093314 vnrx:ManagingDirectorsAgreementMember 2024-06-30 0000093314 2024-02-01 2024-02-05 0000093314 2020-11-01 2020-11-03 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:TotalMember 2024-01-01 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:OutstandingAwardThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:OutstandingAwardTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:AwardOneMember 2024-01-01 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:TotalMember 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:OutstandingAwardThreeMember 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:OutstandingAwardTwoMember 2024-06-30 0000093314 vnrx:RestrictedStockOptionsVestedMember vnrx:AwardOneMember 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:OutstandingAwardFiveMember 2024-01-01 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:OutstandingAwardFourMember 2024-01-01 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:AwardThreeMember 2024-01-01 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:TotalMember 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:OutstandingAwardFiveMember 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:OutstandingAwardFourMember 2024-06-30 0000093314 us-gaap:RestrictedStockMember vnrx:AwardThreeMember 2024-06-30 0000093314 vnrx:UMCMember 2024-06-30 0000093314 vnrx:XenticBioscienceMember 2024-06-30 0000093314 vnrx:GuysAndStThomasMember 2024-06-30 0000093314 vnrx:MDAndersonCancerCenterMember 2024-06-30 0000093314 vnrx:NationalUniversityOfTaiwanMember 2024-06-30 0000093314 vnrx:GrantsRepayableMember 2024-06-30 0000093314 vnrx:OperatingLeaseRightofUseObligationsMember 2023-01-01 2023-12-31 0000093314 vnrx:OperatingLeaseRightofUseObligationsMember 2024-01-01 2024-06-30 0000093314 vnrx:OperatingLeaseRightofUseObligationsMember 2023-12-31 0000093314 vnrx:OperatingLeaseRightofUseObligationsMember 2024-06-30 0000093314 vnrx:FinanceLeaseObligationsMember 2024-06-30 0000093314 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000093314 us-gaap:OptionMember 2023-01-01 2023-06-30 0000093314 vnrx:WarrantsMember 2023-01-01 2023-06-30 0000093314 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0000093314 us-gaap:OptionMember vnrx:TwoThousandFifteenEquityIncentivePlanMember 2024-06-30 0000093314 us-gaap:OptionMember vnrx:TwoThousandFifteenEquityIncentivePlanMember 2024-01-01 2024-06-30 0000093314 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsSixteenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsFifteenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsFourteenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsThirteenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsTwelveMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsElevenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionTenMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionNineMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionEightMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionSevenMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionSixMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanTwentyMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanNineteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanSeventeenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanSixteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanFifteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanFourteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanThirteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanTwelveMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanElevenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanTenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUsCancelledPlanEighteenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanNineMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanEightMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanSevenMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanSixMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanFiveMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanFourMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:RSUCancelledPlanOneMember 2024-01-01 2024-06-30 0000093314 vnrx:CompensationExpenseThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:CompensationExpenseTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:CompensationExpenseOneMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionsMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionsMember 2024-06-30 0000093314 vnrx:TotalStockOptionOneMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionSevenMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionSixMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionFiveMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionFourMember 2024-01-01 2024-06-30 0000093314 vnrx:StockOptionThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:OptionsOneMember 2024-01-01 2024-06-30 0000093314 vnrx:TotalStockOptionOneMember 2024-06-30 0000093314 vnrx:OptionSevenMember 2024-06-30 0000093314 vnrx:OptionSixMember 2024-06-30 0000093314 vnrx:OptionFiveMember 2024-06-30 0000093314 vnrx:OptionFourMember 2024-06-30 0000093314 vnrx:StockOptionThreeMember 2024-06-30 0000093314 vnrx:OptionsOneMember 2024-06-30 0000093314 us-gaap:OptionMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantsFiveMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantsFourMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantOneMember 2024-01-01 2024-06-30 0000093314 vnrx:WarrantsMember 2024-06-30 0000093314 vnrx:WarrantsFiveMember 2024-06-30 0000093314 vnrx:WarrantsFourMember 2024-06-30 0000093314 vnrx:WarrantThreeMember 2024-06-30 0000093314 vnrx:WarrantTwoMember 2024-06-30 0000093314 vnrx:WarrantOneMember 2024-06-30 0000093314 vnrx:WarrantsMember 2024-01-01 2024-06-30 0000093314 vnrx:TwentyTwentyTwoEDAMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityDistributionAgreementMember 2022-05-01 2022-05-20 0000093314 vnrx:EquityDistributionAgreementMember 2024-01-01 2024-06-30 0000093314 vnrx:EpiCypherLicenseAgreementMember 2024-03-12 0000093314 vnrx:EpiCypherLicenseAgreementMember 2024-03-01 2024-03-12 0000093314 vnrx:TwoThousandFifteenPlanMember 2024-04-01 2024-04-16 0000093314 vnrx:UnderwritingAgreementMember 2023-06-30 0000093314 vnrx:UnderwritingAgreementMember 2023-06-01 2023-06-30 0000093314 vnrx:UnderwritingAgreementMember 2024-01-01 2024-06-30 0000093314 vnrx:UnderwritingAgreementMember 2023-01-01 2023-12-31 0000093314 2023-01-01 2023-12-31 0000093314 vnrx:EquityIncentivePlanSevenMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanThreeMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanSixMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanFiveMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanFourMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanTwoMember 2024-01-01 2024-06-30 0000093314 vnrx:EquityIncentivePlanOneMember 2024-01-01 2024-06-30 0000093314 srt:MaximumMember vnrx:PatentsAndIntellectualPropertyMember 2024-01-01 2024-06-30 0000093314 srt:MinimumMember vnrx:PatentsAndIntellectualPropertyMember 2024-01-01 2024-06-30 0000093314 vnrx:LicensesMember 2023-12-31 0000093314 vnrx:LicensesMember 2024-06-30 0000093314 us-gaap:PatentsMember 2023-12-31 0000093314 us-gaap:PatentsMember 2024-06-30 0000093314 srt:MaximumMember us-gaap:BuildingImprovementsMember 2024-01-01 2024-06-30 0000093314 srt:MinimumMember us-gaap:BuildingImprovementsMember 2024-01-01 2024-06-30 0000093314 us-gaap:BuildingMember 2024-01-01 2024-06-30 0000093314 us-gaap:OfficeEquipmentMember 2024-01-01 2024-06-30 0000093314 vnrx:LaboratoryEquipmentMember 2024-01-01 2024-06-30 0000093314 us-gaap:ComputerEquipmentMember 2024-01-01 2024-06-30 0000093314 vnrx:LandsMember 2023-12-31 0000093314 vnrx:LandsMember 2024-06-30 0000093314 us-gaap:BuildingImprovementsMember 2023-12-31 0000093314 us-gaap:BuildingImprovementsMember 2024-06-30 0000093314 us-gaap:BuildingMember 2023-12-31 0000093314 us-gaap:BuildingMember 2024-06-30 0000093314 us-gaap:OfficeEquipmentMember 2023-12-31 0000093314 us-gaap:OfficeEquipmentMember 2024-06-30 0000093314 vnrx:LaboratoryEquipmentMember 2023-12-31

0000093314 vnrx:LaboratoryEquipmentMember 2024-06-30 0000093314 us-gaap:ComputerEquipmentMember 2023-12-31 0000093314 us-gaap:ComputerEquipmentMember 2024-06-30 0000093314 vnrx:LiquidityAndGoingConcernAssessmentMember 2024-01-01 2024-06-30 0000093314 vnrx:LiquidityAndGoingConcernAssessmentMember 2024-06-30 0000093314 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000093314 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000093314 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000093314 us-gaap:NoncontrollingInterestMember 2024-06-30 0000093314 us-gaap:RetainedEarningsMember 2024-06-30 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000093314 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000093314 us-gaap:CommonStockMember 2024-06-30 0000093314 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000093314 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000093314 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000093314 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000093314 2024-03-31 0000093314 us-gaap:NoncontrollingInterestMember 2024-03-31 0000093314 us-gaap:RetainedEarningsMember 2024-03-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000093314 us-gaap:CommonStockMember 2024-03-31 0000093314 2024-01-01 2024-03-31 0000093314 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000093314 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000093314 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000093314 us-gaap:NoncontrollingInterestMember 2023-12-31 0000093314 us-gaap:RetainedEarningsMember 2023-12-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000093314 us-gaap:CommonStockMember 2023-12-31 0000093314 2023-06-30 0000093314 us-gaap:NoncontrollingInterestMember 2023-06-30 0000093314 us-gaap:RetainedEarningsMember 2023-06-30 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000093314 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000093314 us-gaap:CommonStockMember 2023-06-30 0000093314 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000093314 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000093314 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000093314 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000093314 2023-03-31 0000093314 us-gaap:NoncontrollingInterestMember 2023-03-31 0000093314 us-gaap:RetainedEarningsMember 2023-03-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000093314 us-gaap:CommonStockMember 2023-03-31 0000093314 2023-01-01 2023-03-31 0000093314 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000093314 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000093314 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000093314 2022-12-31 0000093314 us-gaap:NoncontrollingInterestMember 2022-12-31 0000093314 us-gaap:RetainedEarningsMember 2022-12-31 0000093314 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000093314 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000093314 us-gaap:CommonStockMember 2022-12-31 0000093314 2023-01-01 2023-06-30 0000093314 2023-04-01 2023-06-30 0000093314 2024-04-01 2024-06-30 0000093314 2023-12-31 0000093314 2024-06-30 0000093314 2024-08-13 iso4217:USD shares iso4217:USD shares pure 0000093314 false --12-31 Q2 2024 0.001 100000000 82928314 81898321 0 0 102647 55305 367808 46310 163546 510000 285860 61588 26142 92343 975933 0 0.57 0.55 10-Q true 2024-06-30 false 001-36833 VolitionRx Limited DE 91-1949078 1489 West Warm Springs Road Suite 110 Henderson NV 89014 646 650-1351 Common Stock, par value $0.001 per share VNRX NYSE Yes Yes Non-accelerated Filer true false false 92101479 5998928 20729983 166262 242617 828965 521370 350927 360125 7345082 21854095 4878417 5523013 512317 549504 332221 23886 13068037 27950498 3348322 3211287 3227595 3928761 22938400 23000000 25073 59625 1043142 1207007 47718 48570 190099 199323 54168 55855 101097 126649 30975614 31837077 3865357 3624860 363927 400022 350810 378054 409940 422707 4990034 4825643 35965648 36662720 100000000 0.001 82928314 81898321 82928 81898 195755863 194448414 282252 243940 -217929441 -202576507 -21808398 -7802255 -1089213 -909967 -22897611 -8712222 13068037 27950498 116090 50163 155866 55519 279707 166147 411466 310599 395797 216310 567332 366118 3715797 5451287 8345324 10356965 2284041 2644957 4537784 5226660 1386378 1669102 3059147 3376559 7386216 9765346 15942255 18960184 -6990419 -9549036 -15374923 -18594066 0 0 0 165795 -33498 0 -33498 0 450 27109 9104 84757 81182 58321 158415 109643 44474 28971 25552 28971 -69756 -2241 -157257 169880 -7060175 -9551277 -15532180 -18424186 74629 80298 179246 173659 -6985546 -9470979 -15352934 -18250527 23286 37712 38312 -18766 -7036889 -9513565 -15493868 -18442952 -0.08 -0.14 -0.19 -0.29 82669335 66884368 82312161 63613224 81898321 81898 194448414 243940 -202576507 -909967 -8712222 13350 13 15721 0 0 0 15734 68169 69 -69 0 0 0 0 129132 129 125129 0 0 0 125258 0 411220 0 0 0 411220 0 -3062 0 0 0 -3062 0 0 15026 0 0 15026 0 0 0 -8367388 -104617 -8472005 82108972 82109 194997353 258966 -210943895 -1014584 -16620051 734155 734 588754 0 0 0 589488 85187 85 -85 0 0 0 0 0 208046 0 0 0 208046 0 -38205 0 0 0 -38205 0 0 23286 0 0 23286 0 0 0 -6985546 -74629 -7060175 82928314 82928 195755863 282252 -217929441 -1089213 -22897611 57873379 57873 164397468 227097 -167257429 -551971 -3126962 5225703 5225 8422430 0 0 0 8427655 26978 27 -27 0 0 0 0 0 693657 0 0 0 693657 0 -14336 0 0 0 -14336 -13294 -13 -31759 0 0 0 -31772 0 0 -56478 0 0 -56478 0 0 0 -8779348 -93561 -8872909 63112766 63112 173467433 170619 -176036777 -645532 -2981145 14950000 14950 17071656 0 0 0 17086606 74598 75 -75 0 0 0 0 0 592174 0 0 0 592174 0 -65895 0 0 0 -65895 0 0 37712 0 0 37712 0 0 0 -9470979 -80298 -9551277 78137364 78137 191065293 208331 -185507756 -725830 5118175 -15532180 -18424186 532504 560313 113034 127210 -33498 0 619266 1285831 25552 28971 -307595 -166351 76357 -196487 9198 -95073 -61600 0 -384567 961764 -34552 9019 -112199 -125393 -15074388 -16092324 68161 501986 171095 0 -239256 -501986 605222 25881221 41267 80231 0 31772 754457 216908 530732 475965 23643 23188 764037 25486973 -181448 -16439 -14731055 8876224 20729983 10867050 5998928 19743274 158415 109643 282 102 0 239772 0 366960 125258 0 294603 356258 Note 1 – Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Reclassifications Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements. The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements. Fair Value Measurements Pursuant to ASC 820, “Fair Value Measurements and Disclosures,” an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"> Fair Value Measurements at June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space:

nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;"> Description </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 1 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 2 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 3 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Total </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> <strong>$ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Warrant Liability</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,649</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Gain on change in fair value of warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,552</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share,” which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, 2024, 9,297,073 potential common shares equivalents from warrants, options, and restricted stock units (“RSUs”) were excluded from the diluted EPS calculations as their effect is anti-dilutive. The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 25, 2024 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Certain reclassifications within operating expenses have been made to the prior period’s financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These

amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements. The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements. Pursuant to ASC 820, “Fair Value Measurements and Disclosures,” an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and a warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates, except for the warrant liability, which is considered Level 2 and is recorded at fair value at the end of each reporting period. Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of June 30, 2024. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"> Fair Value Measurements at June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;"> Description </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 1 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 2 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 3 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Total </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> <strong>$ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of December 31, 2023, the warrant liability was $126,649. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis for the six months ended June 30, 2024, as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Warrant Liability</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,649</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Gain on change in fair value of warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px

solid;width:9%;vertical-align:bottom;text-align:right;">(25,552</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"> Fair Value Measurements at June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;"> Description </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 1 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 2 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Level 3 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Total </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> <strong>$ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td></tr></tbody></table> 0 101097 0 101097 126649 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"> Warrant Liability </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Total </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,649</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Gain on change in fair value of warrant liability </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,552</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Balance at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 126649 -25552 101097 The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share,” which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, 2024, 9,297,073 potential common shares equivalents from warrants, options, and restricted stock units (“RSUs”) were excluded from the diluted EPS calculations as their effect is anti-dilutive. 9297073 Note 2 – Liquidity and Going Concern Assessment The Company’s condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Company’s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the “look-forward period,” as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. For the six months ended June 30, 2024, the Company incurred a net loss of $15.5 million and used

cash flows in operating activities of $15.1 million. As of June 30, 2024, the Company had cash and cash equivalents of $6.0 million and an accumulated deficit of $217.9 million. The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Company's cash conservation efforts, directors and certain employees have elected to exchange a portion of their salary for RSUs in the Company for a period of up to six months. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. Management assessed the mitigating effect of its plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company's ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Company's plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. -15500000 15100000 6000000.0 -217900000 Note 3 - Property and Equipment The Company's property and equipment consisted of the following amounts as of June 30, 2024 and December 31, 2023: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Useful Life </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Computer hardware and software </td><td style="width:1%;white-space: nowrap;"> </td><td> 3 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">723,206</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">724,534</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Laboratory equipment </td><td style="width:1%;white-space: nowrap;"> </td><td> 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,630,385</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,753,253</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Office furniture and equipment </td><td style="width:1%;white-space: nowrap;"> </td><td> 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,493</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Buildings </td><td style="width:1%;white-space: nowrap;"> </td><td> 30 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,049,211</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,113,031</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Building improvements </td><td style="width:1%;white-space: nowrap;"> </td><td> 5-15 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,574,428</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,610,016</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Land </td><td style="width:1%;white-space: nowrap;"> </td><td> Not amortized </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,467</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,468</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total property and equipment </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,476,190</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,712,102</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less accumulated depreciation </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,597,773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,189,089</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total property and equipment net </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new

roman;margin:0px"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,878,417</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,523,013</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $545,128 and $517,921, respectively, in depreciation expense. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"></td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Useful Life </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Computer hardware and software </td><td style="width:1%;white-space: nowrap;"> </td><td> 3 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">723,206</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">724,534</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Laboratory equipment </td><td style="width:1%;white-space: nowrap;"> </td><td> 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,630,385</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,753,253</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Office furniture and equipment </td><td style="width:1%;white-space: nowrap;"> </td><td> 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,493</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Buildings </td><td style="width:1%;white-space: nowrap;"> </td><td> 30 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,049,211</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,113,031</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Building improvements </td><td style="width:1%;white-space: nowrap;"> </td><td> 5-15 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,574,428</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,610,016</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Land </td><td style="width:1%;white-space: nowrap;"> </td><td> Not amortized </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,467</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,468</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total property and equipment </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,476,190</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,712,102</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less accumulated depreciation </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,597,773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,189,089</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total property and equipment net </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,878,417</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,523,013</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> P3Y 723206 724534 P5Y 4630385 4753253 P5Y 370493 378800 P30Y 2049211 2113031 P5Y P15Y 1574428 1610016 128467 132468 9476190 9712102 4597773 4189089 4878417 5523013 545128 517921 Note 4 - Intangible Assets The Company's intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets' estimated useful lives, which range from 8 to 20 years. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td> </td><td> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Useful Life </td><td> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td> </td><td> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> Computer hardware and software </td><td> </td><td> 3 years </td><td> </td><td> </td><td class="ffcell"> 723,206 </td><td> </td><td> </td><td> </td><td class="ffcell"> 724,534 </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> Laboratory equipment </td><td> </td><td> 5 years </td><td> </td><td> </td><td class="ffcell"> 4,630,385 </td><td> </td><td> </td><td> </td><td class="ffcell"> 4,753,253 </td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> Office furniture and equipment </td><td> </td><td> 5 years </td><td> </td><td> </td><td class="ffcell"> 370,493 </td><td> </td><td> </td><td> </td><td class="ffcell"> 378,800 </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> Buildings </td><td> </td><td> 30 years </td><td> </td><td> </td><td class="ffcell"> 2,049,211 </td><td> </td><td> </td><td> </td><td class="ffcell"> 2,113,031 </td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> Building improvements </td><td> </td><td> 5-15 years </td><td> </td><td> </td><td class="ffcell"> 1,574,428 </td><td> </td><td> </td><td> </td><td class="ffcell"> 1,610,016 </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> Land </td><td> </td><td> Not amortized </td><td> </td><td> </td><td class="ffcell"> 128,467 </td><td> </td><td> </td><td> </td><td class="ffcell"> 132,468 </td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> Total property and equipment </td><td> </td><td class="ffcell"> </td><td> </td><td> </td><td class="ffcell"> 9,476,190 </td><td> </td><td> </td><td> </td><td class="ffcell"> 9,712,102 </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> Less accumulated depreciation </td><td> </td><td class="ffcell"> </td><td> </td><td> </td><td class="ffcell"> 4,597,773 </td><td> </td><td> </td><td> </td><td class="ffcell"> 4,189,089 </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> Total property and equipment net </td><td> </td><td class="ffcell"> </td><td> </td><td> </td><td class="ffcell"> 4,878,417 </td><td> </td><td> </td><td> </td><td class="ffcell"> 5,523,013 </td><td> </td></tr></tbody></table>

</td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Patents </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,098,717</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130,936</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Licenses </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">296,353</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Patents and Licenses </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,395,070</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130,936</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less accumulated amortization </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,062,849</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,107,050</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total patents and Licenses, net </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">332,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,886</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the six-month periods ended June 30, 2024 and June 30, 2023, the Company recognized $(12,624) and $42,392, respectively, in amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company amortizes the patents and licenses on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,057</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Greater than 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">234,372</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Intangible Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">332,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 "Property, Plant and Equipment," as of December 31, 2023. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2023. P8Y P20Y <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Cost $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Patents </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,098,717</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130,936</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Licenses </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">296,353</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Patents and Licenses </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,395,070</td><td style="width:1%;white-space: nowrap;"> </td><td

style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130,936</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less accumulated amortization </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,062,049</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,107,050</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total patents and Licenses, net </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">332,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,886</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1098717 1130936 296353 0 1395070 1130936 1062849 1107050 332221 23886 -12624 42392 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,057</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">234,372</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Intangible Assets </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">332,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 16057 20448 20448 20448 20448 234372 332221 Note 5 - Related-Party Transactions See Note 6, Common Stock, for common stock issued to related parties and Note 7, Stock-Based Compensation, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of consultancy services which are accrued under management and directors' fees payable (see condensed consolidated balance sheets). Note 6 - Common Stock As of June 30, 2024, the Company was authorized to issue 100 million shares of common stock, par value $0.001 per share, of which 82,928,314 and 81,898,321 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. Stock Option Exercises During the six months ended June 30, 2024, no shares of common stock were issued pursuant to the exercise of stock options. Stock Options Expired / Cancelled On April 16, 2024, 36,821 vested stock options previously granted to an employee were cancelled and returned as authorized shares under the 2015 Plan on the expiration of the exercise period following the resignation of such employee. RSU Settlements Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Vested (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vest Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Issued (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Withheld for Taxes (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:18%;"> Feb 8, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,057</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,943</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">44,217</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">40,530</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,687</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">51,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"><p style="font-

size:10pt;font-family:times new roman;margin:0px"> </td><td> Apr 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">32,337</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">18,663</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">34,496</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,504</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,500</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,830</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">14,962</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,684</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,278</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">202,261</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">153,356</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48,905</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> Warrants Issued in Equity Capital Raise In connection with the June 2023 underwritten public offering of the Company's common stock pursuant to the underwriting agreement with Prime Executions, Inc. dba Freedom Capital Markets ("Freedom") dated June 1, 2023, the Company issued Freedom warrants to purchase an aggregate of 448,500 shares of Company common stock at an exercise price of $2.00 per share. The Company evaluated the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815-40. The Company determined the warrants issued to Freedom failed the indexation guidance under ASC 815-40, specifically, the warrants provide for a Black-Scholes value calculation in the event of certain transactions ("Fundamental Transactions"), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company's own equity shares. Accordingly, pursuant to ASC 815-40, the Company has classified the fair value of the warrants as a liability upon issuance and marked to market each reporting period in the Company's consolidated statement of operations until their exercise or expiration. Warrants Issued in Equity Capital Raise (continued) The fair value of the warrants as of June 30, 2024, and December 31, 2023, were $101,097 and $126,649 respectively. The warrant liability was estimated using the Black-Scholes pricing model with the following assumptions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">June 30, 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76.30</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected life (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,649</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The fair value of the warrants deemed to be a liability, due to certain contingent put features, was determined using the Black-Scholes option pricing model, which was deemed to be an appropriate model due to

the terms of the warrants issued, including a fixed term and exercise price. Common Stock Issued for EpiCypher License Agreement On March 12, 2024, the Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. at a price of $0.97 per share as partial consideration for license rights in connection with a License Agreement between EpiCypher and Belgian Volition. Equity Distribution Agreement On May 20, 2022, the Company entered into an equity distribution agreement (the "2022 EDA") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock, with an aggregate offering price of up to $25.0 million, from time to time through an "at the market" offering pursuant to the Company's Registration Statement on Form S-3 (File No. 333-259783) effective November 8, 2021) (the "2021 Form S-3") through Jefferies acting as the Company's agent and/or principal. The Company is not obligated to sell any shares under the 2022 EDA. During the six months ended June 30, 2024, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $605,221 under the 2022 EDA through the sale of 747,505 shares of its common stock. As of June 30, 2024, the Company has raised aggregate net proceeds (net of broker commissions and fees) of approximately $2.1 million under the 2022 EDA through the sale of 1,378,037 shares of its common stock. 100000000 0.001 82928314 81898321 36821 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Vested (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vest Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Issued (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Withheld for Taxes (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:18%;"> Feb 8, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,057</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,943</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">44,217</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">40,530</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,687</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">51,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Apr 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">32,337</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">18,663</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">34,496</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,504</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,500</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,830</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">14,962</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,684</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,278</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">202,261</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">153,356</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48,905</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 2015 21582

2024-02-08 21582 0 2015 9000 2024-03-01 6057 2943 2015 44217 2024-03-27 40530 3687 2015 51000 2024-04-04 32337 18663 2015 50000 2024-05-01 34496 15504 2015 11500 2024-06-01 6670 4830 2015 14962 2024-06-15 11684 3278 202261 153356 48905 448500 2.00 101097 126649 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Risk-free interest rate </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Expected volatility </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76.30</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Expected life (years) </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.94</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.44</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Expected dividend yield </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total fair value </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,097</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,649</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0.0443 0.0389 0.8280 0.7630 P3Y11M8D P4Y5M8D 0 0 101097 126649 129132 0.97 25000000.0 605221 747505 2100000 1378037 Note 7 – Stock-Based Compensation a) Warrants The following table summarizes the changes in warrants of the Company outstanding during the six-month period ended June 30, 2024. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Number of Warrants </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Weighted Average Exercise Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Granted </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Expired/Cancelled </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Outstanding at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Exercisable at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Below is a table summarizing the warrants issued and outstanding as of June 30, 2024, which have an aggregate weighted average remaining contractual life of 3.33 years. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Number Outstanding </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number Exercisable </td><td

style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Exercise Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Weighted Average Remaining </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Proceeds to Company </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>if Exercised ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:17%;"> 448,500 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">448,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">3.96</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">897,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 54,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">54,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.26</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">164,700</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 50,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.45</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">172,500</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 125,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">125,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.95</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,51</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">493,750</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 185,000 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">185,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">4.90</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">2.59</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">906,500</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 862,500 </td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,634,450</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> Stock-based compensation expense related to warrants of $5,238 and $20,320 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of June 30, 2024, the total intrinsic value of warrants outstanding was $nil.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) Options</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the changes in options outstanding of the Company during the six-month period ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Number of Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average Exercise Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,699,569</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Expired/Cancelled </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,821</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p

style="font-size:10pt;font-family:times new roman;margin:0px"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,40</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Exercisable at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> b) Options (continued) Below is a table summarizing the options issued and outstanding as of June 30, 2024, all of which were issued pursuant to the Company's 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (the "2015 Plan") (for option and RSU issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 3.71 years. As of June 30, 2024, an aggregate of 9,700,000 shares of common stock were authorized for issuance under the 2015 Plan, of which 354,782 shares of common stock remained available for future issuance thereunder. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Number Outstanding </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number Exercisable </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Exercise Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Proceeds to Company if </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:17%;"> 585,000 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">585,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">3.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">0.62</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">1,901,250</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 944,748 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">944,748</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.40</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">7.10</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,212,143</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 740,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">740,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.60</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.86</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,664,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 1,607,837 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,607,837</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.00</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,431,348</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 89,163 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">89,163</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.38</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.57</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">390,534</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 50,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-

family:times new roman;margin:0px"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.80</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.51</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">240,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 646,000 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">646,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">5.00</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.74</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,230,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 4,662,748 </td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">18,069,275</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> Stock-based compensation expense related to stock options of $nil and $235,368 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of June 30, 2024, the total intrinsic value of stock options outstanding was $nil.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">c) Restricted Stock Units</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">RSUs (#)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average Grant Date Fair Value Share Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,634,952</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.01</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Granted </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">426,340</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.72</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Vested/Settled </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(202,261</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.46</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Cancelled / Forfeited </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(87,206</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,771,825</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.89</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> c) Restricted Stock Units (continued) Below is a table summarizing the RSUs granted during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipient's continued service to the Company, and will result in the RSU compensation expense stated. On June 1, 2024, the Company granted 297,340 RSUs of common stock to certain directors and employees in exchange for their election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on May 1, 2025, subject to continued service by the recipient. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Granted (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Grant Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vesting Period </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> First Vesting Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Second Vesting Date </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Third Vesting Date </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSU Expense ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-

align:right;">2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">14,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Feb 22, 2024 </td><td style="white-space: nowrap;"> </td><td> 36 Months </td><td style="white-space: nowrap;"> </td><td> Feb 22, 2025 </td><td style="white-space: nowrap;"> </td><td colspan="2"> Feb 22, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td colspan="2"> Feb 22, 2027 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">13,589</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">115,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 23, 2024 </td><td style="white-space: nowrap;"> </td><td> 36 Months </td><td style="white-space: nowrap;"> </td><td> May 23, 2025 </td><td style="white-space: nowrap;"> </td><td colspan="2"> May 23, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td colspan="2"> May 23, 2027 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">85,389</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">297,340</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> Jun 1, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> 11 Months </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> May 1, 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">209,832</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">426,340</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">308,810</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> Below is a table summarizing the RSUs vested and settled during the six months ended June 30, 2024, all of which were issued pursuant to the 2015 Plan. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Vested (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vest Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Issued (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Withheld for Taxes (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Feb 8, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,057</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,943</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">44,217</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">40,530</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,687</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space:

nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">51,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Apr 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">32,337</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">18,663</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> May 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">34,496</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,504</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,500</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,830</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">14,962</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,684</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,278</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">202,261</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">153,356</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48,905</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> c) Restricted Stock Units (continued) Below is a table summarizing the RSUs cancelled during the six months ended June 30, 2024, all of which were originally issued pursuant to the 2015 Plan. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Cancellation Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vesting Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Cancelled (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Jan 16, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Sep 28, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-

space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">666</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">666</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,775</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 25, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,775</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,098</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 25, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,098</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,667</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,666</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,666</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,334</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,334</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,334</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;">

style="font-size:10pt;font-family:times new roman;margin:0px"> </td><td> Sep 11, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,334</td><td style="white-space: nowrap;"> </td><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,333</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 11, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">9,333</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 11, 2026 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">9,333</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">87,206</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">87,206</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> c) Restricted Stock Units (continued) Below is a table summarizing the RSUs issued and outstanding as of June 30, 2024 and which have an aggregate weighted average remaining contractual life of 1.37 years. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> RSUs Outstanding (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Weighted Average Grant Date Fair Value Share Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Weighted Average Remaining Contractual Life (Years) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:20%;"> 40,000 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;">0.58</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 450,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.68</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 450,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.69</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.76</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 1,535,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.70</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.25</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 297,340 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.71</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.84</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 115,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.74</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.90</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 14,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.97</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 6,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.31</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.20</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 14,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.32</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.04</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 702,654 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.46</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.76</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td><p

style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">17,332 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.58</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.73</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 12,500 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.23</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 54,333 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.72</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.17</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 29,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.01</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.13</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 666 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.15</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.92</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 34,000 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:right;">2.95</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:right;">0.19</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;"> 3,771,825 </td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> Stock-based compensation expense related to RSUs of $614,028 and $1,030,143 was recorded in the six months ended June 30, 2024 and June 30, 2023, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,256,598.</p> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Number of Warrants</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average Exercise Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Granted </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired/Cancelled </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Outstanding at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Exercisable at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 862500 3.05 0 0 862500 3.05 862500 3.05 P3Y3M29D <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Number Outstanding </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number Exercisable </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Exercise Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-

align:center;"> Weighted Average Remaining Contractual Life (Years) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Proceeds to Company if Exercised ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:17%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">448,500</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">448,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">3.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">897,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">54,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">54,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.05</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.26</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">164,700</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman, MARGIN: 0px; text-align:right;">50,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.45</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">172,500</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">125,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">125,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.95</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.51</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">493,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">185,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">4.90</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">2.59</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">906,500</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">862,500</p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">862,500</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,634,450</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 448500 448500 2.00 P3Y11M15D 897000 54000 54000 3.05 P4Y3M3D 164700 50000 50000 3.45 P1Y8M1D 172500 125000 125000 3.95 P2Y6M3D 493750 185000 185000 4.90 P2Y7M2D 906500 862500 862500 2634450 5238 20320 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Number of Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average Exercise Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,699,569</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Expired/Cancelled </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,821)</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.40</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Outstanding at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td

style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Exercisable at June 30, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>
4699569 3.87 36821 3.40 4662748 3.88 4662748 3.88 P3Y8M15D 9700000 354782 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Number Outstanding </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number Exercisable </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Exercise Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Proceeds to Company if </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:17%;"> 585,000 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">585,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">3.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">0.62</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">1,901,250</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 944,748 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">944,748</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.40</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">7.10</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,212,143</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 740,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">740,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.60</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.86</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,664,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 1,607,837 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,607,837</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.00</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,431,348</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 89,163 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">89,163</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.38</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.57</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">390,534</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 50,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.80</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.51</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">240,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 646,000 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">646,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">5.00</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td

style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.74</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,230,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 4,662,748 </td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">4,662,748</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">18,069,275</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 585000 585000 3.25 P0Y7M13D 1901250 944748 944748 3.40 P7Y1M6D 3212143 740000 740000 3.60 P5Y10M9D 2664000 1607837 1607837 4.00 P2Y2M26D 6431348 89163 89163 4.38 P3Y6M25D 390534 50000 50000 4.80 P2Y6M3D 240000 646000 646000 5.00 P2Y8M26D 3230000 4662748 4662748 18069275 235368 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> RSUs (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Weighted Average Grant Date Fair Value Share Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,634,952</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">426,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Vested/Settled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(202,261</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cancelled / Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(87,206</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,771,825</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.89</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3634952 1.01 426340 0.72 -202261 2.46 -87206 1.13 3771825 0.89 297340 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Equity Incentive Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">RSUs Granted (#)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Grant Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Vesting Period</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">First Vesting Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Second Vesting Date</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Third Vesting Date</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU Expense ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">14,000</td><td style="white-space: nowrap;"> </td><td> Feb 22, 2024 </td><td style="white-space: nowrap;"> </td><td> 36 Months </td><td style="white-space: nowrap;"> </td><td> Feb 22, 2025 </td><td style="white-space: nowrap;"> </td><td colspan="2"> Feb 22, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td colspan="2"> Feb 22, 2027 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">13,589</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">115,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 23, 2024 </td><td style="white-space: nowrap;"> </td><td> 36 Months </td><td style="white-space: nowrap;"> </td><td> May 23, 2025 </td><td style="white-space: nowrap;"> </td><td colspan="2"> May 23, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td colspan="2"> May 23, 2027 </td><td style="white-space: nowrap;"> </td><td

style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">85,389</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">297,340</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> Jun 1, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> 11 Months </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:9%;"> May 1, 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">209,832</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">426,340</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">308,810</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 2015 14000 2024-02-22 36 Months 2025-02-22 2026-02-22 2027-02-22 13589 2015 115000 2024-05-23 36 Months 2025-05-23 2026-05-23 2027-05-23 85389 2015 297340 2024-06-01 11 Months 2025-05-01 209832 426340 308810 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Vested (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vest Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Issued (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Shares Withheld for Taxes (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Feb 8, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">21,582</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,057</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,943</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">44,217</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">40,530</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,687</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">51,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Apr 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">32,337</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">18,663</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">34,496</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,504</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,500</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 1, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,830</td><td style="white-space: nowrap;">

 </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">14,962</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,684</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,278</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">202,261</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">153,356</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">48,905</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 2015 21582 2024-02-08 21582 0 2015 9000 2024-03-01 6057 2943 2015 44217 2024-03-27 40530 3687 2015 51000 2024-04-04 32337 18663 2015 50000 2024-05-01 34496 15504 2015 11500 2024-06-01 6670 4830 2015 14962 2024-06-15 11684 3278 202261 153356 48905 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Equity Incentive Plan </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Cancellation Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Vesting Date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> RSUs Cancelled (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"> 2015 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Jan 16, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;"> Sep 28, 2024 </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2025 </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Jan 16, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">8,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">666</td><td style="white-space: nowrap;"> </td><td> Feb 9, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2026 </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">666</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new

roman;margin:0px"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,775</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> Mar 25, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,775</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,098</td><td style="white-space: nowrap;"> </td><td> Mar 25, 2024 </td><td style="white-space: nowrap;"> </td><td> Jun 15, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,098</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,667</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,667</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,666</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Oct 4, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,666</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Mar 27, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,334</td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2024 </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,334</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2025 </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td><td> May 17, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 28, 2026 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,334</td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 11, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,334</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,333</td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 11, 2025 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,333</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2015 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">9,333</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td> May 31, 2024 </td><td style="white-space: nowrap;"> </td><td> Sep 11, 2026 </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">9,333</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">87,206</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-

BOTTOM: 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">87,206</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> 2015 8000 2024-01-16 2024-09-28 8000 2015 6000 2024-01-16 2024-10-04 6000 2015 8000 2024-01-16 2025-09-28 8000 2015 6000 2024-01-16 2025-10-04 6000 2015 8000 2024-01-16 2026-09-28 8000 2015 667 2024-02-09 2024-06-15 667 2015 667 2024-02-09 2025-06-15 667 2015 666 2024-02-09 2026-06-15 666 2015 1775 2024-03-25 2024-03-27 1775 2015 2098 2024-03-25 2024-06-15 2098 2015 2667 2024-05-17 2024-10-04 2667 2015 2666 2024-05-17 2025-10-04 2666 2015 1000 2024-05-17 2025-03-27 1000 2015 1000 2024-05-17 2026-03-27 1000 2015 3334 2024-05-17 2024-09-28 3334 2015 3333 2024-05-17 2025-09-28 3333 2015 3333 2024-05-17 2026-09-28 3333 2015 9334 2024-05-31 2024-09-11 9334 2015 9333 2024-05-31 2025-09-11 9333 2015 9333 2024-05-31 2026-09-11 9333 87206 87206 P1Y4M13D <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> RSUs Outstanding (#) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Weighted Average Grant Date Fair Value Share Price ($) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Weighted Average Remaining Contractual Life (Years) </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:20%;"> 40,000 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;">0.58</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 450,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.68</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 450,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.69</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.76</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 1,535,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.70</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.25</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 297,340 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.71</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.84</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 115,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.74</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.90</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 14,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.97</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 6,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.31</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.20</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 14,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.32</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.04</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 702,654 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.46</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.76</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 17,332 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.58</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.73</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 12,500 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.23</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 54,333 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.72</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.17</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 29,000 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.01</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.13</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> 666 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-

family:times new roman;margin:0px"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.15</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.92</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 34,000 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:right;">2.95</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:right;">0.19</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;"> 3,771,825 </td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> 40000 0.58 P1Y4M13D 450000 0.68 P2Y9M18D 450000 0.69 P1Y9M3D 1535000 0.70 P1Y3M 297340 0.71 P0Y10M2D 115000 0.74 P1Y10M24D 14000 0.97 P1Y7M24D 6000 1.31 P1Y2M12D 14000 1.32 P1Y14D 702654 1.46 P0Y9M3D 17332 1.58 P0Y8M23D 12500 1.69 P0Y2M23D 54333 1.72 P1Y2M1D 29000 2.01 P0Y1M17D 666 2.15 P0Y11M1D 34000 2.95 P0Y2M8D 3771825 614028 1030143 1256598 Note 8 – Commitments and Contingencies a)Finance Lease Obligations The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2024. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,840</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,672</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,661</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,647</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">194,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">453,848</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,203</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Present value of minimum lease payments </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">411,645</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> b) Operating Lease Right-of-Use Obligations Operating leases as of June 30, 2024, and December 31, 2023, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Operating lease right-of-use assets </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">512,317</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">549,504</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Operating lease liabilities, current portion </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">190,099</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">199,323</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Operating lease liabilities, long term </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">350,810</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">378,054</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total operating lease liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-

BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">540,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">577,377</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Weighted average remaining lease (months) </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Weighted average discount rate </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.02</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> During the six months ended June 30, 2024, cash paid for amounts included for the measurement of lease liabilities was $125,313 and the Company recorded operating lease expense of $126,217.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">b) Operating Lease Right-of-Use Obligations (continued) </p><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, 2024.</p><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman, MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 – Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,231</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,273</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,435</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,151</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,212</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">575,302</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Less: imputed interest </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(34,393</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total Operating Lease Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">540,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company's office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2024, the Company recognized $40,334 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,723</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Operating Lease Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">49,921</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> c) Grants Repayable As of June 30, 2024, the total grant balance repayable was $464,108 and the payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman, MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 – Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,231</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,273</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,435</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,151</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,212</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">575,302</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Less: imputed interest </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(34,393</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total Operating Lease Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">540,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company's office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2024, the Company recognized $40,334 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt, FONT-FAMILY: times new roman, MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td>

roman;margin:0px"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,169</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,305</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,756</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,579</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,951</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Greater than 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,348</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Grants Repayable </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">464,108</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> d) Long-Term Debt As of June 30, 2024, the total balance for long-term debt payable was $4,908,499 and the payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">859,476</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,005,297</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">781,901</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,641</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,437,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Greater than 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">314,022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,981,549</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less: amount representing interest </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,073,050</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Long-Term Debt </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,908,499</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> e) Collaborative Agreement Obligations In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, 2024, $510,000 is still to be paid by the Company under this agreement. In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $449,406. As of June 30, 2024, $449,406 is still to be paid by the Company under this agreement. As of June 30, 2024, $204,087 is due by the Company under this agreement. In July 2023, the Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd to evaluate the anti-tumoral effects of Nu.Q® CAR T cells for a cost to the Company of $107,589. As of June 30, 2024, $81,447 is still to be paid by the Company under this agreement and as of June 30, 2024, $26,142 is due by the Company under this agreement. In August 2023, the Company entered into a project research agreement with Guy's and St Thomas' NHS Foundation Trust to evaluate the practical clinical utility of the Nu.Q®H3.1 nucleosome levels in adult patients with sepsis to facilitate early diagnosis and prognostication for a cost to the Company of $164,235. As of June 30, 2024, $164,235 is still to be paid by the Company under this agreement. As of June 30, 2024, $nil is due by the Company under this agreement. In January 2024, the Company entered into an agreement with the University Medical Centre Amsterdam ("UMC"). UMC will perform a retrospective study to evaluate the diagnostic potential of the Nu.Q® H3.1 nucleosomes as diagnostic, prognostic and phenotyping biomarkers in sepsis for a cost to the Company of $138,653. As of June 30, 2024, $138,653 is still to be paid by the Company under this agreement. As of June 30, 2024, $46,218 is due by the Company under this agreement. e) Collaborative Agreement Obligations (continued) As of June 30, 2024, the total amount to be paid for future research and collaboration commitments was $1,343,741 and the payments remaining were as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total Amount Remaining</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024 - </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Estimated</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2025 - </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Estimated</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-

align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> National University of Taiwan </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">510,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">510,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> MD Anderson Cancer Center </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">449,406</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">285,860</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">163,546</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Guys and St Thomas </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">164,235</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">61,588</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">102,647</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Xenetic Biosciences </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">81,447</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">26,142</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">55,305</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> UMC </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,653</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">92,343</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">46,310</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total Collaborative Obligations </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,343,741</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">975,933</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">367,808</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td></tr></tbody></table> f) Other Commitments Volition Germany As of June 30, 2024, $209 is payable under the royalty agreement with the founder of Volition's former German subsidiary based on sales to date towards the Company's aggregate minimum royalty obligation of $117,761. Volition America Effective February 10, 2024 the Company and Diagnostic Oncology CRO, LLC ("DXOCRO") further amended and restated the August 2022 amended and restated Master Agreement by and between the Company and DXOCRO to expand the scope of DXOCRO's consultant services provided thereunder (the "Second A&R Master Agreement"). The Second A&R Master Agreement requires DXOCRO to conduct a prospective optimization/range finding study of Volition's Nu.Q® H3.1 in vitro diagnostic test proposed for use in sepsis. The study is an extension of the sepsis monitoring clinical trial that was previously covered under a separate exhibit. The Company anticipates DXOCRO's additional services under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million. The Company's payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days' prior written notice. Unless earlier terminated, the Second A&R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of June 30, 2024, $146,221 is payable under the Second A&R Master Agreement, and up to $363,778 may be payable by the Company in future periods for services rendered. VolitionRx On February 5, 2024, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024. As of June 30, 2024, the maximum has been drawn down under this agreement and the principal balance payable was $163,668. The agreement is in relation to the directors and officers insurance policy. g) Legal Proceedings In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company knows of no legal proceedings which the Company believes will have a material adverse effect on its financial position. h) Commitments in Respect of Corporate Goals and Performance-Based Awards As of June 30, 2024, the Company has recognized total compensation expense of $1,291,594 of which $527,940 is in relation to RSUs from grants in 2022 that vested in 2023, $451,490 is in relation to RSUs from such grants that will vest in 2024, and $312,164 is in relation to RSUs from such grants that will vest in 2025. The Company has unrecognized compensation expense of $282,823 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Vesting</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Un-Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Award</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"> Year</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td><p style="font-

size:10pt;font-family:times new roman;margin:0px"> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> <strong>$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;"> 527,940 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;"> 2023 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">393,853</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">134,087</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:15%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 517,613 </td><td> </td><td> </td><td> 2024 </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">126,283</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">260,119</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">65,088</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">66,123</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 528,864 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td> 2025 </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">87,894</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">177,584</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">46,686</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">216,700</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 1,574,417 </td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">214,177</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">831,556</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">245,861</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">282,823</td><td style="PADDING-BOTTOM: 3px;"> </td></tr></tbody></table> In September 2023, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around revenue, operations and regulatory, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Pursuant to the terms of the grants, conditional upon the achievement by December 31, 2023 and June 30, 2024 of specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients to the Company, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of June 30, 2024, the Company has accrued compensation expense of $536,535 in relation to cash bonuses payable on the achievement of specified corporate goals based on the expected outcomes related to the prescribed performance targets. To the extent this is payable, this cash bonus compensation payment has currently been deferred indefinitely. As of June 30, 2024, the Company had recognized total compensation expense of $335,013. The Company has unrecognized compensation expense of $390,276 in relation to the RSUs from grants in 2023, of which $59,290 is in relation to RSUs that will vest in 2024, $150,277 in relation to RSUs that will vest in 2025, and $180,709 in relation to RSUs that will vest in 2026 based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Vesting</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Un-Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Award</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Year</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;"> 241,771 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:18%;"> 2024 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:18%;vertical-align:bottom;text-align:right;">118,511</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"><p style="font-

size:10pt;font-family:times new roman;margin:0px"> </td><td style="width:18%;vertical-align:bottom;text-align:right;">63,970</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:17%;vertical-align:bottom;text-align:right;">59,290</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 241,764 </td><td> </td><td> </td><td> 2025 </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">59,416</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">32,071</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">150,277</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 241,754 </td><td> </td><td> </td><td> 2026 </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">39,645</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">21,400</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">180,709</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 725,289 </td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">217,572</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">117,441</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">390,276</td><td style="PADDING-BOTTOM: 3px;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,840</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,672</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,661</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,647</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">194,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">453,848</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,203</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Present value of minimum lease payments </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">411,645</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 28840 57672 57661 57647 57633 194395 453848 42203 411645 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> June 30, 2024 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> December 31, 2023 </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Operating lease right-of-use assets </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">512,317</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">549,504</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Operating lease liabilities, current portion </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">190,099</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">199,323</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Operating lease liabilities, long term </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">350,810</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px

solid;width:9%;vertical-align:bottom;text-align:right;">378,054</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total operating lease liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">540,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">577,377</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Weighted average remaining lease (months) </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Weighted average discount rate </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.02</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 512317 549504 190099 199323 350810 378054 540909 577377 P32M P33M 0.0324 0.0302 125313 126217 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> For the Six Months Ending June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Amount </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> $</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - Remaining</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,273</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,435</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,151</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,212</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">575,302</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(34,393</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Operating Lease Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">540,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 117231 191273 164435 92151 10212 575302 34393 540909 40334 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For the Six Months Ending June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,723</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Operating Lease Liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">49,921</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 42723 7198 49921 464108 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> For the Six Months Ending June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Amount </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,169</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,305</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,756</td><td style="width:1%;white-space: nowrap;"> </td></tr>

<tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,579</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,951</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Greater than 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,348</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Grants Repayable </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">464,108</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 54169 36305 43756 48579 51951 229348 464108 4908499 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> For the Six Months Ending June 30, 2024 </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Amount </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024 - Remaining </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">859,476</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,005,297</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">781,901</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,641</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,437,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Greater than 5 years </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">314,022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,981,549</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less: amount representing interest </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,073,050</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total Long-Term Debt </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,908,499</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 859476 1005297 781901 583641 2437212 314022 5981549 1073050 4908499 three-year 25500 510000 449406 449406 204087 107589 81447 26142 164235 164235 138653 138653 46218 1343741 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> Total Amount Remaining </td><td> </td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> 2024 - Estimated </td><td> </td><td> </td><td colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> 2025 - Estimated </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> <strong>$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> National University of Taiwan </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">510,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">510,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> MD Anderson Cancer Center </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">449,406</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">285,860</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">163,546</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Guys and St Thomas </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">164,235</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">61,588</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">102,647</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Xenetic Biosciences </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">81,447</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">26,142</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;">

</td><td style="width:9%;vertical-align:bottom;text-align:right;">55,305</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> UMC </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,653</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">92,343</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">46,310</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Total Collaborative Obligations </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,343,741</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">975,933</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">367,808</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td></tr></tbody></table> 510000 449406 164235 81447 138653 1343741 209 117761 under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million 146221 363778 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024 163668 1291594 527940 451490 312164 282823 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Vesting</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Un-Amortized</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Award</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"> Year</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $</p></td><td style="PADDING-BOTTOM: 1px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;"> 527,940 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;"> 2023 </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">393,853</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:14%;vertical-align:bottom;text-align:right;">134,087</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:15%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 517,613 </td><td> </td><td> </td><td> 2024 </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">126,283</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">260,119</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">65,088</td><td> </td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">66,123</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 528,864 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td> 2025 </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">87,894</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">177,584</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">46,686</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">216,700</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 1,574,417 </td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">214,177</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">831,556</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">245,861</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">282,823</td><td style="PADDING-BOTTOM: 3px;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new

roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:center;"> Vesting </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> Amortized </td><td> </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> Amortized </td><td> </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> Un-Amortized </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;"> Award </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:center;"> Year </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> 2024 </td><td> </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> 2023 </td><td> </td><td> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> 2024 </td><td> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"> $</p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> $ </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;"> 241,771 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:18%;"> 2024 </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:18%;text-align:bottom;text-align:right;">118,511</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:18%;vertical-align:bottom;text-align:right;">63,970</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:17%;vertical-align:bottom;text-align:right;">59,290</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> 241,764 </td><td> </td><td> </td><td> 2025 </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">59,416</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">32,071</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;text-align:right;">150,277</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: #000000 1px solid;"> 241,754 </td><td> </td><td> </td><td> 2026 </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">39,645</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">21,400</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">180,709</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: black 3px double;"> 725,289 </td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">217,572</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">117,441</td><td style="PADDING-BOTTOM: 3px;"> </td><td> </td><td style="BORDER-BOTTOM: 3px double;"> </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">390,276</td><td style="PADDING-BOTTOM: 3px;"> </td></tr></tbody></table> 527940 2023 0 393853 134087 0 517613 2024 126283 260119 65088 66123 528864 2025 87894 177584 46686 216700 1574417 214177 831556 245861 282823 536535 335013 390276 59290 150277 180709 241771 2024 118511 63970 59290 241764 2025 59416 32071 150277 241754 2026 39645 21400 180709 725289 217572 117441 390276 Note 9 – Subsequent Events Settlement of RSUs On July 13, 2024, 4,667 RSUs previously granted to various employees vested and resulted in the issuance of 3,165 shares of common stock. 1,502 shares of common stock were withheld for taxes and returned to the 2015 Plan. RSUs Granted Effective July 1, 2024, the Company granted RSUs of 38,198 shares of common stock to an employee of the Company in exchange their valid election to reduce their cash compensation for a period of three months for services provided to the Company. These RSUs will vest on June 1, 2025, subject to continued service by the employee. Effective July 8, 2024, the Company granted RSUs of 21,583 shares of common stock to an advisor of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. These RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025, subject to continued service, and will result in total compensation expense of $13,209. RSUs Cancelled On July 12, 2024, 19,666 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting. On August 4, 2024, 46,333 RSUs previously granted to an employee were cancelled and returned as authorized and unissued shares under the 2015 Plan upon termination of employment prior to vesting. Increase in Authorised Capital At the Annual Meeting on July 2, 2024, the Company's stockholders approved a Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation providing for an increase in authorized shares from one hundred million (100,000,000) to one hundred seventy-five million (175,000,000) shares, consisting of one hundred seventy-five million (175,000,000) shares of common stock, par value $0.001 per share. Equity Capital Raise On August 8, 2024, the Company entered into a securities purchase agreement with a purchaser pursuant to which the Company issued and sold to such purchaser, in a registered direct offering under the 2021 Form S-3, an aggregate of 9,170,000 shares of the Company's common stock, pre-funded warrants to purchase up to 3,557,273 shares of the Company's common stock (the "Pre-Funded Warrants"), Series A common stock warrants to purchase up to 12,727,273 shares of the Company's common stock (the "Series A Warrants") and Series B common stock warrants to purchase up to 12,727,273 shares of the Company's common stock (the "Series B Warrants" and, together with the Series A Warrants, the "Common Warrants"). The exercise prices of the Pre-Funded Warrants and the Common Warrants are $0.001 per share and $0.57 per share, respectively. H.C. Wainwright & Co. acted as the exclusive placement agent for the Company in the offering. The combined offering price for a share of common stock and accompanying Common Warrants was $0.55 and the combined offering price for a Pre-Funded Warrant and accompanying Common Warrants was $0.549. The net proceeds received by the Company for the issuance and sale of the shares of Common Stock, the Pre-Funded Warrants and the Common Warrants (collectively, the "Securities") was $6.4 million, before deducting offering expenses of $0.1 million paid by the Company. In addition, the Company issued warrants to purchase an aggregate of 381,818 shares of Company common stock to the placement agent, on substantially the same terms as the Series B Warrants at an exercise price of $0.6875 per share. The net proceeds above assumes the exercise of the Pre-Funded Warrants but excludes any proceeds arising from the exercise of the Common Warrants or the Placement Agent Warrants. 4667 3165 1502 38198 21583 RSUs vest upon the achievement of advisory services set out in the agreement with 21,583 vesting on January 1, 2025 13209 19666 46333 100000000 175000000 175000000 0.001 9170000 3557273 12727273 12727273 0.001 0.57 0.55 0.549 6400000 100000 381818 0.6875

_"

*?3<##MWC3#&IY8^S"`MF'^7,(!S4*V,:D>36\|"6K@,7?E"%G8N"QT9Y$'(@I"%C|=,'G[^QKJ9*Q.?`MS&*GKI"?]@(NAP:K&|AAWV:EE=V%*;ZD/U^3,PHUUZ[3<9;'RF&OX;$D& Q,/>)>46]*

*MDD4]DI({'/HLD":&%)A3;&2,(1X&DLT>@ *FZPSB7-TLJ,%^U*9HE#[D'0#1+UKPL7#1+EIP)6W8$LV2%>>>:),'L+/=$LV3Y_M'*52-5(ME9ZD;7+#+52B>*

*[!]$B&Z)^NTZ47WI.B>+$U'^^45%UDI'UCO%-9V'`M0.TZ\+`5[.@M1?365)N/QVJW)W>UXB;86I8PB.I);.L'I2LWEQ1T'@(M[\]% M5>_)BBJX6&TN'BLM16[JQ9:ZEM757^G$%,1)YX[9#Z>2.(`0R.<^9U)5KNC MRAU%-%]4FXNZVI/;NFB$JC87E98F.Y?TR);,.E4<<)*3[14'G*C@&B[-MK'FMN&BI+#D32MK6]>J6RL/MP*DFMU_7@BFX72%N;Z!E<\MD7MU(:*[@:,2ZW-MO=?63TGT?@]1$%V?*

*M6"NZ/H479^ER7F_J.NSK=WMR6RUV-MOFKIT8L&GW*6\BNJK+86<@2BJ^.,014&3U46U)$3A $7AN-=9K].KEC'*,'>/MOZ0$5[3UE*BH7Y&U;EO6$+A2=&T(-+/*

M4K7UO)ZFRYL,MM54D)1S3/HC+YW/"M5N!=<SNV^ J9%P=Z?[BS_N3RZOSBZM[-M7F]35V@8(!VL7F$W,1[82=]CQH\38P@O>2\9]l,Q]8\R%O_9MV&#DB&-/#;\ M_>B7P#6//MX3%]RA= 8$A]F!

(V%\C#]9=B$%NVWAXG!.EX[ICIET`#=NO97V-MV;6U 3?QH1MH52C4&78;.,=___)5E7#.?V455-A'$/7[% ^NKZ>\XG)%]-M.5V=H!&-M"(Y.N83#$W\)A8P$#&WG0:2M.*

+)O=ORX5\@>D;Z4U"+;WI% MET$6STCC#8$FU72/R;>!+8RA'>[[8]$U;E=D..PXQ M(U.+O:<+KZ\91U!BAZYMNT^D-KESOD#=@M'"#FG5#+Y)\H75!N8AVUG*WLP]:B!,?*

76FC;7=[+&BCQ2;@G0Z_MO$OD<#9X765+$/(E9&L;S.UK;BCCVTXK;=,:C-1,39E;;$! MXJ!HN=+([S9*|G\\!!^ !|OI@2]U*CU0-YZ+:,GEXOI!]36T%$5N++1I>T>-R

M@+@*KLC;]K]#4Q"=1V0<&CMM]PHJ[< "N$X(.%0FP@-N7IKFQ". Q(_M777+97+RDY2'?O);'%R1PZBE^!9&R>AZZ'>C(@L6U'UFPN/8C'Q*+RY\LN64^ M,SQS1$UV_;*

(-'>"O=)EH%Z9Q71EY[0K:RU=UM1B$/1#H&,U^.@T94UOR[UV M,=;Q(9"S^HP\5N6FHLCM5C'V^ L X?9+FEW? G2,I4.[EXI?W[[0M.ZE8N(+

M^/HA9Q8S=![R+K6D3M=85RKS4<=P5OE=KNXINH0[%E] M/AZWNUVYV]DH//BA65;M4I9U/R7]BVBV)=E(AWC\HLE-O21V5[56EE(lL>KND]SHW/|l$%JQ6SS]8.7G.H.N=! MNJ[@45GZ]=4H"A

[+O98JJRlM^Q-VI^;RT95[[:,L=$6YF)"//QI\"%S .^FI MO=V5C:^7OP6O+>X/^2?TSM/C9N4OKW-F=]+TV:U%.?E$9MU+.LY$'' M%BRN_MS7ZN/D>$HU-M_M5M1^W>0B98@!6RDGL)

*"_C2S0%K+G1-M+8Q7@8OR]VKSL-N2.[J <:TV$X\[NMS6-6%+7VQ+N]5J*MM+L)F8T>@2[))L MHAIL7T7ORBVE/MFB.K"DV9/,K?JHU!]PI-65.YV%9P%Q0XC"*

8K"L09^]GKM@15U\[467V,37CE**2N5L0]-MUQ(6C)@G75(.6S].V\+R*L+++((*E41 ^OZ-)0\[ZL8G;TN<,)NO1CU(!]2KLG M=[M-0=QZL?584SNRHAW"7A0GR6MF &]V=6KDF& ^50"*"$X(B!$4(BA*

4(2@`M*"C525]0O=@.=U'`7]2RO$$7<>7#(_`]RRW;E@+/<'P+/T5HP2&\13(DK^ B'OB_M\<"DP(5G3'<\9IYIP0+ ^]K?R+OO))&5\|@1D.I"]H6=2(8[YI3&E'#ERP>2G@O?FCGN(#2#>_"?4]

*G3&@8%P>Z"AO__LT/ M$Yf,*4OXAGG$]T|Ik0\O]^/#C'^ DGOF.R3SIGOE!0[']ETV!+UAQ1']+CNDQ-MPZ?"HV0"?%86" -(AS3P+/AR0/6]5Y\ *[*WNA),'L,)05ME3=*K]%,/T]WN/3.YIS9BS*]K*

*DS\4(3>RI+L =(BX5V M$ OXT# #U\,)^:9G]>&=?5!K3QL7)#)X\>OZKC=@'AE@H,K[)KV07KU \,AF M-YN_@K,!_M[$& S@-[\?.3%(Y]8T-[@_ROJ*HTE_Y*7S69X6.%KB^_1MP_R1*

*M\8"D^XL_[TNK\XOKNZY_^^V=_2_"!VOH MI" !9B[/,.8[%3#T.KWY\9LE11%=P<6:.)N0UM3Z\BOPEHV6NO]5$/;,.4S ME+/1'K. @$\KG>/\ACY%<\M*ZQ]P&*

*<*38;*P'+0KH)W9^&E3Z@7K6#* ;GS M/Z_/;] EY&'0V:[K:.S.O!.&B[_V93_],.G3[-!M@"?(W>/^R.?[B\P+G'#< M!R.=K@+\C@ZNJZVF3AW\$RD&ZP?:D1\#+[/#<06-W(KE<1V=^;.-AL#6=O=6C*

*M@ETG*4.#94F*7YKTOQSN.WQW7\SL[N4)[IV? M# ^V+Z9GDR$)AS]&[/4QQ=?_C,)BP\B;.\<9"NRKV4)79IPGV599]9]2V5@8& M*]*^WMQQS]*'I&Y@!;&4\)6\D=8_A3B8S;]M5D;$?*

Y.P0!+TW\M6VH56?E/6 MC5;`^^];A51&N0]+2E-#\(+6?EGM*;+>%;*PH7;G9 MV2A$4/D!-^X*DM$E86[UQ4II[+>$1B.U>;BVE/EEN!BQ;EXK*@]N=+WXL.?KWCP61)F5U_,5+FK=65-*

*%9BOU>9C2];!>&N:\.RKS<=C1>ZH+;G9 MW"@4?OE]>XYF4Z3W2\!+DZHN7KNAR9XE3<0BTK &7=55NIPL8=@=%R^IS\5AK MRITE7*RG@\!FX.%;O&<$M;PO=F'.OTN8R#FH9D!=Z\C*

*(L!U&3K;A2SL7!8B MS#0A"PJW.$6D@.;AD@M?WPRB[VY0GZ]"M@6&JQNX(9]FY56=A>F^)(. M]ZZLM719FZDV72[0FM!MAR0@2E/6=/#&VfJ0$"$A!2 93461VRWE91*R"9",*

MY6V+U>_BRS8T?F$,\[%8LZ6!L.19\;6"'[X&T-&8)8,P2H'[a=70YJK M]8;ZX>;JY;V,@Y#@(6SWB7E%G85%859=(.H)7#%'D,%QU2,HU2EBJ-MK6N\18]AR9E0UBXGT6-*

*8=?:)\[/LD_T&);/4Q(]AH*5HL>P9/07/8;5*%\0 M/89;K$16\=[S9O&5SH=_S3KPL=WNRLV6]$2N-A^6YN_\[!\Y_RBQW#KW6DM-MN=.,62K[:7,1FDW9KX>KD@Z)E1;EXK+8[=>.Z0^3ZH*

*M=_A@R(0SOfE.V%)8QOf(/-M-L2'PMJ;DHA%]06RHX+GT=JI1!FN!OCHM*3U9X(-ZK-O:ZL[S^4*W_<(%H7-MR]FBU&W)2G.AT!#=:;@+\&7G44O&WQO.5S0O"@')%1!=5M6VW&ZO?G.*

*(s)"#$I#C=KHGG]9G@_V-PjKW5N64O7/D)67M"K]#641#.QV[<'7ZQO6). MR^>)38K/W7+#(1HTX'&FZG!DFA2%*P43HEH[\H4]QO&W4QQ.5S0O"@')%1!=5M6VW&ZO?G.*

Y1%-IXK8@0!2$*=-'|(M>^&NO[TVH^PE2IEM1O&75(R*+I0RU9!K;M.UN;NU MK6B\<01^SGM4+&=^9.Q@X.T[\4,#^%L _$#:6)8 B/%]A3&'OHLP",3 S> MU4(9

*7CA@VHT[.1;I(434WZ(R^=SPKE MEP7*L6^#9YV)#:3[BS_O3RZOSB^N[CDE\L]\FPGXRI?Y1QD)]]&[:2&=+(8\/2CWX)7//HXSUQ >3W# @.LP_V @8]:D]-MKS1?;XAVWZ!W!9OE]^O7O!GO-3K0*

0K90"'JG#.F$\ ]:8V-@(&R 568N6:0 MBKOW+!_^:!:K*2']+*K&[:CM?I'=JLF>Z]Q#]>;'=H"O3IOK3-MRT#.0 L]" M7 .\[= *IOSX*ZF$,UT_\'>HW'8OUE[:. M>

H"]"N=F%].X9AD(5T0(2>P'&Z2)Z'GP]_F500C(\"G87HP4S_L^P$8<11L=,"# MY'NI'_KP]RCL+VD/AAX7'EVFKAW);YNDTL%/!N.W#"0A]%'SD:ROEKOC.OA M\.23 -,8S=9CFP"V9MTW\LP

ML;]""WXYA?<;$PNSC?0;^ BF0^^(/X= PIQ.%[T1UY;0"%[5@5]H-D$AX9CN("S065)4\< X;>WRY^A&%P(B]7LI9<1=&AH6'M"!SO1)Z\Z\ M(.Z@%Y0;\WCA?2$%PW/VEUB<-*

E$\T$CSFS0UI4)9$N)O*$^IGWZ[G0-PF9 MD"X^G67$5@[V7T"A,VY)O-#&P>(3V&T'(!)M!FQN8*V#%8H9M%,78=%!(_GL22N7)$]4"/"6[$6UE)%]O'6;.F!07+F)@XO.#G"B> MEFSXA9T',?$9(.-

,"(0]9UD5H$GHAY5CZ4!.17IAX&/19H^A]-FBXLV/3_* MODA_@9. +D6B[!*EU9 N*4_!^0^.)8?+5#(0MZ!$OD@ZDYB&%M5Q(OEC-B3E-MS"RA!_TB\.DC1XFM<5ATI[2VS>@8M!0W&9V

*S_6ZPM_LXRGM/3*KSM&%*K41)P\[S,/S*"S+2)(21 M!WL0]T9DW\,&0\K*4NU+U,O'BP5YUT34D8155&;4.1[+)T_1Q],;G_I8=<<2K3.>2&*BQI9IK,+T/L=. "PV4#\=5.T#.DX;7OY)O#*

MHH[.!]]6!BG5I5]5VBYSS0,;":F%L IAW8]P1I X48]&A/&0]O%2)3(S1\Y\-M'2I5GP?8]9'YK)!D$4&9K!0IIY MYB I4\]!S'IPXLB(PQ&KD>P!YA-Q#9!?L8D)^V+(^Z0+EC&3Z.\V1B7UZHL MQ&H-

Z3\Y>=;YB"])$&4E=CX9]\QQ7T0($. ^[37.D]O2<^]>ZR#(GZ+C@9 MGER/>OXA<(4=P.1US^LS+&,&.W0'0(]Y*T6' FV!-M!C/!$:A;HGBF73F% [F,67.694U;.G(;LV;OB9BM4N2B)_8*)Z<+*

*<29D:N_F M9K0Y'5<_/;>>H"@C(V.W3P;<9:W-PHMJQ@98F4R+[?.H9''K0[:)+>H0DY**L]]36IJDP./RIFB\N*JGKG-^'^LYXI/;-ZOEQSY,*^I%>0)RR? MKU%;W+=D8J/Z#CI$9)fG]\'Q7T//" =8*

1-+.T\^R5'?7H#E=>X33UP1.!BA M@:,:UA+C)3,-)'$37@>V4%J_(''JM[!MV2#8U:.U\,G<_G^Y6"6"-CL5WES* M@H.TF8.1R=FJ1O1DYG\P#@FY=&C'8 /8 #S?*

9A4[P>3I!IX!E//EI#.U#T(^ MM/CI;4)>F^?_P)C.NK?M@UB*;?"EA?A!TJ?TLH_R\%!G6RELA^?Z,[.W">R MS_K0R>A9*L<$G:=G\[74!19+1=3)3& /R'&.2^-*

*,9PJW ;:WN),L+@6*4^T% M2TD1B8#$411)U2>.."-L@GA1W0B-7"?'+YFUS01 M=R6EIX%ERO!21)*,#A$$(<8/!F*<.%3V5)XE7?]NZHX*G>B$'5$ MY)W\+]J?YPA\?*

3PAM>W0CXWFD\M], \?"SCZZ'\)&@[S$ATI2S& M_>Q&!-E)<]<)!3$,00R)?H1,3.7/O!08E!S'TL]T\:8M\V2]K9'K#DAN(W@X

MY%^Z4U$!M,$KB"HOBQ]54#ZFIDI1Z>5[!9^L$WCI9+^1 M"J&!^>9$7D25A(G&J./9_KL=G^AW:G&BOR$UEY!EPZ5E^8.\L.]OHAY]O#F] MO9W$J75Y^O;*

[^=WEI>7TF5;OE[+FA8LT%2<;(.2:4A?;WXX.T.S_1&E])$I(7T'AMPT(' MD-)N8%KB?]O&DQ\:$?H+QP6P^,%)O)HH/II(YF7PPCP\O8C ,UE39I,)*.88?P*RP),T/LAURZ,3R*

ML/L)S>"G:S_&1?@@!Q8F\X9DA)QIFGY(WSDS7K+2&%B$=Q;/3 %>Q8OP>&"$ M!;8NM;Q%S6^4!' HR+=L3"MR@XL?>>P!P=$\7OC.G?ZH#G0&PQ&I'\/B1!# MKD>5+UE0A?*

*C2A/C!J)4O_GQ[?<[EV=1&O*E/&]3U+GT^;/;N_OMW=AG[AJU9! MK8D26IF*#L2(PR*/&&'*IY%BKS(!WH8_R"7%YO>H:IA[H1QE)@*944[CO;FL M8ZN.4J/&ID!M2-^O;B^^7-*

[=7IQ>G$MWIU\OI]3KS]+%OI]?WOU\OUK-_OI\\ MOX0/(X'"EOKO=O?X3&0^]BIH-!9!=Z0I OP%@?CN9)3478)>NBRE5N;E7KG.

MYNM^7W\JFZ7_)/1@RW.C'8$3[YSN+WS5E9L#V4MY=2]9ULQ=/O 8^_58"^ZA MTP$KQK3Z >@<+=8Y6D.ZO_A\^OWK_9WT_0:

<]+N+]\OKVXRN;OM*O>66A#@R@IRH%ZUX9D>\TQO+ ,!|E[RI"LVE\C M2K<6:.OJB^9+]V,[WH_MAG3QYS\O/UW>,UUI/B_QF?>_5LQ=&Q?S^U%K2U>=*

MQN]7M_S^BLX_7UG\TJ3_9=3%468F,TO=5K(6,S-RNCH@.\VADK)OR*\TGQ^ MF49?9!+?B]U?LIS:",;N?HZLOA5(V\V+PQ[%2+NSI,",=O1\&ZY;V1%+NG- MHON-*

BYCW2LL3\^B<.N_H@'9-RBFSE-O.6= K2-I9@:+Z+K;#9]<;'R!MM9W0 MUK+Q(JK&,_35:DC??:KR Q3?W:@&R\9\W3FX-0=(XIU(\&<"0_TG>(M8;I-# MY6)WZT,?

@N0'SPV=P0E,VO?>_X)E1L/A0K"R8FO1QM<81\6COB\?_?NZ>FI MX3.S\>_^OCOUS!&67KYC@P?#>S>_Z/)=3].4UCM@E!+J=']'JK.:S9:F:^\> M'>_G_[&?

+;4O"L80YS<4'E%QO?2>S8Z'^KIU4T ML9+LO$TOO-50#TRX.^_4%O?2OM"E/I2CKBZ2[F=*_< %'4X&_<\%[3E;KTQ3.B6^UG/CI[%=F#J-$GO51)6 MNV 3U#D3_/SJ#R

*K_#P1>CW25@>\"Y&!H)PG#X9'D\WYWTIS'B=S/@&I%58Z]A;]X6U%M;ZD -M,V.M M36&M7TO'16N-Y\.>1;>]<'N;VNK%KX2EKI.E%@'W+DRX*4RX,.&''' /,B9*

M($SX.^FX@@G_[EC!,CO.OQ?&7!AS8)OEC#G+&//MXC1L MMPO[@Y@D9=5B&42PK;(K+=T=5/]FSSSR.:]ME^W..SH].@@5/NN(LK?[8V9--F1TM-;66B'O9K:

*M;;>&MFTLJ_W^G>HX(5CEU5X)T_ZL6$BYJDU2$YM4!8R@'=@D=:E-6KA 6]BD MJJB.6MFD"M*_ZO)3.=-3\G:!(C<,AM:\'OPK8GA>.7;CN&0OC+PM[,&U88'[D M&?*

NC=?OC;O&60--"ADN1=.,W'X,W E;G>SC\4.I9CN^Y?7.\/J&P_R3Z\V MF\962&TV56%Y2FI9A.6IM_Q4SO*4*^A!-+++JJN2\^Z%8U_2K5S2GY]NOTJ7 MCA\04_BY.X9XH-*

*00^ZV,^E3HZWK+3^7T=;DB!=37=V?_+#GO-J"OJXV?KN,. MI^#R!\SQT16_,T=L; @%7FX%*Q1XO>6G<@J\? [WV>G7DO-N.PK\S+#-T.;G M!E\MYT??\(4_7G)U*]1YO>6G?*

==M3Y5Z//;(*Z)HA2*O MM_Q43I&7SR^_N;TH.>^VH\AO/.8#'81C7B5]*_1YO>6GLM/Y;1YV;SSO37T;5>3G[GP7NG&>):]5,*FZ M\=P(#.FS93/IF&XS"+ \T?"EK.*GRW5A&*

*,^&>#ENA<_1U;?"H#BRMX:0*N] M2X66%UJ^M*UQ\YK\7=!W!UAT^C;;%,+DV@4>F7\OK[K#9AW DLT+>A??/# MW "9R=IL&'QXL@;!"+YJ_GHDF+"Y[:ETRR:N%^RL84$F[\$?*

*&;8M.6X@-MI9DT0)R5@??/7[JJ"EL#F9XC(:"[<)HEF.Z\:/NOW@_1X;.H]A?:IEP!<(H>A%Z;@X':7S MP9=@;G(8%N6YS%_PKB#!2_',1Z8 SZ7G9D.K@*VYD.(+MF_M>X7/^Z$YBH:?*

*WZW;4<7]R> M?+J^O[_^]E[JVQ!E2,KDI^2[MC7X(-U?_'E_283\94__HXQH*EHW3[J1? M>$?4YEP;YSG0?X$U16+ X0F3PD0='`\L&03=_#_L# Y$BR!K\?^00F*

*M1;^)'J.7#Y@9;,#WM"!(Q_O+K]4[GCD#Q#T*P%;81 ^]"2R()XW&YPI>K#TN + MT& 6#--GH-Z'L?(FDO,'Z,T>"U'1T@N-,!BY'BQXT-@*M5-;N7>E-J/&"D.#*

M]0(D1X+]Q_77R_O+ZZO;/Z6OE]\N[R_.9V4^FN[E=4MIXS>_/7#T?PR9Y[0 MGGU.?^X)19U_8G7UO%7BGJ-#\5XZ#1_@(TF!781H<3.NX*?I^_E%/6.HCL@<- MO//?26?&F'D((6EL#*

M%EW<7=_?O '-?O3Q^#11D-(=R!N/X.BV40\\1VL"'N3"R#,IN$6ZU<|=S-%" M1;NQ4"NMOS>S&BO>1??,LQZD?X8/(S:[0W.46(TV[>RRR[=ABU!B<"/=@[ON MA]X.-VPZ#_S\%

)S<(A W/>Z?U?-OM4XWFU=Z,EWT5O'6SC^^/_#U!+ P04 M " "%@@Y98^V4.' ' #4)0 #@`9N,.W;X,M$197"A1(R6_[-?O.4I^22RW M>>M6;/F2O'PYWO&>NWN.<2?

8M7M1((`W4XF,R6ZT\3,?Q?SHV;S%28[!\5H MYYMZ_4S[>2R2C/E&\$P$+++ MR/LXJO!RU&+-1JQ3,;"LD3,F-$Q3]KL76_XIG]9 MO_#.L>2^%ZN!8?

_-6S>RU^VD2^DDJ'[5_\TK!62Z^>]=_V+7UN[9+=8(YVW M62;F69TK.4E:1DZBK W!-C,ZF72]CV_I)_T1.V]^:G8.RL'.0=IE3W[T\D[V MNM\E8YNVO\P!/EPGS(:%1]YPM+:L_-

*T_[V_V1OW!)1N^<>1^]TP^C_M_B>AC#K#=G[#\.K#[W+$1L-V!>^FRVMK[S3"]VA[U'CD'0>O?7856[XTKOT-MKN]#CQ?>KZQW.J*9PT;C\#_AR?4I_1KKB+A[RF.!JA0+!*M*

*MLYP&"-^<+0 M.I9%/&O]*P;'W$QDTL*NO=W#&1\KL9P:.Q,@D=B4^T@NK4:[XK!0)UFK.G/_M9)!%F&J\V((U2J4\""#FI[V&.\@L3XD$17NK>5QJ$"PG"@&O7[2G='<^5^71*

*MF4[,.TUHOB*SD2]#&[+N(Z+/(CX5S(BI%#.DUBR2EOV9*